<!DOCTYPE html>
<html>
<head>
	<meta http-equiv="content-type" content="text/html; charset=utf-8"/>
	<title></title>
	<meta name="generator" content="LibreOffice 7.3.1.3 (Linux)"/>
	<meta name="created" content="2023-10-26T20:02:29.266697666"/>
	<meta name="changed" content="2023-10-26T20:03:28.427105704"/>
	<style type="text/css">
		@page { size: 8.5in 11in; margin: 0.79in }
		p { line-height: 115%; margin-bottom: 0.1in; background: transparent }
		h1 { margin-bottom: 0.08in; background: transparent; page-break-after: avoid }
		h1.western { font-family: "Liberation Serif", serif; font-size: 24pt; font-weight: bold }
		h1.cjk { font-family: "Noto Serif CJK SC"; font-size: 24pt; font-weight: bold }
		h1.ctl { font-family: "Lohit Devanagari"; font-size: 24pt; font-weight: bold }
		h2 { margin-top: 0.14in; margin-bottom: 0.08in; background: transparent; page-break-after: avoid }
		h2.western { font-family: "Liberation Serif", serif; font-size: 18pt; font-weight: bold }
		h2.cjk { font-family: "Noto Serif CJK SC"; font-size: 18pt; font-weight: bold }
		h2.ctl { font-family: "Lohit Devanagari"; font-size: 18pt; font-weight: bold }
		h3 { margin-top: 0.1in; margin-bottom: 0.08in; background: transparent; page-break-after: avoid }
		h3.western { font-family: "Liberation Serif", serif; font-size: 14pt; font-weight: bold }
		h3.cjk { font-family: "Noto Serif CJK SC"; font-size: 14pt; font-weight: bold }
		h3.ctl { font-family: "Lohit Devanagari"; font-size: 14pt; font-weight: bold }
		td p { orphans: 0; widows: 0; background: transparent }
		th p { font-weight: bold; text-align: center; orphans: 0; widows: 0; background: transparent }
		h4 { margin-top: 0.08in; margin-bottom: 0.08in; background: transparent; page-break-after: avoid }
		h4.western { font-family: "Liberation Serif", serif; font-size: 12pt; font-weight: bold }
		h4.cjk { font-family: "Noto Serif CJK SC"; font-size: 12pt; font-weight: bold }
		h4.ctl { font-family: "Lohit Devanagari"; font-size: 12pt; font-weight: bold }
		h5 { margin-top: 0.08in; margin-bottom: 0.04in; background: transparent; page-break-after: avoid }
		h5.western { font-family: "Liberation Serif", serif; font-size: 10pt; font-weight: bold }
		h5.cjk { font-family: "Noto Serif CJK SC"; font-size: 10pt; font-weight: bold }
		h5.ctl { font-family: "Lohit Devanagari"; font-size: 10pt; font-weight: bold }
		h6 { margin-top: 0.04in; margin-bottom: 0.04in; background: transparent; page-break-after: avoid }
		h6.western { font-family: "Liberation Serif", serif; font-size: 7pt; font-weight: bold }
		h6.cjk { font-family: "Noto Serif CJK SC"; font-size: 7pt; font-weight: bold }
		h6.ctl { font-family: "Lohit Devanagari"; font-size: 7pt; font-weight: bold }
		a:link { color: #000080; so-language: zxx; text-decoration: underline }
		em { font-style: italic }
	</style>
</head>
<body lang="en-US" link="#000080" vlink="#800000" dir="ltr"><p align="left" style="line-height: 0.13in; margin-bottom: 0in">
<font color="#c31c24"><font size="4" style="font-size: 13pt"><b>Circulation</b></font></font><font size="1" style="font-size: 6pt">Volume&nbsp;145,&nbsp;Issue&nbsp;3,&nbsp;18
January 2022;&nbsp;Pages&nbsp;e18-e114</font></p>
<div id="masthead" dir="ltr"><p align="left" style="line-height: 0.13in; margin-bottom: 0in">
	<a href="https://doi.org/10.1161/CIR.0000000000001038"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 6pt">https://doi.org/10.1161/CIR.0000000000001038</font></span></font></a></p>
</div>
<p align="left" style="text-transform: uppercase; line-height: 0.13in; margin-bottom: 0.2in">
<span style="display: inline-block; border-top: none; border-bottom: 1px solid #d93731; border-left: none; border-right: none; padding-top: 0in; padding-bottom: 0.02in; padding-left: 0in; padding-right: 0in"><font size="3" style="font-size: 11pt"><b><font color="#d93731">ACC/AHA/SCAI
CLINICAL PRACTICE GUIDELINE</span></b></font></font></p>
<h1 class="western" align="left" style="line-height: 0.25in; margin-top: 0in; margin-bottom: 0in">
<font size="4" style="font-size: 14pt"><b>2021 ACC/AHA/SCAI Guideline
for Coronary Artery Revascularization: A Report of the American
College of Cardiology/American Heart Association Joint Committee on
Clinical Practice Guidelines</b></font></h1>
<p align="left" style="line-height: 0.18in"><span style="display: inline-block; border-top: 4.80pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in"><b><font size="2" style="font-size: 9pt">Jennifer
S.&nbsp;Lawton,&nbsp;MD, FAHA, Chair,&nbsp;Jacqueline
E.&nbsp;Tamis-Holland,&nbsp;MD, FAHA, FACC, FSCAI, Vice
Chair,&nbsp;Sripal&nbsp;Bangalore,&nbsp;MD, MHA, FACC, FAHA,
FSCAI,&nbsp;Eric R.&nbsp;Bates,&nbsp;MD, FACC, FAHA,&nbsp;Theresa
M.&nbsp;Beckie,&nbsp;PhD, FAHA,&nbsp;James M.&nbsp;Bischoff,&nbsp;MEd,&nbsp;John
A.&nbsp;Bittl,&nbsp;MD, FACC,&nbsp;Mauricio G.&nbsp;Cohen,&nbsp;MD,
FACC, FSCAI,&nbsp;J. Michael&nbsp;DiMaio,&nbsp;MD,&nbsp;Creighton
W.&nbsp;Don,&nbsp;MD, PhD, FACC,&nbsp;Stephen E.&nbsp;Fremes,&nbsp;MD,
FACC,&nbsp;Mario F.&nbsp;Gaudino,&nbsp;MD, PhD, MSCE, FACC,
FAHA,&nbsp;Zachary D.&nbsp;Goldberger,&nbsp;MD, FACC, FAHA,&nbsp;Michael
C.&nbsp;Grant,&nbsp;MD, MSE,&nbsp;Jang B.&nbsp;Jaswal,&nbsp;MS,&nbsp;Paul
A.&nbsp;Kurlansky,&nbsp;MD, FACC,&nbsp;Roxana&nbsp;Mehran,&nbsp;MD,
FACC,&nbsp;Thomas S.&nbsp;Metkus&nbsp;Jr,&nbsp;MD, FACC,&nbsp;Lorraine
C.&nbsp;Nnacheta,&nbsp;DrPH, MPH,&nbsp;Sunil V.&nbsp;Rao,&nbsp;MD,
FACC,&nbsp;Frank W.&nbsp;Sellke,&nbsp;MD, FACC,
FAHA,&nbsp;Garima&nbsp;Sharma,&nbsp;MD, FACC,&nbsp;Celina
M.&nbsp;Yong,&nbsp;MD, MBA, MSc, FSCAI, FACC, FAHA, and&nbsp;Brittany
A.&nbsp;Zwischenberger,&nbsp;MD</span></b></font></p>
<h2 class="western" align="left" style="line-height: 0.22in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="3" style="font-size: 11pt"><b>Contents</b></font></font></h2>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">Abstract
e18</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">Top
10 Take-Home Messages e20</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">Preamble
e21</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">1.
Introduction e22</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">1.1.
Methodology and Evidence Review e22</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">1.2.
Organization of the Writing Committee e24</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">1.3.
Document Review and Approval e24</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">1.4.
Scope of the Guideline e24</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">1.5.
Class of Recommendation and Level of Evidence e25</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">1.6.
Abbreviations e25</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">2.
Improving Equity of Care in Revascularization and Shared
Decision-Making e26</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">2.1.
Improving Equity of Care in Revascularization e26</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">2.2.
Shared Decision-Making and Informed Consent e27</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">3.
Preprocedural Assessment and the Heart Team e29</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">3.1.
The Heart Team e29</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">3.2.
Predicting Patient Risk of Death With CABG e30</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">4.
Defining Lesion Severity e30</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">4.1.
Angiography to Define Anatomy and Assess Lesion Severity e30</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">4.2.
Defining Coronary Artery Lesion Complexity: Calculation of the SYNTAX
(Synergy Between PCI With TAXUS and Cardiac Surgery) Score e31</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">4.3.
Use of Coronary Physiology to Guide Revascularization With PCI e31</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">4.4.
Intravascular Ultrasound to Assess Lesion Severity e32</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">5.
Revascularization in STEMI e33</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">5.1.
Revascularization of the Infarct Artery in Patients With STEMI e33</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">5.2.
Revascularization of the Non-Infarct Artery in Patients With STEMI
e35</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">6.
Revascularization in Non–ST-Segment–Elevation Acute Coronary
Syndrome (NSTE-ACS) e38</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">6.1.
Coronary Angiography and Revascularization in Patients with NSTE-ACS
e38</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">7.
Revascularization in SIHD e40</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">7.1.
Revascularization to Improve Survival in SIHD Compared With Medical
Therapy e40</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">7.2.
Revascularization to REDUCE Cardiovascular Events in SIHD Compared
with Medical Therapy e43</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">7.3.
Revascularization to Improve Symptoms e44</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">8.
Situations in Which PCI or CABG Would Be Preferred e44</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">8.1.
Patients With Complex Disease e44</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">8.2.
Patients With Diabetes e45</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">8.3.
Patients With Previous CABG e46</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">8.4.
DAPT Adherence e47</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">9.
Special Populations and Situations e47</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">9.1.
Revascularization in Pregnant Patients e47</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">9.2.
Revascularization in Older Patients e47</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">9.3.
Revascularization in Patients With Chronic Kidney Disease (CKD) e48</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">9.4.
Revascularization in Patients Before Noncardiac Surgery e49</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">9.5.
Revascularization in Patients to Reduce Ventricular Arrhythmias e50</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">9.6.
Revascularization in Patients With SCAD e50</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">9.7.
Revascularization in Patients With Cardiac Allografts e51</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">9.8.
Revascularization in Patients Before Transcatheter Aortic Valve
Replacement (TAVR) e51</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">9.9.
Revascularization in Patients With Anomalous Coronary Artery e51</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">10.
General Procedural Issues for PCI e52</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">10.1.
Radial and Femoral Approaches for PCI e52</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">10.2.
Choice of Stent Type e52</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">10.3.
Use of Intravascular Imaging e53</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">10.4.
Thrombectomy e54</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">10.5.
Treatment of Calcified Lesions e54</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">10.6.
Treatment of Saphenous Vein Graft (SVG) Disease (Previous CABG) e55</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">10.7.
Treatment of CTO e56</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">10.8.
Treatment of Patients With Stent Restenosis e56</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">10.9.
Hemodynamic Support for Complex PCI e57</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">11.
Pharmacotherapy in Patients Undergoing PCI e57</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">11.1.
Aspirin and Oral P2Y12 Inhibitors in Patients Undergoing PCI e57</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">11.2.
Intravenous P2Y12 Inhibitors in Patients Undergoing PCI e60</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">11.3.
Intravenous Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing
PCI e60</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">11.4.
Heparin, Low-Molecular-Weight Heparin, and Bivalirudin in Patients
Undergoing PCI e61</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">12.
General Procedural Issues for CABG e62</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">12.1.
Perioperative Considerations in Patients Undergoing CABG e62</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">12.2.
Bypass Conduits in Patients Undergoing CABG e63</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">12.3.
CABG in Patients Undergoing Other Cardiac Surgery e64</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">12.4.
Use of Epiaortic Ultrasound in Patients Undergoing CABG e65</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">12.5.
Use of Cardiopulmonary Bypass in Patients Undergoing CABG e66</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">13.
Pharmacotherapy in Patients Undergoing CABG e66</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">13.1.
Insulin Infusion and Other Measures to Reduce Sternal Wound Infection
in Patients Undergoing CABG e66</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">13.2.
Antiplatelet Therapy in Patients Undergoing CABG e68</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">13.3.
Beta Blockers and Amiodarone in Patients Undergoing CABG e69</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">14.
Pharmacotherapy in Patients After Revascularization e70</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">14.1.
Pharmacotherapy for Risk Factor Control in Patients After
Revascularization e70</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">14.2.
Dual Antiplatelet Therapy in Patients After PCI e70</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">14.3.
Antiplatelet Therapy in Patients After CABG e70</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">14.4.
Beta Blockers in Patients After Revascularization e72</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">14.5.
Beta Blockers for the Prevention of Atrial Fibrillation After CABG
e72</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">14.6.
Antiplatelet Therapy in Patients With Atrial Fibrillation on
Anticoagulation After PCI e73</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">15.
Recommendations for Addressing Psychosocial Factors and Lifestyle
Changes After Revascularization e73</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">15.1.
Cardiac Rehabilitation and Education e73</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">15.2.
Smoking Cessation in Patients After Revascularization e74</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">15.3.
Psychological Interventions in Patients After Revascularization e76</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">16.
Revascularization Outcomes e76</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">16.1.
Assessment of Outcomes in Patients After Revascularization e76</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">17.
Unanswered Questions and Future Directions e77</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">17.1.
Special Populations e77</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">17.1.1.
Underrepresented Racial and Ethnic Groups e77</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">17.2.
Special Clinical Situations e77</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">17.2.1.
Left Ventricular Dysfunction e77</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">17.2.2.
SCAD e78</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">17.2.3.
Coronary Artery Aneurysm e78</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">17.2.4.
Myocardial Bridging e78</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">17.2.5.
Treatment of Graft Failure e78</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">17.2.6.
Antiplatelet Therapy in Patients With ACS After CABG With an
Indication for Anticoagulation e78</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">17.3.
Revascularization Considerations e78</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">17.3.1.
Use of the Radial Artery for a Conduit After Radial Artery
Catheterization e78</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">17.3.2.
Completeness of Revascularization in Multivessel Disease e79</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">17.3.3.
Hybrid Coronary Surgery e79</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">17.3.4.
Revascularization Before Percutaneous Valve Procedures e79</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">17.3.5.
Revascularization Before Organ Transplantation e79</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">References
e80</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">Appendix
1 Author Relationships With Industry and Other Entities (Relevant)
e110</font></p>
<p style="line-height: 0.18in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Appendix
2 Reviewer Relationships With Industry and Other Entities
(Comprehensive) e112</span></font></p>
<h2 class="western" align="left" style="line-height: 0.22in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="3" style="font-size: 11pt"><b>Top
10 Take-Home Messages</b></font></font></h2>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">1.</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Treatment
decisions regarding coronary revascularization in patients with
coronary artery disease should be based on clinical indications,
regardless of sex, race, or ethnicity, because there is no evidence
that some patients benefit less than others, and efforts to reduce
disparities of care are warranted.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">2.</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">In
patients being considered for coronary revascularization for whom the
optimal treatment strategy is unclear, a multidisciplinary Heart Team
approach is recommended. Treatment decisions should be patient
centered, incorporate patient preferences and goals, and include
shared decision-making.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">3.</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">For
patients with significant left main disease, surgical
revascularization is indicated to improve survival relative to that
likely to be achieved with medical therapy. Percutaneous
revascularization is a reasonable option to improve survival,
compared with medical therapy, in selected patients with low to
medium anatomic complexity of coronary artery disease and left main
disease that is equally suitable for surgical or percutaneous
revascularization.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">4.</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Updated
evidence from contemporary trials supplement older evidence with
regard to mortality benefit of revascularization in patients with
stable ischemic heart disease, normal left ventricular ejection
fraction, and triple-vessel coronary artery disease. Surgical
revascularization may be reasonable to improve survival. A survival
benefit with percutaneous revascularization is uncertain.
Revascularization decisions are based on consideration of disease
complexity, technical feasibility of treatment, and a Heart Team
discussion.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">5.</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">The
use of a radial artery as a surgical revascularization conduit is
preferred versus the use of a saphenous vein conduit to bypass the
second most important target vessel with significant stenosis after
the left anterior descending coronary artery. Benefits include
superior patency, reduced adverse cardiac events, and improved
survival.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">6.</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Radial
artery access is recommended in patients undergoing percutaneous
intervention who have acute coronary syndromes or stable ischemic
heart disease, to reduce bleeding and vascular complications compared
with a femoral approach. Patients with acute coronary syndromes also
benefit from a reduction in mortality rate with this approach.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">7.</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">A
short duration of dual antiplatelet therapy after percutaneous
revascularization in patients with stable ischemic heart disease is
reasonable to reduce the risk of bleeding events. After consideration
of recurrent ischemia and bleeding risks, select patients may safely
transition to P2Y12 inhibitor monotherapy and stop aspirin after 1 to
3 months of dual antiplatelet therapy.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">8.</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Staged
percutaneous intervention (while in hospital or after discharge) of a
significantly stenosed nonculprit artery in patients presenting with
an ST-segment–elevation myocardial infarction is recommended in
select patients to improve outcomes. Percutaneous intervention of the
nonculprit artery at the time of primary percutaneous coronary
intervention is less clear and may be considered in stable patients
with uncomplicated revascularization of the culprit artery,
low-complexity nonculprit artery disease, and normal renal function.
In contrast, percutaneous intervention of the non-culprit artery can
be harmful in patients in cardiogenic shock.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">9.</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Revascularization
decisions in patients with diabetes and multivessel coronary artery
disease are optimized by the use of a Heart Team approach. Patients
with diabetes who have triple-vessel disease should undergo surgical
revascularization; percutaneous coronary intervention may be
considered if they are poor candidates for surgery.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">10.</span></font></p>
<p style="line-height: 0.18in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Treatment
decisions for patients undergoing surgical revascularization of
coronary artery disease should include the calculation of a patient’s
surgical risk with the Society of Thoracic Surgeons score. The
usefulness of the SYNTAX score calculation in treatment decisions is
less clear because of the interobserver variability in its
calculation and its absence of clinical variables.</span></font></p>
<h2 class="western" align="left" style="line-height: 0.22in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="3" style="font-size: 11pt"><b>Preamble</b></font></font></h2>
<p style="line-height: 0.47in"><span style="display: inline-block; border: none; padding: 0in"><font color="#d93731"><font size="7" style="font-size: 33pt"><b><font size="2" style="font-size: 9pt">S</span></b></font></font>ince
1980, the American College of Cardiology (ACC) and American Heart
Association (AHA) have translated scientific evidence into clinical
practice guidelines with recommendations to improve cardiovascular
health. These guidelines, which are based on systematic methods to
evaluate and classify evidence, provide a foundation for the delivery
of quality cardiovascular care. The ACC and AHA sponsor the
development and publication of clinical practice guidelines without
commercial support, and members volunteer their time to the writing
and review efforts. Guidelines are official policy of the ACC and
AHA. For some guidelines, the ACC and AHA partner with other
organizations.</font></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>Intended
Use</b></font></font></h3>
<p style="line-height: 0.18in"><font size="2" style="font-size: 9pt">Clinical
practice guidelines provide recommendations applicable to patients
with or at risk of developing cardiovascular disease (CVD). The focus
is on medical practice in the United States, but these guidelines are
relevant to patients throughout the world. Although guidelines may be
used to inform regulatory or payer decisions, the intent is to
improve quality of care and align with patients’ interests.
Guidelines are intended to define practices meeting the needs of
patients in most, but not all, circumstances and should not replace
clinical judgment.</font></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>Clinical
Implementation</b></font></font></h3>
<p style="line-height: 0.18in"><font size="2" style="font-size: 9pt">Management,
in accordance with guideline recommendations, is effective only when
followed by both practitioners and patients. Adherence to
recommendations can be enhanced by shared decision-making between
clinicians and patients, with patient engagement in selecting
interventions on the basis of individual values, preferences, and
associated conditions and comorbidities.</font></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>Methodology
and Modernization</b></font></font></h3>
<p style="line-height: 0.11in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">The
ACC/AHA Joint Committee on Clinical Practice Guidelines (Joint
Committee) continuously reviews, updates, and modifies guideline
methodology on the basis of published standards from organizations,
including the Institute of Medicine,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R2"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">2</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
on the basis of internal reevaluation. Similarly, presentation and
delivery of guidelines are reevaluated and modified in response to
evolving technologies and other factors to optimally facilitate
dissemination of information to health care professionals at the
point of care.</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">Numerous
modifications to the guidelines have been implemented to make them
shorter and enhance “user-friendliness.” Guidelines are written
and presented in a modular, “knowledge chunk” format, in which
each chunk includes a table of recommendations, a brief synopsis,
recommendation-specific supportive text and, when appropriate, flow
diagrams or additional tables. Hyperlinked references are provided
for each modular knowledge chunk to facilitate quick access and
review.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">In
recognition of the importance of cost–value considerations, in
certain guidelines, when appropriate and feasible, an analysis of
value for a drug, device, or intervention may be performed in
accordance with the ACC/AHA methodology.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R3"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">3</font></span></font></a></p>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">To
ensure that guideline recommendations remain current, new data will
be reviewed on an ongoing basis by the writing committee and staff.
Going forward, targeted sections or knowledge chunks will be revised
dynamically after publication and timely peer review of potentially
practice-changing science. The previous designations of “full
revision” and “focused update” will be phased out. For
additional information and policies on guideline development, readers
may consult the ACC/AHA guideline methodology manual</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R4"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">4</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
other methodology articles.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R5"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">5-7</font></span></font></a></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>Selection
of Writing Committee Members</b></font></font></h3>
<p style="line-height: 0.18in"><font size="2" style="font-size: 9pt">The
Joint Committee strives to ensure that the guideline writing
committee contains requisite content expertise and is representative
of the broader cardiovascular community by selection of experts
across a spectrum of backgrounds, representing different geographic
regions, sexes, races, ethnicities, intellectual perspectives/biases,
and clinical practice settings. Organizations and professional
societies with related interests and expertise are invited to
participate as partners or collaborators.</font></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>Relationships
With Industry and Other Entities</b></font></font></h3>
<p style="line-height: 0.18in"><font size="2" style="font-size: 9pt">The
ACC and AHA have rigorous policies and methods to ensure that
documents are developed without bias or improper influence. The
complete policy on relationships with industry and other entities
(RWI) can be found&nbsp;</font><a href="http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIR.0000000000001038"><font color="#2b7bb9"><span style="text-decoration: none"><font size="2" style="font-size: 9pt">online</font></span></font></a><font size="2" style="font-size: 9pt">.
Appendix 1 of the guideline lists writing committee members’
relevant RWI; for the purposes of full transparency, their
comprehensive disclosure information is available in a&nbsp;</font><a href="http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIR.0000000000001038"><font color="#2b7bb9"><span style="text-decoration: none"><font size="2" style="font-size: 9pt">Supplemental
Appendix</font></span></font></a><font size="2" style="font-size: 9pt">.
Comprehensive disclosure information for the Joint Committee is also
available&nbsp;</font><a href="http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIR.0000000000001038"><font color="#2b7bb9"><span style="text-decoration: none"><font size="2" style="font-size: 9pt">online</font></span></font></a><font size="2" style="font-size: 9pt">.</font></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>Evidence
Review and Evidence Review Committees</b></font></font></h3>
<p style="line-height: 0.11in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">In
developing recommendations, the writing committee uses evidence-based
methodologies that are based on all available data.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R4"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">4</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R5"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">5</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Literature
searches focus on randomized controlled trials (RCTs) but also
include registries, nonrandomized comparative and descriptive
studies, case series, cohort studies, systematic reviews, and expert
opinion. Only key references are cited.</font></p>
<p style="line-height: 100%"><font size="2" style="font-size: 9pt">An
independent evidence review committee is commissioned when there are
≥1 questions deemed of utmost clinical importance and merit formal
systematic review to determine which patients are most likely to
benefit from a drug, device, or treatment strategy, and to what
degree. Criteria for commissioning an evidence review committee and
formal systematic review include absence of a current authoritative
systematic review, feasibility of defining the benefit and risk in a
time frame consistent with the writing of a guideline, relevance to a
substantial number of patients, and likelihood that the findings can
be translated into actionable recommendations. Evidence review
committee members may include methodologists, epidemiologists,
clinicians, and biostatisticians. Recommendations developed by the
writing committee on the basis of the systematic review are
marked.“SR”</font></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>Guideline-Directed
Management and Therapy</b></font></font></h3>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">The
term guideline-directed medical therapy (GDMT) encompasses clinical
evaluation, diagnostic testing, and both pharmacological and
procedural treatments. For these and all recommended drug treatment
regimens, the reader should confirm dosage with product insert
material and evaluate for contraindications and interactions.
Recommendations are limited to drugs, devices, and treatments
approved for clinical use in the United States.</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt"><i>Patrick
T. O’Gara, MD, MACC, FAHA</i></font></p>
<p style="line-height: 0.18in"><font size="2" style="font-size: 9pt"><i>Chair,
ACC/AHA Joint Committee on Clinical Practice Guidelines</i></font></p>
<h2 class="western" align="left" style="line-height: 0.22in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="3" style="font-size: 11pt"><b>1.
Introduction</b></font></font></h2>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>1.1.
Methodology and Evidence Review</b></font></font></h3>
<p style="line-height: 0.18in"><font size="2" style="font-size: 9pt">The
recommendations listed in this guideline are, whenever possible,
evidence based. An initial extensive evidence review, which included
literature derived from research involving human subjects, published
in English, and indexed in the US National Library of Medicine and
the National Center for Biotechnology information (through PubMed),
EMBASE, the Cochrane Collaboration, CINHL Complete, and other
selected databases relevant to this guideline, was conducted from May
2019 to September 2019. Key search words included but were not
limited to the following:&nbsp;</font><font size="2" style="font-size: 9pt"><i>percutaneous
coronary intervention, angioplasty, coronary artery bypass graft
(CABG) surgery, myocardial infarction, cardiac surgery, stent(s),
angiogram, angiography, percutaneous transluminal coronary
angioplasty, coronary atherosclerosis, saphenous vein graft, internal
mammary artery (IMA) graft, internal thoracic artery graft, arterial
graft, post-bypass, non-ST elevated myocardial infarction, vein graft
lesions, myocardial revascularization, multivessel PCI</i></font><font size="2" style="font-size: 9pt">,
and&nbsp;</font><font size="2" style="font-size: 9pt"><i>left
ventricular dysfunction</i></font><font size="2" style="font-size: 9pt">.
Additional relevant studies, published through May 2021 during the
guideline writing process, were also considered by the writing
committee and added to the evidence tables when appropriate. The
final evidence tables are included in the&nbsp;</font><a href="http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIR.0000000000001038"><font color="#2b7bb9"><span style="text-decoration: none"><font size="2" style="font-size: 9pt">Online
Data Supplement</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
summarize the evidence used by the writing committee to formulate
recommendations. References selected and published in the present
document are representative and not all-inclusive.</font></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>1.2.
Organization of the Writing Committee</b></font></font></h3>
<p style="line-height: 0.18in"><font size="2" style="font-size: 9pt">The
writing committee consisted of clinicians, general cardiologists,
interventional cardiologists, cardiac surgeons, a cardiac
anesthesiologist, an advanced nurse practitioner, and 2 lay/patient
representatives. The writing committee included representatives from
the ACC, AHA, Society for Cardiovascular Angiography and
Interventions (SCAI), American Association for Thoracic Surgery, and
Society of Thoracic Surgeons (STS). Appendix 1 of the present
document lists writing committee members’ relevant RWI. For the
purposes of full transparency, the writing committee members’
comprehensive disclosure information is available in a&nbsp;</font><a href="http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIR.0000000000001038"><font color="#2b7bb9"><span style="text-decoration: none"><font size="2" style="font-size: 9pt">Supplemental
Appendix</font></span></font></a><font size="2" style="font-size: 9pt">.</font></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>1.3.
Document Review and Approval</b></font></font></h3>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">This
document was reviewed by 2 official reviewers each nominated by the
ACC and AHA; 1 reviewer each from the ACC, AHA, STS, American
Association for Thoracic Surgery, and SCAI; and 31 individual content
reviewers. Reviewers’ RWI information was distributed to the
writing committee and is published in Appendix 2.</font></p>
<p style="line-height: 0.18in"><font size="2" style="font-size: 9pt">The
present document was approved for publication by the governing bodies
of the ACC, AHA, and SCAI.</font></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>1.4.
Scope of the Guideline</b></font></font></h3>
<p style="line-height: 0.11in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">The
scope of the “2021 ACC/AHA/SCAI Guideline for Coronary Artery
Revascularization” is to provide an update to and to consolidate
the 2011 coronary artery bypass graft (CABG) surgery</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R8"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
the 2011 and 2015 percutaneous coronary intervention (PCI)
guidelines,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R9"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">2</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R10"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">3</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;with
the added consideration of using a patient-centric disease approach.
The applicable sections on revascularization from the 2012 stable
ischemic heart disease (SIHD) guideline,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R11"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">4</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;as
well as the 2013 ST-segment–elevation myocardial infarction
(STEMI)</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R12"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">5</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
2014 non–ST-segment–elevation myocardial infarction (NSTEMI)
guidelines,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R13"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">6</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;will
also be updated. This present guideline will affect the following
documents:</font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">1.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Replace/retire
the 2011 PCI guideline.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R9">2</span></font></span></font></a></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">2.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Replace/retire
the 2011 CABG guideline.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R8">1</span></font></span></font></a></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">3.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Replace/retire
the 2015 update in PCI in STEMI guideline.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R10">3</span></font></span></font></a></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">4.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Replace/retire
the 2013 STEMI guideline, Sections 4.1, 4.2, 4.3, 4.4, 5.3 (deals
with transfer after lytic with intent to do PCI), 6.2, 6.4, 7.1, and
7.2.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R12">5</span></font></span></font></a></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">5.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Replace/retire
2014 non–ST-segment–elevation acute coronary syndrome (NSTE-ACS)
guideline, Sections 4.4.4, 5.1.1, 5.1.2.1, 5.1.2.2, 5.1.2.3, and
5.2.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R13">6</span></font></span></font></a></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">6.</span></font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Replace/retire
the 2012 SIHD guideline, Section 5.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R11">4</span></font></span></font></a></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">The
intended primary target audience consists of cardiovascular
clinicians who are involved in the care of patients for whom
revascularization is considered or indicated. Coronary artery disease
(CAD) is to be approached with the most current treatment options and
treated as a “condition.” Recommendations are stated in reference
to the patients and their condition. The focus is to provide the most
up-to-date evidence to inform the clinician during shared
decision-making with the patient. Although the document is not
intended to be a procedural-based manual of recommendations that
outlines the best practice for coronary revascularization, there are
certain techniques that surgeons or interventional cardiologists
might use that are associated with improved clinical outcomes.</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">In
developing the 2021 coronary artery revascularization guideline, the
writing committee reviewed previously published guidelines and
related statements.&nbsp;</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/t1.xhtml"><font color="#2b7bb9"><span style="text-decoration: none"><font size="2" style="font-size: 9pt">Table
1</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;contains
a list of these publications and statements deemed pertinent to this
writing effort and is intended for use as a resource, thus obviating
the need to repeat existing guideline recommendations.</font></p>
<p style="line-height: 0.14in; margin-bottom: 0in"><font color="#d93731"><font size="1" style="font-size: 8pt"><b>Table
1</b></font></font>. Associated Guidelines and Statements&nbsp;<font size="1" style="font-size: 8pt">(</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/t1.xhtml"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt">Table
view</font></span></font></a><font size="1" style="font-size: 8pt">)</font></p>
<table cellpadding="2" cellspacing="2">
	<thead>
		<tr>
			<th style="border: 1px solid #2c2e35; padding: 0.02in"><p style="font-weight: normal">
				Title</p>
			</th>
			<th style="border: 1px solid #2c2e35; padding: 0.02in"><p style="font-weight: normal">
				Organization</p>
			</th>
			<th style="border: 1px solid #2c2e35; padding: 0.02in"><p style="font-weight: normal">
				Publication Year (Reference)</p>
			</th>
		</tr>
	</thead>
	<tbody>
		<tr>
			<td colspan="3" style="border: 1px solid #2c2e35; padding: 0.02in"><p>
				<font size="1" style="font-size: 8pt">Guidelines</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p> <font size="1" style="font-size: 8pt">2017
				AHA/ACC/HRS Guideline for Management of Patients With Ventricular
				Arrhythmias and the Prevention of Sudden Cardiac Death</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">AHA/ACC/HRS</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">2017</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R14"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">7</font></span></font></a></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p> <font size="1" style="font-size: 8pt">2020
				ACC/AHA Guideline for the Management of Patients With Valvular
				Heart Disease</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">ACC/AHA</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">2020</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R15"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">8</font></span></font></a></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p> <font size="1" style="font-size: 8pt">2019
				ACC/AHA Guideline on the Primary Prevention of Cardiovascular
				Disease</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">ACC/AHA</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">2019</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R16"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">9</font></span></font></a></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p> <font size="1" style="font-size: 8pt">2016
				ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet
				Therapy in Patients With Coronary Artery Disease: A Report of the
				American College of Cardiology/American Heart Association Task
				Force on Clinical Practice Guidelines: An Update of the 2011
				ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention,
				2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery,
				2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis
				and Management of Patients With Stable Ischemic Heart Disease,
				2013 ACCF/AHA Guideline for the Management of ST-Elevation
				Myocardial Infarction, 2014 AHA/ACC Guideline for the Management
				of Patients With Non–ST-Elevation Acute Coronary Syndromes, and
				2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation
				and Management of Patients Undergoing Noncardiac Surgery</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">ACC/AHA</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">2016</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R17"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">10</font></span></font></a></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p> <font size="1" style="font-size: 8pt">2018
				AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline
				on the Management of Blood Cholesterol</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">2019</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R18"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">11</font></span></font></a></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p> <font size="1" style="font-size: 8pt">2018
				AHA/ACC Guideline for the Management of Adults With Congenital
				Heart Disease</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">AHA/ACC</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">2019</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R19"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">12</font></span></font></a></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p> <font size="1" style="font-size: 8pt">2014
				AHA/ACC/HRS Guideline for the Management of Patients With Atrial
				Fibrillation</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">AHA/ACC/HRS</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">2014</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R20"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">13</font></span></font></a></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p> <font size="1" style="font-size: 8pt">Focused
				Update of the 2014 AHA/ACC/HRS Guideline for the Management of
				Patients With Atrial Fibrillation</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">AHA/ACC/HRS</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">2019</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R21"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">14</font></span></font></a></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p> <font size="1" style="font-size: 8pt">ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS
				2013 Multimodality Appropriate Use Criteria for the Detection and
				Risk Assessment of Stable Ischemic Heart Disease</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">2014</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R22"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">15</font></span></font></a></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p> <font size="1" style="font-size: 8pt">ACC/AHA/SCAI
				Focused Update on Primary Percutaneous Coronary Intervention for
				Patients With ST-Elevation Myocardial Infarction: An Update of
				the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary
				Intervention and the 2013 ACCF/AHA Guideline for the Management
				of ST-Elevation Myocardial Infarction<br/>
  </font><font size="1" style="font-size: 8pt"><i>Levine
				et al., 2016 ACC/AHA/SCAI Focused Update on Primary Percutaneous
				Coronary Intervention for Patients With ST-Elevation Myocardial
				Infarction, is now replaced and retired by the present 2021
				guideline.</i></font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">ACC/AHA</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">2016</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R10"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">3</font></span></font></a></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p> <font size="1" style="font-size: 8pt">2014
				AHA/ACC Guideline for the Management of Patients With
				Non–ST-Elevation Acute Coronary Syndromes</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">AHA/ACC</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">2014</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R13"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">6</font></span></font></a></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p> <font size="1" style="font-size: 8pt">2013
				ACCF/AHA Guideline for the Management of ST-Elevation Myocardial
				Infarction: A Report of the American College of Cardiology
				Foundation/American Heart Association Task Force on Practice
				Guidelines</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">ACCF/AHA</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">2013</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R12"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">5</font></span></font></a></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p> <font size="1" style="font-size: 8pt">2013
				ACCF/AHA Guideline for the Management of Heart Failure</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">ACCF/AHA</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">2013</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R23"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">16</font></span></font></a></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p> <font size="1" style="font-size: 8pt">2017
				ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for
				the Management of Heart Failure</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">ACC/AHA/HFSA</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">2017</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R24"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">17</font></span></font></a></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p> <font size="1" style="font-size: 8pt">2011
				ACCF/AHA Guideline for Coronary Artery Bypass Graft
				Surgery<br/>
  </font><font size="1" style="font-size: 8pt"><i>Hillis
				et al., 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft
				Surgery, is now replaced and retired by the present 2021
				guideline.</i></font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">ACCF/AHA</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">2011</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R8"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1</font></span></font></a></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p> <font size="1" style="font-size: 8pt">2011
				ACCF/AHA/SCAI Guideline for Percutaneous Coronary
				Intervention<br/>
  </font><font size="1" style="font-size: 8pt"><i>Levine
				et al., 2013 ACCF/AHA/SCAI Guideline for Percutaneous Coronary
				Intervention, is now replaced and retired by the present 2021
				guideline.</i></font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">ACCF/AHA/SCAI</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">2013</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R9"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">2</font></span></font></a></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p> <font size="1" style="font-size: 8pt">2017
				AHA/ACC/HRS Guideline for Management of Patients With Ventricular
				Arrhythmias and the Prevention of Sudden Cardiac Death</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">AHA/ACC/HRS</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">2018</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R14"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">7</font></span></font></a></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p> <font size="1" style="font-size: 8pt">2017
				ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for
				the Prevention, Detection, Evaluation, and Management of High
				Blood Pressure in Adults</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">2018</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R25"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">18</font></span></font></a></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p> <font size="1" style="font-size: 8pt">2012
				ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and
				Management of Patients with Stable Ischemic Heart Disease</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">ACCF/AHA/ACP/AATS/PCNA/SCAI/STS</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">2012</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R11"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">4</font></span></font></a></p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="border: 1px solid #2c2e35; padding: 0.02in"><p>
				<font size="1" style="font-size: 8pt">Statements</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p> <font size="1" style="font-size: 8pt">2018
				ACC Expert Consensus Decision Pathway on Tobacco Cessation
				Treatment</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">ACC</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">2018</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R26"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">19</font></span></font></a></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p> <font size="1" style="font-size: 8pt">Clinical
				Practice Guideline Treating Tobacco Use and Dependence 2008
				Update Panel, Liaisons, and Staff: A Clinical Practice Guideline
				for Treating Tobacco Use and Dependence: 2008 Update: A US Public
				Health Service Report</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">US
				Public Health Service report</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">2008</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R27"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">20</font></span></font></a></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p> <font size="1" style="font-size: 8pt">AATS
				Expert Consensus Review on Prevention and Management of Sternal
				Wound Infections</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">AATS</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">2016</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R28"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">21</font></span></font></a></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p> <font size="1" style="font-size: 8pt">2018
				ACC/AHA Clinical Performance and Quality Measures for Cardiac
				Rehabilitation</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">ACC/AHA</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">2018</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R29"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">22</font></span></font></a></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p> <font size="1" style="font-size: 8pt">Spontaneous
				Coronary Artery Dissection: Current State of the Science</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">AHA</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">2018</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R30"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">23</font></span></font></a></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p> <font size="1" style="font-size: 8pt">Contemporary
				Management of Cardiogenic Shock</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">AHA</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">2017</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R31"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">24</font></span></font></a></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p> <font size="1" style="font-size: 8pt">Secondary
				Prevention After Coronary Artery Bypass Graft Surgery: A
				Scientific Statement From the American Heart Association</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">AHA</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">2015</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R32"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">25</font></span></font></a></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p> <font size="1" style="font-size: 8pt">Pharmacologic
				Approaches to Glycemic Treatment: Standards of Medical Care in
				Diabetes—2018</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">ADA</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">2018</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R33"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">26</font></span></font></a></p>
			</td>
		</tr>
	</tbody>
</table>
<p align="justify" style="line-height: 0.13in"><font size="1" style="font-size: 7pt">AACVPR
indicates American Association of Cardiovascular and Pulmonary
Rehabilitation; AAPA, American Association of Physician Assistants;
AATS, American Association for Thoracic Surgery; ABC, Association of
Black Cardiologists; ACC, American College of Cardiology; ACCF,
American College of Cardiology Foundation; ACP, American College of
Physicians; ACPM, American College of Preventive Medicine; ADA,
American Diabetes Association; AGS, American Geriatrics Society; AHA,
American Heart Association; APhA, American Public Health Association;
ASE, American Society of Echocardiography; ASH, American Society of
Hypertension; ASNC, American Society of Nuclear Cardiology; ASPC,
American Society for Preventive Cardiology; HFSA, Heart Failure
Society of America; HRS, Heart Rhythm Society; NLA, National Lipid
Association; NMA, National Medical Association; PCNA, Preventive
Cardiovascular Nurses Association; SCAI, Society for Cardiovascular
Angiography and Interventions; SCCT, Society of Cardiovascular
Computed Tomography; SCMR, Society for Cardiovascular Magnetic
Resonance; and STS, Society of Thoracic Surgeons.</font></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>1.5.
Class of Recommendation and Level of Evidence</b></font></font></h3>
<p style="line-height: 0.11in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">The
Class of Recommendation (COR) indicates the strength of
recommendation, encompassing the estimated magnitude and certainty of
benefit in proportion to risk. The Level of Evidence (LOE) rates the
quality of scientific evidence supporting the intervention on the
basis of the type, quantity, and consistency of data from clinical
trials and other sources (</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/t2.xhtml"><font color="#2b7bb9"><span style="text-decoration: none"><font size="2" style="font-size: 9pt">Table
2</font></span></font></a><font size="2" style="font-size: 9pt">).</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R34"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1</font></span></font></a></p>
<p style="line-height: 0.14in"><font color="#d93731"><font size="1" style="font-size: 8pt"><b>Table
2</b></font></font>. Applying American College of Cardiology/American
Heart Association Class of Recommendation and Level of Evidence to
Clinical Strategies, Interventions, Treatments, or Diagnostic Testing
in Patient Care (Updated May 2019)&nbsp;<font size="1" style="font-size: 8pt">(</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/t2.xhtml"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt">Table
view</font></span></font></a><font size="1" style="font-size: 8pt">)</font><font color="#2b7bb9"><span style="text-decoration: none"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/t2.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.tab02.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image2" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</span></font></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>1.6.
Abbreviations</b></font></font></h3>
<table cellpadding="2" cellspacing="2">
	<thead>
		<tr>
			<th style="border: 1px solid #2c2e35; padding: 0.02in"><p style="font-weight: normal">
				Abbreviation</p>
			</th>
			<th style="border: 1px solid #2c2e35; padding: 0.02in"><p style="font-weight: normal">
				Meaning/Phrase</p>
			</th>
		</tr>
	</thead>
	<tbody>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">ACS</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">acute
				coronary syndrome</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">AKI</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">acute
				kidney injury</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">AMI</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">acute
				myocardial infarction</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">AVR</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">aortic
				valve replacement</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">BIMA</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">bilateral
				internal mammary artery</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">BMS</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">bare-metal
				stent</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">CABG</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">coronary
				artery bypass graft</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">CAD</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">coronary
				artery disease</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">CKD</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">chronic
				kidney disease</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">COR</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Class
				of Recommendation</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">CTO</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">chronic
				total occlusion</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">CVD</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">cardiovascular
				disease</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">DAPT</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">dual
				antiplatelet therapy</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">DES</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">drug-eluting
				stent</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">ECG</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">electrocardiogram</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">FFR</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">fractional
				flow reserve</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">GDMT</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">guideline-directed
				medical therapy</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">iFR</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">instantaneous
				wave-free ratio</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">IMA</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">internal
				mammary artery</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">ISR</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">in-stent
				restenosis</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">IVUS</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">intravascular
				ultrasound</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">LAD</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">left
				anterior descending</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">LIMA</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">left
				internal mammary artery</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">LOE</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Level
				of Evidence</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">MACE</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">major
				adverse cardiovascular events</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">MI</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">myocardial
				infarction</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">NSTE-ACS</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">non–ST-segment–elevation
				acute coronary syndrome</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">NSTEMI</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">non–ST-segment–elevation
				myocardial infarction</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">OCT</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">optical
				coherence tomography</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">PCI</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">percutaneous
				coronary intervention</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">RCT</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">randomized
				controlled trial</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">SCAD</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">spontaneous
				coronary artery dissection</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">SIHD</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">stable
				ischemic heart disease</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">STEMI</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">ST-segment–elevation
				myocardial infarction</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">SVG</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">saphenous
				vein graft</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">SYNTAX</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Synergy
				Between PCI With TAXUS and Cardiac Surgery</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">TAVR</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">transcatheter
				aortic valve replacement</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">UFH</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">unfractionated
				heparin</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">VT</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">ventricular
				tachycardia</font></p>
			</td>
		</tr>
	</tbody>
</table>
<h2 class="western" align="left" style="line-height: 0.22in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="3" style="font-size: 11pt"><b>2.
Improving Equity of Care in Revascularization and Shared
Decision-Making</b></font></font></h2>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>2.1.
Improving Equity of Care in Revascularization</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu1.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab01.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image3" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">Health
disparities by sex and race are evident across the spectrum of CVD in
the United States,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R41"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">7</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R43"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">9</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R47"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">13-15</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
mounting evidence demonstrates that social factors are strongly
associated with cardiovascular health outcomes.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R50"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">16</font></span></font></a><font size="2" style="font-size: 9pt">,&nbsp;</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R51"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">17</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Differences
in access to care, cardiovascular treatment, mortality rate, and
readmission outcomes persist by important sociodemographic
characteristics that include but are not limited to socioeconomic
status, race, and ethnicity.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R52"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">18-22</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;African
Americans,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R57"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">23-25</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Hispanics,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R58"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">24</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
South Asians</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R60"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">26</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;(with
substantial heterogeneity within Asian subgroups) have a higher
prevalence of cardiovascular risk factors and crude
mortality.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R50"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">16</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Although
access to health care remains a problem, even after entering into the
health care system, women and non-White patients are less likely to
receive reperfusion therapy, an invasive strategy, or
revascularization</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R43"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">9</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R47"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">13</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R61"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">27-37</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
more likely to have worse outcomes.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R71"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">37-40</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;As
compared with White male patients, women and Black patients with
acute coronary syndrome (ACS) receive less guideline-based therapy in
hospital and at discharge.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R61"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">27</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R66"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">32</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R75"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">41</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R76"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">42</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Differences
in comorbidities, health education, presentation, socioeconomic
status, regional hospital capability and quality, and insurance and
health care access</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R49"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">15</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R62"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">28</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R63"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">29</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R69"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">35</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R71"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">37</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R77"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">43-48</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;contribute
to the problem, but disparities can persist despite adjustment for
these factors.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R41"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">7</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R64"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">30-32</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R83"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">49</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R84"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">50</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
a study of patients with cardiac symptoms, clinicians were less
likely to recommend cardiac catheterization to women and non-White
patients than to White male patients, despite being given the exact
same clinical vignette for White male patients.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R85"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">51</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Continued
vigilance against conscious and unconscious gender, racial, and
ethnic discrimination and purposeful efforts to increase the
implementation of guideline-based therapy for all patients,
regardless of sex, race, or ethnicity, are needed.</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supportive Text</b></i></font></font></h4>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">After
controlling for greater baseline comorbidities among patients
undergoing revascularization, several observational studies have
demonstrated that Black,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R62"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">28</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R86"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">52-54</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Hispanic,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R58"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">24</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R84"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">50</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
Asian</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R89"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">55</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R90"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">56</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;patients
have outcomes similar to those of White patients. Similarly, after
controlling for baseline comorbidities and treatment strategy, most
studies demonstrate similar outcomes in women and men.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R34"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1-6</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Post
hoc analyses of randomized trials evaluating revascularization
provide compelling evidence, inasmuch as enrolled patients are more
similar and the decision to revascularize is protocol driven. In the
SHOCK (Should We Emergently Revascularize Occluded Coronaries for
Cardiogenic Shock) trial, revascularization rates were lowest and
mortality rates highest for Hispanics and African Americans, but
there was no interaction between race and the mortality benefit of
revascularization.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R43"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">9</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Similar
results have been reported for women with shock in the CULPRIT-SHOCK
(Culprit Lesion Only PCI versus Multivessel PCI in Cardiogenic Shock
trial.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R91"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">57</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
the TACTICS-TIMI 18 (Treat Angina With Aggrastat and Determine Cost
of Therapy With Invasive or Conservative Strategy—Thrombolysis In
Myocardial Infarction 18) trial, evaluating patients with NSTE-ACS,
non-White patients and female patients had more comorbidity and more
major adverse cardiovascular event (MACE) outcomes than White and
male patients but were revascularized at the same rate. After
adjustment for baseline characteristics, the invasive strategy was
equally beneficial for all patients, without evidence of racial
differences.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R44"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">10</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;A
meta-analysis of RCT of invasive vs conservative strategies in women
and men with NSTE-ACS reported a similar proportional benefit of an
invasive strategy in women and men, (although low risk women with
biomarker negative ACS did not derive a benefit to an early invasive
strategy).</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R34"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Additionally,
studies have shown similar relative benefits of primary PCI</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R37"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">3</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
revascularization in SIHD.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R39"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">5</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R40"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">6</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;for
women and men. In view of these findings, the decision to offer
revascularization should be made on the basis of a patient’s
clinical characteristics, and preferences and should be the same for
all patients, regardless of sex, race, or ethnicity.</font></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>2.2.
Shared Decision-Making and Informed Consent</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu2.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab02.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image4" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">Shared
decision-making (</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/f1.xhtml"><font color="#2b7bb9"><span style="text-decoration: none"><font size="2" style="font-size: 9pt">Figure
1</font></span></font></a><font size="2" style="font-size: 9pt">) is
a collaborative approach that provides patients with unbiased,
evidence-based information on treatment choices and encourages a
dialogue between patients and providers, with the aim of making
decisions that use scientific evidence and align with the patient’s
values and preferences.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R94"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">3</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R95"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">4</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R97"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">6</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;It
is essential that the clinician use terminology that the patient
understands to allow effective processing of health information and
to foster the patient’s participation in treatment decisions.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R98"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">7</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
use of online modules, decision aids, or videos about treatment
options can help patients better understand the risks and benefits of
various therapies. Patients are interested in how a recommended
treatment might impact their prognosis and quality of life.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R99"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">8</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
the treatment decision-making process, the patient’s best interest
should be placed first, and the active participation of the patient
and significant others should be engaged. The contributions of social
determinants of health to CVD are poorly understood.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R100"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">9</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R101"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">10</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;but
may impact a patient’s decision with regard to treatments. In
high-income countries, 4 socioeconomic status metrics have been
associated with CVD: income level, educational attainment, employment
status, and environmental factors.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R102"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">11-13</font></span></font></a></p>
<p style="line-height: 0.14in"><font color="#2b7bb9"><span style="text-decoration: none"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/f1.xhtml">
  <font color="#2c2e35">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.fig01.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image5" align="bottom" width="92" height="44" border="1"/>
  </font>
</a>
</span></font><font color="#d93731"><font size="1" style="font-size: 8pt"><b>Figure
1</b></font></font>. Shared Decision-Making Algorithm.</p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supportive Text</b></i></font></font></h4>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">1.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Shared
decision-making is vital to patient-centered care. Shared
decision-making improves patients’ understanding of treatment
options, increases realistic expectations of benefits and harms,
stimulates engagement in decision-making, and improves concordance
between patients’ values and treatment choices.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R105">14-17</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Factors
complicating effective shared decision-making include low health
literacy, adverse social determinants of health, cultural beliefs,
language barriers, advanced age, and complex comorbidities. Health
literacy is associated with socioeconomic position, English
proficiency, and the development of general literacy.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R109">18</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Incorporating
a patient’s preferences into the decision-making process improves
the patient’s well-being through better treatment adherence and
higher satisfaction with health outcomes.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R96">5</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R110">19</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R111">20</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;A
patient’s right to decline recommended treatments must be respected
and should be acknowledged in a written document after the patient
has received sufficient information from the Heart Team.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R99">8</span></font></span></font></a></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">2.</span></font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Patients
cannot engage in shared decision-making until they know the potential
benefits and risks of all treatment options. Clinicians must provide
evidence-based estimates of risks, benefits, and costs of therapeutic
options.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R99">8</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R112">21</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R113">22</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Procedure-related
and long-term risks and benefits, such as survival, quality of life,
and the need for late reintervention, should be included in such
discussions (</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="2" style="font-size: 9pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/t4.xhtml">Table
3</font></span></font></a><font size="2" style="font-size: 9pt">).</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R99">8</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Patients
should also be educated about the need for continued medical therapy
with or without revascularization, as well as lifestyle modification
and other secondary prevention strategies.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R112">21</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R114">23</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
some situations, in which the optimal treatment strategy is
uncertain, it may be appropriate to defer revascularization to allow
time for consultation and discussion. The clinician must act in the
patient’s best interest and convey the risks and benefits of all
revascularization treatment options, consult with additional
specialists when appropriate, and allow the patient to consult
family.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R115">24</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R116">25</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Challenges
exist when scientific data support a treatment, but the patient
prefers an alternative treatment; in 1 study, patients preferred PCI
over CABG, even when the risk of death with PCI was double the risk
with CABG.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R117">26</span></font></span></font></a></p>
<p style="line-height: 0.14in; margin-bottom: 0in"><font color="#d93731"><font size="1" style="font-size: 8pt"><b>Table
3</b></font></font>. Ideal Components of the Shared Decision-Making
and Informed Consent Process&nbsp;<font size="1" style="font-size: 8pt">(</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/t3.xhtml"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt">Table
view</font></span></font></a><font size="1" style="font-size: 8pt">)</font></p>
<table cellpadding="2" cellspacing="2">
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Patient-Centered
			Care</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Assess
			a patient’s ability to understand complex health information</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Seek
			support of family/others</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Elicit
			and respect cultural, racial, ethnic, or religious preferences and
			values</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Evaluate
			social determinants of health (education, income, access to health
			care)</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Improve
			telephone/telemedicine access</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Discuss
			treatment alternatives and how each affects the patient’s
			quality of life</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Shared
			Decision-Making</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Encourage
			questions and explain the patient’s role in the decision-making
			partnership</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Clearly
			and accurately communicate the potential risks and benefits of a
			particular procedure and alternative treatments</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Ensure
			that patients have a key role in deciding what revascularization
			approach is appropriate</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Use
			shared decision aids:<br/>
 Alphabetical List of Decision Aids
			by Health Topic, Ottawa Hospital Research Institute
			(</font><a href="https://decisionaid.ohri.ca/implement.html"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt">https://decisionaid.ohri.ca/implement.html</font></span></font></a><font size="1" style="font-size: 8pt">)</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R118"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">27</font></span></font></a><font size="1" style="font-size: 8pt"><br/>
 SHARE
			Approach Curriculum Tools, Agency for Health care Research and
			Quality
			(</font><a href="https://www.ahrq.gov/health-literacy/curriculum-tools/shareddecisionmaking/tools/tool-1/index.html"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt">https://www.ahrq.gov/health-literacy/curriculum-tools/shareddecisionmaking/tools/tool-1/index.html</font></span></font></a><font size="1" style="font-size: 8pt">)</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R119"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">28</font></span></font></a></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Spend
			sufficient time to engage in shared decision-making; allow for a
			second opinion</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Work
			with a chaplain, social worker, or other team members to
			facilitate shared decision-making</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Encourage
			patients to share their fears, stress, or other emotions, and
			address appropriately</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Negotiate
			decision in partnership with the patient and family members</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Respect
			patient’s autonomy to decline recommended treatment</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Consent
			Procedures</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Use
			plain language, avoiding jargon, and adopt the patient’s words;
			integrate pictures to teach</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Document
			teach-back of patient’s knowledge and understanding</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Conduct
			conversations with a trained interpreter, as needed</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Provide
			patient-specific short- and long-term risks, benefits, and
			alternative treatments</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Provide
			unbiased, evidence-based, reliable, accessible, and relevant
			information to patient</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Discuss
			specific risks and benefits with regard to survival, relief of
			angina, quality of life, and potential additional intervention, as
			well as uncertainties associated with different treatment
			strategies</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Provide
			patient time to reflect on the trade-offs imposed by the outcome
			estimates</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Provide
			information on the level of operator expertise, volume of the
			facility, and local results in the performance of coronary
			revascularization options</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Clearly
			inform of the need for continued medical therapy and lifestyle
			modifications</font></p>
		</td>
	</tr>
</table>
<p style="line-height: 0.14in; margin-bottom: 0in"><font color="#d93731"><font size="1" style="font-size: 8pt"><b>Table
4</b></font></font>. Factors for Consideration by the Heart
Team&nbsp;<font size="1" style="font-size: 8pt">(</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/t4.xhtml"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt">Table
view</font></span></font></a><font size="1" style="font-size: 8pt">)</font></p>
<table cellpadding="2" cellspacing="2">
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Coronary
			Anatomy</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Left
			main disease</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Multivessel
			disease</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">High
			anatomic complexity (ie, bifurcation disease, high SYNTAX score)</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Comorbidities</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Diabetes</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Systolic
			dysfunction</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Coagulopathy</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Valvular
			heart disease</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Frailty</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Malignant
			neoplasm</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">End-stage
			renal disease</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Chronic
			obstructive pulmonary disease</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Immunosuppression</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Debilitating
			neurological disorders</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Liver
			disease/cirrhosis</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Prior
			CVA</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Calcified/porcelain
			aorta</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Aortic
			aneurysm</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Procedural
			Factors</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Local
			and regional outcomes</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Access
			site for PCI</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Surgical
			risk</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">PCI
			risk</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Patient
			Factors</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Unstable
			presentation or shock</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Patient
			preferences</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Inability
			or unwillingness to adhere to DAPT</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Patient
			social support</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Religious
			beliefs</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Patient
			education, knowledge, and understanding</font></p>
		</td>
	</tr>
</table>
<p align="justify" style="line-height: 0.13in"><font size="1" style="font-size: 7pt">CVA
indicates cerebrovascular accident; DAPT, dual antiplatelet therapy;
PCI, percutaneous coronary intervention; and SYNTAX, Synergy Between
PCI With TAXUS and Cardiac Surgery.</font></p>
<h2 class="western" align="left" style="line-height: 0.22in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="3" style="font-size: 11pt"><b>3.
Preprocedural Assessment and the Heart Team</b></font></font></h2>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>3.1.
The Heart Team</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu3.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab03.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image6" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">The
multidisciplinary Heart Team, which involves the cardiologist,
cardiac surgeon, and other specialists, has become a critical
component of the revascularization decision. Initially, the Heart
Team approach to decision-making for coronary disease arose within
the context of randomized trials comparing PCI with CABG to ensure
selected patients were equally suited for either strategy before
randomization.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R127"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">8</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Subsequently,
the Heart Team has become an important paradigm in clinical practice,
emphasizing the importance of team consensus on the optimal approach
to revascularization. Ideal situations for Heart Team consideration
include patients with complex coronary disease, comorbid conditions
that could impact the success of the revascularization strategy, and
other clinical or social situations that may impact outcomes (</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/f2.xhtml"><font color="#2b7bb9"><span style="text-decoration: none"><font size="2" style="font-size: 9pt">Figure
2</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and&nbsp;</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/t5.xhtml"><font color="#2b7bb9"><span style="text-decoration: none"><font size="2" style="font-size: 9pt">Table
4</font></span></font></a><font size="2" style="font-size: 9pt">).
The Heart Team process should rest on the principles of collegiality,
mutual respect, and commitment to excellence. The logistics of
convening the Heart Team should depend on local resources and
workflows. Models include daily to weekly scheduled meetings and ad
hoc activation.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R120"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R121"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">2</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R123"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">4</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R125"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">6</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R128"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">9</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Remote
conferences have also been advocated.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R128"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">9</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Additionally,
there should be a process for rapid activation of the Heart Team for
urgent or emergency clinical situations.</font></p>
<p style="line-height: 0.14in; margin-bottom: 0in"><font color="#d93731"><font size="1" style="font-size: 8pt"><b>Table
5</b></font></font>. Assessment of Risk Factors Not Quantified in the
STS Score&nbsp;<font size="1" style="font-size: 8pt">(</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/t5.xhtml"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt">Table
view</font></span></font></a><font size="1" style="font-size: 8pt">)</font></p>
<table cellpadding="2" cellspacing="2">
	<thead>
		<tr>
			<th style="border: 1px solid #2c2e35; padding: 0.02in"><p style="font-weight: normal">
				Risk Factor</p>
			</th>
			<th style="border: 1px solid #2c2e35; padding: 0.02in"><p style="font-weight: normal">
				Assessment Tool</p>
			</th>
		</tr>
	</thead>
	<tbody>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Cirrhosis</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Model
				for End-Stage Liver Disease (MELD) score</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R131"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1-6</font></span></font></a></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Frailty</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Gait
				speed</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R138"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">8</font></span></font></a><font size="1" style="font-size: 8pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R140"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">10-14</font></span></font></a><font size="1" style="font-size: 8pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R146"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">16</font></span></font></a></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Malnutrition</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Malnutrition
				Universal Screening Tool (MUST)</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R137"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">7</font></span></font></a><font size="1" style="font-size: 8pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R139"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">9</font></span></font></a><font size="1" style="font-size: 8pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R145"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">15</font></span></font></a><font size="1" style="font-size: 8pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R146"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">16</font></span></font></a></p>
			</td>
		</tr>
	</tbody>
</table>
<p align="justify" style="line-height: 0.13in; margin-bottom: 0in"><font size="1" style="font-size: 7pt">STS
indicates Society of Thoracic Surgeons.</font></p>
<p style="line-height: 0.14in"><font color="#2b7bb9"><span style="text-decoration: none"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/f2.xhtml">
  <font color="#2c2e35">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.fig02.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image7" align="bottom" width="92" height="44" border="1"/>
  </font>
</a>
</span></font><font color="#d93731"><font size="1" style="font-size: 8pt"><b>Figure
2</b></font></font>.&nbsp;<b>Phases of Patient-Centric Care in the
Treatment of Coronary Artery Disease.</b>&nbsp;CV indicates
cardiovascular; SIHD, stable ischemic heart disease; and STEMI,
ST-segment–elevation myocardial infarction.</p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supporting Text</b></i></font></font></h4>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">1.</span></font></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Observational
studies using the Heart Team have included interventional cardiology,
cardiac surgery, and noninvasive cardiologists</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R120">1-4</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R125">6</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Additional
professionals who offer input may include the patient’s primary
physician, as well as palliative care, critical care, anesthesiology,
and imaging specialists. Observational studies have demonstrated
favorable outcomes when the Heart Team was used in cases of
unprotected left main disease, triple-vessel disease, double-vessel
disease involving the proximal left anterior descending (LAD) artery,
or single-vessel disease involving the proximal LAD artery in the
context of diabetes, or in cases in which the referring physician
requested such evaluation.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R124">5-7</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R129">10</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R130">11</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Heart
Team decisions are generally reproducible</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R123">4</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
associated with good outcomes.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R121">2</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R125">6</span></font></span></font></a></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>3.2.
Predicting Patient Risk of Death With CABG</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu4.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab04.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image8" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">The
STS risk score is designed to predict adverse outcomes in patients
undergoing CABG, including the risk of death, renal failure,
permanent stroke, prolonged ventilation, deep sternal wound
infection, reoperation, and prolonged length of stay. The STS risk
score is derived from data on patients undergoing CABG in the United
States. The STS score is periodically updated to reflect new risk
models for CABG, with the most recent update in 2018 based on the
Adult Cardiac Surgery Database from 2011–2014.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R133"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">3</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R134"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">4</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Similar
to the STS score, the European System for Cardiac Operative Risk
Evaluation (EuroSCORE) II, developed in 2011, is designed to predict
adverse outcomes in patients undergoing isolated CABG.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R135"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">5</font></span></font></a></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supporting Text</b></i></font></font></h4>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">1.</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">The
STS risk score has been validated in several studies and demonstrates
excellent predictive value for estimating risk of adverse
events.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R132">2-4</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
STS risk score serves as a useful tool when a choice is being made
among various treatment strategies because it allows the clinician,
the patient, and the patient’s family to have a reasonable estimate
of operative risk. The STS risk score performs better than the
EuroSCORE II for the patient population with CABG, particularly at
higher (&gt;5%) predicted mortality rates.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R131">1</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R132">2</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Commonly
used cardiac surgery risk models, such as the STS and EuroSCORE II,
are limited in assessing the influence of risk factors, including
cirrhosis, frailty, and malnutrition, on outcome. Patients with liver
cirrhosis, frailty, and malnutrition have increased risk of
perioperative morbidity and mortality after cardiac surgery</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R136">6-17</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
may be assessed by other tools (</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="2" style="font-size: 9pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/t6.xhtml">Table
5</font></span></font></a><font size="2" style="font-size: 9pt">).</span></font></p>
<p style="line-height: 0.14in; margin-bottom: 0in"><font color="#d93731"><font size="1" style="font-size: 8pt"><b>Table
6</b></font></font>. Angiographic Features Contributing to Increasing
Complexity of CAD&nbsp;<font size="1" style="font-size: 8pt">(</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/t6.xhtml"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt">Table
view</font></span></font></a><font size="1" style="font-size: 8pt">)</font></p>
<table cellpadding="2" cellspacing="2">
	<thead>
		<tr>
			<th style="border: 1px solid #2c2e35; padding: 0.02in"><p style="font-weight: normal">
				Multivessel disease</p>
			</th>
		</tr>
	</thead>
	<tbody>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Left
				main or proximal LAD artery lesion</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Chronic
				total occlusion</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Trifurcation
				lesion</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Complex
				bifurcation lesion</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Heavy
				calcification</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Severe
				tortuosity</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Aorto-ostial
				stenosis</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Diffusely
				diseased and narrowed segments distal to the lesion</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Thrombotic
				lesion</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Lesion
				length &gt;20 mm</font></p>
			</td>
		</tr>
	</tbody>
</table>
<p align="justify" style="line-height: 0.13in"><font size="1" style="font-size: 7pt">CAD
indicates coronary artery disease; and LAD, left anterior descending.</font></p>
<h2 class="western" align="left" style="line-height: 0.22in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="3" style="font-size: 11pt"><b>4.
Defining Lesion Severity</b></font></font></h2>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>4.1.
Angiography to Define Anatomy and Assess Lesion Severity</b></font></font></h3>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">Coronary
angiography remains the default method to define coronary anatomy and
characterize the severity of coronary arterial stenoses. A visually
estimated diameter stenosis severity of ≥70% for non–left main
disease and ≥50% for left main disease has been used to define
significant stenosis and to guide revascularization strategy.
Although the length of a lesion may contribute to physiological
lesion severity (ie, a longer moderate lesion may result in more
ischemia than a focal severe lesion), there are no standard cutoffs
for lesion length used to classify a severe stenosis. An
angiographically intermediate coronary stenosis is defined as a
diameter stenosis severity of 40% to 69%, and generally warrants
additional investigation to assess physiological significance. There
is controversy over whether visually estimated diameter stenosis or
quantitative coronary angiography better predicts the functional
significance of a coronary stenosis.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R148"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R149"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">2</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
difference in mean diameter stenosis between quantitative coronary
angiography and visual estimation varies from 10% to 20% and is
dependent on stenosis severity.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R150"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">3-5</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
use of optimal angiographic projections, multiple angiographic views,
and adjunct imaging or physiology may aid in the assessment of
coronary anatomy when coronary angiography is used.</font></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>4.2.
Defining Coronary Artery Lesion Complexity: Calculation of the SYNTAX
(Synergy Between PCI With TAXUS and Cardiac Surgery) Score</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu5.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab05.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image9" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">The
anatomic complexity of lesions, expected completeness of
revascularization, predicted risk of death, and other adverse
outcomes are important factors to consider for determining the type
of revascularization for patients with CAD. Many factors contribute
to the estimation of the complexity of CAD (</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/t7.xhtml"><font color="#2b7bb9"><span style="text-decoration: none"><font size="2" style="font-size: 9pt">Table
6</font></span></font></a><font size="2" style="font-size: 9pt">).
The SYNTAX score was prospectively derived from the SYNTAX trial to
aid in this decision-making process by providing an objective measure
to grade the anatomic complexity of CAD in patients with multivessel
disease.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R153"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Its
value as an independent predictor of long-term major adverse cardiac
and cerebrovascular events and death was established in the SYNTAX
trial cohort and subsequently validated in external studies of
patients treated with PCI but not CABG.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R154"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">2-4</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
SYNTAX II score and the revised SYNTAX Score II 2020 was
retrospectively developed from the SYNTAX trial cohort.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R157"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">5</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R158"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">6</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;to
incorporate clinical variables in addition to the anatomic variables.
These scores demonstrate modest discrimination in predicting adverse
clinical events after revascularization.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R158"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">6</font></span></font></a></p>
<p style="line-height: 0.14in; margin-bottom: 0in"><font color="#d93731"><font size="1" style="font-size: 8pt"><b>Table
7</b></font></font>. Patient Clinical Status Definitions to Guide
Revascularization<a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R238"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">13-15</font></span></font></a>&nbsp;<font size="1" style="font-size: 8pt">(</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/t7.xhtml"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt">Table
view</font></span></font></a><font size="1" style="font-size: 8pt">)</font></p>
<table cellpadding="2" cellspacing="2">
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Elective</font></p>
		</td>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">The
			patient’s cardiac function has been stable in the days or weeks
			before intervention (whether surgical or procedural). The
			intervention could be deferred without increased risk of
			compromise to cardiac outcome.</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Urgent</font></p>
		</td>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Intervention
			is required during the same hospitalization to minimize chance of
			further clinical deterioration. Examples include, but are not
			limited to, worsening sudden chest pain, heart failure, acute
			myocardial infarction, anatomy, intra-aortic balloon pump,
			unstable angina, with intravenous nitroglycerin, or rest angina.</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Emergency</font></p>
		</td>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Patients
			requiring emergency intervention will have ongoing, refractory
			(difficult, complicated, and/or unmanageable), unrelenting cardiac
			compromise, with or without hemodynamic instability, and not
			responsive to any form of therapy except cardiac intervention. An
			emergency intervention is one in which there should be no delay in
			providing operative intervention.</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Emergency/salvage</font></p>
		</td>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Patients
			requiring emergency/salvage intervention are those who require
			cardiopulmonary resuscitation en route to the operating room, or
			procedure room, before induction of anesthesia or who require
			extracorporeal membrane oxygenation to maintain life.</font></p>
		</td>
	</tr>
</table>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supporting Text</b></i></font></font></h4>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">1.</span></font></p>
<p style="line-height: 0.18in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">The
SYNTAX score remains the most widely used and validated risk score to
guide the choice of revascularization in patients with multivessel
disease. Important limitations of this score include the cumbersome
scoring system required for each lesion and the interobserver
variability in its calculation.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R159">7</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R160">8</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Additionally,
the absence of clinical variables limits its use in estimating the
risk of clinical events after CABG. When estimating a patient’s
complexity of disease, it is important to consider variables that
contribute to disease complexity which might impact the success and
outcomes of revascularization (</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="2" style="font-size: 9pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/t7.xhtml">Table
6</font></span></font></a><font size="2" style="font-size: 9pt">).</span></font></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>4.3.
Use of Coronary Physiology to Guide Revascularization With PCI</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu6.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab06.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image10" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">FFR
and iFR are 2 of the most commonly used physiological methods of
assessing lesion significance. FFR is defined as the ratio of maximal
blood flow in a region distal to a lesion compared with the normal
maximal blood flow of an artery. iFR, an index of lesion severity, is
the instantaneous wave-free ratio (in diastole) of coronary pressure
distal to the coronary lesion (Pd) to the aortic pressure (Pa) The
potential advantage of iFR, which is a resting physiological index,
is that it obviates the use of adenosine because it does not require
a state of maximal hyperemia. These 2 measures—FFR and iFR—have
been studied in randomized trials with clinical endpoints of death,
myocardial infarction (MI), or repeat revascularization.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R161"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1-5</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;There
are other resting indices that have been compared with iFR or FFR in
observational studies.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R169"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">9</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R170"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">10</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;These
resting indices have varying degrees of accuracy relative to FFR and
iFR but have not been studied in randomized trials with clinical
endpoints. The FAME 2 (Fractional Flow-Reserve-Guided PCI versus
Medical Therapy in Stable Coronary Disease) trial</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R162"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">2</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;tested
a strategy of PCI for all lesions with abnormal FFR compared with
optimal medical therapy alone. Recruitment into the trial was stopped
early because of a significant benefit of PCI over medical therapy in
patients with an abnormal FFR with respect to death, MI, or urgent
revascularization, with the benefit derived largely from a reduction
in ischemia-driven revascularization.</font></p>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">The
role of FFR in guiding surgical revascularization is uncertain.
Multiple small observational studies, as well as RCTs and
meta-analyses of these trials, suggest that fewer distal anastomoses
are performed, and off-pump CABG is more often chosen in patients
undergoing CABG with FFR-guided revascularization than in those
undergoing CABG with angiogram-guided
revascularization.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R171"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">11-14</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;However,
in these studies, no differences were found in clinical outcomes in
patients undergoing CABG with FFR guidance compared with patients
undergoing CABG with angiogram guidance.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R171"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">11-14</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Additionally,
not all studies included an angiogram-guided comparison group. Large,
randomized trials that are appropriately powered are warranted to
guide the use of FFR in patients undergoing surgical
revascularization.</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supportive Text</b></i></font></font></h4>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">1.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">In
the FAME trial, PCI for a stenosis ≥50% with an abnormal FFR
reduced the risk of the composite endpoint at 1 year as compared with
PCI guided by angiography only,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R161">1</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;a
benefit that was maintained at 2 years</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R169">9</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;but
not at 5 years. The DEFINE-FLAIR (Functional Lesion Assessment of
Intermediate Stenosis to Guide Revascularisation and the
Instantaneous Wave-free Ratio versus Fractional Flow Reserve in
Patients with Stable Angina Pectoris or Acute Coronary Syndrome)</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R164">4</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
the iFR-SWEDEHEART (Instantaneous Wave-free Ratio versus Fractional
Flow Reserve in Patients with Stable Angina Pectoris or Acute
Coronary Syndrome) trials</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R166">6</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;compared
outcomes with the use of iFR- or FFR-guided PCI. In these trials,
iFR-guided PCI was found to be noninferior to FFR-guided PCI. As
compared with FFR, the use of iFR was associated with lower rates of
procedure-related chest pain and shorter procedural time. In
randomized trials, the rates of short- and long-term MACE were lower
among patients who had PCI guided by physiology with either FFR or
iFR.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R164">4</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R166">6</span></font></span></font></a></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">2.</span></font></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Deferral
of PCI when the FFR is &gt;0.80 or the iFR is &gt;0.89 is associated
with low rates of long-term MACE.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R168">8-10</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
DEFER (Deferral of Percutaneous Intervention) trial demonstrated
similar rates of MACE in follow-up when PCI for angiographic
intermediate lesions and FFR &gt;0.75 was deferred, rather than
performed, at 2 and 5 years of follow-up.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R168">8</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Additionally,
there were lower rates of MI in the deferred group at long-term
follow-up.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R167">7</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
patients enrolled in the FAME trial who had an FFR &gt;0.80, 2-year
rates of MI and revascularization were low, at 0.2% and 3.2%,
respectively.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R169">9</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Finally,
in the DEFINE-FLAIR and the iFR-SWEDEHEART trials, rates of MACE in
patients who had PCI deferred on the basis of an FFR &gt;0.80 or an
iFR &gt;0.89 were 4.05% and 4.12%, respectively,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R170">10</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;with
unplanned revascularization being the most frequent cause of MACE.
The cutoffs of FFR and iFR provided were those used in the clinical
trials. On occasion, borderline values may warrant further ischemia
testing or additional investigations.</span></font></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>4.4.
Intravascular Ultrasound to Assess Lesion Severity</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu7.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab07.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image11" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">IVUS
can offer important anatomic information beyond what is seen on
coronary angiography. IVUS is particularly useful in lesions
involving the left main artery where there may be limitations in
coronary angiography due to overlapping vessels or foreshortening.
IVUS offers significantly greater spatial resolution than angiography
alone (IVUS axial resolution is 100 to 150 μm, and coronary
angiography axial resolution is 300 μm). Detailed cross-sectional
images provide accurate evaluation of lesion characteristics,
including lumen dimensions, lesion length, plaque morphology and
location, thrombus, dissection, and stent apposition and expansion.
Additionally, minimal lumen area on IVUS has been shown to correlate
with physiological indices.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R180"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">6</font></span></font></a></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supportive Text</b></i></font></font></h4>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">1.</span></font></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">In
the case of indeterminate left main disease, studies have shown that
IVUS evaluation with deferral of intervention for a minimum lumen
area of ≥6 to 7.5 mm2&nbsp;is safe,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R175">1</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R176">2</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;although
a smaller cutoff (4.5–4.8 mm2) may be more appropriate in patients
of Asian descent.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R177">3</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Moderate
correlations between FFR values and IVUS minimal lumen area cutoffs
have been demonstrated in left main disease.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R178">4</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R179">5</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Compared
with the left main artery, smaller cutoffs have been suggested for
IVUS of the LAD artery.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R181">7</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Developed
more recently, optical coherence tomography (OCT) has been shown to
correlate well with IVUS measurements.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R182">8</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;However,
because OCT requires blood clearance, its effectiveness for imaging
ostial left main disease is limited.</span></font></p>
<h2 class="western" align="left" style="line-height: 0.22in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="3" style="font-size: 11pt"><b>5.
Revascularization in STEMI</b></font></font></h2>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>5.1.
Revascularization of the Infarct Artery in Patients With STEMI</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu8.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab08.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image12" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">Immediate
reperfusion therapy for patients with STEMI improves mortality rate,
and primary PCI has been shown to be superior to fibrinolytic
therapy</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R183"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;(</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/f3.xhtml"><font color="#2b7bb9"><span style="text-decoration: none"><font size="2" style="font-size: 9pt">Figure
3</font></span></font></a><font size="2" style="font-size: 9pt">).</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R188"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">6</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R205"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">23</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R209"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">27-29</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Fibrinolytic
therapy is recommended only in cases in which primary PCI is not
immediately available and the delay from hospital presentation to PCI
is anticipated to be &gt;120 minutes.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R212"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">30</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Because
approximately 35% of patients treated with fibrinolysis do not
achieve reperfusion,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R213"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">31</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
an additional 10% have ineffective reperfusion (TIMI [Thrombolysis In
Myocardial Infarction] flow grade &lt;3),</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R183"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;early
transfer of patients to centers capable of performing PCI will
facilitate early catheterization and/or PCI.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R197"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">15-17</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R201"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">19</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;CABG
has a limited role in the acute phase of STEMI, and its use in this
setting continues to decrease.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R205"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">23</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Older
case series have highlighted a potential excess mortality risk when
CABG is performed early after STEMI.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R214"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">32</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;However,
contemporary modifications to the standard operative approach,
improved anesthesia and monitoring, improved technical methods, and
adjunctive temporary mechanical circulatory support devices may lead
to improved rates of survival after CABG (</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/f3.xhtml"><font color="#2b7bb9"><span style="text-decoration: none"><font size="2" style="font-size: 9pt">Figure
3</font></span></font></a><font size="2" style="font-size: 9pt">).</font></p>
<p style="line-height: 0.14in"><font color="#2b7bb9"><span style="text-decoration: none"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/f3.xhtml">
  <font color="#2c2e35">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.fig03.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image13" align="bottom" width="92" height="44" border="1"/>
  </font>
</a>
</span></font><font color="#d93731"><font size="1" style="font-size: 8pt"><b>Figure
3</b></font></font>.&nbsp;<b>Indications for Revascularization in
STEMI (Patients Without Fibrinolytics).</b>&nbsp;Colors correspond
to&nbsp;<a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/t2.xhtml"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt">Table
2</font></span></font></a>. CABG indicates coronary artery bypass
graft; PCI, percutaneous coronary intervention; and STEMI,
ST-segment–elevation myocardial infarction. This algorithm
summarizes the recommendations in this guideline for
revascularization of the infarct artery in STEMI. It is not meant to
encompass every patient scenario or situation, and clinicians are
encouraged to use a Heart Team approach when care decisions are
unclear and to see the accompanying supportive text for each
recommendation. Additionally, in situations that lack sufficient data
to make formal recommendations for care, please see Section 17,
“Unanswered Questions and Future Directions.”</p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supportive Text</b></i></font></font></h4>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">1.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Multiple
RCTs and meta-analyses have shown that primary PCI reduces death, MI,
stroke, and major bleeding as compared with fibrinolysis, especially
when treatment delays are minimized.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R183">1-5</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;This
benefit is seen even among patients transferred from non-PCI
hospitals if transfer times are reasonable and total ischemic time
after presentation is &lt;120 minutes.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R186">4</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R212">30</span></font></span></font></a></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">2.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">In
patients with STEMI complicated by cardiogenic shock, an early
revascularization strategy is associated with a significant survival
benefit.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R188">6</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
the SHOCK (Should We Emergently Revascularize Occluded Coronaries for
Cardiogenic Shock) trial, although the primary endpoint of 30-day
survival for patients with STEMI and cardiogenic shock was not
improved with early revascularization, compared with initial medical
stabilization,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R188">6</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;the
secondary outcome of mortality rate at 6 months was significantly
lower in the group of patients randomized to early revascularization
and treated with either PCI or CABG.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">3.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">The
mortality rate associated with emergency CABG and surgical management
of a mechanical complication of STEMI remains high.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R215">33</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;However,
there are currently few medical or percutaneous treatment methods to
effectively treat ventricular rupture, papillary muscle rupture
leading to severe mitral regurgitation, or ischemic ventricular
septal defect. CABG and these associated procedures may be necessary
to treat the mechanical complications of STEMI or cardiogenic shock
in the emergency setting.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R216">34-38</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Placement
of a mechanical support device may be useful in temporizing a patient
with a mechanical complication of STEMI, and urgent or emergency
surgery remains the best treatment.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R221">39</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R222">40</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;No
RCT has examined the benefit of adding CABG at the time of emergent
cardiac surgery for treatment of a mechanical complication of STEMI
versus emergent surgery for the treatment of a mechanical
complication alone. In addition, no RCT has examined the benefit of
emergent cardiac surgery for the treatment of a mechanical
complication of STEMI versus initial medical stabilization and
delayed surgery.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">4.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Rescue
PCI performed in patients with evidence of failed reperfusion after
fibrinolytic therapy has been associated with a reduction in
cardiovascular events,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R192">10-13</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;when
compared with conservative care or repeat fibrinolysis. In these
studies, patients randomized to rescue PCI had higher rates of
bleeding and cerebrovascular accident.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R192">10-12</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;All
these studies were performed in the era of femoral artery access,
with limited options for antiplatelet and anticoagulant therapy.
Previous concerns about increased bleeding or increased stroke risk
in patients undergoing rescue PCI could be mitigated by using
half-dose tenecteplase in patients &gt;75 years of age,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R213">31</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;by
substituting radial access in place of femoral access,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R223">41</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;or
by eliminating the routine use of platelet glycoprotein IIb/IIIa
inhibitors. With these techniques, the reduced complications
associated with PCI would provide a more favorable balance of risk to
benefit with rescue PCI than with conservative care.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">5.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Studies
have shown a reduction in MACE when routine early angiography with
the intent to perform PCI is performed after fibrinolytic
therapy.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R197">15</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R198">16</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R200">18-20</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R224">42</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;This
was further supported by several meta-analyses of these trials, which
showed a reduction in death or infarction with an early invasive
approach after fibrinolytic therapy.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R196">14</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R199">17</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
these early-transfer studies, more than 80% of patients who were
transferred underwent PCI to treat a significant residual stenosis or
suboptimal flow of the infarct artery. The benefit of immediate
angiography was most notable in patients undergoing angiography early
after symptom onset or after administration of fibrinolytic
therapy.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R196">14</span></font></span></font></a></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">6.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">The
benefit of PCI for asymptomatic patients presenting 12 to 24 hours
after symptom onset is not well studied. The BRAVE-2 (Beyond 12 Hours
Reperfusion Alternative Evaluation-2) trial examined the benefits of
PCI in reducing infarct size in asymptomatic patients with STEMI and
symptom onset &gt;12 hours but &lt;48 hours before presentation.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R203">21</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
this small study, an invasive strategy of coronary stenting was
associated with a reduction in left ventricular infarct size (primary
endpoint) compared with a conservative strategy.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R203">21</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Moreover,
an invasive strategy was associated with a reduction in adjusted
4-year mortality rate compared with the conservative
strategy.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R225">43</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Observational
data from the Prospective National Observational study also supported
a lower adjusted 1-year mortality rate in patients with STEMI and
symptom onset 12 to 24 hours before presentation.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R204">22</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;This
information should be balanced by the potential for “harm” when
PCI of a totally occluded artery is performed more than 24 hours
after symptom onset. Therefore, delayed PCI of an infarct artery
beyond 24 hours should be considered only in patients with a patent
artery.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">7.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">In
patients with STEMI, there may be situations in which PCI is not
possible for anatomic reasons or because of the presence of severe
left main or multivessel CAD. Additionally, in unusual circumstances,
PCI may not be successful. In such cases, CABG can be an effective
primary reperfusion strategy, particularly if there is a large area
of myocardium at risk.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R205">23</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R206">24</span></font></span></font></a></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">8.</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">There
are no RCTs examining the benefit of PCI in patients with STEMI
presenting &gt;12 hours after symptom onset who have clinical
evidence of ongoing ischemia, acute severe heart failure, or
life-threatening arrhythmias. Intuitively, a strategy of delayed
reperfusion in these unstable patient subsets would be expected to
improve symptoms and outcomes, and for this reason PCI should be
considered.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">9.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">In
OAT (Occluded Artery Trial), PCI of a totally occluded vessel did not
reduce cardiovascular events at 4 years of follow-up,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R207">25</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
there was a trend toward a higher rate of recurrent infarction in the
group of patients randomized to PCI. Patients who had severe ischemia
on noninvasive stress testing were not enrolled in this trial.
Similar findings were noted in the DECOPI (Desobstruction Coronaire
en Post-Infarctus) trial, which enrolled patients with an occluded
artery presenting 2 to 15 days after symptom onset.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R208">26</span></font></span></font></a></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">10.</span></font></p>
<p style="line-height: 0.18in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Emergency
CABG to restore flow to the infarct artery after failed PCI should be
considered only in patients with ongoing ischemia and a large area of
myocardium at risk. In some cases, after primary PCI, the vessel
remains occluded or with slow flow caused by distal embolization (no
reflow). The no-reflow phenomenon refers to unsuccessful
microvascular reperfusion even in the presence of a widely patent
epicardial coronary artery. This usually occurs with reperfusion in
the setting of PCI for the treatment of STEMI, after prolonged
myocardial ischemia, or with a large thrombus burden. Because CABG is
unlikely to improve perfusion to the subtended myocardium in the
setting of no-reflow, emergency CABG may be harmful in this setting
and may subject the patient to unnecessary risk.</span></font></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>5.2.
Revascularization of the Non-Infarct Artery in Patients With STEMI</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu9.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab09.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image14" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">A
Heart Team approach is utilized to determine optimal
revascularization strategy in patients with STEMI and multivessel
CAD. Revascularization strategies (</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/f4.xhtml"><font color="#2b7bb9"><span style="text-decoration: none"><font size="2" style="font-size: 9pt">Figure
4</font></span></font></a><font size="2" style="font-size: 9pt">) for
patients with STEMI and multivessel disease include multivessel PCI
at the time of primary PCI, PCI of the infarct artery only followed
by staged PCI of a non-infarct artery, PCI of the infarct artery only
with an ischemia-guided approach to treatment of a non-infarct
artery, or PCI of the infarct artery only with elective CABG.
Observational studies and meta-analyses have reported conflicting
results for the superiority of one approach over another.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R236"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">11</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Recent
randomized trials of PCI in STEMI support the safety and efficacy of
multivessel PCI in selected patients with STEMI.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R227"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">2-4</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R231"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">6</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R232"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">7</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
data are strongest for patients undergoing staged PCI.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R229"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">4</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;It
should be noted that only one-third of enrolled patients in these
trials had triple-vessel disease, and most of these trials excluded
patients with left main disease, chronic total occlusion (CTO) of the
non-infarct artery, or complex non-infarct artery disease. For this
reason, CABG remains a reasonable option in patients with residual
complex non-infarct artery disease. Ideal patients who may benefit
from revascularization of non-infarct arteries include those with a
large area of myocardium at risk and those without significant
comorbidities that would increase the risk of revascularization.</font></p>
<p style="line-height: 0.14in"><font color="#2b7bb9"><span style="text-decoration: none"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/f4.xhtml">
  <font color="#2c2e35">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.fig04.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image15" align="bottom" width="92" height="44" border="1"/>
  </font>
</a>
</span></font><font color="#d93731"><font size="1" style="font-size: 8pt"><b>Figure
4</b></font></font>.&nbsp;<b>Revascularization of Noninfarct-Related
Coronary Artery Lesions in Patients With STEMI.</b>&nbsp;Colors
correspond to&nbsp;<a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/t2.xhtml"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt">Table
2</font></span></font></a>. CABG indicates coronary artery bypass
graft; GDMT, guideline-directed medical therapy; PCI, percutaneous
coronary intervention; and STEMI, ST-segment–elevation myocardial
infarction. Normal blood pressure and heart rate left ventricular
end-diastolic pressure &lt;20 mm Hg, no chronic renal insufficiency
or acute kidney injury, and expected total contrast volume &lt;3×
glomerular filtration rate, simple lesion anatomy. †In making the
decision about the need for and mode of revascularization the Heart
Team should consider the suitability of the non-culprit artery for
PCI, the coronary complexity and the risk of revascularization, the
extent of myocardium at risk, and patient comorbidities, including
life expectancy or other significant patient comorbidities, such as
chronic renal insufficiency or acute kidney injury. ‡Staged PCI can
be performed in hospital or after discharge, up to 45 days post
MI.&nbsp;<font color="#2c2e35">
  <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/images/medium/cir.0000000000001038.ufig01.gif?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image16" align="bottom" width="90" height="42" border="1"/>
</font>
&nbsp;Symbol
denotes time elapsed before proceeding to the next procedure. This
algorithm summarizes the recommendations in this guideline for the
care of patients with STEMI and noninfarct artery disease. It is not
meant to encompass every patient scenario or situation, and
clinicians are encouraged to use a Heart Team approach when care
decisions are unclear and to see the accompanying supportive text for
each recommendation. Additionally, in situations that lack sufficient
data to make formal recommendations for care, please see Section 17,
“Unanswered Questions and Future Directions.”</p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supportive Text</b></i></font></font></h4>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">1.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">RCTs
have demonstrated a reduction in MACE with staged PCI (either in
hospital or after discharge) compared with culprit vessel–only
PCI.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R226">1-4</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;This
benefit is driven largely by a reduction in the risk of repeat
revascularization or re-infarction. Most recently, the COMPLETE
(Complete versus Culprit-Only Revascularization Strategies to Treat
Multivessel Disease after Early PCI for STEMI) trial enrolled 4041
patients and demonstrated a 3-year reduction in the combined endpoint
of death or MI with staged PCI of the non-infarct artery (performed
within 45 days of STEMI), compared with conservative care.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R229">4</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;These
benefits were consistent, irrespective of the timing of the
non-infarct artery PCI.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R237">12</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Most
of these trials included patients with low-complexity disease. No
trial has shown a difference in the outcome of mortality rate alone
between the strategies. In the COMPLETE trial, &lt;1% of enrolled
patients had non-infarct artery disease involving the left main
artery, and the baseline SYNTAX score of the enrolled patients was
low. Additionally, these trials enrolled patients with lesions that
had a &gt;70% diameter stenosis. For intermediate lesions,
physiological testing with iFR or FFR may be useful to guide PCI.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R229">4</span></font></span></font></a></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">2.</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">In
patients with STEMI and complex multivessel CAD, elective CABG
remains an appropriate revascularization option after successful PCI
of an infarct artery in patients who meet criteria for CABG (</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="2" style="font-size: 9pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/t8.xhtml">Table
7</font></span></font></a><font size="2" style="font-size: 9pt">).
Although the COMPLETE trial demonstrated that staged PCI of the
non-infarct artery is associated with a reduction in the risk of
death or recurrent infarction in follow-up, patients intended for a
planned surgical revascularization procedure were not included in
this study. In patients with complex non-infarct artery disease, the
decision to proceed with PCI versus CABG of the non-infarct artery
should include a Heart Team discussion.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">3.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Randomized
trials have shown a reduction in MACE with a multivessel PCI strategy
performed at the time of primary PCI as compared with culprit
artery–only PCI.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R226">1</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R227">2</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R230">5-7</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
benefits reported in these trials were driven largely by a reduction
in repeat revascularization with multivessel PCI. PCI of a
non-infarct artery stenosis may be considered at the time of
successful primary PCI, but patients should be carefully selected.
Patients who are most appropriate for complete revascularization at
the time of primary PCI include those with uncomplicated PCI of the
infarct artery and with low-complexity non-infarct artery disease who
have normal left ventricular filling pressures and normal renal
function. Clinicians should integrate clinical data, lesion severity
and complexity, patient stability, risk of volume overload, and risk
of contrast nephropathy before embarking on an immediate multivessel
primary PCI strategy.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">4.</span></font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Culprit
vessel–only primary PCI is recommended as the primary PCI strategy
in most patients with STEMI complicated by cardiogenic shock who have
multivessel disease. This is based on consistent findings from
observational data and 1 randomized trial that showed no advantage
for immediate multivessel PCI.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R233">8-10</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
the CULPRIT-SHOCK (Culprit Lesion Only PCI Versus Multivessel PCI in
Cardiogenic Shock) trial of patients with acute MI (AMI) complicated
by cardiogenic shock, multivessel PCI at the time of primary PCI
resulted in a higher risk of the primary endpoint of death or need
for renal replacement therapy.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R233">8</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R234">9</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Of
note, in this trial, investigators were permitted to proceed with PCI
of all non-infarct vessels with &gt;70% diameter stenosis that were
≥2 mm in diameter, including those that were chronically occluded.
The risks associated with immediate multivessel PCI include volume
overload, contrast nephropathy, and ischemic complications in the
non-infarct artery that could cause further hemodynamic
deterioration.</span></font></p>
<p style="line-height: 0.14in; margin-bottom: 0in"><font color="#d93731"><font size="1" style="font-size: 8pt"><b>Table
8</b></font></font>. Best Practices in the Catheterization Laboratory
for Patients With CKD Undergoing Angiography&nbsp;<font size="1" style="font-size: 8pt">(</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/t8.xhtml"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt">Table
view</font></span></font></a><font size="1" style="font-size: 8pt">)</font></p>
<table cellpadding="2" cellspacing="2">
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Assess
			the risk of contrast-induced AKI before the procedure</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R451"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1-3</font></span></font></a></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Administer
			adequate preprocedural hydration</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R469"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">19</font></span></font></a><font size="1" style="font-size: 8pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R470"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">20</font></span></font></a></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Record
			the volume of contrast media administered, and minimize contrast
			use</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R468"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">18</font></span></font></a><font size="1" style="font-size: 8pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R472"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">22</font></span></font></a><font size="1" style="font-size: 8pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R473"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">23</font></span></font></a></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Pretreat
			with high-intensity statins</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R471"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">21</font></span></font></a><font size="1" style="font-size: 8pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R474"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">24</font></span></font></a><font size="1" style="font-size: 8pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R475"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">25</font></span></font></a></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Use
			radial artery if feasible</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R481"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">31-33</font></span></font></a></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Do
			not administer N-acetyl-L-cysteine to prevent contrast-induced
			AKI</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R488"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">38-40</font></span></font></a></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Do
			not give prophylactic renal replacement therapy</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R491"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">41</font></span></font></a><font size="1" style="font-size: 8pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R492"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">42</font></span></font></a></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Delay
			CABG in stable patients after angiography beyond 24 hours when
			clinically feasible</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R493"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">43-45</font></span></font></a></p>
		</td>
	</tr>
</table>
<p align="justify" style="line-height: 0.13in"><font size="1" style="font-size: 7pt">AKI
indicates acute kidney injury; CABG, coronary artery bypass graft;
and CKD, chronic kidney disease.</font></p>
<h2 class="western" align="left" style="line-height: 0.22in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="3" style="font-size: 11pt"><b>6.
Revascularization in NSTE-ACS</b></font></font></h2>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>6.1.
Coronary Angiography and Revascularization in Patients With NSTE-ACS</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu10.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab10.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image17" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.18in"><font size="2" style="font-size: 9pt">A
routine invasive approach for patients with NSTE-ACS is associated
with improved outcomes.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R241"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1-4</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R260"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">20</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R261"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">21</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Risk
stratification with a validated score (ie, GRACE or TIMI) has been
recommended to guide the timing of coronary angiography.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R262"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">22</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R263"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">23</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
GRACE 2.0 risk calculator
(</font><a href="https://www.outcomes-umassmed.org/grace/acs_risk2/index.html"><font color="#2b7bb9"><span style="text-decoration: none"><font size="2" style="font-size: 9pt">https://www.outcomes-umassmed.org/grace/acs_risk2/index.html</font></span></font></a><font size="2" style="font-size: 9pt">)</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R264"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">24</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;has
been used in most clinical trials to identify patients who were at
high risk of death or MI, and it enables a direct estimation of the
mortality risk during hospitalization and at 1 and 3 years. A GRACE
score of &gt;140 has been used to denote a patient at higher risk of
clinical events. Other factors associated with higher risk include
older age (≥75 years), elevated TIMI risk score
(</font><a href="https://timi.org/calculators/timi-risk-score-calculator-for-ua-nstemi/"><font color="#2b7bb9"><span style="text-decoration: none"><font size="2" style="font-size: 9pt">https://timi.org/calculators/timi-risk-score-calculator-for-ua-nstemi/</font></span></font></a><font size="2" style="font-size: 9pt">),</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R265"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">25</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
elevated cardiac markers.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R251"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">11</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R266"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">26</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Factors
indicating a need for an urgent revascularization (</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/t8.xhtml"><font color="#2b7bb9"><span style="text-decoration: none"><font size="2" style="font-size: 9pt">Table
7</font></span></font></a><font size="2" style="font-size: 9pt">)
with either PCI or CABG include threatening anatomy, ongoing
ischemia, or hemodynamic compromise. In such patients and in those
with complex CAD, treatment should be individualized and involve a
Heart Team discussion.</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supportive Text</b></i></font></font></h4>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">1.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">In
patients with NSTE-ACS, an initial invasive approach is associated
with a lower rate of the combined endpoint of death, MI, or
refractory angina at 4 to 6 months’ follow-up</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R241">1-4</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;(</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="2" style="font-size: 9pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/f5.xhtml">Figure
5</font></span></font></a><font size="2" style="font-size: 9pt">).
Pooled trial data have demonstrated lower rates of recurrent
infarction and recurrent ischemia with an invasive strategy.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R244">4</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
benefits of an invasive approach are most pronounced among patients
with elevated biomarkers or other higher-risk findings.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R241">1</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
invasive approach also provides important prognostic information,
such as extent and severity of CAD, hemodynamics, and left
ventricular function, allowing for precise determination of risk,
antithrombotic treatment guidance, and suitability for
revascularization with PCI or CABG. Roughly 20% to 25% of patients
enrolled in the early trials examining the benefits of a routine
invasive approach underwent CABG. In patients with multivessel
disease, the mode of revascularization should be based on the acuity
of the patient’s condition, the angiographic characteristics of the
culprit lesion, and the complexity of the patient’s anatomy and,
when appropriate, should include a Heart Team discussion.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">2.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">In
the SHOCK trial, patients were randomized to medical therapy or
emergency revascularization. Among the patients randomized to
revascularization, two-thirds of patients were referred for PCI and
one-third for CABG, and the decision to proceed with PCI or CABG was
made by the treating physician.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R249">9</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Median
time from randomization to revascularization was 0.9 hours for PCI
and 2.7 hours for CABG. The SHOCK trial supported a strategy of
emergency angiography with immediate revascularization in patients
with AMI complicated by cardiogenic shock. At 6 months, the mortality
rate was significantly lower in patients randomized to
revascularization than in those randomized to medical therapy.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R249">9</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
the SHOCK trial, there was no difference in mortality rate with PCI
or CABG for those patients randomized to early revascularization,
with a similar survival regardless of the mode of revascularization
at 30 days and 1 year. Additionally, observational studies</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R245">5-7</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R257">17</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;of
patients with cardiogenic shock referred for CABG have reported
acceptable outcomes with emergency revascularization. Patients with
shock may benefit from mechanical circulatory support devices before
revascularization, especially if CABG is planned.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R267">27</span></font></span></font></a></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">3.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Patients
with NSTE-ACS who are clinically unstable because of refractory
angina, intractable arrhythmias, or hemodynamic instability have been
consistently excluded from clinical trials evaluating the optimal
timing of coronary angiography.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R251">11</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R268">28</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Although
evidence from clinical trial data is lacking, intuitively, immediate
angiography (within 2 hours) with plans for appropriate
revascularization would be expected to improve outcomes if
revascularization stabilizes the clinical condition.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">4.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">An
early invasive strategy performed within 24 hours in high-risk (GRACE
score &gt;140) patients is associated with a lower incidence of
recurrent ischemia or need for urgent revascularization and a shorter
hospital stay.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R251">11</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R252">12</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R254">14-16</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Although
clinical trials have not demonstrated a clear advantage with an early
invasive strategy (within 24 hours) as opposed to a delayed invasive
strategy in the overall population of patients with
NSTE-ACS,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R252">12</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R256">16</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;prespecified
subgroup analyses of these trials support the use of an early
invasive strategy for high-risk patients.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R251">11</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R252">12</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R256">16</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
TIMACS (Timing of Intervention in Acute Coronary Syndromes) trial, in
which patients were enrolled within 24 hours of symptoms and
randomized to angiography at ≤ 24 hours versus ≥ 36 hours from
time of randomization, and the VERDICT (Very Early vs Deferred
Invasive Evaluation Using Computerized Tomography) trial, in which
patients were randomized to angiography at &lt;12 hours versus 48 to
72 hours from time of diagnosis, both evaluated the value of early
invasive management of symptoms for patients with NSTE-ACS and
demonstrated a lower rate of cardiovascular events in follow-up in
the high-risk subgroup of patients randomized to early angiography.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">5.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">In
intermediate- or low-risk patients, timing is not critical, and a
delayed invasive strategy within 48 to 72 hours has been demonstrated
to be acceptable</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R251">11-16</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R268">28</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Randomized
trial data have not demonstrated differences in rates of death and MI
between an early invasive strategy (coronary angiography &lt;24 hours
after admission) and a delayed invasive approach (48–72 hours) in a
nonselected population of patients with NSTEMI.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R251">11-16</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R269">29</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R270">30</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;However,
low-risk patients benefit from a routine invasive strategy before
hospital discharge, with a significant reduction in the risk of
cardiovascular death or MI, compared with a selective invasive
strategy.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R261">21</span></font></span></font></a></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">6.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Although
there are no randomized trials specifically evaluating emergency CABG
versus medical therapy or delayed revascularization in patients with
NSTE-ACS and failed PCI who have ongoing ischemia or hemodynamic
compromise, multiple retrospective reviews have noted a reduced
mortality rate in patients with an emergency approach.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R246">6</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R249">9</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R257">17</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
appropriate safe timing of CABG is carefully determined with a Heart
Team approach in patients with NSTE-ACS who are on dual antiplatelet
therapy (DAPT).</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">7.</span></font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">In
the CULPRIT-SHOCK trial, almost 40% of enrolled patients had an
NSTEMI. As mentioned in section 5.2, patients were included in the
trial if they had 2 or more vessels with &gt;70% diameter stenosis
that were ≥2 mm in diameter. Those with chronic total occlusions
were eligible for inclusion in the study. Patients in the
CULPRIT-SHOCK trial who were randomized to culprit-only PCI with the
option of staged revascularization of non-culprit lesions had a lower
rate of the composite endpoint of death and dialysis at 30 days and 1
year. Culprit-vessel PCI was associated with a significant all-cause
mortality rate reduction at 30 days but not at 1 year.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R258">18</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R259">19</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;As
was noted in patients with STEMI, the results of the CULPRIT-SHOCK
trial showed no benefit to immediate multivessel PCI in NSTEMI.</span></font></p>
<p style="line-height: 0.1in"><font color="#2b7bb9"><span style="text-decoration: none"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/f5.xhtml">
  <font color="#2c2e35">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.fig05.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image18" align="bottom" width="92" height="44" border="1"/>
  </font>
</a>
</span></font><font color="#d93731"><font size="1" style="font-size: 8pt"><b>Figure
5</b></font></font>.&nbsp;<b>Recommendations for the Timing of
Invasive Strategy in Patients With NSTE-ACS.</b>&nbsp;Colors
correspond to&nbsp;<a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/t2.xhtml"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt">Table
2</font></span></font></a>. GRACE indicates Global Registry of Acute
Coronary Events; and NSTE-ACS, non–ST-segment–elevation acute
coronary
syndrome.&nbsp;<a href="https://www.mdcalc.com/grace-acs-risk-mortality-calculator"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt">https://www.mdcalc.com/grace-acs-risk-mortality-calculator</font></span></font></a>.<a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R271"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">31</font></span></font></a>&nbsp;This
algorithm summarizes the recommendations in this guideline for
coronary artery angiography with the intent to perform
revascularization in NSTE-ACS. It is not meant to encompass every
patient scenario or situation, and clinicians are encouraged to use a
Heart Team approach when care decisions are unclear and to see the
accompanying supportive text for each recommendation. Additionally,
in situations that lack sufficient data to make formal
recommendations for care, please see Section 17, “Unanswered
Questions and Future Directions.”</p>
<h2 class="western" align="left" style="line-height: 0.22in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="3" style="font-size: 11pt"><b>7.
Revascularization in SIHD</b></font></font></h2>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>7.1.
Revascularization to Improve Survival in SIHD Compared With Medical
Therapy</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu11.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab11.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image19" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">Studies
have shown that CABG confers a survival benefit over medical therapy
in multiple subsets of patients, including those with left main CAD
(</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/f6.xhtml"><font color="#2b7bb9"><span style="text-decoration: none"><font size="2" style="font-size: 9pt">Figure
6</font></span></font></a><font size="2" style="font-size: 9pt">),</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R280"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">9-12</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;triple-vessel
CAD,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R284"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">13</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
ischemic cardiomyopathy.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R272"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R274"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">3-7</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R302"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">31-33</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Many
of these studies were conducted before the widespread use of
antiplatelet and statin therapies and before the broad recognition of
benefit from beta-blockers and ACE inhibitors/ARBs. There are no RCTs
that have demonstrated a survival advantage of PCI over medical
therapy in patients with SIHD.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R285"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">14</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R288"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">17</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R305"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">34-38</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;There
may be an advantage of PCI over medical therapy in patients who have
a clinical indication for CABG but are deemed prohibitive surgical
risk. For this reason, the Heart Team must weigh the risks and
benefits of PCI as compared to medical therapy in such patients. The
ISCHEMIA (International Study of Comparative Health Effectiveness
with Medical and Invasive Approaches) trial randomized patients with
SIHD and moderate-to-severe ischemia on stress testing to an initial
invasive strategy versus an initial conservative strategy. Patients
with left main disease or an ejection fraction &lt;35% were excluded
from enrollment. As compared with a strategy of medical therapy
alone, an invasive strategy including revascularization with PCI or
CABG was not associated with improved outcomes.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R285"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">14</font></span></font></a></p>
<p style="line-height: 0.14in"><font color="#2b7bb9"><span style="text-decoration: none"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/f6.xhtml">
  <font color="#2c2e35">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.fig06.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image20" align="bottom" width="92" height="44" border="1"/>
  </font>
</a>
</span></font><font color="#d93731"><font size="1" style="font-size: 8pt"><b>Figure
6</b></font></font>.&nbsp;<b>Revascularization in Patients With
SIHD.</b>&nbsp;Colors correspond to&nbsp;<a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/t2.xhtml"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt">Table
2</font></span></font></a>. CABG indicates coronary artery bypass
graft; CAD, coronary artery disease; EF, ejection fraction; GDMT,
guideline-directed medical therapy; PCI, percutaneous coronary
intervention; and SIHD, stable ischemic heart disease. This algorithm
summarizes the recommendations in this guideline for the care of
patients with stable CAD. It is not meant to encompass every patient
scenario or situation, and clinicians are encouraged to use a Heart
Team approach when care decisions are unclear and to see the
accompanying supportive text for each recommendation. Additionally,
in situations that lack sufficient data to make formal
recommendations for care, please see Section 17, “Unanswered
Questions and Future Directions.”</p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supporting Text</b></i></font></font></h4>
<h5 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font size="2" style="font-size: 9pt"><i><b>Left Ventricular
Dysfunction and Multivessel CAD</b></i></font></h5>
<p style="line-height: 0.11in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">1.
The strongest evidence in the past decade to support
revascularization with CABG in patients with left ventricular
dysfunction and CAD appropriate for CABG has been the STICH (Surgical
Treatment for Ischemic Heart Failure) trial,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R272"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R310"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">39</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R311"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">40</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;which
randomized patients with left ventricular dysfunction (ejection
fraction ≤35%) to either CABG with medical therapy or medical
therapy alone. This study initially did not demonstrate a survival
benefit for CABG over a median follow-up of 5 years,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R310"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">39</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;but
a subsequent report from this trial evaluating long-term follow-up at
10 years reported a survival benefit of CABG compared with medical
therapy alone.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R272"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R311"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">40</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
use of myocardial viability studies in this study population
demonstrated no relevance to study outcomes; however, this testing
was not standardized.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R312"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">41</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;There
are insufficient data to make recommendations for using PCI in this
patient population.</font></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">2.
Evidence for a survival advantage with CABG in patients with SIHD and
moderate left ventricular dysfunction comes from subgroup analyses of
patients enrolled in the Coronary Artery Surgery Study</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R274">3</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
the Veterans Administration Coronary Artery Bypass Cooperative Study
with LV dysfunction,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R313">42</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;as
well as a meta-analysis</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R281">10</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;of
the RCTs of CABG versus medical therapy. In these studies, patients
with left ventricular dysfunction had a significant survival benefit
with CABG, particularly patients with accompanying triple-vessel
disease. Several registry studies have supported these
findings.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R275">4-7</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R302">31-33</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
use of PCI in this patient population requires more study.</span></font></p>
<h5 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font size="2" style="font-size: 9pt"><i><b>Left Main CAD</b></i></font></h5>
<p style="line-height: 0.11in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">3.
The Veterans Administration Coronary Artery Bypass Surgery
Cooperative Study randomized patients with SIHD to a strategy of CABG
versus medical therapy.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R314"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">43</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
this study, close to 15% of enrolled patients had significant left
main disease.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R314"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">43</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;At
42 months’ follow-up, CABG was associated with a significant
survival benefit in the subgroup of patients with left main
disease.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R282"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">11</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Additionally,
a meta-analysis of the RCTs comparing CABG with medical therapy
supported these findings, with a 70% reduction in 5-year mortality
rate with CABG versus medical therapy for the group of patients with
left main disease.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R281"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">10</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Subsequent
studies have supported these findings.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R280"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">9</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R315"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">44-46</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Although
the evidence to support revascularization with CABG is derived mainly
from older RCTs, there are no new data to refute this evidence, as
all of the contemporary clinical trials comparing revascularization
with medical therapy have excluded patients with significant stenoses
of the left main artery.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R285"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">14</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R295"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">24</font></span></font></a></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">4.
The evidence for a survival advantage for PCI over medical therapy in
patients with left main CAD is inferential but plausible. Several
registry studies have suggested a survival benefit of PCI over
medical therapy in patients with left main CAD.,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R318">47</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R319">48</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;A
network meta-analysis of 19 studies found that the survival advantage
for PCI over medical therapy in patients with left main CAD was
identical to the survival advantage for CABG over medical
therapy.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R280">9</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Additionally,
RCTs and meta-analyses of these trials evaluating outcomes of PCI
versus CABG in patients with low-to-medium anatomic complexity of CAD
and with left main disease that is equally suitable for surgical or
percutaneous revascularization have reported similar survival with
PCI and CABG.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R320">49-55</span></font></span></font></a></p>
<h6 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font size="2" style="font-size: 9pt"><i><b>Multivessel CAD</b></i></font></h6>
<p style="line-height: 0.11in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">5.
The new Class 2b recommendation, which represents a downgrade from a
Class 1 recommendation in the 2011 CABG guideline,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R327"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">56</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;reflects
new evidence showing no advantage of CABG over medical therapy alone
to improve survival in patients with 3-vessel CAD with preserved LV
function and no LM disease. The older recommendation was based on
evidence from registry studies,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R297"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">26</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R300"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">29</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R319"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">48</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R328"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">57</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;a
meta-analysis,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R281"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">10</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
a single RCT,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R284"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">13</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;all
of which were completed &gt;20 to 40 years ago before the development
of newer surgical techniques or advances in medical therapy
associated with improved prognosis.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R329"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">58</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R330"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">59</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Newer
evidence from the ISCHEMIA trial</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R285"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">14</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
from meta-analyses, which incorporated</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R286"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">15</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R331"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">60-62</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;or
did not incorporate</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R308"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">37</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;the
ISCHEMIA results, as well as a more detailed review of earlier
studies</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R334"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">63</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;supported
this downgrade. After several hours of deliberation, the writing
committee concluded that using CABG as a revascularization strategy
versus medical therapy alone “may be reasonable” to improve
survival in stable patients with 3-vessel CAD. The writing committee
recognized that an adequately powered trial to test this hypothesis
is unfeasible in the current era but proposed that revascularization
confers other benefits to patients with multivessel CAD and SIHD.
Accordingly, Section 7.3. highlights the advantages of
revascularization over medical therapy for the prevention of
cardiovascular events.</font></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">6.
The writing committee reviewed newer evidence and concluded that the
ability of PCI to improve survival, compared with medical therapy
alone in patients with multivessel CAD, remains uncertain. The
recommendation, which reflects a weaker endorsement for PCI than for
CABG in patients with multivessel CAD, is supported by evidence from
an older registry study</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R319">48</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
a subgroup analysis of patients receiving everolimus-eluting stents
in a network meta-analysis</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R308">37</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;that
did not incorporate the results of the ISCHEMIA trial.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R285">14</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
preponderance of newer evidence against a survival advantage of PCI
comes from the ISCHEMIA trial itself,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R285">14</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;which
is consistent with the results of multiple earlier RCTs</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R288">17-23</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
multiple contemporary meta-analyses</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R286">15</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R331">60-62</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;incorporating
the ISCHEMIA trial results,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R285">14</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;all
of which have not shown a survival advantage for PCI over medical
therapy for patients with multivessel CAD.</span></font></p>
<h6 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font size="2" style="font-size: 9pt"><i><b>Stenosis in the Proximal
LAD Artery</b></i></font></h6>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">7.
An earlier meta-analysis</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R281">10</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
several earlier registry studies</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R297">26</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R300">29</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;suggested
a survival advantage of CABG over medical therapy in patients with
disease in the proximal LAD. Additionally, a network meta-analysis
found a survival advantage for PCI.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R37">37</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;However,
a dedicated RCT found no survival advantage for either CABG or PCI
over medical therapy in this setting,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R335">64</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R336">65</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
the ISCHEMIA trial</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R285">14</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;showed
no difference in event rates with either CABG or PCI over medical
therapy when patients had multivessel CAD involving the proximal LAD.
In the ISCHEMIA trial, close to half of enrolled patients had &gt;50%
stenosis of the proximal LAD; in this study, there was no
heterogeneity of treatment effect on outcomes with the presence of
LAD disease.</span></font></p>
<h6 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font size="2" style="font-size: 9pt"><i><b>Single- or Double-Vessel
Disease Not Involving the Proximal LAD</b></i></font></h6>
<p style="line-height: 0.11in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">8.
A clinical principle from several studies is that the more myocardium
is at risk, the greater is the survival advantage of
revascularization over medical therapy, and in patients with little
myocardium at risk (1- or 2-vessel CAD without LAD involvement),
there is likely no survival benefit of revascularization in patients
with SIHD.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R281"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">10</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R288"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">17</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R297"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">26</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R300"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">29</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R308"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">37</font></span></font></a></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">9.
In patients without clinical or physiological evidence of significant
disease, bypass surgery of nonobstructive disease has been reported
to stimulate progression of CAD,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R337">66</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
PCI may precipitate periprocedural MIs</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R294">23</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
is not associated with improved outcomes.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R301">30</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R338">67-69</span></font></span></font></a></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>7.2.
Revascularization to Reduce Cardiovascular Events in SIHD Compared
With Medical Therapy</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu12.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab12.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image21" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">Clinical
practice guidelines have traditionally included recommendations for
revascularization in patients with SIHD based on the ability of CABG
or PCI to improve overall survival (Section 7.1.) or to reduce
ischemic symptoms (Section 7.3.), as compared with medical therapy
alone. However, there are other clinical events that can affect a
patient’s overall prognosis, and that remain important
considerations for patients. Several studies suggest that
revascularization with CABG or PCI lowers the risk of adverse events
such as cardiac death, MI, or urgent revascularization compared with
medical therapy alone.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R342"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">2</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R345"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">5</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R346"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">6</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R349"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">9</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R350"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">10</font></span></font></a></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supporting Text</b></i></font></font></h4>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">1.</span></font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">In
MASS (Medicine, Angioplasty or Surgery Study) II, the 10-year rates
of cardiac death were lower after CABG or PCI than after medical
therapy alone.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R342">2</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Lower
rates of cardiac death were seen after revascularization than with
medical therapy alone in a meta-analysis of 25 studies enrolling
19 806 patients.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R343">3</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;However,
a statistically nonsignificant reduction was seen in a concurrent
meta-analysis of 12 103 patients enrolled in 7 RCTs.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R348">8</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Several
other studies found no difference in cardiac death after
revascularization than with medical therapy alone.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R350">10</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R351">11</span></font></span></font></a></p>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">Cardiac
death may be related to the occurrence of MI after
revascularization.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R352"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">12</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
relative prognostic importance of procedural MIs versus that of late
spontaneous MIs remains uncertain.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R353"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">13</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
the ISCHEMIA trial,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R341"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;the
incidence of procedural type 4a or type 5 MIs was increased with
revascularization, but the incidence of late MI (spontaneous MI [type
1], demand-induced MI [type 2], or MIs associated with stent
thrombosis [type 4b] or with restenosis [type 4c]) was reduced. A
preplanned analysis of the MI patterns in the ISCHEMIA trial</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R344"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">4</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;found
that all-cause death was increased with spontaneous MIs but not with
procedural MIs. A large network meta-analysis found that spontaneous
MI was reduced by revascularization compared with medical therapy
alone.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R343"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">3</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;However,
a concurrent analysis found an increased rate of procedural MI, a
reduced rate of nonprocedural MI, and no difference in overall
MI.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R351"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">11</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;On
the contrary, another meta-analysis of stable patients, did not show
a reduction in MI with revascularization,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R350"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">10</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
1 other study reported reduction in MI with CABG but not with
PCI.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R349"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">9</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Revascularization
with CABG or PCI may reduce the need for subsequent urgent
revascularization or hospitalization for acute coronary events.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R345"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">5-8</font></span></font></a></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>7.3.
Revascularization to Improve Symptoms</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu13.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab13.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image22" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">One
of the main goals of coronary revascularization with either PCI or
CABG surgery is to improve symptoms (</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/f6.xhtml"><font color="#2b7bb9"><span style="text-decoration: none"><font size="2" style="font-size: 9pt">Figure
6</font></span></font></a><font size="2" style="font-size: 9pt">). In
the treatment of patients with SIHD, medical therapy can often be an
effective option. However, studies have shown that revascularization
results in a greater improvement in angina or quality of life than
does medical therapy alone.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R354"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1-6</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Additionally,
some patients may be intolerant of or unwilling to take anti-anginal
medications. For these reasons, revascularization is frequently used
to provide symptom relief.</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supportive Text</b></i></font></font></h4>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">1.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Multiple
RCTs have confirmed that revascularization improves anginal symptoms
to a greater degree than optimal medical therapy.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R354">1-4</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R359">6</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R362">9</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R363">10</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
results of the small ORBITA (Objective Randomised Blinded
Investigation With Optimal Medical Therapy of Angioplasty in Stable
Angina) trial,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R364">11</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;which
randomized patients to PCI or a “sham” procedure, did not support
an improvement in symptoms with PCI and raised questions about the
placebo effect of PCI. However, the larger ISCHEMIA trial reported a
clinically relevant improvement in symptoms at 3 years after PCI or
CABG,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R354">1</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;long
after a placebo effect should have dissipated. This difference was
most pronounced among the patients with more frequent angina at
baseline. In the FREEDOM (Future Revascularization Evaluation in
Patients with Diabetes Mellitus: Optimal Management of Multivessel
Disease) trial,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R357">4</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;both
revascularization options were associated with significant
improvement in angina and quality of life as compared with baseline.
A greater improvement in health status was noted with CABG compared
with PCI at intermediate-term follow-up, but this difference was no
longer significant in longer-term follow-up.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">2.</span></font></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Inappropriate
revascularization of nonobstructive plaques with CABG can lead to
progression of underlying CAD,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R360">7</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
inappropriate use of PCI can cause periprocedural MIs</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R361">8</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
would not be expected to improve quality of life or anginal symptoms.</span></font></p>
<h2 class="western" align="left" style="line-height: 0.22in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="3" style="font-size: 11pt"><b>8.
Situations in Which PCI or CABG Would Be Preferred</b></font></font></h2>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>8.1.
Patients With Complex Disease</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu14.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab14.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image23" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">Revascularization
with either CABG or PCI is indicated to treat symptoms or improve
outcomes in specific subsets of patients. However, CABG and PCI are
inherently different in the mechanisms by which they improve blood
flow to the jeopardized myocardium. PCI will directly relieve a
discrete obstruction and increase the arterial lumen in the stented
area but will have no effect on preventing plaque progression or
rupture in other diseased segments within the artery. In contrast,
bypass of a coronary artery will improve blood flow to the
jeopardized myocardium supplied by the diseased artery and will also
protect the distal myocardial beds from future ischemic insult caused
by proximal plaque progression or rupture. Although most studies
comparing CABG and PCI have reported similar
survival,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R365"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R367"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">3</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R369"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">5-17</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;certain
subgroups of patients have been shown to derive a survival benefit
from CABG compared with PCI.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R365"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R366"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">2</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R368"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">4</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R382"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">18</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Additionally,
compared with PCI, CABG may be more effective at reducing the risk of
late spontaneous MI.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R375"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">11</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R383"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">19</font></span></font></a></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supporting Text</b></i></font></font></h4>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">1.</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">The
SYNTAX trial, which included 705 patients with left main stenoses and
a range of complexity of disease, showed a significantly higher MACE
and cardiac mortality rate at 5 years for the subgroup of patients
with left main and high-complexity disease (defined as a SYNTAX score
&gt;33) who were treated with PCI.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R365">1</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;With
the exception of the SYNTAX trial, the other RCTs comparing PCI with
CABG in patients with left main disease excluded patients with
complex disease.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R370">6</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R372">8</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R384">20</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Individual
factors that contribute to anatomic complexity (severe tortuosity,
heavy calcification, complex bifurcation or trifurcation lesion,
aorto-ostial stenosis, thrombotic lesion, etc) are listed in&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="2" style="font-size: 9pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/t7.xhtml">Table
6</font></span></font></a><font size="2" style="font-size: 9pt">. In
choosing between CABG and PCI, it is important to use the Heart Team
to determine the optimal revascularization strategy, with specific
considerations of anatomic complexity, medication compliance, and
patient preference.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">2.</span></font></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">In
the SYNTAX trial, which randomized patients with multivessel disease
to a strategy of CABG or PCI with DES, the SYNTAX score was used a
priori to define the complexity of disease in enrolled patients.
Although the SYNTAX trial reported similar mortality rates with CABG
and PCI in the overall group of patients, extended follow-up of the
SYNTAX trial found a 40% higher mortality rate with PCI in the group
of patients with triple-vessel disease.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R368">4</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Several
analyses found that the extent and diffuseness of CAD on angiography,
as evaluated qualitatively by visual assessment or quantitatively
with the SYNTAX score,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R367">3</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;predicted
a survival advantage of CABG over PCI.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R369">5</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Specifically,
the all-cause mortality rate observed after CABG was lower than that
observed after PCI in patients with a diffuse CAD–associated high
SYNTAX score of ≥33.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R366">2</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R368">4</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R369">5</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
patients with SYNTAX scores &lt;33, there was no difference in
mortality rate.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R366">2-5</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Of
note, the SYNTAX trial included patients with first-generation DES,
and significant progress has been made in stent design since this
trial.</span></font></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>8.2.
Patients With Diabetes</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu15.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab15.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image24" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">Revascularization
decisions in patients with diabetes and multivessel CAD are complex
and are optimized via a Heart Team approach, with consideration of
left ventricular function, patient preferences, symptoms, clinical
presentation, comorbidities, and expected survival.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R385"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R396"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">12-14</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Diabetes
is associated with 2- to 4-fold increased mortality risk from heart
disease, and patients with diabetes have more aggressive
atherosclerosis, more diffuse coronary lesions, smaller coronary
vessels, and more extensive disease. After coronary
revascularization, patients with diabetes experience a higher
mortality rate and greater need for repeat revascularization
procedures.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R399"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">15</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Clinical
trials of patients with diabetes and multivessel CAD have
demonstrated that PCI is associated with a higher mortality rate at 5
years than that associated with CABG. The survival advantage of CABG
becomes evident after 2 years and attenuates after 8 years, as
patients treated with CABG experience a late mortality
catch-up.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R386"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">2</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R400"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">16</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Of
note, CABG is associated with an increased risk of stroke that
persists up to 5 years.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R401"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">17</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
need for repeat revascularization is higher after PCI, regardless of
the use of latest-generation DES.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R385"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R388"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">4-8</font></span></font></a></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supportive Text</b></i></font></font></h4>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">1.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Multiple
RCTs comparing PCI with CABG in patients with multivessel CAD have
included patients with diabetes</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R385">1-3</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;or
have prespecified patients with diabetes as a subgroup of
interest.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R388">4</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R389">5</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R391">7</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
FREEDOM trial was the largest study, comparing CABG with PCI
exclusively in 1900 patients with diabetes.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R388">4</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R389">5</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R391">7</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Inclusion
criteria for the FREEDOM trial were multivessel disease with stenosis
of 70% in ≥2 major epicardial vessels involving at least 2 separate
territories and without left main stenosis. After enrollment, 82% of
patients in the PCI group and 85% of patients in the CABG group had
3-vessel disease, and 91% of patients had involvement of the LAD
artery. At 5-year follow-up, the all-cause mortality rate was higher
in patients treated with PCI than in those treated with CABG;
however, the cardiovascular mortality rate was not statistically
different between the groups. There was no statistical interaction
between SYNTAX score, revascularization strategy, or mortality rate,
which suggests that a benefit was noted irrespective of the
complexity of disease.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R385">1</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
the FREEDOM follow-up study, the all-cause mortality rate up to 8
years was also significantly higher with PCI. A meta-analysis
including individual patient data from 11 RCTs demonstrated
consistent results, with a nearly 50% higher increased 5-year
mortality risk among patients treated with PCI than among those
treated with CABG.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R388">4</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R389">5</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R391">7</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;A
Heart Team discussion may be useful for determining the optimal
approach to care for patients with less extensive disease, including
those with double-vessel disease without involvement of the left main
or LAD artery.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">2.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Patients
with diabetes who are at high surgical risk and require coronary
revascularization are more likely to be treated with PCI in current
practice.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R393">9</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
an observational registry that included high-risk patients with
refractory ischemia, 5-year survival rates were similar among those
treated with CABG and PCI.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R394">10</span></font></span></font></a></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">3.</span></font></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">There
are no RCTs specifically comparing PCI with CABG in patients with
diabetes and left main CAD. However, a large RCT exclusively enrolled
patients with left main CAD, and the subgroup analysis of patients
with diabetes informs this recommendation.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R397">13</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
the EXCEL trial, which included patients with left main CAD and low-
or intermediate-complexity CAD, approximately 30% of patients had
diabetes. At 3 years, the composite of death, stroke, or MI was not
significantly different between PCI and CABG among patients with
diabetes. However, the all-cause mortality rate was almost 2 times
higher in the PCI group. There was no interaction between diabetes
status and revascularization modality.</span></font></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>8.3.
Patients With Previous CABG</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu16.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab16.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image25" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">A
Heart Team approach and shared decision-making are important in
patients who require repeat revascularization after CABG. There are
no randomized trials comparing medical therapy with revascularization
in patients with previous CABG. PCI and repeat CABG in patients with
previous CABG are associated with higher rates of procedural failure
and complications</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R406"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">5</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R407"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">6</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
worse outcomes than those of patients without previous CABG.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R407"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">6-8</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
need for any repeat revascularization after PCI or CABG is itself an
independent predictor of higher mortality risk.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R410"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">9</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Factors
that influence the choice of revascularization modality include the
availability of the IMA for grafting, a patent graft to the LAD,
comorbid conditions, patient factors and preferences, the quality of
the target vessels, anatomic complexity of the native and graft
disease, and the feasibility and risks of the revascularization
method.</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supportive Text</b></i></font></font></h4>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">1.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">In
patients with previous CABG, percutaneous intervention of a native
vessel or a saphenous vein graft (SVG) is probably indicated in
preference to redo CABG, particularly if a LIMA-LAD is not planned or
if the patient already has a patent LIMA-LAD, which increases the
risk of a redo sternotomy. Randomized and retrospective comparisons
of PCI versus repeat CABG show lower in-hospital stroke and mortality
rates associated with PCI,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R403">2</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R404">3</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;although
long-term mortality rates appeared similar. In circumstances of acute
graft closure, PCI of the native vessel is often performed in
preference to redo CABG</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R411">10</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;or
treating an acutely thrombosed graft with fresh suture lines.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R412">11</span></font></span></font></a></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">2.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">A
patient with previous CABG faces increased risk during
revascularization via CABG,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R410">9</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;including
higher rates of in-hospital death and stroke, compared with patients
who undergo revascularization via PCI.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R403">2</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R404">3</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Observational
data suggest that the use of CABG over PCI may result in improved
long-term outcomes; however, results are inconsistent and not
supported by high-quality RCTs.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R404">3</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R413">12</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R414">13</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;If
PCI is not an option, if a patent IMA to LAD is not present, or if an
IMA is available to be used as a conduit for the LAD, CABG is often
chosen as the revascularization strategy in patients with previous
CABG and refractory angina who are at an acceptable risk for
reoperation.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R404">3</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R405">4</span></font></span></font></a></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">3.</span></font></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Two
large observational studies with propensity matching in patients with
previous CABG and complex CAD inform decisions about
revascularization. The first noted that current clinical practice
favored redo CABG over PCI for patients at higher risk and with fewer
functional grafts, more CTOs, and lower systolic function, whereas
PCI was favored in patients with a patent LIMA and amenable
anatomy.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R404">3</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
second noted that LIMA grafting to the LAD confers a long-term
survival advantage.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R405">4</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Thus,
decisions about revascularization should involve consideration of
factors that may favor repeat CABG, such as the availability of an
IMA for LAD grafting, ability to provide left main revascularization,
recurrent restenosis of stents, or high-complexity PCI, in such
patients.</span></font></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>8.4.
DAPT Adherence</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu17.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab17.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image26" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">In
patients undergoing coronary revascularization, careful consideration
should be given to factors that may affect adherence to medications,
including patient preferences and comorbidities, socioeconomic
status, and lifestyle factors. Premature cessation of DAPT after PCI
is associated with stent thrombosis and poor outcomes, including
death.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R414a"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1-10</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Therefore,
PCI is not favored as the mode of revascularization among patients
manifesting risk factors for poor adherence.</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supporting Tex</b></i></font></font></h4>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">1.</span></font></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Stent
thrombosis after PCI is associated with large-territory MI and poor
outcomes, with death rates as high as 50% for early thrombosis
cases.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R414a">1</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R418">5</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R422">9</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Risk
factors for stent thrombosis are many and include patient-, lesion-,
and treatment-specific factors.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R415">2</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Early
DAPT interruption—for bleeding, procedures, or nonadherence—is a
reversible risk factor that is strongly associated with stent
thrombosis, particularly early after PCI, with the relative increase
in stent thrombosis rates between 2-fold and &gt;20-fold.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R415">2</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R417">4</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R421">8</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R423">10</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Given
the morbidity and mortality associated with stent thrombosis and the
strong association of nonuse of DAPT with stent thrombosis, CABG is a
safe revascularization option in patients who are not likely to be
adherent to DAPT.</span></font></p>
<h2 class="western" align="left" style="line-height: 0.22in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="3" style="font-size: 11pt"><b>9.
Special Populations and Situations</b></font></font></h2>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>9.1.
Revascularization in Pregnant Patients</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu18.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab18.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image27" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">In
pregnant patients, an expanded, multidisciplinary Heart Team approach
is often used to determine the appropriate coronary revascularization
treatment, with consideration of patient preferences, comorbidities,
and clinical status. Decisions in pregnant patients are often
difficult and must include consideration of the risk to the unborn
fetus, as well as the risks and benefits to the mother. Pregnant
women are generally excluded from clinical trials, and therefore
there is limited evidence regarding the safety of antiplatelet agents
during pregnancy, especially during the third trimester. Low-dose
aspirin is generally felt to be safe throughout pregnancy. If
clopidogrel is needed, it should be used for the shortest duration
possible</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R426"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">3</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R427"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">4</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;with
close monitoring. In a recent systematic review of 39 publications
with 42 live births, the outcomes for both mothers and neonates when
exposed to clopidogrel at varying durations throughout gestation, did
not suggest higher than acceptable risk, with a congenital anomaly
rate comparable to background risk. The evidence regarding the use of
other antiplatelet agents remains limited.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R427"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">4</font></span></font></a></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supportive Text</b></i></font></font></h4>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">1.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">The
coronary revascularization treatment in the pregnant patient with
STEMI is typically via PCI,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R428">5</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
CABG is usually performed when medical therapy or PCI fails and the
mother’s life is threatened.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R424">1</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R425">2</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
a large, retrospective review of pregnant patients with AMI, STEMI
was noted in 42% of these patients. Approximately 25% to 40% of
pregnant patients with AMI were referred for invasive evaluation, and
roughly 25% of pregnant patients received coronary revascularization
(with most patients receiving PCI). Compared with a conservative
approach, an invasive approach for the treatment of the AMI was
associated with a significantly lower adjusted in-hospital mortality
rate.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">2.</span></font></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">In
a large database of pregnant patients with AMI,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R425">2</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;a
larger proportion of patients with NSTE-ACS were conservatively
treated. If medical therapy is ineffective for the management of
these patients because of ongoing ischemia, hemodynamic comprise, or
electrical instability, an invasive approach was noted to be
reasonable.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R425">2</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R428">5</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R429">6</span></font></span></font></a></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>9.2.
Revascularization in Older Patients</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu19.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab19.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image28" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">Although
the terms “elderly” or “older” have been used to describe
various patient-age subgroups in the literature, most clinical trials
have defined older patients as those ≥75 years of age.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R432"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">3</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Older
patients form a vulnerable subset of patients undergoing coronary
revascularization because of their more complex presentations and
higher prevalence of comorbidities.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R433"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">4</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R434"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">5</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
addition, they have an increased risk of bleeding complications and
stroke after PCI.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R432"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">3</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R435"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">6-8</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;However,
the optimal treatment for older patients with an indication for
revascularization remains poorly defined because most studies have
excluded older patients and included only low-risk populations.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R438"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">9</font></span></font></a></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supportive Text</b></i></font></font></h4>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">1.</span></font></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Older
patients constitute a growing, high-risk population with increased
rates of adverse events.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R439">10-12</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;These
patients pose additional challenges because of adverse interactions
caused by polypharmacy and age-related changes in cardiovascular
function and coronary anatomy.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R434">5</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R442">13-15</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Although
older patients benefit from revascularization to the same, if not
greater, extent as younger patients,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R445">16</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;the
optimal strategy should be chosen according to patient-centered goals
of care.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R446">17</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Subgroup
analyses from recent randomized trials have demonstrated that
relative outcomes after PCI and CABG are comparable in older
patients, with CABG being better at achieving complete
revascularization, whereas PCI is preferred for frail patients at
higher risk of periprocedural events.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R447">18-21</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Careful
consideration of risks and benefits using a Heart Team, and in
accordance with the patient’s preferences, while accounting for
frailty and cognitive status, is vital in decisions about the
appropriate revascularization plan for older patients.</span></font></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>9.3.
Revascularization in Patients With Chronic Kidney Disease (CKD)</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu20.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab20.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image29" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">Patients
with CKD constitute a growing subset of the population</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R457"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">7</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R458"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">8</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
have been found to have worse outcomes after AMI or PCI.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R459"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">9</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R460"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">10</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Risk
of cardiovascular death has been shown to be inversely proportional
to estimated glomerular filtration rate, with impaired renal function
being an independent predictor of cardiovascular risk.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R461"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">11</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R462"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">12</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Although
about 30% to 40% of all patients undergoing PCI have concomitant
CKD,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R463"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">13</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R464"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">14</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;data
on optimal treatment strategies in this population remain scarce
because most RCTs have traditionally excluded patients with severe
CKD. Patients with CKD who present with ACS are less likely to
receive GDMT or invasive angiography than are patients with normal
renal function, and the likelihood of undergoing cardiovascular
interventions decreases with increasing severity of
CKD.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R459"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">9</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R465"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">15-17</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Before
coronary angiography is performed, the risks of AKI and the benefits
of obtaining diagnostic information should be carefully considered.
Preexisting CKD is the strongest independent risk factor for the
development of AKI, with a higher stage of CKD associated with
incrementally higher risk.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R456"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">6</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R457"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">7</font></span></font></a></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supportive Text</b></i></font></font></h4>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">1.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Adequate
hydration</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R468">18-20</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
minimization of the volume of contrast media</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R471">21-23</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;remain
the principal strategies for contrast-induced nephropathy prevention
(</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="2" style="font-size: 9pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/t9.xhtml">Table
8</font></span></font></a><font size="2" style="font-size: 9pt">).
High-dose statins before diagnostic catheterization have been
demonstrated to reduce the occurrence of contrast-induced
AKI</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R471">21</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R474">24</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R475">25</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;because
of their pleotropic effects that decrease systemic inflammation,
possibly by decreasing the synthesis of endothelin-1 and inhibiting
tissue-factor expression by macrophages.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R476">26-29</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Atheroembolism
may have a role in AKI after PCI,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R480">30</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
a transfemoral approach may increase this risk because of the
proximity to renal arteries.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R481">31</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Consistent
with this, the use of radial access has been shown to significantly
reduce the risk of AKI compared with femoral access.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R481">31-33</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;All
other measures believed to reduce the risk of contrast-induced AKI
have not demonstrated significant clinical benefit.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R462">12</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R481">31</span></font></span></font></a></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">2.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">On
the basis of multiple randomized trials, prompt coronary angiography
and revascularization have been recommended for patients presenting
with STEMI.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R484">34</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;However,
patients with severe CKD were often excluded from these studies
because of their higher risk of adverse ischemic and bleeding events,
as well as their higher risk of contrast-induced AKI. Nonetheless,
the mortality benefit of revascularization in patients with STEMI and
CKD outweighs the risk of adverse outcomes when adequate measures to
reduce the risk of AKI are taken before, during, and after the
procedure.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">3.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Several
observational studies have reported worse in-hospital outcomes and
long-term mortality rate for patients with NSTE-ACS and CKD than for
those without CKD.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R485">35-37</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Despite
this, an early invasive strategy in high-risk patients with NSTE-ACS
was shown to be associated with significant risk reduction versus a
noninvasive approach.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R459">9</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Although
the use of PCI for NSTE-ACS has been found to decrease with
increasing CKD severity, revascularization in these patients is
associated with a lower in-hospital mortality rate than that seen
with medical management.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R455">5</span></font></span></font></a></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">4.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Although
a routine invasive approach has been shown to improve outcomes in
patients presenting with NSTE-ACS, this risk reduction was evident
mostly in the high-risk subgroups.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R459">9</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
risk–benefit ratio of revascularization in patients with low-risk
NSTE-ACS remains uncertain because of limited evidence. Therefore, in
low-risk patients with NSTE-ACS with CKD, astute clinical judgment
weighing the trade-off between risks and benefits is required to
determine the optimal approach in this patient subgroup.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">5.</span></font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">ISCHEMIA-CKD
was the first randomized trial to test the benefit of adding cardiac
catheterization and, if feasible, revascularization to GDMT in stable
patients with moderate CKD and at least moderate ischemia.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R456">6</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;With
patients randomized to either an invasive or conservative strategy,
an initial invasive strategy did not demonstrate a reduced risk of
clinical outcomes or improved quality-of-life measures compared with
an initially conservative strategy.</span></font></p>
<p style="line-height: 0.14in; margin-bottom: 0in"><font color="#d93731"><font size="1" style="font-size: 8pt"><b>Table
9</b></font></font>. Oral and Parenteral Antiplatelet Agents for
Patients Undergoing PCI&nbsp;<font size="1" style="font-size: 8pt">(</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/t9.xhtml"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt">Table
view</font></span></font></a><font size="1" style="font-size: 8pt">)</font></p>
<table cellpadding="2" cellspacing="2">
	<thead>
		<tr>
			<th style="border: 1px solid #2c2e35; padding: 0.02in"><p style="font-weight: normal">
				Drug</p>
			</th>
			<th style="border: 1px solid #2c2e35; padding: 0.02in"><p style="font-weight: normal">
				Loading Dose</p>
			</th>
			<th style="border: 1px solid #2c2e35; padding: 0.02in"><p style="font-weight: normal">
				Maintenance Dose</p>
			</th>
		</tr>
	</thead>
	<tbody>
		<tr>
			<td colspan="3" style="border: 1px solid #2c2e35; padding: 0.02in"><p>
				<font size="1" style="font-size: 8pt">Oral antiplatelet agents</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Aspirin</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Loading
				dose of 162-325 mg orally</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R687"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">11</font></span></font></a><font size="1" style="font-size: 8pt"><br/>
Aspirin
				may be chewed to achieve faster action</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Maintenance
				dose of 75-100 mg orally daily</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R700"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">24</font></span></font></a><font size="1" style="font-size: 8pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R701"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">25</font></span></font></a></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Clopidogrel</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Loading
				dose of 600 mg orally</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R695"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">19</font></span></font></a><font size="1" style="font-size: 8pt"><br/>
A
				lower loading dose of 300 mg should be considered in patients
				after fibrinolytic therapy</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R681"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">5</font></span></font></a></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Maintenance
				dose of 75 mg orally daily</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R710"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">34</font></span></font></a></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Prasugrel</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Loading
				dose of 60 mg orally</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R696"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">20</font></span></font></a></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Maintenance
				dose of 10 mg orally daily</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R696"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">20</font></span></font></a><font size="1" style="font-size: 8pt"><br/>
In
				patients with body weight &lt;60 kg, a maintenance dose of 5 mg
				orally daily is recommended</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R711"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">35</font></span></font></a><font size="1" style="font-size: 8pt"><br/>
In
				patients ≥75 years of age, a dose of 5 mg orally daily can be
				used if deemed necessary</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R711"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">35</font></span></font></a></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Ticagrelor</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Loading
				dose of 180 mg orally</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R690"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">14</font></span></font></a><font size="1" style="font-size: 8pt"><br/>
Ticagrelor
				may be chewed to achieve faster action</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Maintenance
				dose of 90 mg orally twice a day</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R690"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">14</font></span></font></a></p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="border: 1px solid #2c2e35; padding: 0.02in"><p>
				<font size="1" style="font-size: 8pt">Intravenous antiplatelet
				agents</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Abciximab
				(GPI)</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#tab9fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt">*</font></span></font></a></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Bolus
				of 0.25 mg/kg</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R712"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">36</font></span></font></a></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Maintenance
				of 0.125 μg/kg/min infusion (maximum 10 g/min) for 12 h.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R712"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">36</font></span></font></a></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Eptifibatide
				(GPI)</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Double
				bolus of 180 μg/kg (given at a 10-min interval)</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R713"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">37</font></span></font></a></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Maintenance
				infusion of 2.0 μg/kg/min for up to 18 h</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R713"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">37</font></span></font></a></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Tirofiban
				(GPI)</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Bolus
				of 25 μg/kg over 3 min</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R714"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">38</font></span></font></a></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Maintenance
				infusion of 0.15 μg/kg/min for up to 18 h</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R714"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">38</font></span></font></a></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Cangrelor</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Bolus
				of 30 μg/kg</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R715"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">39</font></span></font></a></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Maintenance
				infusion 4 μg/kg/min for at least 2 h or duration of the
				procedure, whichever is longer</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R715"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">39</font></span></font></a></p>
			</td>
		</tr>
	</tbody>
</table>
<p align="justify" style="line-height: 0.13in; margin-bottom: 0in"><font size="1" style="font-size: 7pt">GPI
indicates glycoprotein IIb/IIIa inhibitor; and PCI, percutaneous
coronary intervention.</font></p>
<p align="justify" style="line-height: 0.13in; margin-bottom: 0in"><font size="1" style="font-size: 7pt">*</font></p>
<div id="tab9fn1" dir="ltr"><p align="justify" style="line-height: 0.13in; margin-bottom: 0in">
	<font size="1" style="font-size: 7pt">Abciximab may not be readily
	available to clinicians in the United States.</font></p>
</div>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>9.4.
Revascularization in Patients Before Noncardiac Surgery</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu21.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab21.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image30" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">Patients
with significant CAD who are undergoing high-risk surgery, such as
solid organ transplantation</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R497"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">2</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;or
vascular surgery,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R498"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">3</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;have
an increased incidence of perioperative cardiovascular events.
Routine prophylactic revascularization does not reduce the risk of
death or cardiovascular events.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R496"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Clinical
studies have excluded or randomized few patients with high-risk
coronary anatomy such as unprotected left main and multivessel CAD.
Additionally, these studies did not include patients referred for
solid organ transplantation. In such patients, a Heart Team approach
would be used to determine the risks and benefits of
revascularization. In symptomatic patients or patients with other
clinical indications for revascularization, coronary
revascularization should be considered in accordance with the
recommendations otherwise provided for such situations, but
revascularization should not be done for the sole purpose of reducing
perioperative complications.</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supportive Text</b></i></font></font></h4>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">1.</span></font></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">One
clinical trial has shown a lack of benefit for routine
revascularization in patients before vascular surgery.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R496">1</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
CARP (Coronary Artery Revascularization Prophylaxis) study randomized
510 asymptomatic patients with ≥1 significant coronary lesion to
revascularization with PCI or CABG or to medical therapy and found no
difference in 30-day and 1-year rates of death or MI. Most patients
in this study had only single- or 2-vessel CAD, and patients with
left main CAD, left ventricular ejection fraction &lt;20%, or severe
aortic stenosis were excluded.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R496">1</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Nonrandomized
patients with unprotected left main CAD who were excluded from the
CARP study did derive benefit from revascularization.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R498">3</span></font></span></font></a></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>9.5.
Revascularization in Patients to Reduce Ventricular Arrhythmias</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu22.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab22.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image31" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">In
patients with ventricular arrhythmias, the evaluation for potential
ischemic CAD will guide appropriate treatment, including coronary
revascularization.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R508"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">10</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R509"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">11</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
“2017 AHA/ACC/HRS Guideline for Management of Patients With
Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death”
describes situations in which CABG or PCI may benefit patients with
ischemic CAD.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R510"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">12</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Observational
studies have shown that revascularization in patients with
life-threatening ventricular arrhythmias</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R500"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">2</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R511"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">13</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
in survivors of cardiac arrest</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R512"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">14</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;is
associated with arrhythmia reduction and improved survival.
Monomorphic VT may be seen in patients with large AMIs; however, it
is often attributable to reentrant rhythms from scar and not acute
ischemia. Therefore, revascularization alone has not been shown to
improve patient outcomes.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R513"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">15</font></span></font></a></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supportive Text</b></i></font></font></h4>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">1.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">In
patients who survive cardiac arrest or have ventricular fibrillation
or polymorphic VT, revascularization with CABG</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R501">3</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;or
PCI</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R500">2</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;is
associated with a lower likelihood of death.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R499">1</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R514">16</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
patients with decreased left ventricular ejection fraction and
ischemic heart disease amenable to CABG, the risk of sudden cardiac
death is lower with CABG than with medical therapy.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R515">17</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R516">18</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Although
definitive conclusions may not be drawn from these studies because of
the selection and survival biases inherent to these observational
studies, revascularization may reduce the burden of polymorphic VT
and ventricular fibrillation, resulting in improved survival.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">2.</span></font></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">In
contrast to ventricular fibrillation and polymorphic VT, monomorphic
VT in the nonacute setting is typically attributable to scar-related
reentry or increased automaticity, rather than coronary artery
ischemia.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R517">19</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;There
are limited reports of AMIs presenting with monomorphic
VT,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R518">20</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;isolated
coronary artery ischemia causing isolated bundle-branch VT that is
successfully treated with PCI,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R519">21</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
exercise-induced VT associated with ischemia that resolves after
CABG.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R517">19</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R520">22</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Retrospective
studies show an association of incomplete or unsuccessful
revascularization of CAD with a higher VT burden and worse outcomes,
but the association is most likely because of patient-level factors
rather than the success of the intervention.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R499">1</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R507">9</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R521">23</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
numerous large cohort studies, elective coronary artery
revascularization alone has not been shown to reduce ventricular
arrhythmias in stable patients.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R503">5-8</span></font></span></font></a></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>9.6.
Revascularization in Patients With SCAD</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu23.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab23.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image32" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">SCAD
is characterized by the interruption of the coronary artery intimal
layer and intramural hematoma, causing vessel compression, and
typically presenting as an ACS. Although most dissections will heal
without intervention, a notable subset is associated with ongoing
symptomatic ischemia, which can progress to complete occlusion.
Treatment of patients with SCAD is challenging, and guidance from
randomized trials is lacking. Observational studies indicate that
most conservatively managed patients recover without further
intervention. In patients with ongoing ischemia, vessel occlusion, or
patient instability, selective revascularization may be necessary.
However, unlike other forms of ACS, routine revascularization for
patients with SCAD may not confer the same benefit. PCI wires may
propagate the dissection, and balloons and stents can extend the
hematoma and lead to vessel occlusion. CABG onto a dissected vessel
or one with a propensity to dissect is challenging, and as many as
30% of patients have acute graft closure.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R526"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">5</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
current state of the science and best practices for treating SCAD are
described in the AHA scientific statement, which is based on an
evaluation of retrospective studies and expert opinion.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R527"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">6</font></span></font></a></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supportive Text</b></i></font></font></h4>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">1.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Although
SCAD will often heal with conservative management, patients with
ongoing ischemia, vessel occlusion, or instability may require urgent
revascularization. In a retrospective study of 53 patients with SCAD
and presenting with STEMI, 62% underwent revascularization with PCI
and 7.5% with CABG. Although rates of revascularization and PCI
success were lower in patients with SCAD than in age-matched patients
with STEMI attributable to atherosclerosis, overall survival was
higher in patients with SCAD.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R524">3</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;A
single-center, retrospective study of 189 patients with SCAD reported
similar mortality rates at 5 years with a strategy of
revascularization and with conservative care. In this cohort of
patients, there was a higher rate of emergency or urgent CABG in
patients with a patent vessel when they were treated with PCI versus
conservative care.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R526">5</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Although
there are no RCTs comparing revascularization with conservative care
in patients who have failed medical therapy, it is reasonable to
consider revascularization in the presence of ongoing ischemia and
hemodynamic instability.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">2.</span></font></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Three
large, single-center retrospective studies of patients undergoing PCI
for SCAD described a failure rate of 35% to 53% and a need for urgent
CABG of 9% to 13%. In these studies, conservatively treated patients
experienced recurrent symptoms leading to revascularization only 2%
to 10% of the time.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R522">1</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R523">2</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R526">5</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R528">7</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Two
meta-analyses evaluated the outcomes of patients who were treated
conservatively compared with those who were acutely
revascularized.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R522">1</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R525">4</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;There
were no differences in short- or long-term mortality rate, MI, heart
failure, or SCAD recurrence between the groups. However, in the 3
largest retrospective studies, there was a strong indication that
there were more cardiovascular events in patients who had a
first-line revascularization strategy. These studies are limited by
selection and treatment biases, as revascularization was typically
performed on higher-risk patients who were more likely to have an
occluded artery.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R523">2</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R526">5</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R528">7</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Nevertheless,
despite these limitations, the data support a conservative management
approach in clinically stable patients.</span></font></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>9.7.
Revascularization in Patients With Cardiac Allografts</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu24.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab24.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image33" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">In
patients after orthotopic heart transplantation, the onset of
allograft vasculopathy presents a challenging treatment dilemma.
Cardiac allograft vasculopathy is a major cause of death after the
first year following orthotopic heart transplantation.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R531"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">3-5</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Cardiac
allograft vasculopathy is often diffuse and characterized by
concentric and rapidly progressive intimal hyperplasia.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R534"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">6</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R535"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">7</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Multiple
immunologic and nonimmunologic risk factors have been linked to the
accelerated progression of disease.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R536"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">8</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R537"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">9</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Treatment
options are limited, with retransplantation being the only definitive
therapy for cardiac allograft vasculopathy.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R538"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">10</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;However,
the scarcity of donor organs and worse outcomes, compared with
initial transplantation, remain important
limitations.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R539"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">11</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R540"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">12</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Revascularization
with PCI serves as a palliative treatment option in patients with
focal disease.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R530"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">2</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R541"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">13</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Studies
have demonstrated lower periprocedural and intermediate-term
mortality rates with stent implantation than with balloon
angioplasty.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R537"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">9</font></span></font></a></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supportive Text</b></i></font></font></h4>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">1.</span></font></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Because
the pathogenesis of cardiac allograft vasculopathy involves more
diffuse intimal hyperplasia than focal atherosclerotic plaques, rates
of death and MI remain higher in these patients.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R541">13</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R542">14</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Use
of PCI can be beneficial in patients with cardiac allograft
vasculopathy who present with severe, proximal, discrete
lesions.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R529">1</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R530">2</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Although
DES have demonstrated a clear benefit over bare-metal stents (BMS)
for native CAD, patients with cardiac allograft vasculopathy were not
included in these trials. However, there is a signal toward better
outcomes with DES, especially with regard to the occurrence of
restenosis.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R532">4</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R543">15</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R544">16</span></font></span></font></a></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>9.8.
Revascularization in Patients Before Transcatheter Aortic Valve
Replacement (TAVR)</b></font></font></h3>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>9.8.1.
Special Considerations Before Transcatheter Valve Therapy</b></i></font></font></h4>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">Recommendations
for revascularization in patients before TAVR should be accessed in
the 2020 valvular heart disease guideline.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R545"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1</font></span></font></a></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>9.9.
Revascularization in Patients With Anomalous Coronary Artery</b></font></font></h3>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">Coronary
artery anomalies are among the most common congenital cardiovascular
abnormalities. These include the anomalous aortic origin of a
coronary artery, coronary fistula, and myocardial bridge. Natural
history and presentation can be extremely variable, and much of the
historical data from autopsy and surgical studies are now being more
fully informed by increasing diagnostic capability.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R546"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R547"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">2</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Sudden
cardiac death and myocardial ischemia remain the major clinical
concerns. The presentation and most appropriate management of these
patients was reviewed extensively in the “2018 AHA/ACC Guideline
for the Management of Adults With Congenital Heart Disease,” which
has provided guidance that reflects the current state of the evolving
evidence.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R548"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">3</font></span></font></a></p>
<h2 class="western" align="left" style="line-height: 0.22in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="3" style="font-size: 11pt"><b>10.
General Procedural Issues for PCI</b></font></font></h2>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>10.1.
Radial and Femoral Approaches for PCI</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu25.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab25.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image34" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">Over
the past decade, the proportion of patients undergoing radial artery
catheterization and PCI has increased exponentially.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R556"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">8</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Patients
prefer the transradial approach,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R557"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">9</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
this approach offers the advantage of earlier time to ambulation,
lower rate of vascular and bleeding complications, and improved
cardiovascular outcomes in patients with ACS.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R552"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">4</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;An
important caveat to radial access trials</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R549"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R550"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">2</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R557"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">9</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;is
that the treating physicians were required to have experience in
radial artery access, and therefore, it is not surprising that
femoral crossover rates were notably low among patients assigned to
radial access.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R549"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1-4</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;For
this reason, it is encouraged that all operators gain experience in
radial artery access so that they may ultimately acquire the skills
needed to have expertise with this approach. The decision to use the
transradial approach should be tempered with the possibility that the
radial artery may be needed for bypass grafting in the future. In
patients for whom there is a high likelihood of future CABG, the
choice of vascular access may require discussion with the patient and
the cardiac surgeon. In centers where expertise in the transradial
approach is unavailable, or in those patients who are unable to get
radial artery catheterization because of anatomic or clinical
limitations, femoral artery access remains the default strategy.</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supportive Text</b></i></font></font></h4>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">1.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">The
MATRIX (Minimizing Adverse Haemorrhagic Events by TRansradial Access
Site and Systemic Implementation of angioX Access)
trial</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R550">2</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;demonstrated
a significantly lower rate of the coprimary endpoint of net adverse
clinical events (30-day death, nonfatal infarction and stroke, and
non-CABG major bleeding) among patients with ACS randomized to the
transradial approach than among those randomized to the transfemoral
approach. This difference was driven by a lower rate of bleeding
events and a lower 30-day mortality rate. A prespecified subgroup
analysis of patients with STEMI enrolled in RIVAL (Trial of
Trans-radial versus Trans-femoral Percutaneous Coronary Intervention
Access Site Approach in Patients with Unstable Angina or Myocardial
Infarction Managed with an Invasive Strategy) demonstrated a lower
mortality rate at 30 days with transradial access. A meta-analysis of
the RCT supported these findings and reported lower rates of
mortality and bleeding with radial access in patients with
ACS.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R551">3</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R552">4</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Although
the SAFARI-STEMI (Safety and Efficacy of Femoral Access versus Radial
for Primary Percutaneous Intervention in ST-Elevation Myocardial
Infarction) trial showed no difference in 30-day mortality rate
between radial and femoral access, this trial was stopped early for
futility and enrolled less than half its planned sample size.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R558">10</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Of
note, in patients with a high likelihood of needing future CABG,
radial access of the dominant artery will allow preservation of the
nondominant radial artery for use as a bypass graft.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">2.</span></font></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">In
patients undergoing coronary angiography or PCI without ACS, the
transradial approach significantly reduces bleeding and vascular
access site complications but has not been shown to significantly
reduce rates of MACE or mortality.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R552">4</span></font></span></font></a></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>10.2.
Choice of Stent Type</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu26.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab26.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image35" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">Earlier
studies comparing outcomes with first-generation DES and BMS reported
an increase in late stent thrombosis and increased mortality rate
with DES.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R563"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">5-8</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Over
the past 2 decades, there has been a significant evolution in DES
technology, including the optimization of drug, polymer, and stent
design, which has supported the safety as well as the efficacy of
newer DES. To make sense of the small absolute differences between
stent types, several large meta-analyses have been completed</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R559"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1-4</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
have suggested that the currently available DES have higher efficacy
and safety and lower restenosis rates than both first-generation DES
and BMS.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R559"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1-4</font></span></font></a></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supportive Text</b></i></font></font></h4>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">1.</span></font></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">In
the evaluation of early or late stent thrombosis, several
meta-analyses suggest that stents can be ranked from more safe to
less safe as follows: durable-polymer DES ≥ biodegradable-polymer
DES &gt; BMS.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R559">1-4</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;A
meta-analysis of individual-level data of 20 RCTs (N=26 616), in
which 29% of patients had SIHD, 14% had unstable angina, 25% had
NSTEMI, and 28% had STEMI,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R559">1</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;confirmed
a significantly reduced risk of MI and stent thrombosis, as well as a
trend toward a lower cardiac mortality rate, with a newer-generation
DES compared with a BMS. Newer-generation DES were defined as any DES
released after the original sirolimus-eluting or paclitaxel-eluting
DES. For this reason, there are limited roles for the use of BMS
except for unusual circumstances, such as a lack of DES availability
or unique patient circumstances that warrant extremely short-duration
DAPT (ie, &lt;1 month).</span></font></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>10.3.
Use of Intravascular Imaging</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu27.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab27.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image36" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">Because
of limitations in angiography, intracoronary imaging can be a useful
tool to guide coronary stent implantation, particularly in cases
involving the left main artery or complex lesions. IVUS enables
full-thickness visibility of the vessel wall, enabling pre-PCI
assessment of plaque burden, extent of calcification, lesion length,
and external elastic lamina diameter for stent sizing and post-PCI
assessment of minimum stent area, malapposition, underexpansion,
tissue protrusion, edge disease, and edge dissection.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R584"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">18</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R585"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">19</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;OCT
uses infrared light to generate high-resolution images of the vessel
wall, with particular advantages in assessing calcium thickness,
lipid, thrombus, fibroatheroma, and plaque rupture, as well as stent
strut neointimal thickness and apposition, and edge
dissections.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R586"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">20</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;However,
OCT has more limited depth of imaging. It also requires blood
clearance through the use of contrast injection, which diminishes its
use in ostial left main disease. IVUS and OCT can assist with
assessing the need for lesion preparation, stent sizing, minimizing
geographic miss, verifying stent expansion, evaluating complications,
and identifying causes of stent failure.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R586"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">20</font></span></font></a></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supportive Text</b></i></font></font></h4>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">1.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">In
patients undergoing PCI, multiple meta-analyses</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R568">2</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R569">3</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R587">21-23</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;have
shown a reduction in MACE with IVUS-guided versus angiographic-guided
PCI. The ULTIMATE (Intravascular Ultrasound Guided Drug Eluting
Stents Implantation in “All-Comers” Coronary Lesions) trial,
which was the largest trial of routine IVUS-guided PCI, demonstrated
a lower rate of target-vessel failure (cardiac death, target-vessel
infarction, and clinically driven target-vessel revascularization)
with IVUS-guided PCI than with angiographic-guided PCI at 12
months.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R572">6</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Additionally,
at 3 years, there was a significantly lower rate of stent thrombosis
and target-vessel revascularization with IVUS-guided PCI.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R576">10</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Most
of the RCTs focusing on the use of IVUS in complex lesions (left
main, CTOs, and long lesions) were small and not powered to evaluate
clinical endpoints. Some of these trials have reported lower MACE
with IVUS-guided PCI in long lesions,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R570">4</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;CTOs,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R574">8</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;or
left main stenting.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R571">5</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;A
meta-analysis of RCTs of complex lesions also demonstrated lower
rates of MACE, target-vessel revascularization, and target-lesion
revascularization when IVUS guidance was used.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R567">1</span></font></span></font></a></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">2.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">The
ILUMIEN (Optical Coherence Tomography Compared to Intravascular
Ultrasound and Angiography to Guide Coronary Stent Implantation: a
Multicenter Randomized Trial in Percutaneous Coronary Intervention)
study showed noninferiority of OCT compared with IVUS with respect to
the primary endpoint of post-PCI minimum stent area, with similarly
low rates of procedural MACE.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R577">11</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
OPINION (Optical Frequency Domain Imaging Versus Intravascular
Ultrasound in Percutaneous Coronary Intervention) study showed
noninferiority of OCT- compared with IVUS-guided PCI for the combined
endpoint of cardiac death, target-vessel MI, and ischemia-driven
target-lesion revascularization at 1 year.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R590">24</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
DOCTORS (Does Optical Coherence Tomography Optimize Results of
Stenting) trial demonstrated that, compared with angiography-guided
PCI, OCT-guided PCI resulted in improved post-PCI FFR.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R578">12</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Randomized
and registry data have shown that an OCT minimum stent area of &lt;4.5
to 5.0 mm2&nbsp;is an independent predictor of MACE.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R591">25</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R592">26</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
ILUMIEN IV (Optical Coherence Tomography [OCT] Guided Coronary Stent
Implantation Compared to Angiography: a Multicenter Randomized Trial
in PCI) trial is an ongoing trial designed to evaluate clinical
outcomes in patients with OCT-guided PCI versus angiography-guided
PCI.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R577">11</span></font></span></font></a></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">3.</span></font></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">A
combination of stent-, procedure-, and patient-related factors are
involved in the pathophysiology of stent thrombosis or
restenosis.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R580">14</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R593">27</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Early
stent thrombosis is more commonly a result of residual target-lesion
thrombus, stent failure, or nonadherence to DAPT, whereas late stent
thrombosis is associated with inadequate neointimal coverage or
incomplete healing. Assessment of the cause of stent thrombosis with
intracoronary imaging is important to guide subsequent treatment.
Similarly, advanced imaging techniques have an important role in
detecting underlying mechanical and pathophysiological factors that
contribute to in-stent restenosis (ISR), such as neointimal
hyperplasia, stent underexpansion, and fractures.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R580">14</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R581">15</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Detailed
intrastent visualization allows new possibilities for tissue
characterization and may help better identify patients at risk of
ISR.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R594">28</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Registry
and case series data have demonstrated that IVUS and OCT can be
useful for evaluating the mechanisms of stent restenosis and stent
thrombosis.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R582">16</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R583">17</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R595">29</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R596">30</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;OCT
is better at differentiating between stent-related mechanisms,
whereas IVUS is preferred for in-depth vessel wall
characterization.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R596">30</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R597">31</span></font></span></font></a></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>10.4.
Thrombectomy</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu28.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab28.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image37" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">Many
patients with STEMI will have thrombotic occlusion of the infarct
artery on the initial angiogram. Therefore, it is natural to consider
the use of a device that would decrease thrombus burden to decrease
the risk of distal embolization and the no-reflow phenomenon.
However, patients in trials with STEMI undergoing primary PCI did not
derive any clinical benefit from routine rheolytic
thrombectomy.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R603"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">6</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R604"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">7</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Additionally,
although the initial studies of aspiration thrombectomy in STEMI
demonstrated an improvement in myocardial blush grades and rates of
ST-segment–elevation resolution,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R605"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">8-10</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;larger
studies have not demonstrated improved cardiovascular outcomes with
thrombus aspiration.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R598"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1-5</font></span></font></a></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supporting Text</b></i></font></font></h4>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">1.</span></font></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Patients
enrolled in contemporary trials did not derive a benefit of reduction
in infarct size</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R602">5</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;or
improvement in death, reinfarction, stent thrombosis, or
target-lesion revascularization at 30 days or 1 year</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R598">1</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R601">4</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;or
cardiovascular death, recurrent MI, cardiogenic shock, or NYHA Class
IV heart failure at 3 months or 1 year</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R599">2</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R600">3</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;with
aspiration thrombectomy compared with routine stenting. In the TOTAL
(Thrombectomy with PCI vs. PCI Alone in patients with STEMI) trial,
patients who were assigned to aspiration thrombectomy were found to
have a small but statistically significant increased risk of
stroke.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R599">2</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R600">3</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;A
patient-level meta-analysis found no significant reduction in
cardiovascular death at 30 days with routine aspiration thrombectomy
but did find a trend toward a higher rate of stroke.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R608">11</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Moreover,
in the subgroup of patients with high thrombus burden, thrombus
aspiration was associated with a small but statistically significant
reduced rate of cardiovascular death and a small but statistically
significant increased rate of stroke. For this reason, additional
dedicated studies focusing on the selective use of thrombus
aspiration in patients with high thrombus burden are needed.</span></font></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>10.5.
Treatment of Calcified Lesions</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu29.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab29.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image38" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">Fibrotic
or heavily calcified lesions can hinder stent expansion. The presence
of calcium deposits thicker than 500 μm or calcium involving an arc
of the vessel &gt;270° on intravascular imaging predicts the need
for lesion modification to facilitate stent delivery.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R617"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">9</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Lesions
can be modified by using rotational atherectomy, orbital atherectomy,
cutting balloon atherotomy, intracoronary lithotripsy, or excimer
laser angioplasty. Despite promising results from hundreds of small
mechanistic studies, dozens of large, randomized trials have shown
that the routine use of atheroablative devices does not improve
clinical or angiographic outcomes.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R609"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1-3</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R618"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">10</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;However,
the use of atheroablative devices may enhance procedural success in
specific circumstances.</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supportive Text</b></i></font></font></h4>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">1.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Rotational
atherectomy excavates inelastic atherosclerotic tissue through the
use of a diamond-tipped burr that rotates at high speeds. Although
older studies have shown that the use of rotational atherectomy is
associated with increased rates of restenosis</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R611">3</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
increased late lumen loss,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R609">1</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;RCTs
have demonstrated enhanced stent delivery and expansion in heavily
calcified vessels with rotational atherectomy as compared with the
use of conventional balloons</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R609">1</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;or
cutting or sculpting balloons.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R610">2</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;For
this reason, despite the lack of data to support improved long-term
outcomes with rotational atherectomy, rotational atherectomy remains
an important tool in certain situations to properly “prepare” a
lesion for stenting.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">2.</span></font></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Orbital
atherectomy has many features in common with rotational atherectomy
and has similar clinical indications for use.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R612">4</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R613">5</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Cutting
balloons</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R614">6</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
scoring balloons</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R615">7</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;section
atheromatous plaque through a technique called balloon atherotomy,
but their value may be limited to the technical advantage of slipping
less often than conventional balloons in ostial lesions or lesions
associated with ISR. Excimer laser coronary angioplasty uses a
photo-acoustic mechanism</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R619">11</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;that
may facilitate the treatment of calcified lesions or nonexpandable
stents.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R620">12</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R621">13</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
certain lesion subsets, such as stent underexpansion that cannot be
dilated with high-pressure balloon inflations, high-energy laser
angioplasty can disrupt the calcific lesion beneath the stent struts
and facilitate stent expansion.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R622">14</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
evidence base for additional techniques to modify calcified or
fibrotic lesions, including atherectomy, cutting balloons, or laser,
are limited to registry studies and case series.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R618">10</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Other
potentially emerging modalities include intracoronary
lithotripsy.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R616">8</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R623">15</span></font></span></font></a></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>10.6.
Treatment of Saphenous Vein Graft (SVG) Disease (Previous CABG)</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu30.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab30.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image39" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">In
patients with previous CABG undergoing PCI of an SVG, the incidence
of MACE is significantly higher than those with native coronary
artery PCI because of the higher risk of procedural complications,
including the no-reflow phenomenon and periprocedural MI.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R629"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">6</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Compared
with native coronary arteries, atherosclerotic plaques in SVGs are
more diffuse, with thinner, more friable fibrous caps that increase
the risk of distal debris embolization during PCI.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R632"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">9</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
several large prospective registries, patients who underwent SVG PCI
were more likely to have no-reflow,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R628"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">5</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;stent
thrombosis, ischemia-driven target-vessel revascularization,
increased overall adjusted MACE, and increased risk of death</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R627"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">4</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R628"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">5</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R633"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">10</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;in
long-term follow-up than were those who underwent non-SVG PCI.</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supportive Text</b></i></font></font></h4>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">1.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">The
term “embolic protection devices” refers to the group of devices
designed to prevent distal embolization. The SAFER (Saphenous vein
graft Angioplasty Free of Emboli Randomized) trial comparing the
outcomes of SVG PCI with the use of an embolic protection device
(Medtronic Guardwire, Minneapolis, MN) with conventional stenting of
the SVG demonstrated a significant reduction in the primary endpoint
of death, MI, emergency bypass, or target-lesion revascularization at
30 days with the GuardWire distal protection device.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R624">1</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;A
subsequent study comparing different embolic protection devices
reported noninferiority of the FilterWire EX device (Boston
Scientific, Marlborough, MA) to the GuardWire.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R625">2</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
contemporary PCI, embolic protection devices are used in only 14% to
21% of patients,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R634">11</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R635">12</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
only the filter-based devices are currently in use. Observational
studies exploring the “real-world” benefits of embolic protection
devices provide conflicting findings, with 1 study showing no benefit
of embolic protection devices and another showing significant harm
when embolic protection devices are not used.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R634">11</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R635">12</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;A
meta-analysis of 2 randomized studies and 6 observational reports
showed no benefit with the use of embolic protection devices,
although selection biases and unmeasured confounders are important
limitations of these observational studies.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R636">13</span></font></span></font></a></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">2.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">In
patients with previous CABG who require PCI, two-thirds of these
procedures are performed on the native artery instead of the bypass
graft.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R627">4</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R628">5</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Although
there are no randomized studies comparing PCI of a diseased native
artery with PCI of an SVG, observational studies have shown that
intervening in a native coronary artery instead of an SVG is
associated with improved outcomes. In a large prospective registry,
patients with prior CABG who underwent SVG PCI had higher rates of
cardiac death, stent thrombosis, ischemia-driven target-vessel
revascularization, and overall MACE at 2 years than did those who
underwent PCI of the native vessel.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R633">10</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
risk of MACE remained elevated even after adjustment for baseline
variables and propensity matching.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R633">10</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Another
observational study, examining patients with prior CABG undergoing
PCI, reported higher rates of in-hospital death, no-reflow,
periprocedural MI, and cardiogenic shock in patients who underwent
SVG PCI than in patients who underwent PCI of the native vessel. At 3
years, SVG PCI was associated with higher rates of post discharge
death, MI, and repeat revascularization than those seen with native
coronary PCI.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R628">5</span></font></span></font></a></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">3.</span></font></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">In
patients with chronic occlusion of an SVG, PCI of the SVG has been
associated with low success rates and excessive risk of needing
repeat intervention.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R630">7</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R631">8</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;However,
experienced operators have used occluded SVGs as conduits for
retrograde recanalization of CTOs in native coronary arteries.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R636">13</span></font></span></font></a></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>10.7.
Treatment of CTO</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu31.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab31.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image40" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">A
CTO is found in approximately one-quarter of patients undergoing
coronary angiography.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R641"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">5</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R642"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">6</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Considerable
progress in the technical aspects of interventional revascularization
has yielded success rates in excess of 80% in the hands of skilled
operators.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R643"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">7</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;However,
the 30-day mortality rate after CTO PCI is 1.3%, and perforations
occur in 4.8% of cases.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R644"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">8</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Enthusiasm
for treating these lesions was fueled by retrospective data
suggesting improved clinical outcomes for those patients who
underwent successful recanalization compared with those who had
failed.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R645"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">9</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;However,
RCTs have not demonstrated improved function</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R640"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">4</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R646"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">10</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
have been equivocal with regard to symptoms.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R637"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R638"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">2</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;For
this reason, shared decision-making should inform the treatment of
patients with refractory angina despite GDMT with remaining CTO
coronary lesion, with careful discussions of the limitations of
treating these lesions, as well as the potential benefits.</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supportive Text</b></i></font></font></h4>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">1.</span></font></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Despite
considerable retrospective and registry data suggesting a clinical
benefit of PCI of a CTO, a clear demonstration of benefit from
prospective randomized trials has not been forthcoming.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R647">11</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R648">12</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
EXPLORE (Evaluating Xience and left ventricular function in PCI on
occlusions after STEMI) and the REVASC (Randomized Trial to Assess
Regional Left Ventricular Function After Stent Implantation in
Chronic Total Occlusion) trials did not demonstrate any improvement
in ventricular function with CTO PCI versus optimal medical
therapy.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R640">4</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R646">10</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Although
the EURO CTO (Randomized Multicentre Trial to Compare
Revascularization With Optimal Medical Therapy for the Treatment of
Chronic Total Occlusions) trial demonstrated a greater reduction in
angina frequency and improved quality of life with PCI of a CTO than
with optimal medical therapy,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R638">2</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;a
much larger trial, the DECISION-CTO (Drug-Eluting Stent Implantation
Versus Optimal Medical Treatment in Patients With Chronic Total
Occlusion) trial, did not demonstrate any difference in symptoms or
clinical outcomes with CTO PCI.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R637">1</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Future
trials with more definitive endpoints may change the current
landscape.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R639">3</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R649">13</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R650">14</span></font></span></font></a></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>10.8.
Treatment of Patients With Stent Restenosis</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu32.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab32.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image41" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">The
increasing use of newer-generation DES has led to a significant
reduction in the risk of ISR and subsequent target-lesion
revascularization compared with BMS and first-generation
DES.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R656"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">6-8</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Nevertheless,
ISR is still reported in 5% to 10% of patients undergoing
PCI.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R659"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">9</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R660"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">10</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
primary mechanism of ISR after stent implantation is neointimal
hyperplasia, with angiographic and histopathological studies
demonstrating considerable differences in tissue characteristics
based on the type of stent.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R661"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">11-14</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
risk of restenosis is also linked to clinical presentation, patient
profile, lesion location, and procedural
characteristics.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R665"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">15</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R666"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">16</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Numerous
approaches to the treatment of restenosis have been explored and
include balloon angioplasty, DES, drug-coated balloons, scoring or
cutting balloons, vascular brachytherapy, atheroablative therapies,
and CABG. Compared with other therapies, DES appears to provide the
most benefit. However, the type of ISR (ie, focal versus diffuse) may
also affect the decision to treat with one modality over another and,
therefore, treatment of ISR should be individualized. Importantly,
intensive medical therapy is also vital in these patients.</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supportive Text</b></i></font></font></h4>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">1.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">In
patients with ISR, studies have shown that treatment with a DES
resulted in lower rates of target-vessel restenosis in follow-up than
those seen with BMS or balloon angioplasty.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R653">3</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R654">4</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R667">17</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Network
meta-analyses comparing various treatment options (DES, BMS, vascular
brachytherapy, drug-coated balloons, conventional balloons, or
rotational atherectomy) have shown that PCI with a DES was associated
with the lowest rates of restenosis and target-vessel
revascularization. Of the different DES stent types,
everolimus-eluting stents appeared to have the best efficacy.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R651">1</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R652">2</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
these studies, there were no significant differences in other
clinical outcomes, including death or MI, among the therapies
examined.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">2.</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">In
patients with recurrent episodes of restenosis despite repeat PCI
with DES, or in patients who have diffuse ISR in large vessels or a
complex presentation such as CTO with multivessel disease, CABG maybe
the preferred approach if the anatomy is suitable.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">3.</span></font></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">In
patients who already have multiple stent layers or have recurrent ISR
with an artery that is unfavorable to receive another DES, who are
not good candidates for bypass surgery, vascular brachytherapy
provides an additional tool to aid revascularization.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R655">5</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Vascular
brachytherapy circumvents the need to implant another stent, and in
these challenging situations it remains a reasonable option.</span></font></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>10.9.
Hemodynamic Support for Complex PCI</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu33.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab33.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image42" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.18in"><font size="2" style="font-size: 9pt">Patients
undergoing complex PCI are at risk of hypotension, decompensated
heart failure, shock, or arrhythmias that may lead to rapid
hemodynamic deterioration or death. Intra-aortic balloon pump
counterpulsation provides minimal hemodynamic support for PCI but
improves coronary and cerebral perfusion. Its use is limited in
patients with severe peripheral artery or aortic disease. Its
advantages are ease of use and smaller catheter diameter, leading to
lower rates of vascular access site complications. The Impella
percutaneous left ventricular–assist devices (Abiomed, Danvers, MA)
provide greater left ventricular support. The use of the Impella
support devices is limited in patients with left ventricular
thrombus, aortic stenosis, peripheral artery disease, or aortic
disease. Extracorporeal membrane oxygenation and the TandemHeart
(CardiacAssist, Inc, Pittsburgh, PA) devices are rarely used to
support complex PCI. New hemodynamic support devices are undergoing
evaluation in clinical trials.</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supporting Text</b></i></font></font></h4>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">1.</span></font></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">The
routine use of hemodynamic support devices for complex PCI has not
been shown to reduce cardiovascular events.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R668">1</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R669">2</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
the BCIS-1 (Balloon Pump–Assisted Coronary Intervention) study,
there was no difference in the primary composite outcome (death, MI,
cerebrovascular event, or repeat revascularization) with intra-aortic
balloon counterpulsation.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R668">1</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Major
procedural complications (mostly hypotension) were lower with
intra-aortic balloon counterpulsation. The PROTECT II (Prospective,
Multi-center, Randomized Controlled Trial of the Impella Recover LP
2.5 System Versus Intra Aortic Balloon Pump [IABP] in Patients
Undergoing Non Emergent High Risk PCI II) trial, comparing the
Impella System with intra-aortic balloon counterpulsation for
high-risk PCI, was halted for futility after an interim analysis
showed no benefit in the primary endpoint of MACE.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R669">2</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Compared
with balloon counterpulsation, Impella provided better hemodynamic
support. Observational studies have further challenged the efficacy,
safety, and cost of hemodynamic support devices.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R670">3</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R671">4</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Despite
these findings, these devices can provide hemodynamic support in
select patients during complex PCI with multivessel disease, left
main disease, or disease of the last patent conduit and severe left
ventricular dysfunction or cardiogenic shock.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R672">5-9</span></font></span></font></a></p>
<h2 class="western" align="left" style="line-height: 0.22in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="3" style="font-size: 11pt"><b>11.
Pharmacotherapy in Patients Undergoing PCI</b></font></font></h2>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>11.1.
Aspirin and Oral P2Y12 Inhibitors in Patients Undergoing PCI</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu34.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab34.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image43" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">DAPT
with aspirin and oral P2Y12 inhibitors remains the cornerstone of
therapy for the prevention of thrombotic complications with PCI. In
the early days of PCI, aspirin was found to be effective at
decreasing coronary thrombosis with balloon angioplasty,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R677"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
since that time, aspirin has remained a key agent for patients with
chronic vascular disease.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R678"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">2-4</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
contemporary oral P2Y12 inhibitors used in PCI include clopidogrel,
ticagrelor, and prasugrel. Patients should be treated with a loading
dose of these agents, either before PCI or otherwise at the time of
PCI (</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/t10.xhtml"><font color="#2b7bb9"><span style="text-decoration: none"><font size="2" style="font-size: 9pt">Table
9</font></span></font></a><font size="2" style="font-size: 9pt">).
Clopidogrel is the least potent agent, requiring longer time to
platelet inhibition after a loading dose. In patients with stable
angina, there is no compelling evidence to support routine
pretreatment with a P2Y12 inhibitor before coronary angiography when
the coronary anatomy is not known.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R698"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">22</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;This
is especially important because the need for CABG still occurs in a
nonnegligible proportion of patients referred for angiography, and
pretreatment can result in postponement of surgery.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R694"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">18</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
duration of treatment with DAPT is discussed in Section 14.</font></p>
<p style="line-height: 0.14in; margin-bottom: 0in"><font color="#d93731"><font size="1" style="font-size: 8pt"><b>Table
10</b></font></font>. Anticoagulant Dosing During PCI<a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#tab10fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt">*</font></span></font></a>&nbsp;<font size="1" style="font-size: 8pt">(</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/t10.xhtml"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt">Table
view</font></span></font></a><font size="1" style="font-size: 8pt">)</font></p>
<table cellpadding="2" cellspacing="2">
	<thead>
		<tr>
			<th colspan="3" style="border: 1px solid #2c2e35; padding: 0.02in"><p style="font-weight: normal">
				<span style="display: inline-block; border-top: none; border-bottom: 1px solid #888888; border-left: none; border-right: none; padding-top: 0in; padding-bottom: 0.02in; padding-left: 0in; padding-right: 0in"><font size="1" style="font-size: 8pt">Dosing
				of Parenteral Anticoagulants During PCI</span></font></p>
			</th>
		</tr>
	</thead>
	<tbody>
		<tr>
			<th style="border: 1px solid #2c2e35; padding: 0.02in"><p style="font-weight: normal">
				Drug</p>
			</th>
			<th style="border: 1px solid #2c2e35; padding: 0.02in"><p style="font-weight: normal">
				Patient Has Received Previous Anticoagulant Therapy</p>
			</th>
			<th style="border: 1px solid #2c2e35; padding: 0.02in"><p style="font-weight: normal">
				Patient Has Not Received Previous Anticoagulant Therapy</p>
			</th>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">UFH</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Additional
				UFH as needed (eg, 2000–5000 U) to achieve an ACT of 250-300 s</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#tab10fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt">*</font></span></font></a></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">70–100
				U/kg initial bolus to achieve target ACT of 250–300 s</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#tab10fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt">*</font></span></font></a></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Enoxaparin</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">For
				previous treatment with enoxaparin, if the last SC dose was
				administered 8–12 h earlier or if only 1 SC dose of enoxaparin
				has been administered, an IV dose of 0.3 mg/kg of enoxaparin
				should be given</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R771"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">43-45</font></span></font></a><font size="1" style="font-size: 8pt"><br/>
If
				the last SC dose was administered within the previous 8 h, no
				additional enoxaparin should be given</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">0.5–0.75
				mg/kg IV bolus</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Bivalirudin</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">For
				patients who have received UFH, repeat ACT<br/>
If ACT is not in
				therapeutic range, then give 0.75 mg/kg IV bolus, then 1.75
				mg/kg/h IV infusion</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">0.75
				mg/kg bolus, 1.75 mg/kg/h IV infusion</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Argatroban</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">200
				μg/kg IV bolus, then 15 μg/kg/min IV infusion</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">350
				μg/kg, then 15 μg/kg/min IV infusion</font></p>
			</td>
		</tr>
	</tbody>
</table>
<p align="justify" style="line-height: 0.13in; margin-bottom: 0in"><font size="1" style="font-size: 7pt">ACS
indicates acute coronary syndrome; ACT, activated clotting time; CTO,
chronic total occlusion; PCI, percutaneous coronary intervention; and
UFH, unfractionated heparin.</font></p>
<p align="justify" style="line-height: 0.13in; margin-bottom: 0in"><font size="1" style="font-size: 7pt">*</font></p>
<div id="tab10fn1" dir="ltr"><p align="justify" style="line-height: 0.1in; margin-bottom: 0in">
	<font size="1" style="font-size: 7pt">Target ACTs for UFH dosing
	shown for HemoTec (GmbH, Switzerland) or I-Stat (Abbott) device. For
	Hemochron ACT (Werfen) devices, ACT goals are 50 s higher. In the
	case of CTO or ACS, consider higher target ACT. If IV glycoprotein
	IIb/IIIa receptor inhibitor is planned, target ACT 200–250
	s.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R754"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 6pt">26</font></span></font></a><font size="1" style="font-size: 7pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R755"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 6pt">27</font></span></font></a><font size="1" style="font-size: 7pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R759"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 6pt">31</font></span></font></a><font size="1" style="font-size: 7pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R768"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 6pt">40-42</font></span></font></a></p>
</div>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supportive Text</b></i></font></font></h4>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">1.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Aspirin
is protective in most types of patients with an increased risk of
occlusive vascular events, including those with an AMI or ischemic
stroke, unstable or stable angina, and previous MI.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R678">2</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R679">3</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Aspirin
reduces the frequency of ischemic complications after PCI and should
be given in the periprocedural period.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R677">1</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R699">23</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Although
the minimum effective dose of aspirin in the setting of PCI has not
been established, non–enteric-coated aspirin (325 mg) is commonly
administered before PCI in those patients who were not previously on
aspirin.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R677">1</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R700">24</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Observational
data and retrospective analyses of RCTs have demonstrated that a
lower dose of chronic daily aspirin (&lt;100 mg) after PCI results in
the best combination of safety and efficacy.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R700">24-26</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;On
the basis of an analysis of aspirin dosing and outcomes in the PLATO
(Trial to Assess The Study of Platelet Inhibition and Patient
Outcomes) study, a low dose of aspirin (&lt;100 mg) should be used in
patients treated with ticagrelor. There are data to suggest that in
the treatment of ACS, a chewable aspirin formulation may be
preferable to solid tablet aspirin.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R703">27</span></font></span></font></a></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">2.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">P2Y12
inhibitors are essential for treating patients undergoing PCI. Their
use was first evaluated in studies exploring the optimal
antithrombotic regimens after coronary stent implantation. In these
earlier studies, ticlopidine was found to be superior to aspirin
alone or the combination of aspirin and anticoagulant
therapy</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R686">10</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R687">11</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R689">13</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;in
reducing ischemic events after coronary stent implantation. Because
of unacceptable side effects of ticlopidine, clopidogrel was later
used in place of ticlopidine, with clinical trials demonstrating
similar efficacy but lower rates of drug discontinuation attributable
to noncardiac events.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R692">16</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;With
clopidogrel, the introduction of prasugrel and ticagrelor supported
the use of a more potent P2Y12 inhibitor agent for PCI in ACS.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R682">6</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R690">14</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;A
loading dose of a P2Y12 agent should be given to minimize the time to
platelet inhibition. There are conflicting data on the benefits of
pretreatment with a P2Y12 inhibitor before the anatomy is known,
particularly in patients with NSTE-ACS.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R683">7</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R693">17</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R704">28-31</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
contemporary times, with most patients with ACS undergoing early
angiography, a strategy of loading with a P2Y12 inhibitor after the
anatomy is known appears to offer similar benefit to preloading.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R707">31</span></font></span></font></a></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">3.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">The
CREDO (Clopidogrel for the Reduction of Events During Observation)
trial</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R694">18</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;demonstrated
a reduction in ischemic events, including the risk of death, MI, or
stroke, with a loading dose of clopidogrel and treatment up to 9
months after elective PCI. There was a trend toward a lower event
rate when preloading with a 300-mg clopidogrel dose was given &gt;3
hours before PCI. A 600-mg loading dose of clopidogrel is associated
with a shorter time to platelet inhibition and therefore is the
preferred dose. Ticagrelor and prasugrel have not been studied for
long-term clinical outcomes in patients with SIHD undergoing PCI.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">4.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Patients
with STEMI who were treated with fibrinolytic therapy and referred
for PCI are at increased bleeding and ischemic risk. Clopidogrel is
the only P2Y12 inhibitor agent studied in patients immediately after
the administration of fibrinolytic therapy. In the CLARITY
(Clopidogrel as Adjunctive Reperfusion Therapy) trial, clopidogrel
pretreatment in conjunction with fibrinolytic therapy resulted in a
46% reduction in the rate of cardiovascular death or recurrent MI or
stroke at 30 days among patients referred for PCI.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R681">5</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Major
and minor bleeding was similar between the groups. In this study,
patients randomized to clopidogrel were administered a 300-mg load
during or immediately after fibrinolytic therapy, followed by 75 mg
daily.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R681">5</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
contemporary times, the loading dose of clopidogrel for patients
undergoing PCI after fibrinolytic therapy should be individualized. A
larger loading dose of 600 mg may be used for most patients, whereas
the lower 300-mg loading dose is generally reserved for older
patients or those at higher risk of bleeding.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">5.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">TRITON-TIMI-38
(Trial to Assess Improvement in Therapeutic Outcomes by Optimizing
Platelet Inhibition with Prasugrel–Thrombolysis in Myocardial
Infarction)</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R682">6</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
PLATO</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R690">14</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;demonstrated
that treatment with prasugrel (TRITON-TIMI-38) and ticagrelor
(PLATO), compared with clopidogrel, reduced the rate of the composite
endpoint of death from vascular causes, MI, or stroke. These agents
were also associated with a lower rate of stent thrombosis. In the
TRITON-TIMI 38 trial, non-CABG major bleeding was significantly
higher with prasugrel.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R682">6</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
PLATO, although there were no significant differences in the rates of
study-defined bleeding events with ticagrelor, non-CABG major
bleeding was significantly higher among patients treated with
ticagrelor</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R690">14</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;than
among patients treated with clopidogrel.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R690">14</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Because
of the increased bleeding risk, these more potent agents should be
used with caution in older patients. One study suggested that
clopidogrel may be a reasonable alternative for older patients with
ACS undergoing PCI, with similar rates of ischemic events and less
bleeding.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R708">32</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
open-labeled design of this trial and the high rate of crossover
limit the generalization of the study results. Further studies are
needed to determine the ideal P2Y12 inhibitor for use in older
patients with ACS undergoing PCI.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">6.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">In
patients with fibrinolytic-treated STEMI, ticagrelor is associated
with a greater inhibition of platelet reactivity than that seen with
clopidogrel.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R709">33</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
PLATO, patients were excluded from enrollment if they were treated
with fibrinolytic therapy within 24 hours of enrollment. Therefore,
although PLATO supported the use of ticagrelor over clopidogrel in
patients with STEMI treated with fibrinolytic therapy, there were
limited data on the safety of ticagrelor when given early after
fibrinolytic therapy. The TREAT (Ticagrelor in Patients With ST
Elevation Myocardial Infarction Treated With Pharmacological
Thrombolysis) trial was designed to examine the safety of ticagrelor
in patients treated with fibrinolytic therapy for STEMI.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R697">21</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
this study, ticagrelor was found to be noninferior to clopidogrel in
rates of TIMI major bleeding, fatal bleeding, and intracranial
bleeding.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R697">21</span></font></span></font></a></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">7.</span></font></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">A
more detailed analysis of the TRITON study that was designed to
evaluate net clinical benefit (MACE events plus bleeding) with
prasugrel demonstrated no net benefit of prasugrel compared with
clopidogrel for patients with low body weight (&lt;60 kg) or those
≥75 years of age and found net harm with prasugrel for patients
with previous transient ischemic attack or cerebrovascular
accident.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R682">6</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;For
this reason, prasugrel is contraindicated in patients with a history
of transient ischemic attack or stroke. Caution is advised in the use
of prasugrel in patients weighing &lt;60 kg or in patients ≥75
years of age.</span></font></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>11.2.
Intravenous P2Y12 Inhibitors in Patients Undergoing PCI</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu35.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab35.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image44" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">Cangrelor
is a potent, direct, reversible, short-acting intravenous P2Y12
inhibitor with rapid onset of platelet inhibition and restoration of
platelet function within 1 hour of discontinuation. Cangrelor thus
provides rapid, predictable, and profound inhibition of platelets. It
can be efficacious in preventing stent thrombosis and may be
considered in patients who have not been pretreated with a P2Y12
inhibitor, in patients whose absorption of oral medications may be
inhibited, or in patients who are unable to take oral medications.
Cangrelor has been investigated within the CHAMPION (Cangrelor versus
Standard Therapy to Achieve Optimal Management of Platelet
Inhibition) program and compared with a loading dose of clopidogrel
given at the time of PCI in 3 large-scale clinical trials.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R716"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R717"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">2</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R719"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">4</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;There
are no studies comparing cangrelor with a loading dose of ticagrelor
or prasugrel given at the time of PCI.</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supporting Text</b></i></font></font></h4>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">1.</span></font></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">The
CHAMPION PLATFORM and the CHAMPION PCI trials did not show a
reduction in the primary outcome (ie, death, MI, or ischemia-driven
revascularization at 48 hours) with cangrelor. However, in CHAMPION
PLATFORM, cangrelor resulted in lower rates of the prespecified
secondary outcomes of stent thrombosis and death.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R716">1</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
the CHAMPION PHOENIX trial, the primary endpoint, which included
death, MI, ischemia-driven revascularization, or stent thrombosis,
was significantly reduced with cangrelor.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R717">2</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;This
was driven mainly by a reduction in periprocedural MI and
intraprocedural stent thrombosis. A pooled patient-level
meta-analysis of the CHAMPION trials supported these findings,
demonstrating a lower rate of the composite endpoint of death, MI,
ischemia-driven revascularization, or stent thrombosis at 48 hours
with cangrelor than with clopidogrel.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R718">3</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Additionally,
cangrelor was associated with a 41% reduction in stent thrombosis.
Although major bleeding was similar between the groups, minor
bleeding was more frequent in the cangrelor group.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R718">3</span></font></span></font></a></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>11.3.
Intravenous Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing
PCI</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu36.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab36.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image45" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">Glycoprotein
IIb/IIIa receptor inhibitors are direct-acting antiplatelet agents
targeting the glycoprotein IIb/IIIa platelet receptor. Many of the
trials of glycoprotein IIb/IIIa inhibitors in the setting of ACS were
conducted in an era before the use of potent P2Y12 inhibitors or
before routine stenting.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R721"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">2</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R725"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">6</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Additionally,
in the earlier trials, the time from presentation to coronary
angiography was often prolonged. In the contemporary era of shorter
revascularization times and use of potent DAPT, the benefit of
glycoprotein IIb/IIIa receptor inhibitor agents is diminished.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R721"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">2</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R726"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">7</font></span></font></a></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supporting Text</b></i></font></font></h4>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">1.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">In
trials of patients with ACS, glycoprotein IIb/IIIa receptor
inhibitors have not been associated with improved clinical outcomes
and may increase bleeding complications.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R726">7</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R727">8</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Because
the addition of glycoprotein IIb/IIIa receptor inhibitors can
decrease thrombus burden by further inhibiting platelet
aggregation,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R728">9</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;the
use of glycoprotein IIb/IIIa receptor inhibitors in the era of more
potent antiplatelet agents is generally reserved for patients with a
large thrombus burden or no-reflow or slow flow that is believed to
be attributable to distal embolization of thrombus.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">2.</span></font></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">In
patients with SIHD who are undergoing PCI, the use of glycoprotein
IIb/IIIa receptor inhibitors in addition to a clopidogrel load does
not reduce ischemic events.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R722">3</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R723">4</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Patients
enrolled in the ISAR-REACT (iNtracoronary Stenting and Antithrombotic
Regimen: Rapid Early Action for Coronary Treatment) trial who were
randomized to pretreatment with abciximab and a 600-mg loading dose
of clopidogrel had outcomes similar to those of patients receiving
clopidogrel alone.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R722">3</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Major
bleeding was not significantly different between the 2 groups,
although the rate of severe thrombocytopenia was significantly higher
in the abciximab group.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R722">3</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;A
subgroup analysis of the ESPRIT (Enhance Suppression of the Platelet
IIB/IIIA receptor with Integrilin Therapy) trial showed no benefit in
the primary endpoint of death, MI, urgent target-vessel
revascularization, and thrombotic bailout with glycoprotein IIb/IIIa
inhibitor therapy with eptifibatide at 48 hours in the group of
patients undergoing PCI for stable angina.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R724">5</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Six-month
rates of death or MI were also not significantly different in this
subgroup of patients.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R723">4</span></font></span></font></a></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>11.4.
Heparin, Low-Molecular-Weight Heparin, and Bivalirudin in Patients
Undergoing PCI</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu37.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab37.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image46" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">Antithrombotic
therapy is a mainstay of treatment in patients undergoing PCI.
Currently, there are 3 antithrombotic agents that have been studied
in PCI. These are UFH, bivalirudin, and enoxaparin. Fondaparinux is
no longer recommended as the only anticoagulant in PCI because of a
higher incidence of guiding-catheter thrombosis.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R748"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">20</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R749"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">21</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Consideration
of the patient’s clinical presentation (eg, stable disease,
NSTE-ACS, or STEMI) and bleeding risk profile</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R750"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">22</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;may
influence selection of the optimal anticoagulant type. Suggested
dosing regimens of parenteral agents are shown in&nbsp;</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/t11.xhtml"><font color="#2b7bb9"><span style="text-decoration: none"><font size="2" style="font-size: 9pt">Table
10</font></span></font></a><font size="2" style="font-size: 9pt">.</font></p>
<p style="line-height: 0.14in; margin-bottom: 0in"><font color="#d93731"><font size="1" style="font-size: 8pt"><b>Table
11</b></font></font>. Perioperative Anesthetic and Monitoring
Considerations for CABG&nbsp;<font size="1" style="font-size: 8pt">(</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/t11.xhtml"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt">Table
view</font></span></font></a><font size="1" style="font-size: 8pt">)</font></p>
<table cellpadding="2" cellspacing="2">
	<tr>
		<td colspan="2" style="border: 1px solid #2c2e35; padding: 0.02in"><p>
			<font size="1" style="font-size: 8pt">Anesthetic considerations</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Perioperative
			analgesia</font></p>
		</td>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Nonopioid
			medications (eg, acetaminophen, ketamine, dexmedetomidine) and/or
			regional techniques (eg, truncal nerve blocks), particularly as
			part of a multimodal analgesic approach, have been shown to reduce
			perioperative opioid use in cardiac surgery.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R774"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1-16</font></span></font></a></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Maintenance
			anesthesia</font></p>
		</td>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Although
			volatile (versus intravenous) anesthesia may facilitate earlier
			extubation,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R775"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">2</font></span></font></a><font size="1" style="font-size: 8pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R779"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">6-8</font></span></font></a><font size="1" style="font-size: 8pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R785"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">12</font></span></font></a><font size="1" style="font-size: 8pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R787"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">14</font></span></font></a><font size="1" style="font-size: 8pt">&nbsp;recent
			evidence suggests that the choice of maintenance anesthetic likely
			does not impact mortality rate after cardiac surgery.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R790"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">17-21</font></span></font></a></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Mechanical
			ventilation</font></p>
		</td>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">An
			intraoperative lung-protective ventilation strategy (ie, tidal
			volume of 6–8 mL/kg predicted body weight + positive
			end-expiratory pressure) has been shown to improve pulmonary
			mechanics and reduce postoperative pulmonary complications.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R794"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">21-25</font></span></font></a></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Goal-directed
			therapy</font></p>
		</td>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Goal-directed
			therapy, which creates protocols for the use of fluids and
			vasopressors to target specific hemodynamic goals, has yielded
			inconsistent results and requires additional investigation to
			determine its use in cardiac surgery.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R799"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">26</font></span></font></a><font size="1" style="font-size: 8pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R800"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">27</font></span></font></a></p>
		</td>
	</tr>
	<tr>
		<td colspan="2" style="border: 1px solid #2c2e35; padding: 0.02in"><p>
			<font size="1" style="font-size: 8pt">TEE</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">CABG
			+ valve procedures</font></p>
		</td>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Intraoperative
			TEE aids in the real-time assessment of heart valve function and
			pathology in those undergoing combination CABG and valve
			surgery.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R801"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">28-30</font></span></font></a></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Isolated
			CABG procedures</font></p>
		</td>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">The
			use of intraoperative TEE in isolated CABG is less established but
			has been shown to aid in surgical and anesthetic decision-making
			as a tool for real-time assessment of hemodynamic status, regional
			wall motion, ventricular function, valve anatomy, and diastolic
			function.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R801"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">28-35</font></span></font></a></p>
		</td>
	</tr>
	<tr>
		<td colspan="2" style="border: 1px solid #2c2e35; padding: 0.02in"><p>
			<font size="1" style="font-size: 8pt">Pulmonary artery catheters</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">High-risk
			surgery</font></p>
		</td>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Highly
			selective use of pulmonary artery catheters for high-risk patients
			(ie, older, with congestive heart failure, pulmonary hypertension,
			or previous multiple valve procedures) may be safe and may
			potentially aid in the surveillance and treatment of hemodynamic
			instability.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R809"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">36-38</font></span></font></a></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Low-risk
			surgery</font></p>
		</td>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">The
			use of pulmonary artery catheters in low-risk or clinically stable
			patients is discouraged because the practice is associated with
			increased interventions that incur greater health care expense
			without associated improvement in morbidity or mortality
			rates.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R811"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">38-40</font></span></font></a></p>
		</td>
	</tr>
	<tr>
		<td colspan="2" style="border: 1px solid #2c2e35; padding: 0.02in"><p>
			<font size="1" style="font-size: 8pt">CNS monitoring</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Cerebral
			oxygen saturation</font></p>
		</td>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Intraoperative
			monitoring of cerebral oxygen saturation (ie, near-infrared
			spectroscopy) to detect cerebral hypoperfusion has been shown to
			guide anesthetic decision-making and may prevent postoperative
			neurocognitive dysfunction.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R814"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">41-47</font></span></font></a></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Processed
			electroencephalogram</font></p>
		</td>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Routine
			use of intraoperative monitoring of processed electroencephalogram
			(ie, bispectral index) has yielded inconsistent results with
			respect to the prevention of recall, determination of depth of
			anesthesia, or improvement in rate of recovery after cardiac
			surgery.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R821"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">48-51</font></span></font></a></p>
		</td>
	</tr>
</table>
<p align="justify" style="line-height: 0.13in; margin-bottom: 0in"><font size="1" style="font-size: 7pt">CABG
indicates coronary artery bypass graft; CNS, central nervous system;
and TEE, transesophageal echocardiography.</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">Recommendation-Specific
Supportive Text</font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">1.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">As
the only anticoagulant available for many years, UFH has been the
standard of care by default and the primary comparator for novel
agents in RCTs.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R751">23</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Dosing
recommendations were established from early studies that demonstrated
a relationship between activated clotting times and ischemic
complications,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R751">23-26</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;but
it is unclear that these analyses translate to the modern coronary
stent era.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R755">27-31</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Thus,
the exact use of dosing based on activated clotting times in current
practice is uncertain. The routine use of full-dose anticoagulation
therapy after PCI is no longer indicated.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">2.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Heparin-induced
thrombocytopenia occurs when the heparin molecule binds to platelet
factor 4. Argatroban and bivalirudin are direct thrombin inhibitors
and do not bind to platelet factor 4. Because of their different
mechanism of action, argatroban</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R729">1</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
bivalirudin</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R730">2</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;are
acceptable alternative anticoagulants for use in patients with
heparin-induced thrombocytopenia.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">3.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">RCTs
comparing bivalirudin and heparin have reported no difference in
ischemic endpoints; however, less bleeding was reported with
bivalirudin.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R731">3-7</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R737">9</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R757">29</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R760">32-37</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Although
the reduction in bleeding complications with the use of bivalirudin
was seen in most trials, in real-world practice, this benefit may be
less pronounced with routine use of radial artery intervention and
low rates of glycoprotein IIb/IIIa inhibitor use. Meta-analyses of
clinical trial data support these findings, highlighting that the
magnitude of the lower bleeding risk with bivalirudin in various
trials depended on variable inclusion of a glycoprotein IIb/IIIa
inhibitor.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R738">10</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R739">11</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
VALIDATE-SWEDEHEART (Bivalirudin vs Heparin in NSTEMI and STEMI in
Patients on Modern Antiplatelet Therapy in SWEDEHEART)
study</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R766">38</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;examined
a prolonged bivalirudin infusion versus UFH. Patients were treated
with the more potent P2Y12 inhibitors, 90% had radial artery access,
and there was a low rate of glycoprotein IIb/IIIa inhibitor use.
Compared with UFH, bivalirudin was not associated with improved rates
of MACE, major bleeding, or stent thrombosis at 6 months.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">4.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Enoxaparin
is considered a safe alternative to UFH.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R743">15</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R744">16</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
the SYNERGY (Superior Yield of the New Strategy of Enoxaparin,
Revascularization and Glycoprotein IIb/IIIa Inhibitors)</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R742">14</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
AtoZ (Aggrastat to Zocor)</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R741">13</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;trials
of patients with NSTE-ACS, enoxaparin was shown to be noninferior to
UFH, with no difference in rates of death, MI, or major bleeding. In
primary PCI, the ATOLL (Acute STEMI Treated With Primary Angioplasty
and Intravenous Lovenox or UFH to Lower Ischemic and Bleeding
Events)</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R743">15</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;trial
compared intravenous enoxaparin and UFH and showed a reduction in the
main secondary endpoint (composite of death, recurrent ACS, and
urgent revascularization) in the enoxaparin arm, without more
bleeding. These findings have been supported by a subsequent large
meta-analysis that included patients undergoing PCI for STEMI and
NSTE-ACS, which showed a reduction in rates of all-cause death and
bleeding.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R744">16</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Almost
all patients undergoing elective PCI who are administered enoxaparin
(0.5 mg/kg IV) will have a peak anti-Xa level &gt;0.5 IU/mL.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R759">31</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R767">39</span></font></span></font></a></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">5.</span></font></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">In
clinical trials, patients who were given upstream enoxaparin and then
switched to UFH had more complications, which are attributed at least
in part to stacking both medications at the time of PCI, even when
heparin is administered as long as 10 hours after the last dose of
enoxaparin.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R746">18</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R747">19</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;While
these trials were performed prior to the widespread use of radial
artery access, it is preferable to avoid the administration of UFH in
patients that have received enoxaparin in the previous 12 hours to
reduce risk of bleeding.</span></font></p>
<h2 class="western" align="left" style="line-height: 0.22in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="3" style="font-size: 11pt"><b>12.
General Procedural Issues for CABG</b></font></font></h2>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>12.1.
Perioperative Considerations in Patients Undergoing CABG</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu38.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab38.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image47" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">Previous
recommendations with regard to perioperative management assessed the
role of certain monitoring modalities to guide intraoperative and
postoperative decision-making and also emphasized the use of
fast-track cardiac anesthesia, which uses short-acting anesthetic
agents to improve outcomes after CABG.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R777"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">4</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;More
recently, cardiac surgical service lines have been encouraged to
expand the scope of these efforts to develop multidisciplinary
perioperative programs that incorporate bundled evidence-based
surgical, anesthetic, and nursing interventions, including the
targeted use of appropriate monitoring modalities, to optimize care
and improve patient recovery.</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supporting Text</b></i></font></font></h4>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">1.</span></font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Fast-track
cardiac anesthesia was extensively studied in the early 2000s and was
found to reduce opioid use and hasten extubation</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R778">5</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R779">6</font></span></font></a><font size="2" style="font-size: 9pt">;
however, it did not uniformly reduce complications or length of stay
in patients after CABG.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R780">7</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R781">8</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;More
recently, cardiac surgical service lines have expanded on fast-track
anesthetic agents and implemented enhanced recovery programs, which
use more extensive phase-specific perioperative interventions. Such
programs have been shown to prevent early postoperative
complications, minimize exposure to opioid-based analgesia, and
reduce time to extubation, time in the intensive care unit, and
hospital length of stay after CABG.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R774">1-3</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Components
of such programs may include liberation of “nothing by mouth”
status, bundled surgical site infection prevention, multimodal
nonopioid analgesics, protocolized short-acting anesthetics,
targeted-organ perfusion strategies, and early postoperative
ambulation. Assessment of enhanced recovery programs has been
generally limited to moderate-sized observational studies, and
additional research is required to determine the necessary features
and implementation strategies. Providers may consider the use of
specific anesthetic and monitoring modalities outlined in&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="2" style="font-size: 9pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/t12.xhtml">Table
11</font></span></font></a><font size="2" style="font-size: 9pt">.</span></font></p>
<p style="line-height: 0.14in; margin-bottom: 0in"><font color="#d93731"><font size="1" style="font-size: 8pt"><b>Table
12</b></font></font>. Best Practices for the Use of Bypass Conduits
in CABG&nbsp;<font size="1" style="font-size: 8pt">(</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/t12.xhtml"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt">Table
view</font></span></font></a><font size="1" style="font-size: 8pt">)</font></p>
<table cellpadding="2" cellspacing="2">
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Objectively
			assess palmar arch completeness and ulnar compensation before
			harvesting the radial artery. Use the arm with the best ulnar
			compensation for radial artery harvesting.</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Use
			radial artery grafts to target vessels with subocclusive stenoses.</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Avoid
			the use of the radial artery after transradial catheterization.</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Avoid
			the use of the radial artery in patients with chronic kidney
			disease and a high likelihood of rapid progression to
			hemodialysis.</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Use
			oral calcium channel blockers for the first postoperative year
			after radial artery grafting.</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Avoid
			bilateral percutaneous or surgical radial artery procedures in
			patients with coronary artery disease to preserve the artery for
			future use.</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Harvest
			the internal mammary artery using the skeletonization technique to
			reduce the risk of sternal wound complications.</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Use
			an endoscopic saphenous vein harvest technique in patients at risk
			of wound complications.</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Use
			a no-touch saphenous vein harvest technique in patients at low
			risk of wound complications.</font></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Use
			the skeletonized right gastroepiploic artery to graft right
			coronary artery target vessels with subocclusive stenosis if the
			operator is experienced with the use of the artery.</font></p>
		</td>
	</tr>
</table>
<p align="justify" style="line-height: 0.13in"><font size="1" style="font-size: 7pt">CABG
indicates coronary artery bypass graft.</font></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>12.2.
Bypass Conduits in Patients Undergoing CABG</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu39.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab39.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image48" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">In
the choice of conduits for CABG, both clinical and technical factors
(eg, life expectancy, presence of diabetes, presence of CKD, degree
of target stenosis) are considered (</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/t13.xhtml"><font color="#2b7bb9"><span style="text-decoration: none"><font size="2" style="font-size: 9pt">Table
12</font></span></font></a><font size="2" style="font-size: 9pt">).
Decades of data have supported the use of the LIMA to graft the LAD
to prolong survival. These data are from observational studies and,
for the most part, were derived before the introduction of current
optimal medical therapy. The LIMA is preferable unless specific
contraindications are present. The right IMA can be used to graft the
LAD if the LIMA is unusable, or the right IMA can be used in
conjunction with the LIMA (BIMA grafting). Several randomized trials
and meta-analyses have demonstrated better mid- and long-term patency
rates for the radial artery than for the saphenous vein. A pooled
analysis of 6 randomized trials has shown improved clinical outcomes
at 10 years’ follow-up.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R837"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">13</font></span></font></a></p>
<p style="line-height: 0.14in; margin-bottom: 0in"><font color="#d93731"><font size="1" style="font-size: 8pt"><b>Table
13</b></font></font>. Best Practices to Reduce Sternal Wound
Infection in Patients Undergoing CABG&nbsp;<font size="1" style="font-size: 8pt">(</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/t13.xhtml"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt">Table
view</font></span></font></a><font size="1" style="font-size: 8pt">)</font></p>
<table cellpadding="2" cellspacing="2">
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Perform
			nasal swab testing for&nbsp;</font><font size="1" style="font-size: 8pt"><i>Staphylococcus
			aureus</i></font><font size="1" style="font-size: 8pt">.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R910"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">8</font></span></font></a></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Apply
			mupirocin 2% ointment to known nasal carriers of&nbsp;</font><font size="1" style="font-size: 8pt"><i>S
			aureus</i></font><font size="1" style="font-size: 8pt">.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R910"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">8</font></span></font></a></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Apply
			preoperative intranasal mupirocin 2% ointment to those patients
			whose nasal culture or PCR result is unknown.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R910"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">8</font></span></font></a></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Redose
			prophylactic antimicrobials for long procedures (&gt;2 half-lives
			of the antibiotic) or in cases of excessive blood loss during
			CABG.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R912"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">10</font></span></font></a><font size="1" style="font-size: 8pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R913"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">11</font></span></font></a><font size="1" style="font-size: 8pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R929"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">27</font></span></font></a></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Measure
			perioperative HbA1c.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R933"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">31</font></span></font></a></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Treat
			all distant extrathoracic infections before nonemergency surgical
			coronary revascularization.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R921"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">19</font></span></font></a></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Advise
			smoking cessation before elective CABG surgery.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R909"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">7</font></span></font></a></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Apply
			topical antibiotics (vancomycin) to the cut edges of the sternum
			on opening and before closing in cardiac surgical procedures
			involving a median sternotomy.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R906"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">4</font></span></font></a><font size="1" style="font-size: 8pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R934"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">32</font></span></font></a></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Use
			skeletonized harvest of IMA in BIMA grafting.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R918"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">16</font></span></font></a></p>
		</td>
	</tr>
	<tr>
		<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 8pt">Do
			not continue prophylactic antibiotics beyond 48 hours.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R911"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">9</font></span></font></a><font size="1" style="font-size: 8pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R913"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">11</font></span></font></a></p>
		</td>
	</tr>
</table>
<p align="justify" style="line-height: 100%; margin-bottom: 0in"><font size="1" style="font-size: 7pt">BIMA
indicates bilateral internal mammary artery; CABG, coronary artery
bypass graft; HbA1c, glycated hemoglobin A1c; IMA, internal mammary
artery; and PCR, polymerase chain reaction.</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">The
right IMA is biologically equivalent to the LIMA, and BIMA grafting
has shown a survival advantage compared with CABG with a single IMA
in observational studies. The extensive use of arterial conduits (&gt;2)
instead of SVGs for multivessel CABG may provide an additional late
mortality benefit compared with CABG with 2 arterial grafts.</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">Recommendation-Specific
Supportive Text</font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">1.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Several
randomized trials and meta-analyses have reported better mid- and
long-term patency rates for the radial artery than for the saphenous
vein,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R826">2</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R838">14</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;while
observational studies and meta-analyses have suggested a survival
benefit when the radial artery is used instead of the saphenous vein
for CABG.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R827">3</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;A
pooled analysis of 6 randomized trials showed improved clinical
outcome with regard to adverse cardiac events at 5 and 10 years after
surgery when the radial artery was used instead of the saphenous vein
to revascularize the most important non-LAD artery coronary
target.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R825">1</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R837">13</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Patients
&lt;75 years of age, women, and patients with preserved renal
function seem to benefit the most from the use of the radial artery.
The evidence is based largely on the use of the radial artery
constructed as an aortocoronary graft. In observational studies,
composite radial artery grafts have been found to be more vulnerable
to the effect of chronic native competitive flow, but the evidence is
limited.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R839">15</span></font></span></font></a></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">2.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Data
supporting the LIMA versus an SVG for grafting of the LAD are derived
almost exclusively from observational studies reported 25 to 35 years
ago.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R829">5-7</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
the CASS (Coronary Artery Surgery Study) registry, survival was
improved in patients who received the LIMA-LAD compared with the SVG
group after multivariable adjustment.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R831">7</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
another series of nearly 6000 patients undergoing CABG, LIMA grafting
reduced deaths, recurrent infarction, rehospitalization for cardiac
events, and repeat revascularization.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R830">6</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
this study, postoperative angiography revealed substantially higher
LIMA patency. A single small RCT also found improved cardiac
event–free survival at 10 years in the LIMA arm.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R828">4</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R829">5</span></font></span></font></a></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">3.</span></font></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">The
benefit of BIMA in CABG is supported by observational studies and in
several meta-analyses.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R827">3</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R834">10</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R835">11</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R840">16</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;A
meta-analysis of 38 studies, including 174 205 patients, noted a
decreased mortality rate at 7.25 years with BIMA use.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R840">16</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;However,
a single large RCT compared BIMA with single IMA in 3102 patients and
reported no difference in 10-year all-cause mortality rate or in the
composite of death, MI, or stroke.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R836">12</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;However,
a high rate of crossover was noted (14% from BIMA to single IMA, and
22% of the patients with a single IMA received a radial artery). An
as-treated analysis reported improved survival in patients who
received multiple arterial grafts.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R836">12</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Increasing
BIMA volume was associated with protocol adherence, which suggests
the importance of surgical expertise.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R836">12</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Low
institutional BIMA volume has also been associated with a higher
operative mortality rate with BIMA grafting.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R841">17</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Observational
studies and 2 meta-analyses support the use of ≥3 arterial grafts,
including total arterial revascularization.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R842">18</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R843">19</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
increased risk of sternal infection with BIMA grafting should be
considered during preoperative planning.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R841">17</span></font></span></font></a></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>12.3.
CABG in Patients Undergoing Other Cardiac Surgery</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu40.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab40.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image49" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">The
decision to add CABG to another planned cardiac surgery in patients
with significant CAD is multifactorial. Considerations include but
are not limited to comorbidities, technical feasibility of CABG,
extent of the jeopardized myocardium, availability of conduit, left
ventricular ejection fraction, and the additional time needed to
construct the coronary bypass while on cardiopulmonary bypass. A
multidisciplinary discussion with a Heart Team can help weigh the
risks and benefits of adding CABG to the index cardiac operation. Age
does not appear to be a prohibitive risk factor for the addition of
CABG to other cardiac surgery in patients between the ages of 75 and
84 years,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R844"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R845"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">2</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R847"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">4</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;but
risk increases in patients ≥85 years of age.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R855"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">12</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
available evidence supporting CABG at the time of cardiac surgery
performed for another primary indication (ie, valve, aortic, or other
cardiac surgery) is limited and complicated because many studies
include patients with CAD defined as at least 1 vessel with stenosis
≥50%, thus including both intermediate and significant CAD. The
knowledge that incomplete revascularization is associated with
reduced long-term survival rates after surgery compared with patients
who receive complete revascularization may inform decisions about
adding CABG to other cardiac surgery.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R848"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">5</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R853"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">10</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Additionally,
it has become standard practice to bypass significant coronary artery
stenoses in patients undergoing other cardiac surgery.</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supporting Text</b></i></font></font></h4>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">1.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Several
observational studies and meta-analyses compared clinical outcomes in
patients undergoing aortic valve replacement (AVR) with and without
significant CAD (≥70% stenosis of any major epicardial coronary
vessel, including side branches, or ≥50% stenosis of the left
main).</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R849">6-9</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R855">12</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Patients
who underwent AVR with concomitant CABG demonstrated long-term
survival and health-related quality of life similar to that of
patients without CAD. Concomitant CABG may increase the risk of
perioperative morbidity and mortality compared with isolated
AVR.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R845">2-4</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
patients with significant CAD who underwent isolated AVR or AVR plus
CABG, concomitant CABG was associated with a reduced late all-cause
mortality rate (hazard ratio, 0.62; 95% CI, 0.49–0.79;&nbsp;</font><i><font size="2" style="font-size: 9pt">P</i></font><font size="2" style="font-size: 9pt">&lt;0.001).</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R853">10</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;A
large study of 6151 patients found that patients with extensive CAD
(&gt;50% left main stenosis or ≥3 diseased vessels) undergoing AVR
with CABG had more comorbidities and had more perioperative
morbidity, but not mortality, than did patients with less extensive
CAD undergoing AVR with CABG.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R855">12</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;A
large study that propensity-matched patients undergoing AVR to
patients undergoing AVR with CABG demonstrated no differences in
morbidity or mortality between groups, which suggests that survival
is dominated largely by patient comorbidities.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R850">7</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Studies
focusing on CABG as a secondary procedure during other cardiac
operations, including mitral valve, tricuspid valve, aortic, and
pericardial surgery, are limited.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">2.</span></font></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Limited
data are available comparing CABG for intermediate CAD (stenosis,
40%–69%) in patients undergoing other cardiac surgery.
Observational studies comparing patients undergoing AVR with and
without CABG for intermediate CAD suggest that the addition of CABG
may reduce ischemic events.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R848">5</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R850">7</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R853">10</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R855">12</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Patients
with intermediate CAD may benefit from physiological testing with iFR
or FFR to guide decision-making.</span></font></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>12.4.
Use of Epiaortic Ultrasound in Patients Undergoing CABG</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu41.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab41.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image50" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">Atherosclerotic
disease of the aorta is common in patients who undergo CABG surgery,
with a reported prevalence that varies between 19% and 90%, depending
on the patient population and modality of examination.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R857"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">2</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R866"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">11-16</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;There
has been a clear association between aortic atherosclerosis and
stroke,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R872"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">17</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;especially
in patients undergoing CABG.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R866"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">11</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R867"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">12</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R873"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">18-21</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Epiaortic
ultrasound has been demonstrated to be far superior to either
surgical digital palpation or transesophageal echocardiography for
defining the presence and extent of disease and has come to be
recognized as the “gold standard” for the detection of aortic
atherosclerosis.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R868"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">13-15</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R877"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">22-24</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;There
has been considerable variability in the extent to which epiaortic
ultrasound has changed operative strategy, varying from 4% to
22%.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R856"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R857"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">2</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R861"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">6</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R864"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">9</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R871"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">16</font></span></font></a></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supporting Text</b></i></font></font></h4>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">1.</span></font></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">The
ability of routine epiaortic ultrasound to decrease stroke risk in
patients undergoing CABG is unclear. One small prospective trial
failed to meet a prespecified 50% difference in neurocognitive
testing.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R859">4</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Although
it is not uniformly reported,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R858">3</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;several
large retrospective and registry studies,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R856">1</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R857">2</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R861">6</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R862">7</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R864">9</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R865">10</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;as
well as most single-center prospective studies, found an association
with reduced risk of stroke.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R858">3-5</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R863">8</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Procedural
risk, extra time required, and cost are minimal. The use of epiaortic
ultrasound to evaluate the presence, location, and severity of
atherosclerotic plaque in the ascending aorta allows for the
intraoperative adjustment of operative technique to avoid
atheroembolic complications.</span></font></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>12.5.
Use of Cardiopulmonary Bypass in Patients Undergoing CABG</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu42.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab42.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image51" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">When
the operative strategy for CABG for a patient is being planned, it
may be determined that the risks of aortic manipulation preclude the
safe use of a cross-clamp or cannulation of the ascending aorta, and
significant pulmonary disease may increase risk of cardiopulmonary
bypass. In such cases, the risks and benefits of alternative
operative strategies (off-pump or beating heart) are considered,
along with surgeon experience with such strategies. Excellent
surgical results can be achieved by surgeons experienced in off-pump
techniques with either on-pump or off-pump CABG.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R881"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">2</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R883"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">4-15</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
major concerns with the off-pump approach relate to the technical
difficulty of bypassing coronary arteries in the circumflex
distribution, as well as the small and intramyocardial segments.
These issues have resulted in a tendency toward fewer grafts per
patient,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R881"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">2</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R895"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">16</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R896"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">17</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;a
potential for incomplete revascularization,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R881"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">2</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R894"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">15</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
a concern about long-term graft patency.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R896"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">17-20</font></span></font></a></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">Recommendation-Specific
Supportive Text</font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">1.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Off-pump
CABG was developed to reduce the risks associated with
cardiopulmonary bypass and aortic manipulation and the associated
potential for neurological, renal, and myocardial injury. There are
discrepant findings between observational and retrospective studies
and prospective RCTs.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R885">6</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R891">12</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R894">15</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R895">16</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R899">20</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R900">21</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
use of an off-pump approach with minimized aortic manipulation may
result in a decreased incidence of perioperative stroke in the
presence of a calcified ascending aorta.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R880">1</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R881">2</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Reported
short-term benefits of decreased blood product use and length of stay
may be operator driven rather than procedure driven and may be
achievable with either approach.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R901">22</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Reduced
perioperative renal injury may not be sustained on longer
follow-up.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R902">23</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;To
the extent that the off-pump technique permits less manipulation of
the aorta, there appears to be a decreased incidence of perioperative
stroke that is difficult to discern from individual studies.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R880">1</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R881">2</span></font></span></font></a></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">2.</span></font></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Off-pump
CABG has been shown to be associated with earlier extubation, reduced
blood transfusion, and reduced duration of mechanical ventilation
compared with on-pump CABG and may improve outcomes for patients with
increased pulmonary risk, which is perhaps related to avoidance of
the systemic inflammatory response attributable to cardiopulmonary
bypass and its impact on pulmonary function.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R881">2-6</span></font></span></font></a></p>
<h2 class="western" align="left" style="line-height: 0.22in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="3" style="font-size: 11pt"><b>13.
Pharmacotherapy in Patients Undergoing CABG</b></font></font></h2>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>13.1.
Insulin Infusion and Other Measures to Reduce Sternal Wound Infection
in Patients Undergoing CABG</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu43.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab43.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image52" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">Sternal
wound infection has become less common in CABG surgery, with current
rates reported to be &lt;1%.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R918"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">16</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;However,
the associated risk of death may increase several-fold,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R919"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">17</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;while
the associated morbidity and expense can be considerable.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R909"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">7</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Management
of hyperglycemia with perioperative insulin infusion to maintain a
glucose level &lt;180 mg/dL, both in patients with known diabetes and
in patients with stress hyperglycemia, has emerged as an important
strategy to prevent infection, as well as to improve survival and
reduce recurrent ischemic events.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R903"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1-3</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R920"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">18</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R921"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">19</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Continuous
intravenous insulin infusion after CABG reduces postoperative
complications, such as mediastinitis, cardiac arrhythmias, deep
sternal would infections, renal failure, and length of stay.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R905"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">3</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R907"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">5</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R908"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">6</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
addition to standard antibiotic prophylaxis, several other strategies
have emerged as best practices to reduce the risk of sternal
infection (</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/t14.xhtml"><font color="#2b7bb9"><span style="text-decoration: none"><font size="2" style="font-size: 9pt">Table
13</font></span></font></a><font size="2" style="font-size: 9pt">).</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">Recommendation-Specific
Supportive Text</font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">1.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Continuous
intravenous infusion of insulin is effective in maintaining blood
glucose &lt;180 mg/dL in patients undergoing CABG with the intent of
reducing the risk of sternal wound infection. Perioperative glucose
management has been found to be effective both in patients who are
recognized to have diabetes and in those who experience stress
hyperglycemia.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R903">1-3</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R921">19</span></font></span></font></a></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">2.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">The
optimal level of glycemic control needed to improve outcomes in
patients undergoing cardiac surgery remains controversial. One study
evaluating intensive insulin therapy to target a glucose level of
between 100 mg/dL and 140 mg/dL in the intensive care unit did not
demonstrate reduced perioperative complications after CABG compared
with a target glucose level of between 141 mg/dL and 180 mg/dL.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R906">4</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;An
RCT and multiple observational studies have demonstrated that
continuous intravenous insulin infusion is associated with reduced
variability in glucose concentration, reduced hospital length of
stay, reduced ischemic events, reduced wound complications, and
improved survival compared with subcutaneous insulin in patients with
diabetes who undergo CABG.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R905">3</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R907">5</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R908">6</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R922">20</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R923">21</span></font></span></font></a></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">3.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">With
an aggressive preventive approach, some centers report zero incidence
of sternal infection.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R916">14</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R924">22</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;However,
there is no evidence-based preventive “bundle.”</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R909">7</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R925">23-25</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Strong
evidence supports the perioperative administration of
antibiotics,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R911">9</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R928">26</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;with
general agreement that continuation of prophylactic antibiotics for
&gt;48 hours lacks additional benefit. Mupirocin has been found to be
effective in reducing&nbsp;</font><i><font size="2" style="font-size: 9pt">Staphylococcus
aureus</i></font><font size="2" style="font-size: 9pt">&nbsp;infection
in patients who are nasal carriers, and there is no evidence that it
is beneficial for those who are not. Topical vancomycin paste may
have benefit,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R913">11</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R916">14</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R924">22</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;whereas
the formerly ubiquitous use of bone wax is falling into increasing
disfavor.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R914">12</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R915">13</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R929">27</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
use of BIMAs as bypass conduits has generally been associated with an
increased risk of sternal wound infection,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R930">28</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;although
there is considerable center-specific evidence that this risk can be
ameliorated by use of the “skeletonized” technique,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R931">29</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;which
may cause less disruption of sternal perfusion and lymphatic
drainage.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">4.</span></font></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">An
RCT of 400 patients compared intraoperative intensive treatment
(glucose levels 80–100 mg/dL) or conventional treatment (insulin
given only for a glucose concentration ≥200 mg/dL)</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R917">15</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
found no difference between groups in a composite endpoint of death,
deep sternal wound infection, prolonged ventilation, cardiac
arrhythmias, stroke, or renal failure within 30 days. There was an
increased incidence of death and stroke in the patients who received
intensive treatment.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R917">15</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
another RCT, 381 patients without diabetes undergoing isolated CABG
were given intraoperative infusions of insulin or placebo when their
blood glucose concentrations exceeded 100 mg/dL. Insulin infusion
during cardiopulmonary bypass had no significant effect on the
combined incidence of neurological, neuro-ophthalmologic, or
neurobehavioral deficits or neurological death and did not shorten
the length of hospital stay.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R932">30</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Thus,
these data highlight the evidence that extremely tight control of
blood glucose after CABG is not associated with improved outcomes.</span></font></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>13.2.
Antiplatelet Therapy in Patients Undergoing CABG</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu44.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab44.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image53" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">The
use of aspirin and antiplatelet agents in patients undergoing CABG is
discussed with the Heart Team to determine the optimal treatment for
each patient, with careful consideration of the risk of myocardial
ischemia, significant bleeding, reoperation, and transfusion. The
present recommendations are based on the severity of the patient’s
condition and the associated surgical necessity. When the various
therapies are considered, the urgency of the planned surgery should
be determined, as outlined in&nbsp;</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/t8.xhtml"><font color="#2b7bb9"><span style="text-decoration: none"><font size="2" style="font-size: 9pt">Table
7</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;(Section
5.2).</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R960"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">26</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R961"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">27</font></span></font></a></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supporting Text</b></i></font></font></h4>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">1.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Most
patients who undergo CABG are already taking aspirin for primary or
secondary prevention of new cardiovascular events. Early
observational data showed an association between preoperative aspirin
administration and reduced in-hospital mortality rate.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R935">1</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R936">2</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Although
more recent meta-analyses of randomized and nonrandomized trials have
yielded somewhat conflicting results, continuation of existing
preoperative aspirin is likely associated with a reduction in the
risk of MI but not death.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R937">3-5</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Continuation
of aspirin until the time of surgery is associated with an increased
risk of perioperative bleeding and transfusion, although this does
not appear to increase the likelihood of surgical
reoperation.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R937">3-7</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Patients
at risk of significant bleeding (eg, redo operations or underlying
bleeding dyscrasias) may warrant individualized consideration but are
underrepresented in the literature.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">2.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">The
coadministration of aspirin and a P2Y12 receptor inhibitor (ie,
clopidogrel, ticagrelor, prasugrel) is common, particularly in the
setting of ACS or recent stent placement. In such patients, the risk
of ischemic events must be weighed against the risks of bleeding when
decisions are made about the cessation of P2Y12 receptor inhibitors
before CABG.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R942">8-11</span></font></span></font></a></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">3.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Glycoprotein
IIb/IIIa inhibitors (ie, eptifibatide, tirofiban, abciximab) are
sometimes given to patients who are at high risk of acute ischemic
events while they are awaiting CABG. The therapeutic half-life for
each glycoprotein IIb/IIIa inhibitor, in addition to a patient’s
renal function, are considered in the determination of safe
discontinuation before CABG, and data from observational studies have
established optimal cessation periods before CABG for each agent with
reasonable safety profiles.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R946">12-14</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Abciximab
may not be readily available to clinicians in the United States.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">4.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">CABG
performed &lt;5 days after the discontinuation of clopidogrel is
associated with an increased risk of major bleeding complications,
such as tamponade or reoperation, a finding that was suggested by
early observational data.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R943">9</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R949">15</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
confirmed by more recent randomized and nonrandomized
trials.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R944">10</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R950">16-18</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Early
experience also suggested that preoperative ticagrelor should be
withheld for a similar time frame (5 days) before surgery to reduce
bleeding and blood product administration.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R945">11</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R953">19</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;However,
platelet inhibition assay results from 1 randomized study</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R954">20</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
more recent data from 2 separate observational trials have revealed
that delaying surgery for 72 hours is likely sufficient.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R942">8</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R955">21</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
timing for prasugrel is less established but results from the
TRITON-TIMI-38 trial suggested that among patients who underwent
CABG, prasugrel resulted in a higher rate of major bleeding than that
seen with clopidogrel.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R956">22</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
a subset of patients in the ACCOAST (A Comparison of Prasugrel at PCI
or Time of Diagnosis of Non–ST-Elevation Myocardial Infarction)
study, early surgery (&lt;3 days after discontinuation of prasugrel)
led to an increased risk of bleeding and ischemic complications,
whereas later surgery (&gt;7 days) did not.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R957">23</span></font></span></font></a></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">5.</span></font></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Initiation
of aspirin therapy in the immediate preoperative period (&lt;24
hours) has been investigated in 2 randomized trials. In the first
trial,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R958">24</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;patients
undergoing CABG who received 100 mg of aspirin 1 to 2 hours before
surgery experienced a composite outcome of death and thrombotic
complications at 30 days and an incidence of major bleeding and
cardiac tamponade that were similar to those seen with placebo.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R958">24</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
the second trial,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R959">25</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;patients
randomized to receive 300 mg of aspirin the night before surgery had
increased episodes of major bleeding (&gt;750 mL in 24 hours, or 1000
mL overall) and increased transfusion rates, but no significant
differences were found in major cardiovascular events at early (30
days) or long-term (36 months) time points</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R959">25</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;compared
with placebo.</span></font></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>13.3.
Beta Blockers and Amiodarone in Patients Undergoing CABG</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu45.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab45.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image54" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.18in"><font size="2" style="font-size: 9pt">In
patients undergoing elective CABG, the risks and benefits of
beta-blocker and amiodarone administration before surgery should be
carefully considered. Although preoperative beta blockers are
associated with reduced incidence of postoperative atrial
fibrillation, recent data, including meta-analyses of RCTs and
several large observational trials, have yielded conflicting results
with regard to their impact on other outcomes, including death, MACE,
and other arrhythmias.</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supporting Text</b></i></font></font></h4>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">1.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Several
small RCTs</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R962">1-5</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
multiple meta-analyses of RCTs</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R967">6-8</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;have
investigated preoperative beta blockers and found that their use is
associated with a reduced incidence of atrial fibrillation after
CABG. Although the recommendation stems from what is considered
high-quality evidence, full interpretation of the data is limited
because the trials tended to incorporate multiple intervention arms,
had variable timing of initiation of therapy, and were unable to
establish the relative impact of preoperative beta-blocker
administration in the context of postoperative use. The overwhelming
majority of trials investigating the use of preoperative beta
blockers are confounded by concomitant postoperative administration.
As a result, the optimal agent selection, schedule, and duration to
prevent atrial fibrillation are unclear.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">2.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Studies
have demonstrated that preoperative prophylactic oral amiodarone
significantly decreased the incidence of postoperative atrial
arrhythmias and stroke and reduced hospital length of stay compared
with placebo without any adverse complications other than occasional
bradycardia.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R970">9</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R972">11</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R980">19</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Amiodarone
may cause toxicity or systemic hypotension, and thus its use is
determined on an individualized basis, particularly in patients who
are at high risk of developing atrial fibrillation.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">3.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Results
from a large observational database suggested that preoperative
beta-blocker administration was associated with a reduction in
in-hospital and 30-day mortality rate after CABG.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R977">16</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;These
findings underpin the inclusion of preoperative beta blockers as a
quality indicator for CABG surgery. Newer observational studies have
yielded more conflicting results,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R973">12-14</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;showing
little or no mortality benefit, particularly when comparisons between
propensity-matched participants are analyzed. Beta-blocker
pharmacogenetic variation may have a role. One study found that, when
compared with no preoperative beta blockers, noncytochrome P4502D6
metabolized agents (ie, atenolol and sotalol) were associated with a
lower incidence of operative death; however, P4502D6 metabolized
agents (ie, metoprolol, propranolol, carvedilol, and labetalol) were
not.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R978">17</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
impact of preoperative beta-blocker administration in patients with
reduced left ventricular ejection fraction requires additional
investigation.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R976">15</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R977">16</span></font></span></font></a></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">4.</span></font></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Observational
studies do not reveal a consistent association between preoperative
beta-blocker use and other postoperative outcomes, including
myocardial ischemia, stroke or transient ischemic attack, and
AKI.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R973">12-14</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;An
area that likely requires further investigation is the efficacy of
preoperative beta blockers in the prevention of ventricular
arrhythmias. One meta-analysis of RCTs did suggest improved rates of
ventricular arrhythmia, but most of the studies included the outcome
as a secondary endpoint.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R967">6</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R979">18</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Patients
undergoing CABG who receive beta blockers are closely monitored for
bradycardia or hypotension, with subsequent dose adjustment to avoid
these adverse effects.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R965">4-7</span></font></span></font></a></p>
<h2 class="western" align="left" style="line-height: 0.22in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="3" style="font-size: 11pt"><b>14.
Pharmacotherapy in Patients After Revascularization</b></font></font></h2>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>14.1.
Pharmacotherapy for Risk Factor Control in Patients After
Revascularization</b></font></font></h3>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">Patients
undergoing coronary revascularization require aggressive secondary
preventive measures, including lifestyle modifications and
medications for control of cholesterol, blood sugar, and blood
pressure, as well as antiplatelet therapies. A detailed discussion of
the pharmacotherapies used for secondary prevention after
revascularization and the lifestyle measures used to optimize heart
health are beyond the scope of the present guideline and are
discussed in more detail elsewhere.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R981"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1-4</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;This
section will focus on the therapies that are especially relevant to
patients undergoing revascularization.</font></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>14.2.
Dual Antiplatelet Therapy in Patients After PCI</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu46.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab46.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image55" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">After
PCI, the use of DAPT prevents stent thrombosis and reduces ischemic
events at the cost of increased bleeding.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R989"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">5</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Pooled
data have demonstrated less bleeding with shorter-term DAPT (3–6
months) and fewer ischemic events (including stent thrombosis) with
longer-term DAPT (&gt;12 months)</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R989"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">5</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;(</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/f7.xhtml"><font color="#2b7bb9"><span style="text-decoration: none"><font size="2" style="font-size: 9pt">Figure
7</font></span></font></a><font size="2" style="font-size: 9pt">).
The 2016 guideline focused update on duration of DAPT</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R990"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">6</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;highlights
the importance of balancing ischemic and bleeding risk when DAPT is
considered and provides recommendations for short and prolonged DAPT
followed by aspirin monotherapy after revascularization. Since the
release of those guidelines, more recent trials have been
published.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R985"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1-4</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R985"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">7</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;For
this reason, additional recommendations for DAPT are provided. These
recommendations should act as a supplement to the prior guideline
focused update. Given the multiplicity of possible antiplatelet
regimens available for use after revascularization, clinicians should
weigh the risks of bleeding and recurrent ischemia when determining
the choice of DAPT.</font></p>
<p style="line-height: 0.1in"><font color="#2b7bb9"><span style="text-decoration: none"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/f7.xhtml">
  <font color="#2c2e35">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.fig07.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image56" align="bottom" width="92" height="44" border="1"/>
  </font>
</a>
</span></font><font color="#d93731"><font size="1" style="font-size: 8pt"><b>Figure
7</b></font></font>.&nbsp;<b>Use of DAPT for Patients After
PCI.</b>&nbsp;Colors correspond to&nbsp;<a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/t2.xhtml"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt">Table
2</font></span></font></a>. ACS indicates acute coronary syndrome;
BMS, bare metal stent; DAPT, dual antiplatelet therapy; DES,
drug-eluting stent; P2Y12, platelet adenosine diphosphate P2Y12
receptor; PCI, percutaneous coronary intervention; and SIHD, stable
ischemic heart disease. This algorithm is adapted from the 2016 DAPT
guideline<a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R990"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">6</font></span></font></a>&nbsp;and
includes new recommendations from this guideline for the care of
patients with CAD. It is not meant to encompass every patient
scenario or situation, and clinicians are encouraged to use a Heart
Team approach when care decisions are unclear and to see the
accompanying supportive text for each recommendation. Additionally,
in situations that lack sufficient data to make formal
recommendations for care, please see Section 17, “Unanswered
Questions and Future Directions.”</p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supporting Text</b></i></font></font></h4>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">1.</span></font></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Since
the 2016 guideline focused update, 5 large trials have tested a
strategy of shorter-duration DAPT followed by P2Y12 inhibitor
monotherapy after PCI.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R985">1-4</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R991">7</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;DAPT
durations ranged from 1 month</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R987">3</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R991">7</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;to
3 months.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R985">1</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R986">2</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R988">4</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
aggregate, these data support a shorter course of DAPT followed by
P2Y12 monotherapy, with a reduction in bleeding events (when compared
with standard DAPT) and equivalent rates of ischemic events. Most
supported clopidogrel and ticagrelor monotherapy, but prasugrel
monotherapy was included in 1 trial.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R986">2</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;A
meta-analysis of the duration of DAPT incorporating these 5 trials
reported a 40% reduction in the rate of major bleeding events with
shorter-term DAPT followed by P2Y12 monotherapy and no significant
difference in MACE. The trials evaluating the use of shorter-duration
DAPT followed by P2Y12 monotherapy were not powered to assess
differences in stent thrombosis. These trials included few patients
with STEMI. No trial has compared short-term DAPT followed by P2Y12
monotherapy with short-term DAPT followed by aspirin alone.</span></font></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>14.3.
Antiplatelet Therapy in Patients After CABG</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu47.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab47.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image57" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">The
mechanisms warranting DAPT therapy in patients who have undergone
CABG are distinct from those in patients who have had ACS and have
undergone PCI. The pathophysiology of vein graft occlusion involves a
different mechanism from that of native vessel disease with
atherosclerosis, plaque rupture, or stent thrombosis. Additionally, a
larger percentage of the coronary tree is bypassed with CABG in
contrast to the focal lesions treated with PCI. Finally, surgical
bleeding is more of a concern in the perioperative and immediate
postoperative period following CABG. Observational and small
randomized trials and meta-analyses of these studies support that
DAPT after CABG improves vein graft patency, primarily among patients
undergoing off-pump surgery and those with higher SYNTAX scores. The
role of DAPT in patients who undergo CABG after ACS is addressed in
the DAPT guideline.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1002"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">11</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
role of prolonged DAPT for general secondary prevention in patients
with a distant history of CABG is not well established.</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supporting Text</b></i></font></font></h4>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">1.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Surgical
bleeding remains a concern in the perioperative and immediate
postoperative periods, and therefore bleeding risk is an important
consideration in the use of antiplatelet therapy. Older data have
shown that aspirin improves vein graft patency.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R992">1</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R993">2</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R996">5</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R997">6</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Although
1 small study demonstrated higher rates of bleeding with aspirin
after CABG,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1003">12</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;the
totality of evidence supports the early use</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R992">1-6</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;of
aspirin to improve SVG patency and reduce ischemic complications.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">2.</span></font></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Small
RCTs, observational data, and meta-analyses have demonstrated that
DAPT (mostly with aspirin and clopidogrel) after CABG improves vein
graft patency, primarily among patients undergoing off-pump surgery.
The DACAB (Different Antiplatelet Therapy Strategy After Coronary
Artery Bypass Graft Surgery) trial</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1001">10</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;compared
DAPT with a single antiplatelet regimen in 500 patients undergoing
CABG. Off-pump procedures were performed in 75% of these patients. At
1-year follow-up, the DAPT group was found to have the highest vein
graft patency, when assessed with coronary computed tomography
angiogram, compared with aspirin alone.</span></font></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>14.4.
Beta Blockers in Patients After Revascularization</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu48.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab48.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image58" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">In
patients who have undergone revascularization, the risks and benefits
of beta blockers should be considered before the initiation of
therapy. The benefit of beta blockers for secondary prevention after
acute infarction or for those with left ventricular dysfunction has
been clearly reported in clinical trials examining these subgroups,
and recommendations based on this evidence are outlined in previous
guidelines.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1010"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">7</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1011"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">8</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;However,
in patients without acute infarction or left ventricular dysfunction,
there is a paucity of data to support a benefit of the routine use of
beta blockers after revascularization, especially in patients without
residual disease. Further risk reduction may not be useful in
patients after MI with normal left ventricular ejection fraction in
the presence of GDMT with antiplatelet treatment, statins, and
angiotensin-converting enzyme inhibitors or angiotensin-receptor
blockers. Thus, in the absence of new data to guide current therapy,
clinicians will need to make decisions on an individualized basis.</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">Recommendation-Specific
Supportive Text</font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">1.</span></font></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">A
large meta-analysis of patients undergoing PCI for stable angina
showed no differences in adjusted rates of death, MI, stroke, or
revascularization but a higher rate of heart failure readmissions
among patients who were prescribed a beta blocker at hospital
discharge.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1004">1</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
REACH (Reduction of Atherothrombosis for Continued Health) Registry’s
investigators showed that, after a median of 44 months’ follow-up,
beta-blocker use was not associated with a reduction in the composite
cardiovascular outcome in a large cohort of patients with
SIHD.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1005">2</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Additional
studies have also supported an increased incidence of heart failure
in patients treated with beta blockers in the reperfusion era.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1012">9</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
a large cohort of patients with newly diagnosed CAD, a modest benefit
of beta-blocker use was reported, although this benefit was noted
only in patients with a previous MI.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1007">4</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Hence,
the decision to continue beta blockers in the long term in patients
after revascularization should be made on an individualized basis.</span></font></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>14.5.
Beta Blockers for the Prevention of Atrial Fibrillation After CABG</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu49.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab49.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image59" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">New-onset
postoperative atrial fibrillation occurs in about 18% of patients
after CABG and is associated with a 4-fold increased risk of stroke
and a 3-fold increase in all-cause mortality rate.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1020"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">8</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1021"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">9</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Postoperative
atrial fibrillation after CABG can be challenging to prevent and
treat.</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">Recommendation-Specific
Supportive Text</font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">1.</span></font></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">RCTs
have yielded conflicting results with regard to the ability of beta
blockers to influence perioperative cardiovascular morbidity and
mortality. A large meta-analysis found that beta-blocker use may
reduce the incidence of atrial fibrillation and ventricular
arrhythmias and hospital stay</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1022">10</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;but
found no evidence of a difference in rates of early all-cause death,
MI, cerebrovascular events, hypotension, or bradycardia.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1022">10</span></font></span></font></a></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>14.6.
Antiplatelet Therapy in Patients With Atrial Fibrillation on
Anticoagulation After PCI</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu50.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab50.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image60" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">Patients
undergoing PCI frequently have or develop concomitant indications for
anticoagulant therapy, including atrial fibrillation, venous
thromboembolism, and prosthetic heart valves. The most robust
evidence for anticoagulant management in such patients comes from
trials in patients with atrial fibrillation. The 2019 focused update
of the atrial fibrillation guidelines</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1030"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">8</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;gave
a Class 2a recommendation to a P2Y12 inhibitor with a non–vitamin K
oral anticoagulant (rivaroxaban or dabigatran) or a vitamin K
antagonist (warfarin) rather than triple therapy with an
anticoagulant and DAPT. Since the publication of this guideline
focused update, there have been 2 additional trials</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1023"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1026"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">4</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;examining
the benefits of dual anticoagulant therapy after PCI in patients with
atrial fibrillation. On the basis of analyses of these trials, the
recommendations for antiplatelet and anticoagulant therapy after PCI
in patients with atrial fibrillation have been updated.</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supporting Text</b></i></font></font></h4>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">1.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Two
recent trials—the AUGUSTUS (Safety and Efficacy of Apixaban Versus
Vitamin K Antagonist and Aspirin Versus Aspirin Placebo in Patients
With Atrial Fibrillation and ACS and/or PCI) trial</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1023">1</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
the ENTRUST-AF-PCI (Edoxaban–Based Versus Vitamin K
Antagonist–Based Antithrombotic Regimen After Successful Coronary
Stenting in Patients With Atrial Fibrillation) trial</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1026">4</font></span></font></a><font size="2" style="font-size: 9pt">—examined
regimens of apixaban and edoxaban and supported earlier
findings,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1028">6</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1029">7</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;reporting
lower bleeding rates in patients with atrial fibrillation who were
treated with a non–vitamin K oral anticoagulant and P2Y12 inhibitor
than in those treated with triple therapy after PCI. Although none of
the trials was powered for ischemic endpoints, pooled data from these
trials</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1023">1</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;have
shown rates of death, MI, and stent thrombosis with dual therapy that
are similar to those seen with triple therapy. All patients enrolled
in these trials were briefly treated with triple therapy after PCI
before the aspirin was discontinued. An analysis of stent thrombosis
rates suggested that 80% of events occur within 30 days of PCI.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1025">3</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;For
this reason, it is possible that prolonging aspirin therapy to 1
month after PCI may reduce the risk of stent thrombosis.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1025">3</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Therefore,
in patients deemed to be at high risk of stent thrombosis, aspirin
could be maintained for up to 30 days.</span></font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">2.</span></font></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">The
AUGUSTUS trial</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1024">2</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;randomized
patients with atrial fibrillation undergoing PCI and found that
apixaban, as compared with warfarin, reduced the rate of bleeding and
was associated with a lower incidence of the combined endpoint of
death or hospitalization. Compared with other treatment regimens, the
combination of apixaban with a P2Y12 inhibitor was associated with
the lowest rates of bleeding. The ENTRUST-AF-PCI trial</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1026">4</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;compared
edoxaban and P2Y12 monotherapy with triple therapy with a vitamin K
antagonist in patients with atrial fibrillation undergoing PCI.
Although there were fewer bleeding events in the first 14 days in the
vitamin K antagonist arm, a landmark analysis from 14 days onward
demonstrated less bleeding in the dual-therapy group.</span></font></p>
<h2 class="western" align="left" style="line-height: 0.22in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="3" style="font-size: 11pt"><b>15.
Recommendations for Addressing Psychosocial Factors and Lifestyle
Changes After Revascularization</b></font></font></h2>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>15.1.
Cardiac Rehabilitation and Education</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu51.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab51.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image61" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">Cardiac
rehabilitation is an evidence-based intervention comprising patient
education, behavior modification, and exercise training to improve
secondary prevention outcomes in patients with CVD.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1038"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">8</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Cardiac
rehabilitation assists patients with adherence to healthy lifestyle
habits; addresses comorbid conditions (eg, diabetes); monitors for
safety issues, including new or recurrent symptoms; and facilitates
adherence to evidence-based medical therapies.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1039"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">9</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Cardiac
rehabilitation may include a center-based cardiac rehabilitation
program that incorporates face-to-face supervised exercise or an
alternative cardiac rehabilitation delivery model that meets criteria
for safety and effectiveness, as specified by the cardiac
rehabilitation guidelines of the American Association of
Cardiovascular and Pulmonary Rehabilitation.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1040"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">10</font></span></font></a></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">Recommendation-Specific
Supportive Text</font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">1.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">The
safety and effectiveness of the traditional, medically supervised
center-based cardiac rehabilitation model are well established.
Observational studies and RCTs have demonstrated that center-based
cardiac rehabilitation is effective in reducing hospital
readmissions, secondary events, and deaths in patients with
CVD.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1031">1</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1032">2</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1034">4</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1041">11</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Guidelines
and standards of care have been well defined for center-based cardiac
rehabilitation, including core components,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1040">10</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;core
competencies,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1042">12</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;clinical
practice guidelines,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1043">13</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;performance
measures,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1042">12</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
certification (program and individual).</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1039">9</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Home-based
cardiac rehabilitation can help improve delivery of cardiac
rehabilitation to eligible patients by overcoming common barriers
that impede a patient’s participation in center-based cardiac
rehabilitation, including transportation challenges, competing time
demands, and lack of a center-based cardiac rehabilitation program
near the patient’s home.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1044">14</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Core
components of home-based cardiac rehabilitation are similar to those
for center-based cardiac rehabilitation.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1044">14</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Cochrane
reviews concluded that home- and center-based cardiac rehabilitation
have similar effects on quality of life and costs among patients with
recent MI or coronary revascularization.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1045">15-17</span></font></span></font></a></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">2.</span></font></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Patients
and caregivers should receive a comprehensive plan of care and
educational materials during the hospital stay that support adherence
to evidence-based therapies. The “2019 ACC/AHA Guideline on the
Primary Prevention of Cardiovascular Disease”</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1048">18</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;provides
comprehensive recommendations for improving risk factors for CVD
(unhealthy dietary pattern, lack of exercise and physical activity,
obesity, diabetes, high blood cholesterol, hypertension, and tobacco
use). This information and management can be accomplished in a
center-based or a home-based cardiac rehabilitation program and
should be tailored to age, health literacy, cultural practices, and
socioeconomic status.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1037">7</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
basic self-care activities important to CVD management are captured
in the AHA’s Life’s Simple 7 program (eg, smoking cessation,
maintenance of body mass index, physical activity, healthy diet,
maintaining low cholesterol, maintaining normal blood pressure, and
maintaining normal fasting plasma glucose).</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1049">19</span></font></span></font></a></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>15.2.
Smoking Cessation in Patients After Revascularization</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu52.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab52.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image62" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">Tobacco
use, especially cigarette smoking, is a major risk factor for
cardiovascular morbidity and mortality and is the leading preventable
cause of death worldwide.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1055"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">6</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1056"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">7</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Among
patients with coronary heart disease, continued cigarette smoking
after revascularization is associated with adverse clinical
outcomes,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1057"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">8</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;particularly
stent thrombosis.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1058"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">9</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Electronic
nicotine delivery systems or e-cigarettes</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1059"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">10</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;are
a class of tobacco product that emit aerosol containing fine and
ultrafine particulates, nicotine, and toxic gases that may increase
risk of CVD and pulmonary disease.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1060"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">11-13</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
dominant pattern of e-cigarette use in adults is dual use of both
combustible cigarettes and e-cigarettes.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1063"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">14</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1064"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">15</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;When
patients are counseled about risk factor management after
revascularization, the topic of tobacco abuse is paramount and
timely, because patients who are hospitalized after revascularization
are often at their most attentive state. The recommendations for
smoking cessation counseling and treatment are outlined in the “2019
ACC/AHA Guideline on the Primary Prevention of Cardiovascular
Disease”</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1065"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">16</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
are also applicable to the secondary prevention of patients after
coronary artery revascularization.</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supportive Text</b></i></font></font></h4>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">1.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">The
US Public Health Service’s&nbsp;</font><i><font size="2" style="font-size: 9pt">Clinical
Practice Guideline for Smoking Cessation</i></font><font size="2" style="font-size: 9pt">&nbsp;recommends
smoking-cessation pharmacotherapy for all smokers attempting to
quit.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1066">17</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
most effective smoking-cessation therapies include both behavioral
and pharmacological interventions.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1050">1</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1055">6</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;High-quality
evidence showed that using a combination of behavioral support and
medication increases the chances of successfully quitting for at
least 6 months.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1051">2</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1054">5</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Moreover,
the chance of success was increased by 70% to 100% compared with just
brief advice or support. Among patients with CVD who were motivated
to quit smoking, varenicline and bupropion are efficacious for
smoking cessation, as are individual and telephone
counseling.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1051">2</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1054">5</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Varenicline
was the most efficacious of therapies in patients with stable CVD who
were motivated to quit smoking.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1051">2</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1054">5</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1067">18</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1068">19</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
1 study, abstinence rates in the group of patients treated with
varenicline were higher than in those treated with placebo, a result
that persisted for 52 weeks.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1068">19</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Given
the uncertainties of the long-term effects of e-cigarettes on health,
clinicians have been urged to advise cigarette smokers seeking to
quit to use evidence-based, US Food and Drug Administration–approved,
safe and effective smoking cessation pharmacotherapies as first-line
treatments in preference to e-cigarettes.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1056">7</span></font></span></font></a></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">2.</span></font></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Studies
have shown that when hospitalized tobacco users receive counseling
with supportive follow-up for ≥1 month after discharge, smoking
cessation rates increase by 37% at 6 to 12 months after
discharge.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1053">4</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Varenicline
use for hospitalized smokers with ACS who were motivated to quit
significantly increased abstinence versus placebo at 1 year after
discharge.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1069">20-22</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;At
week 24, using varenicline increased smoking abstinence and reduced
cigarette use by ≥50%. There is no evidence that pharmacotherapies
(varenicline, bupropion, and nicotine replacement versus placebo)
increase the risk of cardiovascular adverse events during or after
treatment.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1068">19</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1070">21</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1072">23</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
EAGLES (Neuropsychiatric Safety and Efficacy of Varenicline,
Bupropion, and Nicotine Patch in Smokers With and Without Psychiatric
Disorders) trial showed that pharmacotherapies do not increase the
risk of cardiovascular or neuropsychiatric adverse events compared
with nicotine patch or placebo in smokers with and without
psychiatric disorders.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1067">18</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1072">23</span></font></span></font></a></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>15.3.
Psychological Interventions in Patients After Revascularization</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu53.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab53.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image63" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.11in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">Cardiac
events and coronary revascularization can be distressing life events
that lead to psychosocial morbidity.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1082"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">10-13</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Anxiety,
depression, and stress are associated with poor adherence to healthy
behaviors and prescribed medications, compromised quality of life,
increased health care costs, and increased recurrent cardiac
events</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1084"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">12</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1086"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">14-18</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
are independent risk factors for CVD morbidity and
mortality</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1091"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">19-24</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;(</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/f8.xhtml"><font color="#2b7bb9"><span style="text-decoration: none"><font size="2" style="font-size: 9pt">Figure
8</font></span></font></a><font size="2" style="font-size: 9pt">).
Presurgery estimates of depression in patients undergoing CABG range
from 14% to 43%,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1095"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">23</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1097"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">25-27</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
depression increases length of hospital stay</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1100"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">28</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
mortality rate.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1086"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">14</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1095"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">23</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1101"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">29</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;About
20% of patients who undergo CABG remain depressed
postoperatively.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1102"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">30</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Several
psychological therapies have been used as part of secondary
prevention to improve psychological outcomes. These include
relaxation and stress management, enhancement of coping skills, and
cognitive behavioral therapy, many of which are incorporated into
cardiac rehabilitation programs.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1075"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">3</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1103"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">31</font></span></font></a></p>
<p style="line-height: 0.14in; margin-bottom: 0in"><font color="#2b7bb9"><span style="text-decoration: none"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/f8.xhtml">
  <font color="#2c2e35">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.fig08.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image64" align="bottom" width="92" height="44" border="1"/>
  </font>
</a>
</span></font><font color="#d93731"><font size="1" style="font-size: 8pt"><b>Figure
8</b></font></font>.&nbsp;<b>Traditional and Psychosocial Risk
Factors for ASCVD.</b>&nbsp;ASCVD indicates atherosclerotic
cardiovascular disease.</p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">Recommendation-Specific
Supportive Text</font></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">1.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">In
the EsDEPACS (Escitalopram for Depression in Acute Coronary Syndrome)
trial, escitalopram was superior to placebo in reducing depression
during the 24-week trial.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1104">32</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Long-term
follow-up showed that escitalopram resulted in a significantly lower
risk of MACE and MI but not death.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1074">2</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
ENRICHD (Enhancing Recovery in Coronary Heart Disease Patients) trial
demonstrated that therapy with counseling or selective serotonin
reuptake inhibitors was associated with improved depression but not
event-free survival after 24 months of follow-up.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1077">5</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;A
subgroup analysis of this study, however, found a 42% lower risk of
death or MI in patients treated with a selective serotonin reuptake
inhibitor.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1105">33</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
Bypassing the Blues trial randomized depressed patients undergoing
CABG to 8 months of collaborative care or usual care and demonstrated
a 50% reduction in depression scores and improved quality of life in
the collaborative care group.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1079">7</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1106">34</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;A
meta-analysis of these trials reported a reduction in cardiovascular
deaths but not overall deaths, MI, or revascularization with
psychological interventions.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1073">1</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;These
interventions also improved depression, anxiety, and stress as
compared with controls.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1073">1</span></font></span></font></a></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">2.</span></font></p>
<p style="line-height: 0.11in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Depression
remains an important comorbidity after revascularization, and
treatment options are underused. On the basis of observational data
and the availability of effective depression treatments,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1107">35</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;multiple
professional societies recommend depression screening for patients
with ACS, followed by treatment when depression is
identified.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1080">8</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1091">19</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1108">36</font></span></font></a><font size="2" style="font-size: 9pt">,</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1109">37</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Programs
combining depression screening, with support systems in place,
improve clinical outcomes in adults.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1073">1</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;However,
in the CODIACS-QoL (Comparison of Depression Interventions After
Acute Coronary Syndrome: Quality of Life) trial evaluating 1500
patients with ACS without a history of depression, providing
universal depression screening and notifying treating clinicians of
positive results of screening, either with or without provision of
enhanced depression care, did not alter quality of life,
depression-free days, depressive symptoms, mortality rate, or
patient-reported harms in patients with ACS.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1081">9</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
this trial, a smaller-than-expected proportion of patients with
screening were found to have depression.</span></font></p>
<h2 class="western" align="left" style="line-height: 0.22in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="3" style="font-size: 11pt"><b>16.
Revascularization Outcomes</b></font></font></h2>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>16.1.
Assessment of Outcomes in Patients After Revascularization</b></font></font></h3>
<p style="line-height: 0.14in; text-decoration: none"><font color="#2b7bb9"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/tu54.xhtml">
  <font color="#000080">
    <img src="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/graphic/cir.0000000000001038.utab54.jpg?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D" name="Image65" align="bottom" width="95" height="47" border="1"/>
  </font>
</a>
</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Synopsis</b></i></font></font></h4>
<p style="line-height: 0.18in"><font size="2" style="font-size: 9pt">Centers
that provide coronary revascularization should participate in
clinical data registries with the intent to review and continuously
improve patient outcomes. Comparison of outcomes through the use of
national databases allows individual- and program-level assessment of
the care provided and the opportunity to enhance care with quality
improvement initiatives. Collaboration with other centers allows peer
review and discussion, as well as sharing and adoption of effective
quality improvement measures.</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>Recommendation-Specific
Supporting Text</b></i></font></font></h4>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">1.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Participation
in regional, state, or national registries that provide regular,
risk-adjusted outcomes is beneficial in quality assessment and
improvement. It allows participants to compare their performance to
regional or national validated benchmarks, identify opportunities for
improvement, and disseminate best practices.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1110">1-8</span></font></span></font></a></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">2.</font></p>
<p style="line-height: 0.11in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Quality
and performance measures are defined by attributes related to
structure, processes, and risk-adjusted outcomes. Structural
attributes include elements such as equipment, supplies, staffing,
institution- and operator-level volumes, and electronic health
records. Processes include strategies for appropriate patient
selection; protocols for pre- and postprocedural care, procedural
execution, and management of complications; and participation in
databases and registries for benchmarking the performance of the
program and individual operator. Risk-adjusted outcomes are the end
result of these structures and processes of care, and when available,
they may be more reliable measures of quality than the
institutional-level and individual operator–level volumes.</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1118">9-11</span></font></span></font></a></p>
<p align="right" style="line-height: 0.18in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">3.</span></font></p>
<p style="line-height: 0.18in"><span style="display: inline-block; border: none; padding: 0in"><font size="2" style="font-size: 9pt">Smaller-volume
coronary revascularization programs may benefit from affiliation and
collaboration with larger volume programs. Standardized processes
from both centers may be shared bidirectionally, and periodic
exchange of staff will facilitate the transfer of best practices.
Teaching conferences, as well as conferences on morbidity and
mortality in both centers, may be shared via videoconferencing. In
addition, residents and fellows may rotate between programs. Program
size is typically defined by the specific database.</span></font></p>
<h2 class="western" align="left" style="line-height: 0.22in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="3" style="font-size: 11pt"><b>17.
Unanswered Questions and Future Directions</b></font></font></h2>
<p style="line-height: 0.18in"><font size="2" style="font-size: 9pt">The
indications for revascularization and the approach to treatment in
patients with CAD are generally based on evidence supporting benefit
or lack thereof. Many recommendations for revascularization are
derived from the results of RCTs or observational studies of large
registries or cohorts of patients that show consistent trends in
outcomes. However, there are some patient subgroups and clinical
scenarios for which there is a paucity of evidence to support a
formal recommendation. In addition, in some circumstances, it is
inappropriate or unethical to perform a randomized trial comparing 2
treatments. Furthermore, in some situations, even in the absence of
strong evidence, recommendations are created on the basis of
experiential consensus on best practices for the delivery of care. In
these cases, further research is needed to inform practice, which
would enable updated recommendations based on clinical trial results.</font></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>17.1.
Special Populations</b></font></font></h3>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>17.1.1.
Underrepresented Racial and Ethnic Groups</b></i></font></font></h4>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">Despite
advances in the identification of risk factors for CVD and the
widespread use of evidence-based strategies to manage CVD, there are
persistent sex, racial, and ethnic disparities in the delivery of
care and in morbidity and mortality.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1121"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">1-8</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Studies
have shown that Black patients and patients of South Asian descent
with CAD have worse outcomes than do White patients.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1122"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">2</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1124"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">4</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Additionally,
studies have reported worse outcomes in women than in men, although
this finding is largely attenuated after adjustment for differences
in baseline presentation and treatment.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1129"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">9</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Recommendations
for care in patients with CAD are often derived from RCT data with an
unequal representation of women and racial and ethnic
groups.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1130"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">10</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Although
a study’s findings might be extrapolated to such populations, it is
unclear whether similar outcomes can be assumed from the reported
trial results across all populations of patients. For this reason, in
the planning of clinical trials, measures to ensure the enrollment of
underrepresented racial and ethnic groups should be implemented to
inform better care of patients.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1131"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">11</font></span></font></a></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>17.2.
Special Clinical Situations</b></font></font></h3>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>17.2.1.
Left Ventricular Dysfunction</b></i></font></font></h4>
<p style="line-height: 0.11in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">RCT
data support the use of CABG for the treatment of patients with
coronary heart disease and left ventricular dysfunction to improve
survival.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1132"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">12-14</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Although
the STICH trial reported improved outcomes with CABG compared with
medical therapy, the advantage of CABG over medical therapy was
independent of the presence or absence of myocardial
viability.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1135"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">15-17</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Critics
have argued that the lack of a relative benefit of myocardial
viability in predicting outcome with CABG was largely a result of the
type of testing used.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1138"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">18</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Many
surgeons still use viability testing to guide decisions about
revascularization in patients with severe left ventricular
dysfunction. Nevertheless, in view of the lack of association of
myocardial viability with derived benefit from revascularization, it
remains unclear whether viability studies should be used to inform
clinical practice, and if they are used, it remains unclear which
method of assessment provides the most useful information.</font></p>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">There
are currently insufficient data on the role of PCI in patients with
left ventricular dysfunction to improve survival or cardiovascular
outcomes. To address this gap in evidence, the ongoing REVIVED-BCIS2
(Percutaneous Revascularization for Ischemic Ventricular
Dysfunction)</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1139"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">19</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;study
will evaluate the benefits of PCI versus medical therapy in reducing
the combined endpoint of death or hospitalization for heart failure
at 2 years’ follow-up. Additional studies are also currently under
way, including the ISCHEMIA–Heart Failure Planning Study,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1140"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">20</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;which
is expected to pave the way for a larger phase 3 trial of PCI in
patients with systolic heart failure.</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>17.2.2.&nbsp;</b></i></font></font></h4>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">SCAD
is increasingly recognized as a cause of ACS in young patients,
particularly women, and is present in roughly one-fourth of women ≤50
years of age presenting with AMI.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1141"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">21</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
management of SCAD has evolved over the years toward a more cautious
use of PCI after various case series demonstrated low success rates
and higher rates of complications with PCI for SCAD, as well as good
long-term outcomes in conservatively treated patients.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1142"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">22</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;For
this reason, expert consensus statements emphasize conservative care
in most patients.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1143"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">23</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;However,
managing patients with SCAD who have ongoing symptoms, hemodynamic
instability, or severely compromised blood flow of an artery
subtending a large amount of myocardium (ie, the proximal LAD or left
main lesions) is particularly problematic, as conservative care may
not be a good option. Further investigation therefore is needed to
understand the ideal scenarios for proceeding with revascularization
and the optimal techniques for revascularization in SCAD.</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>17.2.3.
Coronary Artery Aneurysm</b></i></font></font></h4>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">Coronary
artery aneurysms and fistulas are uncommon findings on coronary
angiography, with a reported prevalence of 0.02% to 0.2%.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1144"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">24</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1145"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">25</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Most
patients with coronary artery aneurysms are asymptomatic, but
coronary artery aneurysms can lead to ischemia, vessel thrombosis,
fistula formation, or rupture.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1144"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">24-27</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;There
are no randomized studies evaluating the most effective therapy for
these patients. Case reports and case series have described various
methods for repair of aneurysms or fistulas, including covered
stenting, coil embolization, Amplatzer device implantation, and
surgical bypass with exclusion of the aneurysm.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1144"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">24-27</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Because
many patients remain asymptomatic and treatments for aneurysms or
fistulas are not well defined, information on the timing of
intervention (with respect to size and/or symptoms) and the ideal
approach to treatment (surgical excision versus percutaneous
therapies) is strongly needed.</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>17.2.4.
Myocardial Bridging</b></i></font></font></h4>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">Myocardial
bridging occurs when there is systolic compression of a coronary
artery because of a segmental intramyocardial course of the vessel,
and it is seen in up to 25% of patients undergoing coronary
angiography.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1148"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">28</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Although
most myocardial bridging is clinically insignificant, severe bridging
has been inferred to produce myocardial ischemia, coronary
thrombosis, AMI, and stress cardiomyopathy.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1148"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">28</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
patients with ischemic pain and a myocardial bridge, provocative
testing can be performed by measuring FFR under baseline conditions
and during dobutamine stress or by obtaining positron emission
tomographic imaging during adenosine vasodilator challenge.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1149"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">29</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;If
a patient has evidence of severe ischemia and a significant
myocardial bridge, surgical approaches are available; small studies
have reported subsequent improvement in angina, as documented by the
Seattle Angina Questionnaire.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1150"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">30</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Although
these data appear promising, the long-term risks and benefits of
surgery for myocardial bridging are uncertain, and larger studies are
needed to define best practices in these circumstances.</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>17.2.5.
Treatment of Graft Failure</b></i></font></font></h4>
<p style="line-height: 0.18in"><font size="2" style="font-size: 9pt">Robust
data are also lacking for recommendations for clinical situations
that include acute graft failure after CABG, the percutaneous
treatment of significant arterial graft disease after CABG, and
percutaneous interventions via an arterial graft after CABG. Such
circumstances warrant discussion with a Heart Team and further
investigation.</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>17.2.6.
Antiplatelet Therapy in Patients With ACS After CABG With an
Indication for Anticoagulation</b></i></font></font></h4>
<p style="line-height: 0.18in"><font size="2" style="font-size: 9pt">Although
antiplatelet therapy in patients with atrial fibrillation who are on
anticoagulation after PCI is detailed in Section 14.5., there are no
data to inform the treatment of patients after ACS who undergo CABG
and also have an indication for anticoagulation (atrial fibrillation
or mechanical valve). Care in such patients requires further study
and careful consideration of bleeding risks, recurrent ischemic
events, graft patency, and risk of thromboembolic events.</font></p>
<h3 class="western" align="left" style="line-height: 0.21in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>17.3.
Revascularization Considerations</b></font></font></h3>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>17.3.1.
Use of the Radial Artery for a Conduit After Radial Artery
Catheterization</b></i></font></font></h4>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">The
number of patients undergoing radial artery catheterization has
increased exponentially over the years.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1151"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">31</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Some
patients undergoing radial artery catheterization will ultimately
require CABG. In patients undergoing CABG, the radial artery is the
preferred conduit after the use of the LIMA.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1152"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">32</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;However,
if the radial artery has been manipulated (eg, for access to perform
coronary angiography or intervention), there is informal agreement
among surgeons to generally avoid the use of this artery as a conduit
for grafting, because of the findings of reduced acute and long-term
graft patency in such patients.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1153"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">33</font></span></font></a><font size="2" style="font-size: 9pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1154"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">34</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Intimal
tears, medial dissections, and increased intimal thickness are
frequently found after radial artery catheterization,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1155"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">35</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;and
greater intimal hyperplasia was noted in the radial artery in
pathology studies after radial artery catheterization.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1154"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">34</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
studies, which evaluated the integrity of the radial artery early
after radial artery catheterization, were generally performed within
6 weeks of the radial artery procedure. The persistence of these
abnormal findings in the radial artery in longer-term follow-up is
uncertain. Given the increase in the use of radial access for
coronary angiography and intervention, it would be important to know
whether these pathological findings remain over time. Further
research is needed to determine whether there is healing of the
radial artery and, if so, whether the radial artery might be
considered suitable for graft harvesting after a prespecified period
of time that allows for resumption of normal endothelial integrity.</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>17.3.2.
Completeness of Revascularization in Multivessel Disease</b></i></font></font></h4>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">In
patients with multivessel disease, when feasible, operators often
attempt to treat all vessels to allow for a complete
revascularization. There are no randomized studies prospectively
comparing planned complete versus incomplete revascularization in
SIHD, but several observational studies have concluded that patients
who undergo CABG or PCI have worse outcomes if major epicardial
vessels with significant stenoses are not revascularized during the
index procedure.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1156"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">36-41</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;In
the SYNTAX trial, in which complete revascularization was attempted
in all patients, patients who underwent CABG or PCI with incomplete
revascularization had worse cardiovascular outcomes at long-term
follow-up.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1162"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">42</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Nevertheless,
patients who have incomplete revascularization are more likely to
have a greater burden of comorbidities, including older age,
diabetes, renal failure, previous MI, lower left ventricular
function, and more extensive and complex coronary anatomy, that may
also impact the completeness of revascularization. The observational
studies comparing patients who receive complete or incomplete
revascularization cannot fully account for the underlying reasons why
an operator might choose to revascularize only a limited area. It is
reasonable to rationalize that complete revascularization to improve
perfusion of as large an amount of myocardium as possible is a good
strategy and likely improves patient outcomes. Nevertheless, the
ISCHEMIA trial, which encouraged complete revascularization
(especially if the arteries supplied areas in which there was
ischemia on stress testing), did not demonstrate improved
cardiovascular outcomes with revascularization. As such, when
considering multivessel PCI or additional bypass grafting during a
CABG procedure, one must be mindful of the theoretical benefits of
complete revascularization for the individual patient. RCTs are
needed to examine the benefits of complete revascularization in SIHD,
with trial designs that mimic the trials performed on patients with
STEMI and multivessel disease.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1163"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">43</font></span></font></a></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>17.3.3.
Hybrid Coronary Surgery</b></i></font></font></h4>
<p style="line-height: 0.18in"><font size="2" style="font-size: 9pt">The
hybrid approach to coronary revascularization (which combines
minimally invasive off-pump grafting of the LIMA to the LAD, with PCI
of the remaining vessels) has gained increasing popularity in recent
years, although it is still performed by few select centers in the
United States.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1164"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">44</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Small
RCTs and observational studies with propensity-matching of hybrid
revascularization versus conventional CABG</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1165"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">45-47</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;have
found similar rates of death, MI, stroke, and repeat
revascularization. Unfortunately, the Hybrid Coronary
Revascularization trial, a phase 3, large-scale, randomized trial
designed to compare multivessel PCI with hybrid coronary surgery in
patients with disease of the LAD and ≥1 additional stenoses, was
terminated early because of low enrollment
(</font><a href="http://clinicaltrials.gov/"><font color="#2b7bb9"><span style="text-decoration: none"><font size="2" style="font-size: 9pt">ClinicalTrials.gov</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;identifier:
NCT03089398). For this reason, the role of hybrid surgery as an
alternative to multivessel PCI for patients with multivessel disease
involving the LAD remains unclear. Furthermore, the Hybrid Coronary
Revascularization trial did not compare hybrid surgery as an
alternative to traditional CABG and, as such, additional studies to
evaluate the use of hybrid surgery in these circumstances are needed.
Other areas in need of further research include the use of
non-sternotomy coronary artery revascularization.</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>17.3.4.
Revascularization Before Percutaneous Valve Procedures</b></i></font></font></h4>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">The
presence of CAD in patients referred for TAVR is variable, with 15%
to 81% of patients enrolled in the landmark trials of TAVR having
obstructive CAD.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1168"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">48</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Although
the presence of CAD, particularly complex CAD, is associated with
worse outcomes after TAVR,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1169"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">49</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;observational
studies have not demonstrated improved outcomes when PCI is performed
before TAVR.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1170"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">50</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;The
RCT that evaluated TAVR versus surgical AVR advised that PCI be
performed before TAVR in patients with proximal obstruction of large
vessels.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1171"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">51</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;For
this reason, PCI is often planned before valve procedures, and
guidelines indicate that PCI may be reasonable in patients with
severe disease of the proximal arteries.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1172"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">52</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Nevertheless,
this recommendation is based on limited data, and therefore, further
research is needed to determine whether the routine use of PCI before
percutaneous valve procedures improves outcomes.</font></p>
<h4 class="western" align="left" style="line-height: 0.18in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><i><b>17.3.5.
Revascularization Before Organ Transplantation</b></i></font></font></h4>
<p style="line-height: 0.11in"><font size="2" style="font-size: 9pt">There
are currently no RCTs evaluating the role of revascularization before
solid organ transplantation, although the RCT of revascularization
before vascular surgery did not report improved outcomes with
PCI.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1173"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">53</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;Nonetheless,
because of the increased risk of cardiovascular events among renal
transplant recipients,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#R1174"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">54</font></span></font></a><font size="2" style="font-size: 9pt">&nbsp;routine
risk assessment is often performed before consideration for
transplantation. When obstructive CAD is noted, many transplantation
surgeons are hesitant to proceed with surgery in this complex group
of patients without revascularization; therefore, it is common for a
patient to be referred for revascularization in preparation for organ
transplantation. In the Ischemia CKD trial, there were no differences
in outcomes with routine revascularization even in the presence of
severe ischemia, although only about 10% of enrolled patients were on
the waitlist for transplantation. Even less is known about
revascularization before liver transplantation. For this reason, it
remains unclear whether revascularization before organ
transplantation imparts a better outcome, and RCTs are needed to
further inform care in this complex group of patients.</font></p>
<h2 class="western" align="left" style="line-height: 0.22in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="3" style="font-size: 11pt"><b>ACC/AHA
Joint Committee Members</b></font></font></h2>
<p style="line-height: 0.18in"><font size="2" style="font-size: 9pt">Patrick
T. O’Gara, MD, MACC, FAHA, Chair; Joshua A. Beckman, MD, MS, FAHA,
FACC, Chair-Elect; Glenn N. Levine, MD, FACC, FAHA, Immediate Past
Chair; Sana M. Al-Khatib, MD, MHS, FACC, FAHA; Anastasia L.
Armbruster, PharmD, FACC; Kim K. Birtcher, PharmD, MS, AACC; Joaquin
E. Cigarroa, MD, FACC; Lisa de las Fuentes, MD, MS, FAHA; Anita
Deswal, MD, MPH, FACC, FAHA; Dave L. Dixon, PharmD, FACC; Lee A.
Fleisher, MD, FACC, FAHA; Federico Gentile, MD, FACC; Zachary D.
Goldberger, MD, FACC, FAHA; Bulent Gorenek, MD, FACC; Norrisa Haynes,
MD, MPH; Adrian F. Hernandez, MD, MHS; Mark A. Hlatky, MD, FACC,
FAHA; José A. Joglar, MD, FACC, FAHA; W. Schuyler Jones, MD, FACC;
Joseph E. Marine, MD, FACC; Daniel B. Mark, MD, MPH, FACC, FAHA;
Debabrata Mukherjee, MD, FACC, FAHA, FSCAI; Latha P. Palaniappan, MD,
MS, FACC, FAHA; Mariann R. Piano, RN, PhD, FAHA; Tanveer Rab, MD,
FACC; Erica S. Spatz, MD, MS, FACC; Jacqueline E. Tamis-Holland, MD,
FAHA, FACC, FSCAI; Duminda N. Wijeysundera, MD, PhD; Y. Joseph Woo,
MD, FACC, FAHA</font></p>
<h2 class="western" align="left" style="line-height: 0.22in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="3" style="font-size: 11pt"><b>Presidents
and Staff</b></font></font></h2>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt"><b>American
College of Cardiology</b>&nbsp;Dipti N. Itchhaporia, MD, FACC,
President</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">Cathleen
C. Gates, Chief Executive Officer</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">MaryAnne
Elma, MPH, Senior Director, Enterprise Content and Digital Strategy</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">Grace
D. Ronan, Team Leader, Clinical Policy Publications</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">Timothy
W. Schutt, MA, Clinical Practice Guidelines Analyst</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt"><b>American
College of Cardiology/American Heart Association</b>&nbsp;Thomas S.D.
Getchius, Director, Guideline Strategy and Operations</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">Abdul
R. Abdullah, MD, Director, Guideline Science and Methodology</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt"><b>American
Heart Association</b>&nbsp;Mitchell S.V. Elkind, MD, MS, FAAN, FAHA,
President</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">Nancy
Brown, Chief Executive Officer</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">Mariell
Jessup, MD, FAHA, Chief Science and Medical Officer</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">Radhika
Rajgopal Singh, PhD, Senior Vice President, Office of Science and
Medicine</font></p>
<p style="line-height: 0.18in; margin-bottom: 0in"><font size="2" style="font-size: 9pt">Johanna
A. Sharp, MSN, RN, Science and Medicine Advisor, Office of Science,
Medicine and Health</font></p>
<p style="line-height: 0.18in"><font size="2" style="font-size: 9pt">Jody
Hundley, Production and Operations Manager, Scientific Publications,
Office of Science Operations</font></p>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>Article
Information</b></font></font></h2>
<p style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">Published
online December 9, 2021.</font></p>
<p style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">This
document was approved by the American College of Cardiology Clinical
Policy Approval Committee, the American Heart Association Science
Advisory and Coordinating Committee, the American College of
Cardiology Science and Quality Committee, the American Heart
Association Executive Committee, and the Society for Cardiovascular
Angiography and Interventions Executive Committee in August 2021.</font></p>
<p style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">The
Comprehensive RWI Data Supplement table is available with this
article
at&nbsp;</font><a href="http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIR.0000000000001038"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt">http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIR.0000000000001038</font></span></font></a><font size="1" style="font-size: 8pt">.</font></p>
<p style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">This
article has been copublished in the&nbsp;<i>Journal of the American
College of Cardiology</i>.</font></p>
<p style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">Copies:
This document is available on the websites of the American Heart
Association (</font><a href="http://professional.heart.org/"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt">professional.heart.org</font></span></font></a><font size="1" style="font-size: 8pt">)
and the American College of Cardiology (</font><a href="http://www.acc.org/"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt">www.acc.org</font></span></font></a><font size="1" style="font-size: 8pt">).
A copy of the document is also available
at&nbsp;</font><a href="https://professional.heart.org/statements"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt">https://professional.heart.org/statements</font></span></font></a><font size="1" style="font-size: 8pt">&nbsp;by
selecting the “Guidelines &amp; Statements” button. To purchase
additional reprints, call 215-356-2721 or
email&nbsp;</font><a href="mailto:Meredith.Edelman@wolterskluwer.com"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt">Meredith.Edelman@wolterskluwer.com</font></span></font></a><font size="1" style="font-size: 8pt">.</font></p>
<p style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">The
expert peer review of AHA-commissioned documents (eg, scientific
statements, clinical practice guidelines, systematic reviews) is
conducted by the AHA Office of Science Operations. For more on AHA
statements and guidelines development,
visit&nbsp;</font><a href="https://professional.heart.org/statements"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt">https://professional.heart.org/statements</font></span></font></a><font size="1" style="font-size: 8pt">.
Select the “Guidelines &amp; Statements” drop-down menu near the
top of the webpage, then click “Publication Development.”</font></p>
<p style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">Permissions:
Multiple copies, modification, alteration, enhancement, and/or
distribution of this document are not permitted without the express
permission of the American Heart Association. Instructions for
obtaining permission are located
at&nbsp;</font><a href="https://www.heart.org/permissions"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt">https://www.heart.org/permissions</font></span></font></a><font size="1" style="font-size: 8pt">.
A link to the “Copyright Permissions Request Form” appears in the
second paragraph
(</font><a href="https://www.heart.org/en/aboutus/statements-and-policies/copyright-request-form"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt">https://www.heart.org/en/aboutus/statements-and-policies/copyright-request-form</font></span></font></a><font size="1" style="font-size: 8pt">).</font></p>
<p style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">ACC/AHA
Joint Committee on Clinical Practice Guidelines Members, see page
e80.</font></p>
<p style="line-height: 0.17in"><font size="1" style="font-size: 8pt">The
American Heart Association requests that this document be cited as
follows: Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie
TM, Bischoff JM, Bittl JA, Cohen MG, DiMaio JM, Don CW, Fremes SE,
Gaudino MF, Goldberger ZD, Grant MC, Jaswal JB, Kurlansky PA, Mehran
R, Metkus TS Jr, Nnacheta LC, Rao SV, Sabik JF, Sellke FW, Sharma G,
Yong CM, Zwischenberger BA. 2021 ACC/AHA/SCAI guideline for coronary
artery revascularization: a report of the American College of
Cardiology/American Heart Association Joint Committee on Clinical
Practice Guidelines.&nbsp;<i>Circulation</i>. 2022;145:e18–e114.
doi: 10.1161/CIR.0000000000001038</font></p>
<h3 class="western" align="left" style="line-height: 0.19in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><b>Affiliations</b></font></font></h3>
<p style="line-height: 0.17in"><font size="1" style="font-size: 8pt">Writing
committee members are required to recuse themselves from voting on
sections to which their specific relationships with industry may
apply; see Appendix 1 for detailed information.&nbsp;ACC/AHA
Representative.&nbsp;ACC/AHA Joint Committee on Clinical Practice
Guidelines Liaison.&nbsp;ACC/AHA Task Force on Data Standards
Representative.&nbsp;SCAI Representative.</font></p>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>References</b></font></font></h2>
<p style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt"><b>Preamble</b></font></p>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R1" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Committee
	on Standards for Developing Trustworthy Clinical Practice
	Guidelines, Institute of Medicine (US).&nbsp;</font><font size="1" style="font-size: 8pt"><em>Clinical
	Practice Guidelines We Can Trust</font></em><font size="1" style="font-size: 8pt">.
	National Academies Press; 2011.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R2" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Committee
	on Standards for Systematic Reviews of Comparative Effectiveness
	Research, Institute of Medicine (US).&nbsp;</font><font size="1" style="font-size: 8pt"><em>Finding
	What Works in Health Care: Standards for Systematic Reviews</font></em><font size="1" style="font-size: 8pt">.
	National Academies Press; 2011.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R3" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Anderson
	JL, Heidenreich PA, Barnett PG, et al. ACC/AHA statement on
	cost/value methodology in clinical practice guidelines and
	performance measures: a report of the American College of
	Cardiology/American Heart Association Task Force on Performance
	Measures and Task Force on Practice Guidelines.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2014;129:2329–2345.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0000000000000042">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24677315">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R4" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">ACCF/AHA/Task
	Force on Practice Guidelines. Methodology Manual and Policies From
	the ACCF/AHA Task Force on Practice Guidelines. American College of
	Cardiology and American Heart Association. 2010. Accessed April 12,
	2021. Available
	at:&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.acc.org/Guidelines/About-Guidelines-and-Clinical-Documents/Methodology">https://www.acc.org/Guidelines/About-Guidelines-and-Clinical-Documents/Methodology</font></span></font></a><font size="1" style="font-size: 8pt">&nbsp;and&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://professional.heart.org/-/media/phd-files/guidelines-and-statements/methodology_manual_and_policies_ucm_319826.pdf">https://professional.heart.org/-/media/phd-files/guidelines-and-statements/methodology_manual_and_policies_ucm_319826.pdf</span></font></span></font></a></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R5" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Halperin
	JL, Levine GN, Al-Khatib SM, et al. Further evolution of the ACC/AHA
	clinical practice guideline recommendation classification system: a
	report of the American College of Cardiology/American Heart
	Association Task Force on Clinical Practice Guidelines.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2016;133:1426–1428.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0000000000000312">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26399660">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R6" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Arnett
	DK, Goodman RA, Halperin JL, et al. AHA/ACC/HHS strategies to
	enhance application of clinical practice guidelines in patients with
	cardiovascular disease and comorbid conditions: from the American
	Heart Association, American College of Cardiology, and US Department
	of Health and Human Services.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2014;130:1662–1667.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0000000000000128">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25212466">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">7.</span></font></p>
<div id="R7" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Levine
	GN, O’Gara PT, Beckman JA, et al. Recent innovations,
	modifications, and evolution of ACC/AHA Clinical Practice
	Guidelines: an update for our constituencies: a report of the
	American College of Cardiology/American Heart Association Task Force
	on Clinical Practice Guidelines.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2019;139:e879–e886.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0000000000000651">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30892927">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>1.4.
Scope of the Guideline</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R8" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Hillis
	LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for
	coronary artery bypass graft surgery: a report of the American
	College of Cardiology Foundation/American Heart Association Task
	Force on Practice Guidelines.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2011;124:e652–e735.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0b013e31823c074e">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22064599">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R9" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Levine
	GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline
	for percutaneous coronary intervention: a report of the American
	College of Cardiology Foundation/American Heart Association Task
	Force on Practice Guidelines and the Society for Cardiovascular
	Angiography and Interventions.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2011;124:e574–e651.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0b013e31823ba622">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22064601">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R10" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Levine
	GN, Bates ER, Blankenship JC, et al. 2015 ACC/AHA/SCAI focused
	update on primary percutaneous coronary intervention for patients
	with ST-elevation myocardial infarction: an update of the 2011
	ACCF/AHA/SCAI guideline for percutaneous coronary intervention and
	the 2013 ACCF/AHA guideline for the management of ST-elevation
	myocardial infarction: a report of the American College of
	Cardiology/American Heart Association Task Force on Clinical
	Practice Guidelines and the Society for Cardiovascular Angiography
	and Interventions.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2016;133:1135–1147.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/cir.0000000000000336">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26490017">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R11" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Fihn
	SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS
	guideline for the diagnosis and management of patients with stable
	ischemic heart disease: a report of the American College of
	Cardiology Foundation/American Heart Association Task Force on
	Practice Guidelines, and the American College of Physicians,
	American Association for Thoracic Surgery, Preventive Cardiovascular
	Nurses Association, Society for Cardiovascular Angiography and
	Interventions, and Society of Thoracic Surgeons.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2012;126:e354–e471.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/cir.0b013e318277d6a0">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23166211">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R12" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">O’Gara
	PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the
	management of ST-elevation myocardial infarction: a report of the
	American College of Cardiology Foundation/American Heart Association
	Task Force on Practice Guidelines.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2013;127:e362–e425.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0b013e3182742c84">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23247304">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R13" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Amsterdam
	EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the
	management of patients with non-ST-elevation acute coronary
	syndromes: a report of the American College of Cardiology/American
	Heart Association Task Force on Practice Guidelines.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2014;130:e344–e426.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R14" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Al-Khatib
	SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for
	management of patients with ventricular arrhythmias and the
	prevention of sudden cardiac death: a report of the American College
	of Cardiology/American Heart Association Task Force on Clinical
	Practice Guidelines and the Heart Rhythm Society.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2018;138:e272–e391.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0000000000000549">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29084731">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R15" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Otto
	CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the
	management of patients with valvular heart disease: a report of the
	American College of Cardiology/American Heart Association Joint
	Committee on Clinical Practice Guidelines.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2021;143:e72–e227.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">9.</font></p>
<div id="R16" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Arnett
	DK, Blumenthal R, Albert M, et al. 2019 ACC/AHA guideline on the
	primary prevention of cardiovascular disease: a report of the
	American College of Cardiology/American Heart Association Task Force
	on Clinical Practice Guidelines.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2019;140:e596–e646.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0000000000000678">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30879355">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">10.</font></p>
<div id="R17" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Levine
	GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update
	on duration of dual antiplatelet therapy in patients with coronary
	artery disease: a report of the American College of
	Cardiology/American Heart Association Task Force on Clinical
	Practice Guidelines: an update of the 2011 ACCF/AHA/SCAI guideline
	for percutaneous coronary intervention, 2011 ACCF/AHA guideline for
	coronary artery bypass graft surgery, 2012
	ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and
	management of patients with stable ischemic heart disease, 2013
	ACCF/AHA guideline for the management of ST-elevation myocardial
	infarction, 2014 AHA/ACC guideline for the management of patients
	with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA
	guideline on perioperative cardiovascular evaluation and management
	of patients undergoing noncardiac surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2016;134:e123–e155.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/cir.0000000000000404">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27026020">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">11.</font></p>
<div id="R18" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Grundy
	SM, Stone NJ, Bailey AL, et al. 2018
	AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on
	the management of blood cholesterol: a report of the American
	College of Cardiology/American Heart Association Task Force on
	Clinical Practice Guidelines.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2019;139:e1082–e1143.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0000000000000625">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30586774">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">12.</font></p>
<div id="R19" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Stout
	KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC Guideline for the
	management of adults with congenital heart disease: a report of the
	American College of Cardiology/American Heart Association Task Force
	on Clinical Practice Guidelines.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2019;139:e698–e800.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0000000000000603">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30586767">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">13.</font></p>
<div id="R20" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">January
	CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the
	management of patients with atrial fibrillation: a report of the
	American College of Cardiology/American Heart Association Task Force
	on Practice Guidelines and the Heart Rhythm Society.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2014;130:e199–e267.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/cir.0000000000000041">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24682347">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">14.</font></p>
<div id="R21" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">January
	CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of
	the 2014 AHA/ACC/HRS guideline for the management of patients with
	atrial fibrillation: a report of the American College of
	Cardiology/American Heart Association Task Force on Clinical
	Practice Guidelines and the Heart Rhythm Society.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2019;140:e125–e151.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0000000000000665">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30686041">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">15.</font></p>
<div id="R22" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Wolk
	MJ, Bailey SR, Doherty JU, et al.
	ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality
	appropriate use criteria for the detection and risk assessment of
	stable ischemic heart disease: a report of the American College of
	Cardiology Foundation Appropriate Use Criteria Task Force, American
	Heart Association, American Society of Echocardiography, American
	Society of Nuclear Cardiology, Heart Failure Society of America,
	Heart Rhythm Society, Society for Cardiovascular Angiography and
	Interventions, Society of Cardiovascular Computed Tomography,
	Society for Cardiovascular Magnetic Resonance, and Society of
	Thoracic Surgeons.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2014;63:380–406.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2013.11.009">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24355759">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">16.</font></p>
<div id="R23" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Yancy
	CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the
	management of heart failure: a report of the American College of
	Cardiology Foundation/American Heart Association Task Force on
	practice guidelines.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2013;128:e240–e327.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/cir.0b013e31829e8776">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23741058">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">17.</font></p>
<div id="R24" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Yancy
	CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA fupdate of the
	2013 ACCF/AHA guideline for the management of heart failure: a
	report of the American College of Cardiology/American Heart
	Association Task Force on Clinical Practice Guidelines and the Heart
	Failure Society of America.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2017;136:e137–e161.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0000000000000509">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28455343">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">18.</font></p>
<div id="R25" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Whelton
	PK, Carey RM, Aronow WS, et al. 2017
	ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the
	prevention, detection, evaluation, and management of high blood
	pressure in adults: a report of the American College of
	Cardiology/American Heart Association Task Force on Clinical
	Practice Guidelines.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Hypertension</font></em><font size="1" style="font-size: 8pt">.
	2018;71:e13–e115.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/HYP.0000000000000065">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29133356">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">19.</font></p>
<div id="R26" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Barua
	RS, Rigotti NA, Benowitz NL, et al. 2018 ACC expert consensus
	decision pathway on tobacco cessation treatment: a report of the
	American College of Cardiology Task Force on Clinical Expert
	Consensus Documents.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2018;72:3332–3365.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2018.10.027">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30527452">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">20.</font></p>
<div id="R27" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Clinical
	Practice Guideline Treating Tobacco Use and Dependence 2008 Update
	Panel, Liaisons, and Staff. A clinical practice guideline for
	treating tobacco use and dependence: 2008 update. A US Public Health
	Service report.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Prev Med</font></em><font size="1" style="font-size: 8pt">.
	2008;35:158–176.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.amepre.2008.04.009">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18617085">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">21.</font></p>
<div id="R28" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Lazar
	HL, Salm TV, Engelman R, et al. Prevention and management of sternal
	wound infections.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Thorac Cardiovasc Surg</font></em><font size="1" style="font-size: 8pt">.
	2016;152:962–972.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jtcvs.2016.01.060">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27555340">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">22.</font></p>
<div id="R29" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Thomas
	RJ, Balady G, Banka G, et al. 2018 ACC/AHA clinical performance and
	quality measures for cardiac rehabilitation: a report of the
	American College of Cardiology/American Heart Association Task Force
	on Performance Measures.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Qual Outcomes</font></em><font size="1" style="font-size: 8pt">.
	2018;11:e000037.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/HCQ.0000000000000037">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29599285">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">23.</font></p>
<div id="R30" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Hayes
	SN, Kim ESH, Saw J, et al. Spontaneous coronary artery dissection:
	current state of the science: a scientific statement from the
	American Heart Association.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2018;137:e523–e557.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0000000000000564">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29472380">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">24.</font></p>
<div id="R31" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">van
	Diepen S, Katz JN, Albert NM, et al. Contemporary management of
	cardiogenic shock: a scientific statement from the American Heart
	Association.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2017;136:e232–e268.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0000000000000525">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28923988">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">25.</font></p>
<div id="R32" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kulik
	A, Ruel M, Jneid H, et al. Secondary prevention after coronary
	artery bypass graft surgery: a scientific statement from the
	American Heart Association.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2015;131:927–964.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/cir.0000000000000182">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25679302">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">26.</span></font></p>
<div id="R33" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">American
	Diabetes Association. 8. Pharmacologic approaches to glycemic
	treatment: standards of medical care in diabetes—2018.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Diabetes
	Care</font></em><font size="1" style="font-size: 8pt">.
	2018;41:S73–S85.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.2337/dc18-S008">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29222379">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>1.5.
Class of Recommendation and Level of Evidence</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">1.</span></font></p>
<div id="R34" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">ACCF/AHA
	Task Force on Practice Guidelines. Methodology Manual and Policies
	From the ACCF/AHA Task Force on Practice Guidelines. American
	College of Cardiology and American Heart Association. 2010. Accessed
	April 12, 2021. Available
	at:&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.acc.org/Guidelines/About-Guidelines-and-Clinical-Documents/Methodology">https://www.acc.org/Guidelines/About-Guidelines-and-Clinical-Documents/Methodology</font></span></font></a><font size="1" style="font-size: 8pt">&nbsp;and&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://professional.heart.org/-/media/phd-files/guidelines-and-statements/methodology_manual_and_policies_ucm_319826.pdf">https://professional.heart.org/-/media/phd-files/guidelines-and-statements/methodology_manual_and_policies_ucm_319826.pdf</span></font></span></font></a></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>2.1.
Improving Equity of Care in Revascularization</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R35" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">O’Donoghue
	M, Boden WE, Braunwald E, et al. Early invasive vs conservative
	treatment strategies in women and men with unstable angina and
	non-ST-segment elevation myocardial infarction: a
	meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA</font></em><font size="1" style="font-size: 8pt">.
	2008;300:71–80.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jama.300.1.71">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18594042">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R36" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Lee
	LC, Poh KK, Tang TPL, et al. The impact of gender on the outcomes of
	invasive versus conservative management of patients with
	non-ST-segment elevation myocardial infarction.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Acad Med Singap</font></em><font size="1" style="font-size: 8pt">.
	2010;39:168–172.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20372750">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R37" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Tamis-Holland
	JE, Palazzo A, Stebbins AL, et al. Benefits of direct angioplasty
	for women and men with acute myocardial infarction: results of the
	Global Use of Strategies to Open Occluded Arteries in Acute Coronary
	Syndromes Angioplasty (GUSTO II-B) Angioplasty Substudy.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2004;147:133–139.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.ahj.2003.06.002">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/14691431">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R38" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Heer
	T, Hochadel M, Schmidt K, et al. Sex differences in percutaneous
	coronary intervention-insights from the coronary angiography and PCI
	registry of the German Society of Cardiology.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Heart Assoc</font></em><font size="1" style="font-size: 8pt">.
	2017;6: e004972.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/JAHA.116.004972">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28320749">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R39" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Tamis-Holland
	JE, Lu J, Korytkowski M, et al. Sex differences in presentation and
	outcome among patients with type 2 diabetes and coronary artery
	disease treated with contemporary medical therapy with or without
	prompt revascularization: a report from the BARI 2D Trial (Bypass
	Angioplasty Revascularization Investigation 2 Diabetes).&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2013;61:1767–1776.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2013.01.062">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23500245">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R40" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Davis
	KB, Chaitman B, Ryan T, et al. Comparison of 15-year survival for
	men and women after initial medical or surgical treatment for
	coronary artery disease: a CASS registry study. Coronary Artery
	Surgery Study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	1995;25:1000–1009.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/0735-1097(94)00518-U">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/7897108">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R41" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Gudnadottir
	GS, Andersen K, Thrainsdottir IS, et al. Gender differences in
	coronary angiography, subsequent interventions, and outcomes among
	patients with acute coronary syndromes.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2017;191:65–74.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.ahj.2017.06.014">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28888272">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R42" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Golomb
	M, Redfors B, Crowley A, et al. Prognostic impact of race in
	patients undergoing PCI: analysis from 10 randomized coronary stent
	trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2020;13:1586–1595.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jcin.2020.04.020">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/32646701">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">9.</font></p>
<div id="R43" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Palmeri
	ST, Lowe AM, Sleeper LA, et al. Racial and ethnic differences in the
	treatment and outcome of cardiogenic shock following acute
	myocardial infarction.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2005;96:1042–1049.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.amjcard.2005.06.033">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16214435">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">10.</font></p>
<div id="R44" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Sabatine
	MS, Blake GJ, Drazner MH, et al. Influence of race on death and
	ischemic complications in patients with non-ST-elevation acute
	coronary syndromes despite modern, protocol-guided
	treatment.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2005;111:1217–1224.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/01.CIR.0000157733.50479.B9">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15769761">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">11.</font></p>
<div id="R45" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Cantor
	JC, DeLia D, Tiedemann A, et al. Reducing racial disparities in
	coronary angiography.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Health
	Aff (Millwood)</font></em><font size="1" style="font-size: 8pt">.
	2009;28:1521–1531.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1377/hlthaff.28.5.1521">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19738272">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">12.</font></p>
<div id="R46" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Miller
	CD, Stopyra JP, Mahler SA, et al. ACES (Accelerated Chest Pain
	Evaluation With Stress Imaging) protocols eliminate testing
	disparities in patients with chest pain.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Crit
	Pathw Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2019;18:5–9.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1097/HPC.0000000000000161">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30747758">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">13.</font></p>
<div id="R47" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Rashid
	M, Fischman DL, Martinez SC, et al. Temporal trends and predictors
	of time to coronary angiography following non-ST-elevation acute
	coronary syndrome in the USA.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Coron
	Artery Dis</font></em><font size="1" style="font-size: 8pt">.
	2019;30:159–170.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1097/MCA.0000000000000693">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30676387">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">14.</font></p>
<div id="R48" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Zhao
	M, Woodward M, Vaartjes I, et al. Sex differences in cardiovascular
	medication prescription in primary care: a systematic review and
	meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Heart Assoc</font></em><font size="1" style="font-size: 8pt">.
	2020;9: e014742.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/JAHA.119.014742">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/32431190">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">15.</font></p>
<div id="R49" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Arora
	S, Stouffer GA, Kucharska-Newton A, et al. Fifteen-year trends in
	management and outcomes of non-ST-segment-elevation myocardial
	infarction among black and white patients: the ARIC community
	surveillance study, 2000-2014.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Heart Assoc</font></em><font size="1" style="font-size: 8pt">.
	2018;7:e010203.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/JAHA.118.010203">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30371336">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">16.</font></p>
<div id="R50" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Havranek
	EP, Mujahid MS, Barr DA, et al. Social determinants of risk and
	outcomes for cardiovascular disease: a scientific statement from the
	American Heart Association.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2015;132:873–898.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0000000000000228">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26240271">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">17.</font></p>
<div id="R51" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Walli-Attaei
	M, Joseph P, Rosengren A, et al. Variations between women and men in
	risk factors, treatments, cardiovascular disease incidence, and
	death in 27 high-income, middle-income, and low-income countries
	(PURE): a prospective cohort study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2020;396:97–109.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(20)30543-2">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/32445693">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">18.</font></p>
<div id="R52" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Backholer
	K, Peters SAE, Bots SH, et al. Sex differences in the relationship
	between socioeconomic status and cardiovascular disease: a
	systematic review and meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Epidemiol Community Health</font></em><font size="1" style="font-size: 8pt">.
	2017;71:550–557.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1136/jech-2016-207890">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27974445">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">19.</font></p>
<div id="R53" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Malambo
	P, Kengne AP, De Villiers A, et al. Built environment, selected risk
	factors and major cardiovascular disease outcomes: a systematic
	review.&nbsp;</font><font size="1" style="font-size: 8pt"><em>PLoS
	One</font></em><font size="1" style="font-size: 8pt">. 2016;11:
	e0166846.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1371/journal.pone.0166846">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27880835">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">20.</font></p>
<div id="R54" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Carnethon
	MR, Pu J, Howard G, et al. Cardiovascular health in African
	Americans: a scientific statement from the American Heart
	Association.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2017;136:e393–e423.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0000000000000534">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29061565">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">21.</font></p>
<div id="R55" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Volgman
	AS, Palaniappan LS, Aggarwal NT, et al. Atherosclerotic
	cardiovascular disease in South Asians in the United States:
	epidemiology, risk factors, and treatments: a scientific statement
	from the American Heart Association.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2018;138:e1–e34.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0000000000000580">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29794080">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">22.</font></p>
<div id="R56" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Rodriguez
	CJ, Allison M, Daviglus ML, et al. Status of cardiovascular disease
	and stroke in Hispanics/Latinos in the United States: a science
	advisory from the American Heart Association.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2014;130:593–625.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0000000000000071">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25098323">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">23.</font></p>
<div id="R57" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Beohar
	N, Davidson CJ, Massaro EM, et al. The impact of race/ethnicity on
	baseline characteristics and the burden of coronary atherosclerosis
	in the Bypass Angioplasty Revascularization Investigation 2 Diabetes
	trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2011;161:755–763.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.ahj.2010.12.013">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21473976">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">24.</font></p>
<div id="R58" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Mehran
	R, Chandrasekhar J, Davis S, et al. Impact of race and ethnicity on
	the clinical and angiographic characteristics, social determinants
	of health, and 1-year outcomes after everolimus-eluting coronary
	stent procedures in women.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2019;12:e006918.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCINTERVENTIONS.118.006918">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30998393">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">25.</font></p>
<div id="R59" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Feinstein
	M, Ning H, Kang J, et al. Racial differences in risks for first
	cardiovascular events and noncardiovascular death: the
	Atherosclerosis Risk in Communities study, the Cardiovascular Health
	Study, and the Multi-Ethnic Study of Atherosclerosis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2012;126:50–59.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circulationaha.111.057232">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22693351">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">26.</font></p>
<div id="R60" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Pursnani
	S, Merchant M. South Asian ethnicity as a risk factor for coronary
	heart disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Atherosclerosis</font></em><font size="1" style="font-size: 8pt">.
	2020;315:126–130.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.atherosclerosis.2020.10.007">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/33317714">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">27.</font></p>
<div id="R61" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Sonel
	AF, Good CB, Mulgund J, et al. Racial variations in treatment and
	outcomes of black and white patients with high-risk non-ST-elevation
	acute coronary syndromes: insights from CRUSADE (Can Rapid Risk
	Stratification of Unstable Angina Patients Suppress Adverse Outcomes
	With Early Implementation of the ACC/AHA Guidelines?).&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2005;111:1225–1232.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/01.cir.0000157732.03358.64">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15769762">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">28.</font></p>
<div id="R62" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Pearte
	CA, Myerson M, Coresh J, et al. Variation and temporal trends in the
	use of diagnostic testing during hospitalization for acute
	myocardial infarction by age, gender, race, and geography (the
	Atherosclerosis Risk In Communities Study).&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2008;101:1219–1225.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.amjcard.2008.01.001">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18435947">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">29.</font></p>
<div id="R63" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Freund
	KM, Jacobs AK, Pechacek JA, et al. Disparities by race, ethnicity,
	and sex in treating acute coronary syndromes.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Womens Health (Larchmt)</font></em><font size="1" style="font-size: 8pt">.
	2012;21:126–132.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1089/jwh.2010.2580">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22032760">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">30.</font></p>
<div id="R64" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Vaccarino
	V, Rathore SS, Wenger NK, et al. Sex and racial differences in the
	management of acute myocardial infarction, 1994 through 2002.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2005;353:671–682.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMsa032214">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16107620">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">31.</font></p>
<div id="R65" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Cenko
	E, Yoon J, Kedev S, et al. Sex differences in outcomes after STEMI:
	effect modification by treatment strategy and age.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA
	Intern Med</font></em><font size="1" style="font-size: 8pt">.
	2018;178:632–639.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jamainternmed.2018.0514">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29630703">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">32.</font></p>
<div id="R66" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Blomkalns
	AL, Chen AY, Hochman JS, et al. Gender disparities in the diagnosis
	and treatment of non-ST-segment elevation acute coronary syndromes:
	large-scale observations from the CRUSADE (Can Rapid Risk
	Stratification of Unstable Angina Patients Suppress Adverse Outcomes
	With Early Implementation of the American College of
	Cardiology/American Heart Association Guidelines) National Quality
	Improvement Initiative.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2005;45:832–837.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2004.11.055">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15766815">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">33.</font></p>
<div id="R67" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Asleh
	R, Manemann SM, Weston SA, et al. Sex differences in outcomes after
	myocardial infarction in the community.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Med</font></em><font size="1" style="font-size: 8pt">.
	2021;134:114–121.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.amjmed.2020.05.040">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/32622868">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">34.</font></p>
<div id="R68" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Iantorno
	M, Rogers T, Torguson R, et al. Racial disparities in clinical
	characteristics and outcomes of women undergoing percutaneous
	coronary intervention.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Cardiovasc
	Revasc Med</font></em><font size="1" style="font-size: 8pt">.
	2019;20:1039–1042.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.carrev.2019.09.020">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31678115">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">35.</font></p>
<div id="R69" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Hravnak
	M, Whittle J, Kelley ME, et al. Symptom expression in coronary heart
	disease and revascularization recommendations for black and white
	patients.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am J
	Public Health</font></em><font size="1" style="font-size: 8pt">.
	2007;97:1701–1708.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.2105/AJPH.2005.084103">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17329655">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">36.</font></p>
<div id="R70" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Mirvis
	DM, Graney MJ. Impact of race and age on the effects of
	regionalization of cardiac procedures in the Department of Veterans
	Affairs health care system.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	1998;81:982–987.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0002-9149(98)00076-9">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/9576157">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">37.</font></p>
<div id="R71" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Vaccarino
	V, Parsons L, Every NR, et al. Sex-based differences in early
	mortality after myocardial infarction. National Registry of
	Myocardial Infarction 2 Participants.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	1999;341:217–225.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJM199907223410401">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/10413733">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">38.</font></p>
<div id="R72" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Shaw
	LJ, Shaw RE, Merz CNB, et al. Impact of ethnicity and gender
	differences on angiographic coronary artery disease prevalence and
	in-hospital mortality in the American College of Cardiology-National
	Cardiovascular Data Registry.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2008;117:1787–1801.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circulationaha.107.726562">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18378615">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">39.</font></p>
<div id="R73" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Thomas
	KL, Honeycutt E, Shaw LK, et al. Racial differences in long-term
	survival among patients with coronary artery disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2010;160:744–751.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.ahj.2010.06.014">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20934570">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">40.</font></p>
<div id="R74" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Lichtman
	JH, Wang Y, Jones SB, et al. Age and sex differences in inhospital
	complication rates and mortality after percutaneous coronary
	intervention procedures: evidence from the NCDR.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2014;167:376–383.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.ahj.2013.11.001">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24576523">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">41.</font></p>
<div id="R75" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Mehta
	JL, Bursac Z, Mehta P, et al. Racial disparities in prescriptions
	for cardioprotective drugs and cardiac outcomes in Veterans Affairs
	Hospitals.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2010;105:1019–1023.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.amjcard.2009.11.031">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20346324">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">42.</font></p>
<div id="R76" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Gregory
	PC, LaVeist TA, Simpson C. Racial disparities in access to cardiac
	rehabilitation.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Phys Med Rehabil</font></em><font size="1" style="font-size: 8pt">.
	2006;85:705–710.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1097/01.phm.0000233181.34999.3d">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16924182">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">43.</font></p>
<div id="R77" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Lutfiyya
	MN, Lipsky MS, Bales RW, et al. Disparities in knowledge of heart
	attack and stroke symptoms among adult men: an analysis of
	behavioral risk factor surveillance survey data.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Natl Med Assoc</font></em><font size="1" style="font-size: 8pt">.
	2008;100:1116–1124.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0027-9684(15)31483-8">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18942272">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">44.</font></p>
<div id="R78" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Pamboukian
	SV, Funkhouser E, Child IG, et al. Disparities by insurance status
	in quality of care for elderly patients with unstable angina.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ethn
	Dis</font></em><font size="1" style="font-size: 8pt">.
	2006;16:799–807.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17061730">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">45.</font></p>
<div id="R79" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Trivedi
	AN, Sequist TD, Ayanian JZ. Impact of hospital volume on racial
	disparities in cardiovascular procedure mortality.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2006;47:417–424.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2005.08.068">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16412871">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">46.</font></p>
<div id="R80" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Nallamothu
	BK, Lu X, Vaughan-Sarrazin MS, et al. Coronary revascularization at
	specialty cardiac hospitals and peer general hospitals in Black
	Medicare beneficiaries.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Qual Outcomes</font></em><font size="1" style="font-size: 8pt">.
	2008;1:116–122.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circoutcomes.108.800086">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20031798">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">47.</font></p>
<div id="R81" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kim
	DH, Daskalakis C, Lee AN, et al. Racial disparity in the
	relationship between hospital volume and mortality among patients
	undergoing coronary artery bypass grafting.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Surg</font></em><font size="1" style="font-size: 8pt">.
	2008;248:886–892.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1097/SLA.0b013e318189b1bc">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18948819">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">48.</font></p>
<div id="R82" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Li
	S, Chen A, Mead K. Racial disparities in the use of cardiac
	revascularization: does local hospital capacity matter?&nbsp;</font><font size="1" style="font-size: 8pt"><em>PLoS
	One</font></em><font size="1" style="font-size: 8pt">. 2013;8:
	e69855.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1371/journal.pone.0069855">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23875005">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">49.</font></p>
<div id="R83" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Cram
	P, Bayman L, Popescu I, et al. Racial disparities in
	revascularization rates among patients with similar insurance
	coverage.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Natl Med Assoc</font></em><font size="1" style="font-size: 8pt">.
	2009;101:1132–1139.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0027-9684(15)31109-3">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19998642">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">50.</font></p>
<div id="R84" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Mahajan
	AM, Claessen BE, Chandrasekhar J, et al. Outcomes by gender and
	ethnicity after percutaneous coronary intervention.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2019;123:1941–1948.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.amjcard.2019.03.019">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31005238">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">51.</font></p>
<div id="R85" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Schulman
	KA, Berlin JA, Harless W, et al. The effect of race and sex on
	physicians’ recommendations for cardiac catheterization.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	1999;340:618–626.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJM199902253400806">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/10029647">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">52.</font></p>
<div id="R86" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Sullivan
	LT, Mulder H, Chiswell K, et al. Racial differences in long-term
	outcomes among black and white patients with drug-eluting stents.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2019;214:46–53.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.ahj.2019.04.005">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31154196">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">53.</font></p>
<div id="R87" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Gaglia
	MA, Steinberg DH, Pinto Slottow TL, et al. Racial disparities in
	outcomes following percutaneous coronary intervention with
	drug-eluting stents.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2009;103:653–658.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.amjcard.2008.10.043">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19231328">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">54.</font></p>
<div id="R88" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Chen
	MS, Bhatt DL, Chew DP, et al. Outcomes in African Americans and
	Whites after percutaneous coronary intervention.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Med</font></em><font size="1" style="font-size: 8pt">.
	2005;118:1019–1025.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.amjmed.2004.12.035">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16164889">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">55.</font></p>
<div id="R89" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kaul
	U, Patel TM, Zambahari R, et al. Evaluation of the XIENCE V
	everolimus eluting coronary stent system in the Asian population of
	the SPIRIT V single arm study. 2-year clinical follow-up
	data.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Indian
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2011;63:402–408.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23550416">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">56.</font></p>
<div id="R90" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Krishnamurthy
	A, Keeble C, Burton-Wood N, et al. Clinical outcomes following
	primary percutaneous coronary intervention for ST-elevation
	myocardial infarction according to sex and race.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J Acute Cardiovasc Care</font></em><font size="1" style="font-size: 8pt">.
	2019;8:264–272.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1177/2048872617735803">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28980483">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">57.</span></font></p>
<div id="R91" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Rubini
	Gimenez M, Zeymer U, Desch S, et al. Sex-Specific management in
	patients with acute myocardial infarction and cardiogenic shock: a
	substudy of the CULPRIT-SHOCK trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2020;13:e008537.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCINTERVENTIONS.119.008537">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/32151161">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>2.2.
Shared Decision-Making and Informed Consent</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R92" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Lamore
	K, Montalescot L, Untas A. Treatment decision-making in chronic
	diseases: what are the family members’ roles, needs and attitudes?
	A systematic review.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Patient
	Educ Couns</font></em><font size="1" style="font-size: 8pt">.
	2017;100:2172–2181.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.pec.2017.08.003">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28838630">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R93" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Stacey
	D, Bennett CL, Barry MJ, et al. Decision aids for people facing
	health treatment or screening decisions.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Cochrane
	Database Syst Rev</font></em><font size="1" style="font-size: 8pt">.
	2011;10:CD001431.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R94" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Lin
	GA, Fagerlin A. Shared decision making: state of the science.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Qual Outcomes</font></em><font size="1" style="font-size: 8pt">.
	2014;7:328–334.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCOUTCOMES.113.000322">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24496297">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R95" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Ting
	HH, Brito JP, Montori VM. Shared decision making: science and
	action.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Qual Outcomes</font></em><font size="1" style="font-size: 8pt">.
	2014;7:323–327.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCOUTCOMES.113.000288">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24496298">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R96" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Hughes
	TM, Merath K, Chen Q, et al. Association of shared decision-making
	on patient-reported health outcomes and healthcare utilization.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Surg</font></em><font size="1" style="font-size: 8pt">.
	2018;216:7–12.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.amjsurg.2018.01.011">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29395026">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R97" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Chewning
	B, Bylund CL, Shah B, et al. Patient preferences for shared
	decisions: a systematic review.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Patient
	Educ Couns</font></em><font size="1" style="font-size: 8pt">.
	2012;86:9–18.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.pec.2011.02.004">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21474265">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R98" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Magnani
	JW, Mujahid MS, Aronow HD, et al. Health literacy and cardiovascular
	disease: fundamental relevance to primary and secondary prevention:
	a scientific statement from the American Heart
	Association.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2018;138:e48–e74.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0000000000000579">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29866648">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R99" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Neumann
	F-J, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS guidelines on
	myocardial revascularization.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2019;40:87–165.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/eurheartj/ehy394">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30165437">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">9.</font></p>
<div id="R100" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Schultz
	WM, Kelli HM, Lisko JC, et al. Socioeconomic status and
	cardiovascular outcomes: challenges and interventions.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2018;137:2166–2178.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCULATIONAHA.117.029652">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29760227">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">10.</font></p>
<div id="R101" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Martínez-García
	M, Salinas-Ortega M, Estrada-Arriaga I, et al. A systematic approach
	to analyze the social determinants of cardiovascular disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>PLoS
	One</font></em><font size="1" style="font-size: 8pt">. 2018;13:
	e0190960.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1371/journal.pone.0190960">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29370200">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">11.</font></p>
<div id="R102" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Mosquera
	PA, San Sebastian M, Waenerlund A-K, et al. Income-related
	inequalities in cardiovascular disease from mid-life to old age in a
	northern Swedish cohort: a decomposition analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Soc
	Sci Med</font></em><font size="1" style="font-size: 8pt">.
	2016;149:135–144.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.socscimed.2015.12.017">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26717560">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">12.</font></p>
<div id="R103" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Khaing
	W, Vallibhakara SA, Attia J, et al. Effects of education and income
	on cardiovascular outcomes: a systematic review and
	meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	J Prev Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2017;24:1032–1042.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1177/2047487317705916">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28406328">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">13.</font></p>
<div id="R104" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Baggett
	TP, Liauw SS, Hwang SW. Cardiovascular disease and homelessness.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2018;71:2585–2597.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2018.02.077">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29852981">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">14.</font></p>
<div id="R105" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Stacey
	D, Légaré F, Lewis K, et al. Decision aids for people facing
	health treatment or screening decisions.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Cochrane
	Database Syst Rev</font></em><font size="1" style="font-size: 8pt">.
	2017;4:CD001431.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28402085">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">15.</font></p>
<div id="R106" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Perez
	Jolles M, Richmond J, Thomas KC. Minority patient preferences,
	barriers, and facilitators for shared decision-making with health
	care providers in the USA: a systematic review.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Patient
	Educ Couns</font></em><font size="1" style="font-size: 8pt">.
	2019;102:1251–1262.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.pec.2019.02.003">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30777613">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">16.</font></p>
<div id="R107" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Provance
	JB, Spertus JA, Decker C, et al. Assessing patient preferences for
	shared decision-making in peripheral artery disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Qual Outcomes</font></em><font size="1" style="font-size: 8pt">.
	2019;9:e005730.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">17.</font></p>
<div id="R108" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Arnett
	DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the
	primary prevention of cardiovascular disease: a report of the
	American College of Cardiology/American Heart Association Task Force
	on Clinical Practice Guidelines.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2019;140:e596–e646.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0000000000000678">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30879355">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">18.</font></p>
<div id="R109" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Havranek
	EP, Mujahid MS, Barr DA, et al. Social determinants of risk and
	outcomes for cardiovascular disease: a scientific statement from the
	American Heart Association.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2015;132:873–898.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0000000000000228">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26240271">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">19.</font></p>
<div id="R110" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Elwyn
	G, Frosch DL, Kobrin S. Implementing shared decision-making:
	consider all the consequences.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Implement
	Sci</font></em><font size="1" style="font-size: 8pt">.
	2016;11:114.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1186/s13012-016-0480-9">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27502770">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">20.</font></p>
<div id="R111" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Milky
	G, Thomas J Shared decision making, satisfaction with care and
	medication adherence among patients with diabetes.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Patient
	Educ Couns</font></em><font size="1" style="font-size: 8pt">.
	2020;103:661–669.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.pec.2019.10.008">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31676101">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">21.</font></p>
<div id="R112" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Fihn
	SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS
	guideline for the diagnosis and management of patients with stable
	ischemic heart disease: a report of the American College of
	Cardiology Foundation/American Heart Association Task Force on
	Practice Guidelines, and the American College of Physicians,
	American Association for Thoracic Surgery, Preventive Cardiovascular
	Nurses Association, Society for Cardiovascular Angiography and
	Interventions, and Society of Thoracic Surgeons.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2012;126:e354–e471.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/cir.0b013e318277d6a0">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23166211">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">22.</font></p>
<div id="R113" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Whitney
	SN, McGuire AL, McCullough LB. A typology of shared decision making,
	informed consent, and simple consent.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Intern Med</font></em><font size="1" style="font-size: 8pt">.
	2004;140:54–59.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.7326/0003-4819-140-1-200401060-00012">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/14706973">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">23.</font></p>
<div id="R114" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Smith
	SC, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and
	risk reduction therapy for patients with coronary and other
	atherosclerotic vascular disease: 2011 update: a guideline from the
	American Heart Association and American College of Cardiology
	Foundation.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2011;124:2458–2473.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0b013e318235eb4d">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22052934">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">24.</font></p>
<div id="R115" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Levine
	GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline
	for percutaneous coronary intervention: a report of the American
	College of Cardiology Foundation/American Heart Association Task
	Force on Practice Guidelines and the Society for Cardiovascular
	Angiography and Interventions.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2011;124:e574–e651.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0b013e31823ba622">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22064601">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">25.</font></p>
<div id="R116" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Hillis
	LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for
	coronary artery bypass graft surgery: a report of the American
	College of Cardiology Foundation/American Heart Association Task
	Force on Practice Guidelines.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2011;124:e652–e735.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0b013e31823c074e">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22064599">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">26.</font></p>
<div id="R117" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kipp
	R, Lehman J, Israel J, et al. Patient preferences for coronary
	artery bypass graft surgery or percutaneous intervention in
	multivessel coronary artery disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Catheter
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2013;82:212–218.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1002/ccd.24399">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22517566">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">27.</font></p>
<div id="R118" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Ottawa
	Hospital Research Institute. Patient Decision Aids: Implementation
	Toolkit. 2014. Accessed June 25, 2021. Available
	at:&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://decisionaid.ohri.ca/implement.html">https://decisionaid.ohri.ca/implement.html</span></font></span></font></a></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">28.</span></font></p>
<div id="R119" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Agency
	for Healthcare Research and Quality. The SHARE Approach—Essential
	Steps of Shared Decisionmaking: Quick Reference Guide. 2020.
	Accessed June 25, 2021. Available
	at:&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ahrq.gov/health-literacy/professional-training/shared-decision/tools/resource-1.html">https://www.ahrq.gov/health-literacy/professional-training/shared-decision/tools/resource-1.html</span></font></span></font></a></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>3.1.
The Heart Team</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R120" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Bonzel
	T, Schächinger V, Dörge H. Description of a Heart Team approach to
	coronary revascularization and its beneficial long-term effect on
	clinical events after PCI.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Clin
	Res Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2016;105:388–400.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1007/s00392-015-0932-2">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26508415">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R121" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Chu
	D, Anastacio MM, Mulukutla SR, et al. Safety and efficacy of
	implementing a multidisciplinary heart team approach for
	revascularization in patients with complex coronary artery disease:
	an observational cohort pilot study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA
	Surg</font></em><font size="1" style="font-size: 8pt">.
	2014;149:1109–1112.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jamasurg.2014.2059">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25207883">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R122" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Leonardi
	S, Marino M, Crimi G, et al. APpropriAteness of percutaneous
	Coronary interventions in patients with ischaemic HEart disease in
	Italy: the APACHE pilot study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>BMJ
	Open</font></em><font size="1" style="font-size: 8pt">. 2017;7:
	e016909.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1136/bmjopen-2017-016909">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28877948">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R123" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Pavlidis
	AN, Perera D, Karamasis GV, et al. Implementation and consistency of
	Heart Team decision-making in complex coronary
	revascularisation.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Int
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2016;206:37–41.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.ijcard.2016.01.041">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26774827">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R124" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Sanchez
	CE, Dota A, Badhwar V, et al. Revascularization heart team
	recommendations as an adjunct to appropriate use criteria for
	coronary revascularization in patients with complex coronary artery
	disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Catheter
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2016;88:e103–e112.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1002/ccd.26276">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26527352">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R125" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Yamasaki
	M, Abe K, Horikoshi R, et al. Enhanced outcomes for coronary artery
	disease obtained by a multidisciplinary heart team approach.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Gen
	Thorac Cardiovasc Surg</font></em><font size="1" style="font-size: 8pt">.
	2019;67:841–848.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1007/s11748-019-01108-4">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30877648">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R126" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Patterson
	T, McConkey HZR, Ahmed-Jushuf F, et al. Long-term outcomes following
	heart team revascularization recommendations in complex coronary
	artery disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Heart Assoc</font></em><font size="1" style="font-size: 8pt">.
	2019;8: e011279.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/JAHA.118.011279">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30943827">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R127" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Mohr
	FW, Morice M-C, Kappetein AP, et al. Coronary artery bypass graft
	surgery versus percutaneous coronary intervention in patients with
	three-vessel disease and left main coronary disease: 5-year
	follow-up of the randomised, clinical SYNTAX trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2013;381:629–638.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(13)60141-5">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23439102">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">9.</font></p>
<div id="R128" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Ram
	E, Goldenberg I, Kassif Y, et al. Comparison of patients with
	multivessel disease treated at centers with and without on-site
	cardiac surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Thorac Cardiovasc Surg</font></em><font size="1" style="font-size: 8pt">.
	2018;155:865–873.e3.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jtcvs.2017.09.144">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29452484">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">10.</font></p>
<div id="R129" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">King
	SB, Barnhart HX, Kosinski AS, et al. Angioplasty or surgery for
	multivessel coronary artery disease: comparison of eligible registry
	and randomized patients in the EAST trial and influence of treatment
	selection on outcomes. Emory Angioplasty versus Surgery Trial
	Investigators.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	1997;79:1453–1459.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0002-9149(97)00170-7">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/9185632">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">11.</span></font></p>
<div id="R130" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Feit
	F, Brooks MM, Sopko G, et al. Long-term clinical outcome in the
	Bypass Angioplasty Revascularization Investigation Registry:
	comparison with the randomized trial. BARI
	Investigators.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2000;101:2795–2802.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/01.CIR.101.24.2795">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/10859284">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>3.2.
Predicting Patient Risk of Death With CABG</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R131" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Osnabrugge
	RL, Speir AM, Head SJ, et al. Performance of EuroSCORE II in a large
	US database: implications for transcatheter aortic valve
	implantation.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	J Cardiothorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2014;46:400–408.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/ejcts/ezu033">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24574449">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R132" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Ad
	N, Holmes SD, Patel J, et al. Comparison of EuroSCORE II, Original
	EuroSCORE, and The Society of Thoracic Surgeons Risk Score in
	Cardiac Surgery Patients.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2016;102:573–579.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.athoracsur.2016.01.105">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27112651">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R133" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">O’Brien
	SM, Feng L, He X, et al. The Society of Thoracic Surgeons 2018 adult
	cardiac surgery risk models: part 2-statistical methods and
	results.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2018;105:1419–1428.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29577924">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R134" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Shahian
	DM, Jacobs JP, Badhwar V, et al. The Society of Thoracic Surgeons
	2018 adult cardiac surgery risk models: part 1-background, design
	considerations, and model development.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2018;105:1411–1418.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.athoracsur.2018.03.002">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29577925">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R135" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Nashef
	SA, Roques F, Sharples LD, et al. EuroSCORE II.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	J Cardiothorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2012;41:734–744. discussion 44–5.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/ejcts/ezs043">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22378855">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R136" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Thielmann
	M, Mechmet A, Neuhäuser M, et al. Risk prediction and outcomes in
	patients with liver cirrhosis undergoing open-heart surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	J Cardiothorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2010;38:592–599.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.ejcts.2010.02.042">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20413316">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R137" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Modi
	A, Vohra HA, Barlow CW. Do patients with liver cirrhosis undergoing
	cardiac surgery have acceptable outcomes?&nbsp;</font><font size="1" style="font-size: 8pt"><em>Interact
	Cardiovasc Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2010;11:630–634.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1510/icvts.2010.241190">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20739405">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R138" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Reichart
	D, Rosato S, Nammas W, et al. Clinical frailty scale and outcome
	after coronary artery bypass grafting.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	J Cardiothorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2018;54:1102–1109.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/ejcts/ezy222">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29897529">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">9.</font></p>
<div id="R139" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Sündermann
	S, Dademasch A, Rastan A, et al. One-year follow-up of patients
	undergoing elective cardiac surgery assessed with the Comprehensive
	Assessment of Frailty test and its simplified form.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Interact
	Cardiovasc Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2011;13:119–123; discussion 23.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1510/icvts.2010.251884">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21378017">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">10.</font></p>
<div id="R140" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Sündermann
	SH, Dademasch A, Seifert B, et al. Frailty is a predictor of short-
	and mid-term mortality after elective cardiac surgery independently
	of age.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Interact
	Cardiovasc Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2014;18:580–585.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/icvts/ivu006">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24497604">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">11.</font></p>
<div id="R141" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Afilalo
	J, Eisenberg MJ, Morin JF, et al. Gait speed as an incremental
	predictor of mortality and major morbidity in elderly patients
	undergoing cardiac surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2010;56:1668–1676.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2010.06.039">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21050978">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">12.</font></p>
<div id="R142" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Afilalo
	J, Mottillo S, Eisenberg MJ, et al. Addition of frailty and
	disability to cardiac surgery risk scores identifies elderly
	patients at high risk of mortality or major morbidity.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Qual Outcomes</font></em><font size="1" style="font-size: 8pt">.
	2012;5:222–228.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCOUTCOMES.111.963157">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22396586">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">13.</font></p>
<div id="R143" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Lytwyn
	J, Stammers AN, Kehler DS, et al. The impact of frailty on
	functional survival in patients 1 year after cardiac surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Thorac Cardiovasc Surg</font></em><font size="1" style="font-size: 8pt">.
	2017;154:1990–1999.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jtcvs.2017.06.040">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28734627">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">14.</font></p>
<div id="R144" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Sepehri
	A, Beggs T, Hassan A, et al. The impact of frailty on outcomes after
	cardiac surgery: a systematic review.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Thorac Cardiovasc Surg</font></em><font size="1" style="font-size: 8pt">.
	2014;148:3110–3117.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jtcvs.2014.07.087">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25199821">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">15.</font></p>
<div id="R145" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Ringaitienė
	D, Gineitytė D, Vicka V, et al. Impact of malnutrition on
	postoperative delirium development after on pump coronary artery
	bypass grafting.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Cardiothorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2015;10:74.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1186/s13019-015-0278-x">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25990791">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">16.</font></p>
<div id="R146" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Lomivorotov
	VV, Efremov SM, Boboshko VA, et al. Prognostic value of nutritional
	screening tools for patients scheduled for cardiac surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Interact
	Cardiovasc Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2013;16:612–618.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/icvts/ivs549">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23360716">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">17.</span></font></p>
<div id="R147" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Bayir
	H, Yildiz I. Malnutrition and adverse effects in cardiac
	surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Thorac
	Cardiovasc Surg</font></em><font size="1" style="font-size: 8pt">.
	2015;63:349–350.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1055/s-0035-1548999">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25938269">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>4.1.
Angiography to Define Anatomy and Assess Lesion Severity</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R148" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Adjedj
	J, Xaplanteris P, Toth G, et al. Visual and quantitative assessment
	of coronary stenoses at angiography versus fractional flow reserve:
	the impact of risk factors.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Imaging</font></em><font size="1" style="font-size: 8pt">.
	2017;10:e006243.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circimaging.117.006243">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28687539">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R149" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Beauman
	GJ, Vogel RA. Accuracy of individual and panel visual
	interpretations of coronary arteriograms: implications for clinical
	decisions.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	1990;16:108–113.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/0735-1097(90)90465-2">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/2358583">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R150" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Fleming
	RM, Kirkeeide RL, Smalling RW, et al. Patterns in visual
	interpretation of coronary arteriograms as detected by quantitative
	coronary arteriography.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	1991;18:945–951.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/0735-1097(91)90752-U">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/1894868">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R151" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Goldberg
	RK, Kleiman NS, Minor ST, et al. Comparison of quantitative coronary
	angiography to visual estimates of lesion severity pre and post
	PTCA.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am Heart
	J</font></em><font size="1" style="font-size: 8pt">.
	1990;119:178–184.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0002-8703(05)80098-5">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/2404387">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">5.</span></font></p>
<div id="R152" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Nallamothu
	BK, Spertus JA, Lansky AJ, et al. Comparison of clinical
	interpretation with visual assessment and quantitative coronary
	angiography in patients undergoing percutaneous coronary
	intervention in contemporary practice: the Assessing Angiography
	(A2) project.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2013;127:1793–1800.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circulationaha.113.001952">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23470859">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>4.2.
Defining Coronary Artery Lesion Complexity: Calculation of the SYNTAX
(Synergy Between PCI With TAXUS and Cardiac Surgery) Score</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R153" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Sianos
	G, Morel M-A, Kappetein AP, et al. The SYNTAX Score: an angiographic
	tool grading the complexity of coronary artery
	disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>EuroIntervention</font></em><font size="1" style="font-size: 8pt">.
	2005;1:219–227.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19758907">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R154" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Garg
	S, Serruys PW, Silber S, et al. The prognostic utility of the SYNTAX
	score on 1-year outcomes after revascularization with zotarolimus-
	and everolimus-eluting stents: a substudy of the RESOLUTE All Comers
	Trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2011;4:432–441.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jcin.2011.01.008">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21511223">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R155" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Wykrzykowska
	JJ, Garg S, Girasis C, et al. Value of the SYNTAX score for risk
	assessment in the all-comers population of the randomized
	multicenter LEADERS (Limus Eluted from A Durable versus ERodable
	Stent coating) trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2010;56:272–277.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2010.03.044">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20633818">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R156" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Cavalcante
	R, Sotomi Y, Mancone M, et al. Impact of the SYNTAX scores I and II
	in patients with diabetes and multivessel coronary disease: a pooled
	analysis of patient level data from the SYNTAX, PRECOMBAT, and BEST
	trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2017;38:1969–1977.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/eurheartj/ehx138">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28431047">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R157" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Farooq
	V, van Klaveren D, Steyerberg EW, et al. Anatomical and clinical
	characteristics to guide decision making between coronary artery
	bypass surgery and percutaneous coronary intervention for individual
	patients: development and validation of SYNTAX score II.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2013;381:639–650.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(13)60108-7">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23439103">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R158" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Takahashi
	K, Serruys PW, Fuster V, et al. Redevelopment and validation of the
	SYNTAX score II to individualise decision making between
	percutaneous and surgical revascularisation in patients with complex
	coronary artery disease: secondary analysis of the multicentre
	randomised controlled SYNTAXES trial with external cohort
	validation.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2020;396:1399–1412.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(20)32114-0">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/33038944">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R159" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Généreux
	P, Palmerini T, Caixeta A, et al. SYNTAX score reproducibility and
	variability between interventional cardiologists, core laboratory
	technicians, and quantitative coronary measurements.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2011;4:553–561.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circinterventions.111.961862">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22028472">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">8.</span></font></p>
<div id="R160" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Zhang
	Y-J, Iqbal J, Campos CM, et al. Prognostic value of site SYNTAX
	score and rationale for combining anatomic and clinical factors in
	decision making: insights from the SYNTAX trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2014;64:423–432.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2014.05.022">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25082573">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>4.3.
Use of Coronary Physiology to Guide Revascularization With PCI</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R161" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Tonino
	PAL, De Bruyne B, Pijls NHJ, et al. Fractional flow reserve versus
	angiography for guiding percutaneous coronary intervention.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2009;360:213–224.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa0807611">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19144937">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R162" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">De
	Bruyne B, Pijls NHJ, Kalesan B, et al. Fractional flow
	reserve-guided PCI versus medical therapy in stable coronary
	disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2012;367:991–1001.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1205361">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22924638">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R163" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">De
	Bruyne B, Fearon WF, Pijls NHJ, et al. Fractional flow
	reserve-guided PCI for stable coronary artery disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2014;371:1208–1217.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1408758">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25176289">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R164" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Davies
	JE, Sen S, Dehbi H-M, et al. Use of the instantaneous wave-free
	ratio or fractional flow reserve in PCI.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2017;376:1824–1834.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1700445">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28317458">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R165" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Xaplanteris
	P, Fournier S, Pijls NHJ, et al. Five-year outcomes with PCI guided
	by fractional flow reserve.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2018;379:250–259.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1803538">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29785878">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R166" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Götberg
	M, Christiansen EH, Gudmundsdottir IJ, et al. Instantaneous
	wave-free ratio versus fractional flow reserve to guide PCI.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2017;376:1813–1823.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1616540">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28317438">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R167" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Zimmermann
	FM, Ferrara A, Johnson NP, et al. Deferral vs. performance of
	percutaneous coronary intervention of functionally non-significant
	coronary stenosis: 15-year follow-up of the DEFER trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2015;36:3182–3188.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/eurheartj/ehv452">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26400825">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R168" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Pijls
	NHJ, van Schaardenburgh P, Manoharan G, et al. Percutaneous coronary
	intervention of functionally nonsignificant stenosis: 5-year
	follow-up of the DEFER study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2007;49:2105–2111.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2007.01.087">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17531660">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">9.</font></p>
<div id="R169" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Pijls
	NHJ, Fearon WF, Tonino PAL, et al. Fractional flow reserve versus
	angiography for guiding percutaneous coronary intervention in
	patients with multivessel coronary artery disease: 2-year follow-up
	of the FAME (Fractional Flow Reserve Versus Angiography for
	Multivessel Evaluation) study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2010;56:177–184.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2010.04.012">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20537493">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">10.</font></p>
<div id="R170" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Escaned
	J, Ryan N, Mejía-Rentería H, et al. Safety of the deferral of
	coronary revascularization on the basis of instantaneous wave-free
	ratio and fractional flow reserve measurements in stable coronary
	artery disease and acute coronary syndromes.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2018;11:1437–1449.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jcin.2018.05.029">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30093050">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">11.</font></p>
<div id="R171" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Bruno
	F, D’Ascenzo F, Marengo G, et al. Fractional flow reserve guided
	versus angiographic guided surgical revascularization: a
	meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Catheter
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2020;98:e18–e23.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/33315297">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">12.</font></p>
<div id="R172" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Timbadia
	D, Ler A, Sazzad F, et al. FFR-guided versus coronary
	angiogram-guided CABG: a review and meta-analysis of prospective
	randomized controlled trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Card Surg</font></em><font size="1" style="font-size: 8pt">.
	2020;35:2785–2793.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1111/jocs.14880">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/32697006">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">13.</font></p>
<div id="R173" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Thuesen
	AL, Riber LP, Veien KT, et al. Fractional flow reserve versus
	angiographically-guided coronary artery bypass grafting.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2018;72:2732–2743.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2018.09.043">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30497559">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">14.</span></font></p>
<div id="R174" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Toth
	GG, De Bruyne B, Kala P, et al. Graft patency after FFR-guided
	versus angiography-guided coronary artery bypass grafting: the
	GRAFFITI trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>EuroIntervention</font></em><font size="1" style="font-size: 8pt">.
	2019;15:e999–e1005.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.4244/EIJ-D-19-00463">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31270037">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>4.4.
Intravascular Ultrasound to Assess Lesion Severity</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R175" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">de
	la Torre Hernandez JM, Hernandez Hernandez F, Alfonso F, et al.
	Prospective application of pre-defined intravascular ultrasound
	criteria for assessment of intermediate left main coronary artery
	lesions results from the multicenter LITRO study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2011;58:351–358.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2011.02.064">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21757111">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R176" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Fassa
	AA, Wagatsuma K, Higano ST, et al. Intravascular ultrasound-guided
	treatment for angiographically indeterminate left main coronary
	artery disease: a long-term follow-up study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2005;45:204–211.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2004.09.066">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15653016">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R177" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Park
	SJ, Ahn JM, Kang SJ, et al. Intravascular ultrasound-derived minimal
	lumen area criteria for functionally significant left main coronary
	artery stenosis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2014;7:868–874.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jcin.2014.02.015">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25147031">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R178" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Jasti
	V, Ivan E, Yalamanchili V, et al. Correlations between fractional
	flow reserve and intravascular ultrasound in patients with an
	ambiguous left main coronary artery stenosis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2004;110:2831–2836.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/01.cir.0000146338.62813.e7">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15492302">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R179" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kang
	SJ, Lee JY, Ahn JM, et al. Intravascular ultrasound-derived
	predictors for fractional flow reserve in intermediate left main
	disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2011;4:1168–1174.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jcin.2011.08.009">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22115656">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R180" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Waksman
	R, Legutko J, Singh J, et al. FIRST: Fractional Flow Reserve and
	Intravascular Ultrasound Relationship Study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2013;61:917–923.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2012.12.012">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23352786">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R181" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Koo
	BK, Yang HM, Doh JH, et al. Optimal intravascular ultrasound
	criteria and their accuracy for defining the functional significance
	of intermediate coronary stenoses of different locations.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2011;4:803–811.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jcin.2011.03.013">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21777890">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">8.</span></font></p>
<div id="R182" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kubo
	T, Akasaka T, Shite J, et al. OCT compared with IVUS in a coronary
	lesion assessment: the OPUS-CLASS study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Cardiovasc Imaging</font></em><font size="1" style="font-size: 8pt">.
	2013;6:1095–1104.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jcmg.2013.04.014">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24011777">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>5.1.
Revascularization of the Infarct Artery in Patients With STEMI</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R183" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Keeley
	EC, Boura JA, Grines CL. Primary angioplasty versus intravenous
	thrombolytic therapy for acute myocardial infarction: a quantitative
	review of 23 randomised trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2003;361:13–20.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(03)12113-7">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12517460">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R184" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Zijlstra
	F, Hoorntje JC, de Boer MJ, et al. Long-term benefit of primary
	angioplasty as compared with thrombolytic therapy for acute
	myocardial infarction.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	1999;341:1413–1419.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJM199911043411901">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/10547403">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R185" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Global
	Use of Strategies to Open Occluded Coronary Arteries in Acute
	Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. A
	clinical trial comparing primary coronary angioplasty with tissue
	plasminogen activator for acute myocardial infarction.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	1997;336:1621–1628.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJM199706053362301">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/9173270">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R186" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Andersen
	HR, Nielsen TT, Rasmussen K, et al. A comparison of coronary
	angioplasty with fibrinolytic therapy in acute myocardial
	infarction.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2003;349:733–742.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa025142">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12930925">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R187" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Grines
	CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty
	with thrombolytic therapy for acute myocardial infarction. The
	Primary Angioplasty in Myocardial Infarction Study Group.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	1993;328:673–679.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJM199303113281001">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/8433725">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R188" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Hochman
	JS, Sleeper LA, Webb JG, et al. Early revascularization in acute
	myocardial infarction complicated by cardiogenic shock. SHOCK
	Investigators. Should We Emergently Revascularize Occluded
	Coronaries for Cardiogenic Shock?&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	1999;341:625–634.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJM199908263410901">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/10460813">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R189" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Mehta
	RH, Lopes RD, Ballotta A, et al. Percutaneous coronary intervention
	or coronary artery bypass surgery for cardiogenic shock and
	multivessel coronary artery disease?&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2010;159:141–147.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.ahj.2009.10.035">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20102880">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R190" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Chevalier
	P, Burri H, Fahrat F, et al. Perioperative outcome and long-term
	survival of surgery for acute post-infarction mitral
	regurgitation.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	J Cardiothorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2004;26:330–335.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.ejcts.2004.04.027">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15296892">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">9.</font></p>
<div id="R191" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Russo
	A, Suri RM, Grigioni F, et al. Clinical outcome after surgical
	correction of mitral regurgitation due to papillary muscle
	rupture.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2008;118:1528–1534.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circulationaha.107.747949">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18809799">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">10.</font></p>
<div id="R192" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Gershlick
	AH, Stephens-Lloyd A, Hughes S, et al. Rescue angioplasty after
	failed thrombolytic therapy for acute myocardial infarction.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2005;353:2758–2768.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa050849">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16382062">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">11.</font></p>
<div id="R193" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Sutton
	AGC, Campbell PG, Graham R, et al. A randomized trial of rescue
	angioplasty versus a conservative approach for failed fibrinolysis
	in ST-segment elevation myocardial infarction: the Middlesbrough
	Early Revascularization to Limit INfarction (MERLIN) trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2004;44:287–296.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2003.12.059">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15261920">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">12.</font></p>
<div id="R194" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Wijeysundera
	HC, Vijayaraghavan R, Nallamothu BK, et al. Rescue angioplasty or
	repeat fibrinolysis after failed fibrinolytic therapy for ST-segment
	myocardial infarction: a meta-analysis of randomized trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2007;49:422–430.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2006.09.033">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17258087">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">13.</font></p>
<div id="R195" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Collet
	J-P, Montalescot G, Le May M, et al. Percutaneous coronary
	intervention after fibrinolysis: a multiple meta-analyses approach
	according to the type of strategy.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2006;48:1326–1335.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2006.03.064">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17010790">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">14.</font></p>
<div id="R196" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Madan
	M, Halvorsen S, Di Mario C, et al. Relationship between time to
	invasive assessment and clinical outcomes of patients undergoing an
	early invasive strategy after fibrinolysis for ST-segment elevation
	myocardial infarction: a patient-level analysis of the randomized
	early routine invasive clinical trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2015;8:166–174.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jcin.2014.09.005">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25616922">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">15.</font></p>
<div id="R197" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Cantor
	WJ, Fitchett D, Borgundvaag B, et al. Routine early angioplasty
	after fibrinolysis for acute myocardial infarction.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2009;360:2705–2718.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa0808276">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19553646">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">16.</font></p>
<div id="R198" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Di
	Mario C, Dudek D, Piscione F, et al. Immediate angioplasty versus
	standard therapy with rescue angioplasty after thrombolysis in the
	Combined Abciximab REteplase Stent Study in Acute Myocardial
	Infarction (CARESS-in-AMI): an open, prospective, randomised,
	multicentre trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2008;371:559–568.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(08)60268-8">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18280326">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">17.</font></p>
<div id="R199" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Borgia
	F, Goodman SG, Halvorsen S, et al. Early routine percutaneous
	coronary intervention after fibrinolysis vs. standard therapy in
	ST-segment elevation myocardial infarction: a meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2010;31:2156–2169.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/eurheartj/ehq204">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20601393">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">18.</font></p>
<div id="R200" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Armstrong
	PW, WEST Steering Committee. A comparison of pharmacologic therapy
	with/without timely coronary intervention vs. primary percutaneous
	intervention early after ST-elevation myocardial infarction: the
	WEST (Which Early ST-elevation myocardial infarction Therapy)
	study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2006;27:1530–1538.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/eurheartj/ehl088">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16757491">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">19.</font></p>
<div id="R201" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Fernandez-Avilés
	F, Alonso JJ, Castro-Beiras A, et al. Routine invasive strategy
	within 24 hours of thrombolysis versus ischaemia-guided conservative
	approach for acute myocardial infarction with ST-segment elevation
	(GRACIA-1): a randomised controlled trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2004;364:1045–1053.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(04)17059-1">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15380963">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">20.</font></p>
<div id="R202" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Le
	May MR, Wells GA, Labinaz M, et al. Combined angioplasty and
	pharmacological intervention versus thrombolysis alone in acute
	myocardial infarction (CAPITAL AMI study).&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2005;46:417–424.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2005.04.042">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16053952">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">21.</font></p>
<div id="R203" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Schömig
	A, Mehilli J, Antoniucci D, et al. Mechanical reperfusion in
	patients with acute myocardial infarction presenting more than 12
	hours from symptom onset: a randomized controlled trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA</font></em><font size="1" style="font-size: 8pt">.
	2005;293:2865–2872.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jama.293.23.2865">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15956631">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">22.</font></p>
<div id="R204" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Gierlotka
	M, Gasior M, Wilczek K, et al. Reperfusion by primary percutaneous
	coronary intervention in patients with ST-segment elevation
	myocardial infarction within 12 to 24 hours of the onset of symptoms
	(from a prospective national observational study [PL-ACS]).&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2011;107:501–508.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.amjcard.2010.10.008">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21195380">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">23.</font></p>
<div id="R205" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Pi
	Y, Roe MT, Holmes DN, et al. Utilization, characteristics, and
	in-hospital outcomes of coronary artery bypass grafting in patients
	with ST-segment-elevation myocardial infarction: results from the
	National Cardiovascular Data Registry Acute Coronary Treatment and
	Intervention Outcomes Network Registry—Get With The
	Guidelines.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Qual Outcomes</font></em><font size="1" style="font-size: 8pt">.
	2017;10:e003490.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCOUTCOMES.116.003490">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28794118">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">24.</font></p>
<div id="R206" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Grothusen
	C, Friedrich C, Loehr J, et al. Outcome of stable patients with
	acute myocardial infarction and coronary artery bypass surgery
	within 48 hours: a single-center, retrospective experience.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Heart Assoc</font></em><font size="1" style="font-size: 8pt">.
	2017;6: e005498.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/JAHA.117.005498">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28974496">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">25.</font></p>
<div id="R207" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Hochman
	JS, Lamas GA, Buller CE, et al. Coronary intervention for persistent
	occlusion after myocardial infarction.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2006;355:2395–2407.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa066139">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17105759">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">26.</font></p>
<div id="R208" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Steg
	PG, Thuaire C, Himbert D, et al. DECOPI (DEsobstruction COronaire en
	Post-Infarctus): a randomized multi-centre trial of occluded artery
	angioplasty after acute myocardial infarction.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2004;25:2187–2194.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.ehj.2004.10.019">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15589635">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">27.</font></p>
<div id="R209" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Mehta
	RH, Grab JD, O’Brien SM, et al. Clinical characteristics and
	in-hospital outcomes of patients with cardiogenic shock undergoing
	coronary artery bypass surgery: insights from the Society of
	Thoracic Surgeons National Cardiac Database.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2008;117:876–885.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCULATIONAHA.107.728147">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18250266">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">28.</font></p>
<div id="R210" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Acharya
	D, Gulack BC, Loyaga-Rendon RY, et al. Clinical characteristics and
	outcomes of patients with myocardial infarction and cardiogenic
	shock undergoing coronary artery bypass surgery: data from the
	Society of Thoracic Surgeons National Database.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2016;101:558–566.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.athoracsur.2015.10.051">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26718859">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">29.</font></p>
<div id="R211" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Santarpino
	G, Ruggieri VG, Mariscalco G, et al. Outcome in patients having
	salvage coronary artery bypass grafting.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2015;116:1193–1198.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.amjcard.2015.07.034">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26303635">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">30.</font></p>
<div id="R212" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Pinto
	DS, Kirtane AJ, Nallamothu BK, et al. Hospital delays in reperfusion
	for ST-elevation myocardial infarction: implications when selecting
	a reperfusion strategy.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2006;114:2019–2025.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circulationaha.106.638353">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17075010">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">31.</font></p>
<div id="R213" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Armstrong
	PW, Gershlick AH, Goldstein P, et al. Fibrinolysis or primary PCI in
	ST-segment elevation myocardial infarction.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2013;368:1379–1387.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1301092">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23473396">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">32.</font></p>
<div id="R214" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Braxton
	JH, Hammond GL, Letsou GV, et al. Optimal timing of coronary artery
	bypass graft surgery after acute myocardial infarction.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	1995;92:II66–II68.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/01.CIR.92.9.66">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/7586463">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">33.</font></p>
<div id="R215" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Tavakoli
	R, Weber A, Brunner-La Rocca H, et al. Results of surgery for
	irreversible moderate to severe mitral valve regurgitation secondary
	to myocardial infarction.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	J Cardiothorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2002;21:818–824.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S1010-7940(02)00065-9">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12062269">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">34.</font></p>
<div id="R216" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Shamshad
	F, Kenchaiah S, Finn PV, et al. Fatal myocardial rupture after acute
	myocardial infarction complicated by heart failure, left ventricular
	dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion
	Trial (VALIANT)&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2010;160:145–151.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.ahj.2010.02.037">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20598985">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">35.</font></p>
<div id="R217" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Schroeter
	T, Lehmann S, Misfeld M, et al. Clinical outcome after mitral valve
	surgery due to ischemic papillary muscle rupture.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2013;95:820–824.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.athoracsur.2012.10.050">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23219255">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">36.</font></p>
<div id="R218" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Arnaoutakis
	GJ, Zhao Y, George TJ, et al. Surgical repair of ventricular septal
	defect after myocardial infarction: outcomes from the Society of
	Thoracic Surgeons National Database.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2012;94:436–443. discussion 43-4.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.athoracsur.2012.04.020">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22626761">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">37.</font></p>
<div id="R219" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Singh
	V, Rodriguez AP, Bhatt P, et al. Ventricular septal defect
	complicating ST-elevation myocardial infarctions: a call for
	action.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am J
	Med</font></em><font size="1" style="font-size: 8pt">.
	2017;130:863.e1–863.e12.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.amjmed.2016.12.004">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">38.</font></p>
<div id="R220" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Lanz
	J, Wyss D, Räber L, et al. Mechanical complications in patients
	with ST-segment elevation myocardial infarction: a single centre
	experience.&nbsp;</font><font size="1" style="font-size: 8pt"><em>PLoS
	One</font></em><font size="1" style="font-size: 8pt">. 2019;14:
	e0209502.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1371/journal.pone.0209502">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30794547">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">39.</font></p>
<div id="R221" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Wan
	Y-D, Sun T-W, Kan Q-C, et al. The effects of intra-aortic balloon
	pumps on mortality in patients undergoing high-risk coronary
	revascularization: a meta-analysis of randomized controlled trials
	of coronary artery bypass grafting and stenting era.&nbsp;</font><font size="1" style="font-size: 8pt"><em>PLoS
	One11</font></em><font size="1" style="font-size: 8pt">;2016,
	e0147291.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26784578">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">40.</font></p>
<div id="R222" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kettner
	J, Sramko M, Holek M, et al. Utility of intra-aortic balloon pump
	support for ventricular septal rupture and acute mitral
	regurgitation complicating acute myocardial infarction.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2013;112:1709–1713.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.amjcard.2013.07.035">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24035169">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">41.</font></p>
<div id="R223" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Mason
	PJ, Shah B, Tamis-Holland JE, et al. An update on radial artery
	access and best practices for transradial coronary angiography and
	intervention in acute coronary syndrome: a scientific statement from
	the American Heart Association.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2018;11:e000035.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/HCV.0000000000000035">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30354598">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">42.</font></p>
<div id="R224" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">D’Souza
	SP, Mamas MA, Fraser DG, et al. Routine early coronary angioplasty
	versus ischaemia-guided angioplasty after thrombolysis in acute
	ST-elevation myocardial infarction: a meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2011;32:972–982.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/eurheartj/ehq398">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21036776">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">43.</span></font></p>
<div id="R225" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Ndrepepa
	G, Kastrati A, Mehilli J, et al. Mechanical reperfusion and
	long-term mortality in patients with acute myocardial infarction
	presenting 12 to 48 hours from onset of symptoms.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA</font></em><font size="1" style="font-size: 8pt">.
	2009;301:487–488.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jama.2009.32">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19190313">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>5.2.
Revascularization of the Non-Infarct Artery in Patients With STEMI</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R226" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Politi
	L, Sgura F, Rossi R, et al. A randomised trial of target-vessel
	versus multi-vessel revascularisation in ST-elevation myocardial
	infarction: major adverse cardiac events during long-term
	follow-up.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Heart</font></em><font size="1" style="font-size: 8pt">.
	2010;96:662–667.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1136/hrt.2009.177162">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19778920">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R227" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Gershlick
	AH, Khan JN, Kelly DJ, et al. Randomized trial of complete versus
	lesion-only revascularization in patients undergoing primary
	percutaneous coronary intervention for STEMI and multivessel
	disease: the CvLPRIT trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2015;65:963–972.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2014.12.038">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25766941">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R228" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Engstrom
	T, Kelbaek H, Helqvist S, et al. Complete revascularisation versus
	treatment of the culprit lesion only in patients with ST-segment
	elevation myocardial infarction and multivessel disease
	(DANAMI-3-PRIMULTI): an open-label, randomised controlled
	trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2015;386:665–671.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(15)60648-1">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26347918">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R229" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Mehta
	SR, Wood DA, Storey RF, et al. Complete revascularization with
	multivessel PCI for myocardial infarction.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2019;381:1411–1421.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1907775">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31475795">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R230" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Di
	Mario C, Mara S, Flavio A, et al. Single vs multivessel treatment
	during primary angioplasty: results of the multicentre randomised
	HEpacoat for cuLPrit or multivessel stenting for Acute Myocardial
	Infarction (HELP AMI) Study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Int
	J Cardiovasc Intervent</font></em><font size="1" style="font-size: 8pt">.
	2004;6:128–133.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1080/14628840310030441">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16146905">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R231" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Wald
	DS, Morris JK, Wald NJ, et al. Randomized trial of preventive
	angioplasty in myocardial infarction.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2013;369:1115–1123.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1305520">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23991625">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R232" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Smits
	PC, Abdel-Wahab M, Neumann FJ, et al. Fractional flow reserve-guided
	multivessel angioplasty in myocardial infarction.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2017;376:1234–1244.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1701067">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28317428">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R233" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Thiele
	H, Akin I, Sandri M, et al. PCI strategies in patients with acute
	myocardial infarction and cardiogenic shock.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2017;377:2419–2432.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1710261">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29083953">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">9.</font></p>
<div id="R234" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Thiele
	H, Akin I, Sandri M, et al. One-year outcomes after PCI strategies
	in cardiogenic shock.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2018;379:1699–1710.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1808788">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30145971">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">10.</font></p>
<div id="R235" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kolte
	D, Sardar P, Khera S, et al. Culprit vessel-only versus multivessel
	percutaneous coronary intervention in patients with cardiogenic
	shock complicating ST-segment-elevation myocardial infarction: a
	collaborative meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2017;10:e005582.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCINTERVENTIONS.117.005582">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29146672">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">11.</font></p>
<div id="R236" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Bates
	ER, Tamis-Holland JE, Bittl JA, et al. PCI strategies in patients
	with ST-segment elevation myocardial infarction and multivessel
	coronary artery disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2016;68:1066–1081.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2016.05.086">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27585512">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">12.</font></p>
<div id="R237" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Wood
	DA, Cairns JA, Wang J, et al. Timing of staged nonculprit artery
	revascularization in patients with ST-segment elevation myocardial
	infarction: COMPLETE Trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2019;74:2713–2723.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2019.09.051">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31779786">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">13.</font></p>
<div id="R238" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Dehmer
	GJ, Badhwar V, Bermudez EA, et al. 2020 AHA/ACC key data elements
	and definitions for coronary revascularization: a report of the
	American College of Cardiology/American Heart Association Task Force
	on Clinical Data Standards (Writing Committee to Develop Clinical
	Data Standards for Coronary Revascularization).&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Qual Outcomes</font></em><font size="1" style="font-size: 8pt">.
	2020;13:e000059.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/HCQ.0000000000000059">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/32202924">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">14.</font></p>
<div id="R239" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">STS.
	ACSD Training Manual. 2019. Accessed March 30, 2021. Available
	at&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.sts.org/sites/default/files/ACSD_TrainingManualV2-9_July2019.pdf">https://www.sts.org/sites/default/files/ACSD_TrainingManualV2-9_July2019.pdf</span></font></span></font></a></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">15.</span></font></p>
<div id="R240" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Eagle
	KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update for
	coronary artery bypass graft surgery: a report of the American
	College of Cardiology/American Heart Association Task Force on
	Practice Guidelines (Committee to Update the 1999 Guidelines for
	Coronary Artery Bypass Graft Surgery).&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2004;110:e340–e437.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/01.CIR.0000138790.14877.7D">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15466654">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>6.1.
Coronary Angiography and Revascularization in Patients With NSTE-ACS</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R241" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Cannon
	CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive
	and conservative strategies in patients with unstable coronary
	syndromes treated with the glycoprotein IIb/IIIa inhibitor
	tirofiban.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2001;344:1879–1887.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJM200106213442501">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/11419424">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R242" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Fox
	KA, Poole-Wilson PA, Henderson RA, et al. Interventional versus
	conservative treatment for patients with unstable angina or
	non-ST-elevation myocardial infarction: the British Heart Foundation
	RITA 3 randomised trial. Randomized Intervention Trial of unstable
	Angina.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2002;360:743–751.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(02)09894-X">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12241831">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R243" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Invasive
	compared with non-invasive treatment in unstable coronary-artery
	disease: FRISC II prospective randomised multicentre study. FRagmin
	and Fast Revascularisation during InStability in Coronary artery
	disease Investigators.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	1999;354:708–715.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(99)07349-3">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/10475181">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R244" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Mehta
	SR, Cannon CP, Fox KAA, et al. Routine vs selective invasive
	strategies in patients with acute coronary syndromes: a
	collaborative meta-analysis of randomized trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA</font></em><font size="1" style="font-size: 8pt">.
	2005;293:2908–2917.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jama.293.23.2908">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15956636">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R245" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Liakopoulos
	OJ, Schlachtenberger G, Wendt D, et al. Early clinical outcomes of
	surgical myocardial revascularization for acute coronary syndromes
	complicated by cardiogenic shock: a report from the
	North-Rhine-Westphalia Surgical Myocardial Infarction Registry.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Heart Assoc</font></em><font size="1" style="font-size: 8pt">.
	2019;8: e012049.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/JAHA.119.012049">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31070076">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R246" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Acharya
	D, Gulack BC, Loyaga-Rendon RY, et al. Clinical characteristics and
	outcomes of patients with myocardial infarction and cardiogenic
	shock undergoing coronary artery bypass surgery: data from the
	Society of Thoracic Surgeons National Database.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2016;101:558–566.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.athoracsur.2015.10.051">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26718859">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R247" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Mehta
	RH, Grab JD, O’Brien SM, et al. Clinical characteristics and
	in-hospital outcomes of patients with cardiogenic shock undergoing
	coronary artery bypass surgery: insights from the Society of
	Thoracic Surgeons National Cardiac Database.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2008;117:876–885.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCULATIONAHA.107.728147">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18250266">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R248" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">White
	HD, Assmann SF, Sanborn TA, et al. Comparison of percutaneous
	coronary intervention and coronary artery bypass grafting after
	acute myocardial infarction complicated by cardiogenic shock:
	results from the Should We Emergently Revascularize Occluded
	Coronaries for Cardiogenic Shock (SHOCK) trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2005;112:1992–2001.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circulationaha.105.540948">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16186436">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">9.</font></p>
<div id="R249" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Hochman
	JS, Sleeper LA, Webb JG, et al. Early revascularization in acute
	myocardial infarction complicated by cardiogenic shock. SHOCK
	Investigators. Should we emergently revascularize occluded
	coronaries for cardiogenic shock?&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	1999;341:625–634.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJM199908263410901">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/10460813">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">10.</font></p>
<div id="R250" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kolte
	D, Khera S, Dabhadkar KC, et al. Trends in coronary angiography,
	revascularization, and outcomes of cardiogenic shock complicating
	non-ST-elevation myocardial infarction.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2016;117:1–9.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.amjcard.2015.10.006">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26541908">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">11.</font></p>
<div id="R251" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Jobs
	A, Mehta SR, Montalescot G, et al. Optimal timing of an invasive
	strategy in patients with non-ST-elevation acute coronary syndrome:
	a meta-analysis of randomised trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2017;390:737–746.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(17)31490-3">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28778541">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">12.</font></p>
<div id="R252" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kofoed
	KF, Kelbæk H, Hansen PR, et al. Early versus standard care invasive
	examination and treatment of patients with non-ST-segment elevation
	acute coronary syndrome.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2018;138:2741–2750.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCULATIONAHA.118.037152">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30565996">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">13.</font></p>
<div id="R253" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Milosevic
	A, Vasiljevic-Pokrajcic Z, Milasinovic D, et al. Immediate versus
	delayed invasive intervention for non-STEMI patients: the
	RIDDLE-NSTEMI study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2016;9:541–549.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jcin.2015.11.018">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26777321">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">14.</font></p>
<div id="R254" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Reuter
	P-G, Rouchy C, Cattan S, et al. Early invasive strategy in high-risk
	acute coronary syndrome without ST-segment elevation. The Sisca
	randomized trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Int
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2015;182:414–418.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.ijcard.2014.12.089">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25596468">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">15.</font></p>
<div id="R255" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Deharo
	P, Ducrocq G, Bode C, et al. Timing of angiography and outcomes in
	high-risk patients with non-ST-segment-elevation myocardial
	infarction managed invasively: insights from the TAO trial
	(Treatment of Acute Coronary Syndrome With Otamixaban).&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2017;136:1895–1907.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCULATIONAHA.117.029779">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28893843">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">16.</font></p>
<div id="R256" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Mehta
	SR, Granger CB, Boden WE, et al. Early versus delayed invasive
	intervention in acute coronary syndromes.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2009;360:2165–2175.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa0807986">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19458363">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">17.</font></p>
<div id="R257" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Axelsson
	TA, Mennander A, Malmberg M, et al. Is emergency and salvage
	coronary artery bypass grafting justified? The Nordic
	Emergency/Salvage Coronary Artery Bypass Grafting study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	J Cardiothorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2016;49:1451–1456.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/ejcts/ezv388">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26582345">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">18.</font></p>
<div id="R258" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Thiele
	H, Akin I, Sandri M, et al. PCI strategies in patients with acute
	myocardial infarction and cardiogenic shock.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2017;377:2419–2432.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1710261">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29083953">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">19.</font></p>
<div id="R259" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Thiele
	H, Akin I, Sandri M, et al. One-year outcomes after PCI strategies
	in cardiogenic shock.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2018;379:1699–1710.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1808788">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30145971">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">20.</font></p>
<div id="R260" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Qayyum
	R, Khalid MR, Adomaityte J, et al. Systematic review: comparing
	routine and selective invasive strategies for the acute coronary
	syndrome.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Intern Med</font></em><font size="1" style="font-size: 8pt">.
	2008;148:186–196.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.7326/0003-4819-148-3-200802050-00005">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18252682">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">21.</font></p>
<div id="R261" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Fox
	KAA, Clayton TC, Damman P, et al. Long-term outcome of a routine
	versus selective invasive strategy in patients with non-ST-segment
	elevation acute coronary syndrome a meta-analysis of individual
	patient data.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2010;55:2435–2445.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2010.03.007">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20359842">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">22.</font></p>
<div id="R262" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">de
	Araújo Gonçalves P, Ferreira J, Aguiar C, et al. TIMI, PURSUIT,
	and GRACE risk scores: sustained prognostic value and interaction
	with revascularization in NSTE-ACS.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2005;26:865–872.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/eurheartj/ehi187">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15764619">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">23.</font></p>
<div id="R263" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Fox
	KAA, Fitzgerald G, Puymirat E, et al. Should patients with acute
	coronary disease be stratified for management according to their
	risk? Derivation, external validation and outcomes using the updated
	GRACE risk score.&nbsp;</font><font size="1" style="font-size: 8pt"><em>BMJ
	Open</font></em><font size="1" style="font-size: 8pt">. 2014;4:
	e004425.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1136/bmjopen-2013-004425">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24561498">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">24.</font></p>
<div id="R264" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Global
	Registry of Acute Coronary Events (GRACE). The GRACE ACS Risk Score
	Calculator 2.0; 2021. Accessed June 9, 2021. Available
	at&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.outcomes-umassmed.org/grace/acs_risk2/index.html">https://www.outcomes-umassmed.org/grace/acs_risk2/index.html</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">25.</font></p>
<div id="R265" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">TIMI
	Study Group. TIMI Risk Score Calculator for UA/NSTEMI; 2020.
	Accessed June 9, 2021. Available
	at&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://timi.org/calculators/timi-risk-score-calculator-for-ua-nstemi/">https://timi.org/calculators/timi-risk-score-calculator-for-ua-nstemi/</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">26.</font></p>
<div id="R266" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Antman
	EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable
	angina/non-ST elevation MI: a method for prognostication and
	therapeutic decision making.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA</font></em><font size="1" style="font-size: 8pt">.
	2000;284:835–842.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jama.284.7.835">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/10938172">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">27.</font></p>
<div id="R267" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Wan
	Y-D, Sun T-W, Kan Q-C, et al. The effects of intra-aortic balloon
	pumps on mortality in patients undergoing high-risk coronary
	revascularization: a meta-analysis of randomized controlled trials
	of coronary artery bypass grafting and stenting era.&nbsp;</font><font size="1" style="font-size: 8pt"><em>PLoS
	One</font></em><font size="1" style="font-size: 8pt">. 2016;11:
	e0147291.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1371/journal.pone.0147291">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26784578">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">28.</font></p>
<div id="R268" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Awan
	A, Ogunti R, Fatima U, et al. Timing of percutaneous coronary
	intervention in non-ST elevation acute coronary
	syndrome—meta-analysis and systematic review of
	literature.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Cardiovasc
	Revasc Med</font></em><font size="1" style="font-size: 8pt">.
	2020;21:1398–1404.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.carrev.2019.10.004">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31761637">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">29.</font></p>
<div id="R269" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Badings
	EA, The SHK, Dambrink J-HE, et al. Early or late intervention in
	high-risk non-ST-elevation acute coronary syndromes: results of the
	ELISA-3 trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>EuroIntervention</font></em><font size="1" style="font-size: 8pt">.
	2013;9:54–61.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.4244/EIJV9I1A9">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23685295">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">30.</font></p>
<div id="R270" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Navarese
	EP, Gurbel PA, Andreotti F, et al. Optimal timing of coronary
	invasive strategy in non-ST-segment elevation acute coronary
	syndromes: a systematic review and meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Intern Med</font></em><font size="1" style="font-size: 8pt">.
	2013;158:261–270.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.7326/0003-4819-158-4-201302190-00006">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23420234">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">31.</span></font></p>
<div id="R271" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Gore,
	J, Fox, KAA. GRACE ACS Risk and Mortality Calculator. 2021, Accessed
	September 20, 2019. Available
	at&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.mdcalc.com/grace-acs-risk-mortality-calculator">https://www.mdcalc.com/grace-acs-risk-mortality-calculator</span></font></span></font></a></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>7.1.
Revascularization to Improve Survival in SIHD Compared With Medical
Therapy</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R272" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Velazquez
	EJ, Lee KL, Jones RH, et al. Coronary-artery bypass surgery in
	patients with ischemic cardiomyopathy.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2016;374:1511–1520.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1602001">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27040723">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R273" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Gaudino
	M, Hameed I, Khan FM, et al. Treatment strategies in ischaemic left
	ventricular dysfunction: a network meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	J Cardiothorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2021;59:293–301.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/ejcts/ezaa319">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R274" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Coronary
	artery surgery study (CASS): a randomized trial of coronary artery
	bypass surgery: survival data.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	1983;68:939–950.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circ.68.5.6137292">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/6137292">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R275" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Marui
	A, Kimura T, Nishiwaki N, et al. Comparison of five-year outcomes of
	coronary artery bypass grafting versus percutaneous coronary
	intervention in patients with left ventricular ejection fractions
	≤50% versus &gt;50% (from the CREDO-Kyoto PCI/CABG Registry
	Cohort-2).&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2014;114:988–996.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.amjcard.2014.07.007">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25124184">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R276" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Zhang
	D, Lyu S, Song X, et al. Coronary artery bypass grafting versus
	percutaneous coronary intervention in patients with left ventricular
	systolic dysfunction: a meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Angiology</font></em><font size="1" style="font-size: 8pt">.
	2017;68:19–28.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1177/0003319716639197">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27069109">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R277" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Orlandini
	A, Castellana N, Pascual A, et al. Myocardial viability for
	decision-making concerning revascularization in patients with left
	ventricular dysfunction and coronary artery disease: a meta-analysis
	of non-randomized and randomized studies.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Int
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2015;182:494–499.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.ijcard.2015.01.025">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25617608">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R278" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Wolff
	G, Dimitroulis D, Andreotti F, et al. Survival benefits of invasive
	versus conservative strategies in heart failure in patients with
	reduced ejection fraction and coronary artery disease: a
	meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Heart Fail</font></em><font size="1" style="font-size: 8pt">.
	2017;10:e003255.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCHEARTFAILURE.116.003255">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28087687">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R279" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Passamani
	E, Davis KB, Gillespie MJ, et al. A randomized trial of coronary
	artery bypass surgery: survival of patients with a low ejection
	fraction.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	1985;312:1665–1671.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJM198506273122603">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/3873614">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">9.</font></p>
<div id="R280" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Bittl
	JA, He Y, Jacobs AK, et al. Bayesian methods affirm the use of
	percutaneous coronary intervention to improve survival in patients
	with unprotected left main coronary artery disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2013;127:2177–2185.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCULATIONAHA.112.000646">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23674397">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">10.</font></p>
<div id="R281" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Yusuf
	S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass
	graft surgery on survival: overview of 10-year results from
	randomised trials by the Coronary Artery Bypass Graft Surgery
	Trialists Collaboration.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	1994;344:563–570.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(94)91963-1">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/7914958">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">11.</font></p>
<div id="R282" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Takaro
	T, Peduzzi P, Detre KM, et al. Survival in subgroups of patients
	with left main coronary artery disease. Veterans Administration
	Cooperative Study of Surgery for Coronary Arterial Occlusive
	Disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	1982;66:14–22.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/01.CIR.66.1.14">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/6979435">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">12.</font></p>
<div id="R283" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Talano
	JV, Scanlon PJ, Meadows WR, et al. Influence of surgery on survival
	in 145 patients with left main coronary artery disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	1975;52(suppl 2):I-105–I-111.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">13.</font></p>
<div id="R284" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Long-term
	results of prospective randomised study of coronary artery bypass
	surgery in stable angina pectoris. European Coronary Surgery Study
	Group.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	1982;2:1173–1180.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/6128492">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">14.</font></p>
<div id="R285" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Maron
	DJ, Hochman JS, Reynolds HR, et al. Initial invasive or conservative
	strategy for stable coronary disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2020;382:1395–1407.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1915922">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/32227755">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">15.</font></p>
<div id="R286" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Bangalore
	S, Maron DJ, Stone GW, et al. Routine revascularization versus
	initial medical therapy for stable ischemic heart disease: a
	systematic review and meta-analysis of randomized
	trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2020;142:841–857.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCULATIONAHA.120.048194">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/32794407">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">16.</font></p>
<div id="R287" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Chacko
	L, P Howard J, Rajkumar C, et al. Effects of percutaneous coronary
	intervention on death and myocardial infarction stratified by stable
	and unstable coronary artery disease: a meta-analysis of randomized
	controlled trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Qual Outcomes</font></em><font size="1" style="font-size: 8pt">.
	2020;13:e006363.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCOUTCOMES.119.006363">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/32063040">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">17.</font></p>
<div id="R288" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Boden
	WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy with or
	without PCI for stable coronary disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2007;356:1503–1516.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa070829">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17387127">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">18.</font></p>
<div id="R289" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Sedlis
	SP, Hartigan PM, Teo KK, et al. Effect of PCI on long-term survival
	in patients with stable ischemic heart disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2015;373:1937–1946.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1505532">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26559572">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">19.</font></p>
<div id="R290" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Hueb
	W, Soares PR, Gersh BJ, et al. The medicine, angioplasty, or surgery
	study (MASS-II): a randomized, controlled clinical trial of three
	therapeutic strategies for multivessel coronary artery disease:
	one-year results.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2004;43:1743–1751.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2003.08.065">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15145093">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">20.</font></p>
<div id="R291" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Hueb
	W, Lopes N, Gersh BJ, et al. Ten-year follow-up survival of the
	Medicine, Angioplasty, or Surgery Study (MASS II): a randomized
	controlled clinical trial of 3 therapeutic strategies for
	multivessel coronary artery disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2010;122:949–957.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCULATIONAHA.109.911669">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20733102">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">21.</font></p>
<div id="R292" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Hueb
	W, Lopes NH, Gersh BJ, et al. Five-year follow-up of the Medicine,
	Angioplasty, or Surgery Study (MASS II): a randomized controlled
	clinical trial of 3 therapeutic strategies for multivessel coronary
	artery disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2007;115:1082–1089.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circulationaha.106.625475">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17339566">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">22.</font></p>
<div id="R293" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">TIME
	Investigators. Trial of invasive versus medical therapy in elderly
	patients with chronic symptomatic coronary-artery disease (TIME): a
	randomised trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2001;358:951–957.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(01)06100-1">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/11583747">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">23.</font></p>
<div id="R294" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Pitt
	B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy
	compared with angioplasty in stable coronary artery disease.
	Atorvastatin versus Revascularization Treatment Investigators.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	1999;341:70–76.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJM199907083410202">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/10395630">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">24.</font></p>
<div id="R295" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Chaitman
	BR, Hardison RM, Adler D, et al. The Bypass Angioplasty
	Revascularization Investigation 2 Diabetes randomized trial of
	different treatment strategies in type 2 diabetes mellitus with
	stable ischemic heart disease: impact of treatment strategy on
	cardiac mortality and myocardial infarction.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2009;120:2529–2540.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circulationaha.109.913111">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19920001">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">25.</font></p>
<div id="R296" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kapoor
	JR, Gienger AL, Ardehali R, et al. Isolated disease of the proximal
	left anterior descending artery comparing the effectiveness of
	percutaneous coronary interventions and coronary artery bypass
	surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2008;1:483–491.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jcin.2008.07.001">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19463349">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">26.</font></p>
<div id="R297" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Jones
	RH, Kesler K, Phillips HR, et al. Long-term survival benefits of
	coronary artery bypass grafting and percutaneous transluminal
	angioplasty in patients with coronary artery disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Thorac Cardiovasc Surg</font></em><font size="1" style="font-size: 8pt">.
	1996;111:1013–1025.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0022-5223(96)70378-1">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/8622299">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">27.</font></p>
<div id="R298" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Aziz
	O, Rao C, Panesar SS, et al. Meta-analysis of minimally invasive
	internal thoracic artery bypass versus percutaneous
	revascularisation for isolated lesions of the left anterior
	descending artery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>BMJ</font></em><font size="1" style="font-size: 8pt">.
	2007;334:617.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1136/bmj.39106.476215.BE">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17337458">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">28.</font></p>
<div id="R299" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Hannan
	EL, Samadashvili Z, Cozzens K, et al. Comparative outcomes for
	patients who do and do not undergo percutaneous coronary
	intervention for stable coronary artery disease in New
	York.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2012;125:1870–1879.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circulationaha.111.071811">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22441935">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">29.</font></p>
<div id="R300" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Smith
	PK, Califf RM, Tuttle RH, et al. Selection of surgical or
	percutaneous coronary intervention provides differential longevity
	benefit.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2006;82:1420–1428. discussion 8-9.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.athoracsur.2006.04.044">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16996946">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">30.</font></p>
<div id="R301" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Pijls
	NHJ, van Schaardenburgh P, Manoharan G, et al. Percutaneous coronary
	intervention of functionally nonsignificant stenosis: 5-year
	follow-up of the DEFER study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2007;49:2105–2111.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2007.01.087">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17531660">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">31.</font></p>
<div id="R302" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Hamad
	MAS, van Straten AHM, Schönberger JPAM, et al. Preoperative
	ejection fraction as a predictor of survival after coronary artery
	bypass grafting: comparison with a matched general population.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Cardiothorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2010;5:29.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1186/1749-8090-5-29">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20416050">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">32.</font></p>
<div id="R303" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Jiang
	L, Xu L, Song L, et al. Comparison of three treatment strategies for
	patients with triple-vessel coronary disease and left ventricular
	dysfunction.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Interv Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2018;31:310–318.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1111/joic.12497">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29468730">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">33.</font></p>
<div id="R304" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Uyar
	IS, Sahin V, Akpinar MB, et al. Decision making and results of
	coronary artery bypass grafting for patients with poor left
	ventricular function.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Heart
	Surg Forum</font></em><font size="1" style="font-size: 8pt">.
	2013;16:E118–E124.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1532/HSF98.20121124">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23803233">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">34.</font></p>
<div id="R305" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Katritsis
	DG, Ioannidis JPA. Percutaneous coronary intervention versus
	conservative therapy in nonacute coronary artery disease: a
	meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2005;111:2906–2912.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circulationaha.104.521864">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15927966">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">35.</font></p>
<div id="R306" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Doenst
	T, Haverich A, Serruys P, et al. PCI and CABG for treating stable
	coronary artery disease: JACC review topic of the week.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2019;73:964–976.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2018.11.053">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30819365">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">36.</font></p>
<div id="R307" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Stergiopoulos
	K, Brown DL. Initial coronary stent implantation with medical
	therapy vs medical therapy alone for stable coronary artery disease:
	meta-analysis of randomized controlled trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Arch
	Intern Med</font></em><font size="1" style="font-size: 8pt">.
	2012;172:312–319.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/archinternmed.2011.1484">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22371919">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">37.</font></p>
<div id="R308" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Windecker
	S, Stortecky S, Stefanini GG, et al. Revascularisation versus
	medical treatment in patients with stable coronary artery disease:
	network meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>BMJ</font></em><font size="1" style="font-size: 8pt">.
	2014;348:g3859.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1136/bmj.g3859">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24958153">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">38.</font></p>
<div id="R309" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Group
	BDS, Frye RL, August P, et al. A randomized trial of therapies for
	type 2 diabetes and coronary artery disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2009;360:2503–2515.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa0805796">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19502645">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">39.</font></p>
<div id="R310" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Velazquez
	EJ, Lee KL, Deja MA, et al. Coronary-artery bypass surgery in
	patients with left ventricular dysfunction.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2011;364:1607–1616.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1100356">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21463150">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">40.</font></p>
<div id="R311" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Petrie
	MC, Jhund PS, She L, et al. Ten-year outcomes after coronary artery
	bypass grafting according to age in patients with heart failure and
	left ventricular systolic dysfunction: an analysis of the extended
	follow-up of the STICH trial (Surgical Treatment for Ischemic Heart
	Failure).&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2016;134:1314–1324.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCULATIONAHA.116.024800">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27573034">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">41.</font></p>
<div id="R312" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Bonow
	RO, Maurer G, Lee KL, et al. Myocardial viability and survival in
	ischemic left ventricular dysfunction.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2011;364:1617–1625.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1100358">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21463153">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">42.</font></p>
<div id="R313" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Veterans
	Administration Coronary Artery Bypass Surgery Cooperative Study
	Group. Eleven-year survival in the Veterans Administration
	randomized trial of coronary bypass surgery for stable angina.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	1984;311:1333–1339.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJM198411223112102">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/6333636">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">43.</font></p>
<div id="R314" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Murphy
	ML, Hultgren HN, Detre K, et al. Treatment of chronic stable angina.
	A preliminary report of survival data of the randomized Veterans
	Administration cooperative study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	1977;297:621–627.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJM197709222971201">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/331107">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">44.</font></p>
<div id="R315" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Varnauskas
	E. Twelve-year follow-up of survival in the randomized European
	Coronary Surgery Study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	1988;319:332–337.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJM198808113190603">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/3260659">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">45.</font></p>
<div id="R316" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Mathur
	VS, Guinn GA. Prospective randomized study of the surgical therapy
	of stable angina.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Cardiovasc
	Clin</font></em><font size="1" style="font-size: 8pt">.
	1977;8:131–144.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/332367">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">46.</font></p>
<div id="R317" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Chaitman
	BR, Fisher LD, Bourassa MG, et al. Effect of coronary bypass surgery
	on survival patterns in subsets of patients with left main coronary
	artery disease: report of the Collaborative Study in Coronary Artery
	Surgery (CASS).&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	1981;48:765–777.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/0002-9149(81)90156-9">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/7025604">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">47.</font></p>
<div id="R318" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Lee
	PH, Ahn J-M, Chang M, et al. Left main coronary artery disease:
	secular trends in patient characteristics, treatments, and
	outcomes.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J Am
	Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2016;68:1233–1246.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2016.05.089">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27609687">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">48.</font></p>
<div id="R319" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Dzavik
	V, Ghali WA, Norris C, et al. Long-term survival in 11 661 patients
	with multivessel coronary artery disease in the era of stenting: a
	report from the Alberta Provincial Project for Outcome Assessment in
	Coronary Heart Disease (APPROACH) Investigators.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2001;142:119–126.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1067/mhj.2001.116072">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/11431667">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">49.</font></p>
<div id="R320" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Morice
	M-C, Serruys PW, Kappetein AP, et al. Five-year outcomes in patients
	with left main disease treated with either percutaneous coronary
	intervention or coronary artery bypass grafting in the synergy
	between percutaneous coronary intervention with taxus and cardiac
	surgery trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2014;129:2388–2394.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCULATIONAHA.113.006689">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24700706">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">50.</font></p>
<div id="R321" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Mäkikallio
	T, Holm NR, Lindsay M, et al. Percutaneous coronary angioplasty
	versus coronary artery bypass grafting in treatment of unprotected
	left main stenosis (NOBLE): a prospective, randomised, open-label,
	non-inferiority trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2016;388:2743–2752.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(16)32052-9">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27810312">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">51.</font></p>
<div id="R322" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Holm
	NR, Mäkikallio T, Lindsay MM, et al. Percutaneous coronary
	angioplasty versus coronary artery bypass grafting in the treatment
	of unprotected left main stenosis: updated 5-year outcomes from the
	randomised, non-inferiority NOBLE trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2020;395:191–199.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(19)32972-1">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31879028">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">52.</font></p>
<div id="R323" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kuno
	T, Ueyama H, Rao SV, et al. Percutaneous coronary intervention or
	coronary artery bypass graft surgery for left main coronary artery
	disease: a meta-analysis of randomized trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2020;227:9–10.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.ahj.2020.06.001">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/32640370">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">53.</font></p>
<div id="R324" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Park
	D-W, Ahn J-M, Park H, et al. Ten-year outcomes after drug-eluting
	stents versus coronary artery bypass grafting for left main coronary
	disease: extended follow-up of the PRECOMBAT trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2020;141:1437–1446.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCULATIONAHA.120.046039">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/32223567">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">54.</font></p>
<div id="R325" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Ahmad
	Y, Howard JP, Arnold AD, et al. Mortality after drug-eluting stents
	vs. coronary artery bypass grafting for left main coronary artery
	disease: a meta-analysis of randomized controlled trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2020;41:3228–3235.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/eurheartj/ehaa135">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/32118272">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">55.</font></p>
<div id="R326" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Gallo
	M, Blitzer D, Laforgia PL, et al. Percutaneous coronary intervention
	versus coronary artery bypass graft for left main coronary artery
	disease: a meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Thorac Cardiovasc Surg</font></em><font size="1" style="font-size: 8pt">.
	2020. S0022-5223(20)30888-6.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">56.</font></p>
<div id="R327" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Hillis
	LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for
	coronary artery bypass graft surgery: a report of the American
	College of Cardiology Foundation/American Heart Association Task
	Force on Practice Guidelines. Developed in collaboration with the
	American Association for Thoracic Surgery, Society of Cardiovascular
	Anesthesiologists, and Society of Thoracic Surgeons.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2011;124:e652–e735.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0b013e31823c074e">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22064599">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">57.</font></p>
<div id="R328" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Myers
	WO, Schaff HV, Gersh BJ, et al. Improved survival of surgically
	treated patients with triple vessel coronary artery disease and
	severe angina pectoris: a report from the Coronary Artery Surgery
	Study (CASS) registry.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Thorac Cardiovasc Surg</font></em><font size="1" style="font-size: 8pt">.
	1989;97:487–495.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0022-5223(19)34538-6">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/2648078">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">58.</font></p>
<div id="R329" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Collins
	R, Reith C, Emberson J, et al. Interpretation of the evidence for
	the efficacy and safety of statin therapy.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2016;388:2532–2561.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(16)31357-5">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27616593">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">59.</font></p>
<div id="R330" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Levine
	GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update
	on duration of dual antiplatelet therapy in patients with coronary
	artery disease: a report of the American College of
	Cardiology/American Heart Association Task Force on Clinical
	Practice Guidelines: an update of the 2011 ACCF/AHA/SCAI guideline
	for percutaneous coronary intervention, 2011 ACCF/AHA guideline for
	coronary artery bypass graft surgery, 2012
	ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and
	management of patients with stable ischemic heart disease, 2013
	ACCF/AHA guideline for the management of ST-elevation myocardial
	infarction, 2014 AHA/ACC guideline for the management of patients
	with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA
	guideline on perioperative cardiovascular evaluation and management
	of patients undergoing noncardiac surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2016;134:e123–e155.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/cir.0000000000000404">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27026020">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">60.</font></p>
<div id="R331" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Navarese
	EP, Lansky AJ, Kereiakes DJ, et al. Cardiac mortality in patients
	randomised to elective coronary revascularisation plus medical
	therapy or medical therapy alone: a systematic review and
	meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2021:ehab246.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/eurheartj/ehab246">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.
	Online ahead of print May 18, 2021.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">61.</font></p>
<div id="R332" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Vij
	A, Kassab K, Chawla H, et al. Invasive therapy versus conservative
	therapy for patients with stable coronary artery disease: an updated
	meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Clin
	Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2021;44:675–682.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1002/clc.23592">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/33742721">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">62.</font></p>
<div id="R333" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Laukkanen
	JA, Kunutsor SK. Revascularization versus medical therapy for the
	treatment of stable coronary artery disease: a meta-analysis of
	contemporary randomized controlled trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Int
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2021;324:13–21.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.ijcard.2020.10.016">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/33068645">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">63.</font></p>
<div id="R334" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Brooks
	MM, Chaitman BR, Nesto RW, et al. Clinical and angiographic risk
	stratification and differential impact on treatment outcomes in the
	Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI
	2D) trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2012;126:2115–2124.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circulationaha.112.092973">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23008442">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">64.</font></p>
<div id="R335" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Hueb
	WA, Bellotti G, de Oliveira SA, et al. The Medicine, Angioplasty or
	Surgery Study (MASS): a prospective, randomized trial of medical
	therapy, balloon angioplasty or bypass surgery for single proximal
	left anterior descending artery stenoses.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	1995;26:1600–1605.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/0735-1097(95)00384-3">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/7594092">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">65.</font></p>
<div id="R336" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Hueb
	WA, Soares PR, Almeida De Oliveira S, et al. Five-year follow-up of
	the medicine, angioplasty, or surgery study (MASS): a prospective,
	randomized trial of medical therapy, balloon angioplasty, or bypass
	surgery for single proximal left anterior descending coronary artery
	stenosis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	1999;100:II-107–II-113.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circ.100.suppl_2.Ii-107">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">66.</font></p>
<div id="R337" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Cashin
	WL, Sanmarco ME, Nessim SA, et al. Accelerated progression of
	atherosclerosis in coronary vessels with minimal lesions that are
	bypassed.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	1984;311:824–828.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJM198409273111304">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/6332274">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">67.</font></p>
<div id="R338" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Pijls
	NHJ, Fearon WF, Tonino PAL, et al. Fractional flow reserve versus
	angiography for guiding percutaneous coronary intervention in
	patients with multivessel coronary artery disease: 2-year follow-up
	of the FAME (Fractional Flow Reserve Versus Angiography for
	Multivessel Evaluation) study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2010;56:177–184.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2010.04.012">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20537493">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">68.</font></p>
<div id="R339" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Escaned
	J, Ryan N, Mejía-Rentería H, et al. Safety of the deferral of
	coronary revascularization on the basis of instantaneous wave-free
	ratio and fractional flow reserve measurements in stable coronary
	artery disease and acute coronary syndromes.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2018;11:1437–1449.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jcin.2018.05.029">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30093050">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">69.</span></font></p>
<div id="R340" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Zimmermann
	FM, Ferrara A, Johnson NP, et al. Deferral vs. performance of
	percutaneous coronary intervention of functionally non-significant
	coronary stenosis: 15-year follow-up of the DEFER trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2015;36:3182–3188.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/eurheartj/ehv452">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26400825">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>7.2.
Revascularization to Reduce Cardiovascular Events in SIHD Compared
With Medical Therapy</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R341" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Maron
	DJ, Hochman JS, Reynolds HR, et al. Initial invasive or conservative
	strategy for stable coronary disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2020;382:1395–1407.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1915922">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/32227755">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R342" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Hueb
	W, Lopes N, Gersh BJ, et al. Ten-year follow-up survival of the
	Medicine, Angioplasty, or Surgery Study (MASS II): a randomized
	controlled clinical trial of 3 therapeutic strategies for
	multivessel coronary artery disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2010;122:949–957.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCULATIONAHA.109.911669">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20733102">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R343" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Navarese
	EP, Lansky AJ, Kereiakes DJ, et al. Cardiac mortality in patients
	randomised to elective coronary revascularisation plus medical
	therapy or medical therapy alone: a systematic review and
	meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2021:ehab246.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/eurheartj/ehab246">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.
	Online ahead of print May 18, 2021.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R344" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Chaitman
	BR, Alexander KP, Cyr DD, et al. Myocardial infarction in the
	ISCHEMIA Trial: impact of different definitions on incidence,
	prognosis, and treatment comparisons.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2021;143:790–804.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCULATIONAHA.120.047987">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/33267610">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R345" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">De
	Bruyne B, Fearon WF, Pijls NHJ, et al. Fractional flow
	reserve-guided PCI for stable coronary artery disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2014;371:1208–1217.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1408758">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25176289">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R346" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">De
	Bruyne B, Pijls NHJ, Kalesan B, et al. Fractional flow
	reserve-guided PCI versus medical therapy in stable coronary
	disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2012;367:991–1001.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1205361">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22924638">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R347" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Laukkanen
	JA, Kunutsor SK. Revascularization versus medical therapy for the
	treatment of stable coronary artery disease: a meta-analysis of
	contemporary randomized controlled trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Int
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2021;324:13–21.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.ijcard.2020.10.016">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/33068645">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R348" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Vij
	A, Kassab K, Chawla H, et al. Invasive therapy versus conservative
	therapy for patients with stable coronary artery disease: an updated
	meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Clin
	Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2021;44:675–682.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1002/clc.23592">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/33742721">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">9.</font></p>
<div id="R349" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Windecker
	S, Stortecky S, Stefanini GG, et al. Revascularisation versus
	medical treatment in patients with stable coronary artery disease:
	network meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>BMJ</font></em><font size="1" style="font-size: 8pt">.
	2014;348:g3859.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1136/bmj.g3859">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24958153">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">10.</font></p>
<div id="R350" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Chacko
	L, P Howard J, Rajkumar C, et al. Effects of percutaneous coronary
	intervention on death and myocardial infarction stratified by stable
	and unstable coronary artery disease: a meta-analysis of randomized
	controlled trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Qual Outcomes</font></em><font size="1" style="font-size: 8pt">.
	2020;13:e006363.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCOUTCOMES.119.006363">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/32063040">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">11.</font></p>
<div id="R351" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Bangalore
	S, Maron DJ, Stone GW, et al. Routine revascularization versus
	initial medical therapy for stable ischemic heart disease: a
	systematic review and meta-analysis of randomized
	trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2020;142:841–857.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCULATIONAHA.120.048194">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/32794407">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">12.</font></p>
<div id="R352" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Doenst
	T, Haverich A, Serruys P, et al. PCI and CABG for treating stable
	coronary artery disease: JACC review topic of the week.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2019;73:964–976.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2018.11.053">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30819365">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">13.</span></font></p>
<div id="R353" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Thygesen
	K, Alpert JS, Jaffe AS, et al. Fourth universal definition of
	myocardial infarction (2018).&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2018;138:e618–e651.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0000000000000617">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30571511">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>7.3.
Revascularization to Improve Symptoms</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R354" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Spertus
	JA, Jones PG, Maron DJ, et al. Health-status outcomes with invasive
	or conservative care in coronary disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2020;382:1408–1419.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1916370">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/32227753">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R355" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Nishigaki
	K, Yamazaki T, Kitabatake A, et al. Percutaneous coronary
	intervention plus medical therapy reduces the incidence of acute
	coronary syndrome more effectively than initial medical therapy only
	among patients with low-risk coronary artery disease a randomized,
	comparative, multicenter study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2008;1:469–479.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jcin.2008.08.002">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19463347">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R356" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Fearon
	WF, Nishi T, De Bruyne B, et al. Clinical outcomes and
	cost-effectiveness of fractional flow reserve-guided percutaneous
	coronary intervention in patients with stable coronary artery
	disease: three-year follow-up of the FAME 2 trial (Fractional Flow
	Reserve Versus Angiography for Multivessel Evaluation).&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2018;137:480–487.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCULATIONAHA.117.031907">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29097450">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R357" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Abdallah
	MS, Wang K, Magnuson EA, et al. Quality of life after PCI vs CABG
	among patients with diabetes and multivessel coronary artery
	disease: a randomized clinical trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA</font></em><font size="1" style="font-size: 8pt">.
	2013;310:1581–1590.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jama.2013.279208">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24129463">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R358" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Baron
	SJ, Chinnakondepalli K, Magnuson EA, et al. Quality-of-life after
	everolimus-eluting stents or bypass surgery for left-main disease:
	results from the EXCEL Trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2017;70:3113–3122.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2017.10.036">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29097293">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R359" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Brooks
	MM, Chung SC, Helmy T, et al. Health status after treatment for
	coronary artery disease and type 2 diabetes mellitus in the Bypass
	Angioplasty Revascularization Investigation 2 Diabetes
	trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2010;122:1690–1699.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCULATIONAHA.109.912642">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20937978">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R360" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Cashin
	WL, Sanmarco ME, Nessim SA, et al. Accelerated progression of
	atherosclerosis in coronary vessels with minimal lesions that are
	bypassed.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	1984;311:824–828.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJM198409273111304">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/6332274">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R361" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Pitt
	B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy
	compared with angioplasty in stable coronary artery disease.
	Atorvastatin versus Revascularization Treatment Investigators.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	1999;341:70–76.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJM199907083410202">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/10395630">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">9.</font></p>
<div id="R362" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Wijeysundera
	HC, Nallamothu BK, Krumholz HM, et al. Meta-analysis: effects of
	percutaneous coronary intervention versus medical therapy on angina
	relief.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Intern Med</font></em><font size="1" style="font-size: 8pt">.
	2010;152:370–379.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.7326/0003-4819-152-6-201003160-00007">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20231568">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">10.</font></p>
<div id="R363" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Weintraub
	WS, Spertus JA, Kolm P, et al. Effect of PCI on quality of life in
	patients with stable coronary disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2008;359:677–687.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa072771">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18703470">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">11.</span></font></p>
<div id="R364" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Al-Lamee
	R, Thompson D, Dehbi HM, et al. Percutaneous coronary intervention
	in stable angina (ORBITA): a double-blind, randomised controlled
	trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2018;391:31–40.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(17)32714-9">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29103656">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>8.1.
Patients With Complex Disease</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R365" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Morice
	MC, Serruys PW, Kappetein AP, et al. Five-year outcomes in patients
	with left main disease treated with either percutaneous coronary
	intervention or coronary artery bypass grafting in the synergy
	between percutaneous coronary intervention with taxus and cardiac
	surgery trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2014;129:2388–2394.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCULATIONAHA.113.006689">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24700706">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R366" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Mohr
	FW, Morice MC, Kappetein AP, et al. Coronary artery bypass graft
	surgery versus percutaneous coronary intervention in patients with
	three-vessel disease and left main coronary disease: 5-year
	follow-up of the randomised, clinical SYNTAX trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2013;381:629–638.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(13)60141-5">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23439102">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R367" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Serruys
	PW, Morice MC, Kappetein AP, et al. Percutaneous coronary
	intervention versus coronary-artery bypass grafting for severe
	coronary artery disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2009;360:961–972.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa0804626">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19228612">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R368" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Thuijs
	D, Kappetein AP, Serruys PW, et al. Percutaneous coronary
	intervention versus coronary artery bypass grafting in patients with
	three-vessel or left main coronary artery disease: 10-year follow-up
	of the multicentre randomised controlled SYNTAX trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2019;394:1325–1334.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(19)31997-X">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31488373">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R369" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Head
	SJ, Milojevic M, Daemen J, et al. Mortality after coronary artery
	bypass grafting versus percutaneous coronary intervention with
	stenting for coronary artery disease: a pooled analysis of
	individual patient data.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2018;391:939–948.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(18)30423-9">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29478841">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R370" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Makikallio
	T, Holm NR, Lindsay M, et al. Percutaneous coronary angioplasty
	versus coronary artery bypass grafting in treatment of unprotected
	left main stenosis (NOBLE): a prospective, randomised, open-label,
	non-inferiority trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2016;388:2743–2752.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(16)32052-9">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27810312">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R371" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Buszman
	PE, Buszman PP, Banasiewicz-Szkrobka I, et al. Left main stenting in
	comparison with surgical revascularization: 10-year outcomes of the
	(Left Main Coronary Artery Stenting) LE MANS Trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2016;9:318–327.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jcin.2015.10.044">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26892080">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R372" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Park
	SJ, Kim YH, Park DW, et al. Randomized trial of stents versus bypass
	surgery for left main coronary artery disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2011;364:1718–1727.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1100452">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21463149">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">9.</font></p>
<div id="R373" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Boudriot
	E, Thiele H, Walther T, et al. Randomized comparison of percutaneous
	coronary intervention with sirolimus-eluting stents versus coronary
	artery bypass grafting in unprotected left main stem stenosis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2011;57:538–545.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2010.09.038">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21272743">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">10.</font></p>
<div id="R374" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Seung
	KB, Park DW, Kim YH, et al. Stents versus coronary-artery bypass
	grafting for left main coronary artery disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2008;358:1781–1792.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa0801441">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18378517">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">11.</font></p>
<div id="R375" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Gallo
	M, Blitzer D, Laforgia PL, et al. Percutaneous coronary intervention
	versus coronary artery bypass graft for left main coronary artery
	disease: a meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Thorac Cardiovasc Surg</font></em><font size="1" style="font-size: 8pt">.
	Published online April 15, 2020.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jtcvs.2020.04.010">Crossref</span></font></span></font></a></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">12.</font></p>
<div id="R376" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Ahmad
	Y, Howard JP, Arnold AD, et al. Mortality after drug-eluting stents
	vs. coronary artery bypass grafting for left main coronary artery
	disease: a meta-analysis of randomized controlled trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2020;41:3228–3235.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/eurheartj/ehaa135">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/32118272">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">13.</font></p>
<div id="R377" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Bittl
	JA, He Y, Jacobs AK, et al. Bayesian methods affirm the use of
	percutaneous coronary intervention to improve survival in patients
	with unprotected left main coronary artery disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2013;127:2177–2185.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCULATIONAHA.112.000646">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23674397">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">14.</font></p>
<div id="R378" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Cavalcante
	R, Sotomi Y, Lee CW, et al. Outcomes after percutaneous coronary
	intervention or bypass surgery in patients with unprotected left
	main disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2016;68:999–1009.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2016.06.024">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27585503">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">15.</font></p>
<div id="R379" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Farkouh
	ME, Domanski M, Sleeper LA, et al. Strategies for multivessel
	revascularization in patients with diabetes.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2012;367:2375–2384.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1211585">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23121323">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">16.</font></p>
<div id="R380" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Rodriguez
	AE, Baldi J, Fernandez Pereira C, et al. Five-year follow-up of the
	Argentine randomized trial of coronary angioplasty with stenting
	versus coronary bypass surgery in patients with multiple vessel
	disease (ERACI II).&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2005;46:582–588.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2004.12.081">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16098419">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">17.</font></p>
<div id="R381" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Hueb
	W, Lopes N, Gersh BJ, et al. Ten-year follow-up survival of the
	Medicine, Angioplasty, or Surgery Study (MASS II): a randomized
	controlled clinical trial of 3 therapeutic strategies for
	multivessel coronary artery disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2010;122:949–957.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCULATIONAHA.109.911669">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20733102">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">18.</font></p>
<div id="R382" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Gaudino
	M, Hameed I, Farkouh ME, et al. Overall and cause-specific mortality
	in randomized clinical trials comparing percutaneous interventions
	with coronary bypass surgery: a meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA
	Intern Med</font></em><font size="1" style="font-size: 8pt">.
	2020;180:1638–1646.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jamainternmed.2020.4748">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/33044497">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">19.</font></p>
<div id="R383" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Doenst
	T, Haverich A, Serruys P, et al. PCI and CABG for treating stable
	coronary artery disease: JACC review topic of the week.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2019;73:964–976.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2018.11.053">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30819365">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">20.</span></font></p>
<div id="R384" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Stone
	GW, Kappetein AP, Sabik JF, et al. Five-year outcomes after PCI or
	CABG for left main coronary disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2019;381:1820–1830.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1909406">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31562798">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>8.2.
Patients With Diabetes</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R385" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Farkouh
	ME, Domanski M, Sleeper LA, et al. Strategies for multivessel
	revascularization in patients with diabetes.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2012;367:2375–2384.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1211585">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23121323">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R386" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Farkouh
	ME, Domanski M, Dangas GD, et al. Long-term survival following
	multivessel revascularization in patients with diabetes: the FREEDOM
	follow-on study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2019;73:629–638.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2018.11.001">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30428398">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R387" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kamalesh
	M, Sharp TG, Tang XC, et al. Percutaneous coronary intervention
	versus coronary bypass surgery in United States veterans with
	diabetes.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J Am
	Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2013;61:808–816.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2012.11.044">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23428214">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R388" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kappetein
	AP, Head SJ, Morice MC, et al. Treatment of complex coronary artery
	disease in patients with diabetes: 5-year results comparing outcomes
	of bypass surgery and percutaneous coronary intervention in the
	SYNTAX trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	J Cardiothorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2013;43:1006–1013.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/ejcts/ezt017">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23413014">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R389" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Head
	SJ, Mil ojevic M, Daemen J, et al. Mortality after coronary artery
	bypass grafting versus percutaneous coronary intervention with
	stenting for coronary artery disease: a pooled analysis of
	individual patient data.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2018;391:939–948.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(18)30423-9">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29478841">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R390" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Verma
	S, Farkouh ME, Yanagawa B, et al. Comparison of coronary artery
	bypass surgery and percutaneous coronary intervention in patients
	with diabetes: a meta-analysis of randomised controlled
	trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet
	Diabetes Endocrinol</font></em><font size="1" style="font-size: 8pt">.
	2013;1:317–328.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S2213-8587(13)70089-5">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24622417">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R391" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Park
	SJ, Ahn JM, Kim YH, et al. Trial of everolimus-eluting stents or
	bypass surgery for coronary disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2015;372:1204–1212.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1415447">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25774645">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R392" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Park
	DW, Kim YH, Song HG, et al. Long-term outcome of stents versus
	bypass surgery in diabetic and nondiabetic patients with multivessel
	or left main coronary artery disease: a pooled analysis of 5775
	individual patient data.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2012;5:467–475.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCINTERVENTIONS.112.969915">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22872052">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">9.</font></p>
<div id="R393" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Pandey
	A, McGuire DK, de Lemos JA, et al. Revascularization trends in
	patients with diabetes mellitus and multivessel coronary artery
	disease presenting with non-ST elevation myocardial infarction:
	insights from the National Cardiovascular Data Registry Acute
	Coronary Treatment and Intervention Outcomes Network Registry-get
	with the guidelines (NCDR ACTION Registry-GWTG).&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Qual Outcomes</font></em><font size="1" style="font-size: 8pt">.
	2016;9:197–205.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circoutcomes.115.002084">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27166210">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">10.</font></p>
<div id="R394" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Sedlis
	SP, Morrison DA, Lorin JD, et al. Percutaneous coronary intervention
	versus coronary bypass graft surgery for diabetic patients with
	unstable angina and risk factors for adverse outcomes with bypass:
	outcome of diabetic patients in the AWESOME randomized trial and
	registry.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J Am
	Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2002;40:1555–1566.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0735-1097(02)02346-X">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12427406">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">11.</font></p>
<div id="R395" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Milojevic
	M, Serruys PW, Sabik JF, et al. Bypass surgery or stenting for left
	main coronary artery disease in patients with diabetes.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2019;73:1616–1628.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2019.01.037">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30947913">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">12.</font></p>
<div id="R396" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Mohr
	FW, Morice MC, Kappetein AP, et al. Coronary artery bypass graft
	surgery versus percutaneous coronary intervention in patients with
	three-vessel disease and left main coronary disease: 5-year
	follow-up of the randomised, clinical SYNTAX trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2013;381:629–638.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(13)60141-5">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23439102">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">13.</font></p>
<div id="R397" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Stone
	GW, Sabik JF, Serruys PW, et al. Everolimus-eluting stents or bypass
	surgery for left main coronary artery disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2016;375:2223–2235.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1610227">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27797291">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">14.</font></p>
<div id="R398" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Makikallio
	T, Holm NR, Lindsay M, et al. Percutaneous coronary angioplasty
	versus coronary artery bypass grafting in treatment of unprotected
	left main stenosis (NOBLE): a prospective, randomised, open-label,
	non-inferiority trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2016;388:2743–2752.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(16)32052-9">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27810312">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">15.</font></p>
<div id="R399" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Armstrong
	EJ, Rutledge JC, Rogers JH. Coronary artery revascularization in
	patients with diabetes mellitus.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2013;128:1675–1685.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCULATIONAHA.113.002114">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24100481">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">16.</font></p>
<div id="R400" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Thuijs
	D, Kappetein AP, Serruys PW, et al. Percutaneous coronary
	intervention versus coronary artery bypass grafting in patients with
	three-vessel or left main coronary artery disease: 10-year follow-up
	of the multicentre randomised controlled SYNTAX trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2019;394:1325–1334.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(19)31997-X">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31488373">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">17.</span></font></p>
<div id="R401" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Head
	SJ, Milojevic M, Daemen J, et al. Stroke rates following surgical
	versus percutaneous coronary revascularization.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2018;72:386–398.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2018.04.071">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30025574">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>8.3.
Patients With Previous CABG</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R402" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Yap
	C-H, Sposato L, Akowuah E, et al. Contemporary results show repeat
	coronary artery bypass grafting remains a risk factor for operative
	mortality.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2009;87:1386–1391.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.athoracsur.2009.02.006">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19379870">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R403" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Morrison
	DA, Sethi G, Sacks J, et al. Percutaneous coronary intervention
	versus repeat bypass surgery for patients with medically refractory
	myocardial ischemia: AWESOME randomized trial and registry
	experience with post-CABG patients.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2002;40:1951–1954.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0735-1097(02)02560-3">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12475454">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R404" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Brener
	SJ, Lytle BW, Casserly IP, et al. Predictors of revascularization
	method and long-term outcome of percutaneous coronary intervention
	or repeat coronary bypass surgery in patients with multivessel
	coronary disease and previous coronary bypass surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2006;27:413–418.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/eurheartj/ehi646">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16272211">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R405" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Sabik
	JF, Raza S, Blackstone EH, et al. Value of internal thoracic artery
	grafting to the left anterior descending coronary artery at coronary
	reoperation.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2013;61:302–310.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2012.09.045">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23328610">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R406" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Tajti
	P, Karmpaliotis D, Alaswad K, et al. In-hospital outcomes of chronic
	total occlusion percutaneous coronary interventions in patients with
	prior coronary artery bypass graft surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2019;12:e007338.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCINTERVENTIONS.118.007338">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30871357">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R407" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Toma
	A, Stähli BE, Gick M, et al. Long-term follow-up of patients with
	previous coronary artery bypass grafting undergoing percutaneous
	coronary intervention for chronic total occlusion.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2016;118:1641–1646.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.amjcard.2016.08.038">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27692593">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R408" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Pershad
	A, Gulati M, Karmpaliotis D, et al. A sex stratified outcome
	analysis from the OPEN-CTO registry.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Catheter
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2019;93:1041–1047.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1002/ccd.28023">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30569618">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R409" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">van
	der Heijden LC, Kok MM, Zocca P, et al. Long-term outcome of
	consecutive patients with previous coronary bypass surgery, treated
	with newer-generation drug-eluting stents.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Heart Assoc</font></em><font size="1" style="font-size: 8pt">.
	2018;7:e007212.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/JAHA.117.007212">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29382666">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">9.</font></p>
<div id="R410" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Brilakis
	ES, Rao SV, Banerjee S, et al. Percutaneous coronary intervention in
	native arteries versus bypass grafts in prior coronary artery bypass
	grafting patients: a report from the National Cardiovascular Data
	Registry.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2011;4:844–850.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jcin.2011.03.018">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21851896">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">10.</font></p>
<div id="R411" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Alkhouli
	M, Alqahtani F, Alreshidan M, et al. Incidence, predictors, and
	outcomes of early acute myocardial infarction following coronary
	artery bypass grafting.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2019;124:1027–1030.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.amjcard.2019.06.023">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31383352">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">11.</font></p>
<div id="R412" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Abdel-Karim
	A-RR, Banerjee S, Brilakis ES. Percutaneous intervention of acutely
	occluded saphenous vein grafts: contemporary techniques and
	outcomes.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Invasive Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2010;22:253–257.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20516502">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">12.</font></p>
<div id="R413" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Subramanian
	S, Sabik JF, Houghtaling PL, et al. Decision-making for patients
	with patent left internal thoracic artery grafts to left anterior
	descending.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2009;87:1392–1398; discussion 400.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.athoracsur.2009.02.032">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19379872">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">13.</span></font></p>
<div id="R414" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Gyenes
	G, Norris CM, Graham MM. Percutaneous revascularization improves
	outcomes in patients with prior coronary artery bypass
	surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Catheter
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2013;82:E148–E154.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1002/ccd.24711">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23208677">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>8.4.
DAPT Adherence</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R414a" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Almalla
	M, Schroder J, Hennings V, et al. Long-term outcome after
	angiographically proven coronary stent thrombosis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2013;111:1289–1294.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.amjcard.2013.01.268">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23415513">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R415" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Brodie
	BR, Garg A, Stuckey TD, et al. Fixed and modifiable correlates of
	drug-eluting stent thrombosis from a large all-comers registry:
	insights from ADAPT-DES.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2015;8:e002568.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCINTERVENTIONS.114.002568">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26415600">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R416" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Cutlip
	DE, Kereiakes DJ, Mauri L, et al. Thrombotic complications
	associated with early and late nonadherence to dual antiplatelet
	therapy.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2015;8:404–410.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jcin.2014.10.017">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25703885">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R417" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Genereux
	P, Rutledge DR, Palmerini T, et al. Stent thrombosis and dual
	antiplatelet therapy interruption with everolimus-eluting stents:
	insights from the Xience V coronary stent system trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2015;8: e001362.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCINTERVENTIONS.114.001362">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25940520">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R418" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Jeger
	RV, Pfisterer ME, Sorensen R, et al. Tradeoff between bleeding and
	stent thrombosis in different dual antiplatelet therapy regimes:
	importance of case fatality rates and effective treatment
	durations.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2014;168:698–705.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.ahj.2014.07.019">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25440798">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R419" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Koskinas
	KC, Zanchin T, Klingenberg R, et al. Incidence, predictors, and
	clinical impact of early prasugrel cessation in patients with
	ST-elevation myocardial infarction.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Heart Assoc</font></em><font size="1" style="font-size: 8pt">.
	2018;7:e008085.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/JAHA.117.008085">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29654204">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R420" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Mehran
	R, Baber U, Steg PG, et al. Cessation of dual antiplatelet treatment
	and cardiac events after percutaneous coronary intervention (PARIS):
	2 year results from a prospective observational study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2013;382:1714–1722.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(13)61720-1">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24004642">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R421" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Rozemeijer
	R, Wing Wong C, Leenders G, et al. Incidence, angiographic and
	clinical predictors, and impact of stent thrombosis: a 6-year survey
	of 6 545 consecutive patients.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Neth
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2019;27:321–329.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1007/s12471-019-1253-2">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30895527">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">9.</font></p>
<div id="R422" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Secemsky
	EA, Matteau A, Yeh RW, et al. Comparison of short- and long-term
	cardiac mortality in early versus late stent thrombosis (from pooled
	PROTECT trials).&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2015;115:1678–1684.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.amjcard.2015.03.010">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25910523">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">10.</span></font></p>
<div id="R423" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Silber
	S, Kirtane AJ, Belardi JA, et al. Lack of association between dual
	antiplatelet therapy use and stent thrombosis between 1 and 12
	months following resolute zotarolimus-eluting stent
	implantation.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2014;35:1949–1956.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/eurheartj/ehu026">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24510638">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>9.1.
Revascularization in Pregnant Patients</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R424" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Baris
	L, Hakeem A, Moe T, et al. Acute coronary syndrome and ischemic
	heart disease in pregnancy: data from the EURObservational Research
	Programme-European Society of Cardiology registry of pregnancy and
	cardiac disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Heart Assoc</font></em><font size="1" style="font-size: 8pt">.
	2020;9:e015490.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/JAHA.119.015490">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/32750301">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R425" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Smilowitz
	NR, Gupta N, Guo Y, et al. Acute myocardial infarction during
	pregnancy and the puerperium in the United States.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Mayo
	Clin Proc</font></em><font size="1" style="font-size: 8pt">.
	2018;93:1404–1414.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.mayocp.2018.04.019">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30031555">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R426" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Mehta
	LS, Warnes CA, Bradley E, et al. Cardiovascular considerations in
	caring for pregnant patients: a scientific statement from the
	American Heart Association.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2020;141:e884–e903.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0000000000000772">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/32362133">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R427" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Nana
	M, Morgan H, Moore S, et al. Antiplatelet therapy in pregnancy: a
	systematic review.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Pharmacol
	Res</font></em><font size="1" style="font-size: 8pt">.
	2021;168:105547.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.phrs.2021.105547">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/33716166">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R428" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Regitz-Zagrosek
	V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC guidelines for
	the management of cardiovascular diseases during pregnancy.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2018;39:3165–3241.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/eurheartj/ehy340">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30165544">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">6.</span></font></p>
<div id="R429" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Amsterdam
	EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the
	management of patients with non-ST-elevation acute coronary
	syndromes: a report of the American College of Cardiology/American
	Heart Association Task Force on Practice Guidelines.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2014;130:e344–e426.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0000000000000134">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25249585">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>9.2.
Revascularization in Older Patients</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R430" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Tinetti
	ME, Bogardus ST, Agostini JV. Potential pitfalls of disease-specific
	guidelines for patients with multiple conditions.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2004;351:2870–2874.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMsb042458">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15625341">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R431" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Yourman
	LC, Lee SJ, Schonberg MA, et al. Prognostic indices for older
	adults: a systematic review.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA</font></em><font size="1" style="font-size: 8pt">.
	2012;307:182–192.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jama.2011.1966">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22235089">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R432" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Varenne
	O, Cook S, Sideris G, et al. Drug-eluting stents in elderly patients
	with coronary artery disease (SENIOR): a randomised single-blind
	trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2018;391:41–50.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(17)32713-7">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29102362">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R433" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Roberts
	WC, Shirani J. Comparison of cardiac findings at necropsy in
	octogenarians, nonagenarians, and centenarians.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	1998;82:627–631.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0002-9149(98)00385-3">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/9732892">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R434" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Seki,
	A, Fishbein, MC. Age-related cardiovascular changes and diseases.
	4th ed. Buja, LM, Butany, J, eds.&nbsp;</font><font size="1" style="font-size: 8pt"><em>In:
	Cardiovascular Pathology</font></em><font size="1" style="font-size: 8pt">.
	Elsevier, Inc; 2016:57–83.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R435" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Guagliumi
	G, Stone GW, Cox DA, et al. Outcome in elderly patients undergoing
	primary coronary intervention for acute myocardial infarction:
	results from the Controlled Abciximab and Device Investigation to
	Lower Late Angioplasty Complications (CADILLAC) trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2004;110:1598–1604.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/01.CIR.0000142862.98817.1F">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15353506">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R436" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Li
	L, Geraghty OC, Mehta Z, et al. Age-specific risks, severity, time
	course, and outcome of bleeding on long-term antiplatelet treatment
	after vascular events: a population-based cohort study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2017;390:490–499.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(17)30770-5">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28622955">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R437" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Urban
	P, Meredith IT, Abizaid A, et al. Polymer-free drug-coated coronary
	stents in patients at high bleeding risk.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2015;373:2038–2047.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1503943">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26466021">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">9.</font></p>
<div id="R438" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Lee
	PY, Alexander KP, Hammill BG, et al. Representation of elderly
	persons and women in published randomized trials of acute coronary
	syndromes.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA</font></em><font size="1" style="font-size: 8pt">.
	2001;286:708–713.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jama.286.6.708">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/11495621">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">10.</font></p>
<div id="R439" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Batchelor
	WB, Anstrom KJ, Muhlbaier LH, et al. Contemporary outcome trends in
	the elderly undergoing percutaneous coronary interventions: results
	in 7 472 octogenarians. National Cardiovascular Network
	Collaboration.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2000;36:723–730.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0735-1097(00)00777-4">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/10987591">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">11.</font></p>
<div id="R440" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Johnman
	C, Oldroyd KG, Mackay DF, et al. Percutaneous coronary intervention
	in the elderly: changes in case-mix and periprocedural outcomes in
	31 758 patients treated between 2000 and 2007.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2010;3:341–345.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circinterventions.109.928705">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20606133">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">12.</font></p>
<div id="R441" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Singh
	M, Peterson ED, Roe MT, et al. Trends in the association between age
	and in-hospital mortality after percutaneous coronary intervention:
	National Cardiovascular Data Registry experience.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2009;2:20–26.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCINTERVENTIONS.108.826172">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20031689">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">13.</font></p>
<div id="R442" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Capodanno
	D, Angiolillo DJ. Antithrombotic therapy in the elderly.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2010;56:1683–1692.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2010.04.063">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21070918">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">14.</font></p>
<div id="R443" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Lakatta
	EG, Levy D. Arterial and cardiac aging: major shareholders in
	cardiovascular disease enterprises: part II: the aging heart in
	health: links to heart disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2003;107:346–354.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/01.cir.0000048893.62841.f7">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12538439">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">15.</font></p>
<div id="R444" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Newman
	AB, Naydeck BL, Sutton-Tyrrell K, et al. Coronary artery
	calcification in older adults to age 99: prevalence and risk
	factors.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2001;104:2679–2684.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/hc4601.099464">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/11723018">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">16.</font></p>
<div id="R445" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Graham
	MM, Ghali WA, Faris PD, et al. Survival after coronary
	revascularization in the elderly.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2002;105:2378–2384.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/01.cir.0000016640.99114.3d">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12021224">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">17.</font></p>
<div id="R446" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Afilalo
	J, Karunananthan S, Eisenberg MJ, et al. Role of frailty in patients
	with cardiovascular disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2009;103:1616–1621.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.amjcard.2009.01.375">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19463525">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">18.</font></p>
<div id="R447" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Stone
	GW, Sabik JF, Serruys PW, et al. Everolimus-eluting stents or bypass
	surgery for left main coronary artery disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2016;375:2223–2235.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1610227">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27797291">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">19.</font></p>
<div id="R448" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Park
	SJ, Ahn JM, Kim YH, et al. Trial of everolimus-eluting stents or
	bypass surgery for coronary disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2015;372:1204–1212.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1415447">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25774645">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">20.</font></p>
<div id="R449" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Ahn
	JM, Roh JH, Kim YH, et al. Randomized trial of stents versus bypass
	surgery for left main coronary artery disease: 5-year outcomes of
	the PRECOMBAT Study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2015;65:2198–2206.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2015.03.033">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25787197">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">21.</span></font></p>
<div id="R450" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Madhavan
	MV, Gersh BJ, Alexander KP, et al. Coronary artery disease in
	patients ≥80 years of age.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2018;71:2015–2040.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2017.12.068">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29724356">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>9.3.
Revascularization in Patients With Chronic Kidney Disease (CKD)</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R451" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Mehran
	R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction
	of contrast-induced nephropathy after percutaneous coronary
	intervention: development and initial validation.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2004;44:1393–1399.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2004.06.068">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15464318">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R452" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Moscucci
	M, Rogers EK, Montoye C, et al. Association of a continuous quality
	improvement initiative with practice and outcome variations of
	contemporary percutaneous coronary interventions.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2006;113:814–822.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCULATIONAHA.105.541995">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16461821">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R453" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Mehran
	R, Dangas GD, Weisbord SD. Contrast-associated acute kidney
	injury.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N Engl
	J Med</font></em><font size="1" style="font-size: 8pt">.
	2019;380:2146–2155.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMra1805256">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31141635">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R454" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Smilowitz
	NR, Gupta N, Guo Y, et al. Management and outcomes of acute
	myocardial infarction in patients with chronic kidney disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Int
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2017;227:1–7.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.ijcard.2016.11.026">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27846456">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R455" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Bhatia
	S, Arora S, Bhatia SM, et al. Non-ST-segment-elevation myocardial
	infarction among patients with chronic kidney disease: a propensity
	score-matched comparison of percutaneous coronary intervention
	versus conservative management.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Heart Assoc</font></em><font size="1" style="font-size: 8pt">.
	2018;7:e007920.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R456" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Bangalore
	S, Maron DJ, Fleg JL, et al. International Study of Comparative
	Health Effectiveness with Medical and Invasive Approaches—Chronic
	Kidney Disease (ISCHEMIA-CKD): rationale and design.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2018;205:42–52.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.ahj.2018.07.023">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30172098">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R457" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Collins
	AJ, Foley RN, Gilbertson DT, et al. United States Renal Data System
	public health surveillance of chronic kidney disease and end-stage
	renal disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Kidney
	Int Suppl (2011)</font></em><font size="1" style="font-size: 8pt">.
	2015;5:2–7.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1038/kisup.2015.2">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26097778">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R458" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Coresh
	J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease
	in the United States.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA</font></em><font size="1" style="font-size: 8pt">.
	2007;298:2038–2047.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jama.298.17.2038">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17986697">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">9.</font></p>
<div id="R459" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Fox
	KAA, Clayton TC, Damman P, et al. Long-term outcome of a routine
	versus selective invasive strategy in patients with non-ST-segment
	elevation acute coronary syndrome a meta-analysis of individual
	patient data.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2010;55:2435–2445.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2010.03.007">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20359842">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">10.</font></p>
<div id="R460" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Eagle
	KA, Lim MJ, Dabbous OH, et al. A validated prediction model for all
	forms of acute coronary syndrome: estimating the risk of 6-month
	postdischarge death in an international registry.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA</font></em><font size="1" style="font-size: 8pt">.
	2004;291:2727–2733.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jama.291.22.2727">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15187054">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">11.</font></p>
<div id="R461" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Fox
	CS, Matsushita K, Woodward M, et al. Associations of kidney disease
	measures with mortality and end-stage renal disease in individuals
	with and without diabetes: a meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2012;380:1662–1673.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(12)61350-6">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23013602">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">12.</font></p>
<div id="R462" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Matsushita
	K, van der Velde M, Astor BC, et al. Association of estimated
	glomerular filtration rate and albuminuria with all-cause and
	cardiovascular mortality in general population cohorts: a
	collaborative meta-analysis. Chronic Kidney Disease Prognosis
	Consortium.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2010;375:2073–2081.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(10)60674-5">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20483451">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">13.</font></p>
<div id="R463" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Tsai
	TT, Messenger JC, Brennan JM, et al. Safety and efficacy of
	drug-eluting stents in older patients with chronic kidney disease: a
	report from the linked CathPCI Registry-CMS claims database.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2011;58:1859–1869.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2011.06.056">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22018296">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">14.</font></p>
<div id="R464" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Dehmer
	GJ, Weaver D, Roe MT, et al. A contemporary view of diagnostic
	cardiac catheterization and percutaneous coronary intervention in
	the United States: a report from the CathPCI Registry of the
	National Cardiovascular Data Registry, 2010 through June 2011.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2012;60:2017–2031.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2012.08.966">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23083784">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">15.</font></p>
<div id="R465" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Blicher
	TM, Hommel K, Olesen JB, et al. Less use of standard guideline-based
	treatment of myocardial infarction in patients with chronic kidney
	disease: a Danish nation-wide cohort study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2013;34:2916–2923.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/eurheartj/eht220">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23798578">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">16.</font></p>
<div id="R466" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Han
	JH, Chandra A, Mulgund J, et al. Chronic kidney disease in patients
	with non-ST-segment elevation acute coronary syndromes.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Med</font></em><font size="1" style="font-size: 8pt">.
	2006;119:248–254.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.amjmed.2005.08.057">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16490471">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">17.</font></p>
<div id="R467" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Wong
	JA, Goodman SG, Yan RT, et al. Temporal management patterns and
	outcomes of non-ST elevation acute coronary syndromes in patients
	with kidney dysfunction.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2009;30:549–557.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/eurheartj/ehp014">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19201761">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">18.</font></p>
<div id="R468" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Marenzi
	G, Assanelli E, Campodonico J, et al. Contrast volume during primary
	percutaneous coronary intervention and subsequent contrast-induced
	nephropathy and mortality.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Intern Med</font></em><font size="1" style="font-size: 8pt">.
	2009;150:170–177.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.7326/0003-4819-150-3-200902030-00006">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19189906">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">19.</font></p>
<div id="R469" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Merten
	GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced
	nephropathy with sodium bicarbonate: a randomized controlled
	trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA</font></em><font size="1" style="font-size: 8pt">.
	2004;291:2328–2334.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jama.291.19.2328">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15150204">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">20.</font></p>
<div id="R470" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Mueller
	C, Buerkle G, Buettner HJ, et al. Prevention of contrast
	media-associated nephropathy: randomized comparison of 2 hydration
	regimens in 1620 patients undergoing coronary angioplasty.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Arch
	Intern Med</font></em><font size="1" style="font-size: 8pt">.
	2002;162:329–336.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/archinte.162.3.329">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/11822926">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">21.</font></p>
<div id="R471" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Giacoppo
	D, Gargiulo G, Buccheri S, et al. Preventive strategies for
	contrast-induced acute kidney injury in patients undergoing
	percutaneous coronary procedures: evidence from a hierarchical
	Bayesian network meta-analysis of 124 trials and 28 240
	patients.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2017;10:e004383.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCINTERVENTIONS.116.004383">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28487354">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">22.</font></p>
<div id="R472" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Laskey
	WK, Jenkins C, Selzer F, et al. Volume-to-creatinine clearance
	ratio: a pharmacokinetically based risk factor for prediction of
	early creatinine increase after percutaneous coronary
	intervention.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2007;50:584–590.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2007.03.058">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17692741">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">23.</font></p>
<div id="R473" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">McCullough
	PA, Wolyn R, Rocher LL, et al. Acute renal failure after coronary
	intervention: incidence, risk factors, and relationship to
	mortality.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Med</font></em><font size="1" style="font-size: 8pt">.
	1997;103:368–375.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0002-9343(97)00150-2">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/9375704">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">24.</font></p>
<div id="R474" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Li
	Y, Liu Y, Fu L, et al. Efficacy of short-term high-dose statin in
	preventing contrast-induced nephropathy: a meta-analysis of seven
	randomized controlled trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>PLoS
	One</font></em><font size="1" style="font-size: 8pt">. 2012;7:
	e34450.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1371/journal.pone.0034450">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22511942">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">25.</font></p>
<div id="R475" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Leoncini
	M, Toso A, Maioli M, et al. Early high-dose rosuvastatin and
	cardioprotection in the protective effect of rosuvastatin and
	antiplatelet therapy on contrast-induced acute kidney injury and
	myocardial damage in patients with acute coronary syndrome
	(PRATO-ACS) study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2014;168:792–797.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.ahj.2014.08.005">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25440809">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">26.</font></p>
<div id="R476" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Davignon
	J. Beneficial cardiovascular pleiotropic effects of
	statins.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2004;109:III-39–III-43.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/01.CIR.0000131517.20177.5a">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">27.</font></p>
<div id="R477" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Ichiki
	T, Takeda K, Tokunou T, et al. Downregulation of angiotensin II type
	1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A
	reductase inhibitors in vascular smooth muscle cells.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Arterioscler
	Thromb Vasc Biol</font></em><font size="1" style="font-size: 8pt">.
	2001;21:1896–1901.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/hq1201.099430">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/11742861">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">28.</font></p>
<div id="R478" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Hernández-Perera
	O, Pérez-Sala D, Navarro-Antolín J, et al. Effects of the
	3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin
	and simvastatin, on the expression of endothelin-1 and endothelial
	nitric oxide synthase in vascular endothelial cells.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Clin Invest</font></em><font size="1" style="font-size: 8pt">.
	1998;101:2711–2719.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1172/JCI1500">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/9637705">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">29.</font></p>
<div id="R479" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Bonetti
	PO, Lerman LO, Napoli C, et al. Statin effects beyond lipid
	lowering—are they clinically relevant?&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2003;24:225–248.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0195-668X(02)00419-0">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12590901">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">30.</font></p>
<div id="R480" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Stratta
	P, Bozzola C, Quaglia M. Pitfall in nephrology: contrast nephropathy
	has to be differentiated from renal damage due to atheroembolic
	disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Nephrol</font></em><font size="1" style="font-size: 8pt">.
	2012;25:282–289.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.5301/jn.5000093">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22419233">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">31.</font></p>
<div id="R481" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Cortese
	B, Sciahbasi A, Sebik R, et al. Comparison of risk of acute kidney
	injury after primary percutaneous coronary interventions with the
	transradial approach versus the transfemoral approach (from the
	PRIPITENA urban registry).&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2014;114:820–825.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.amjcard.2014.06.010">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25073568">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">32.</font></p>
<div id="R482" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Andò
	G, Cortese B, Russo F, et al. Acute kidney injury after radial or
	femoral access for invasive acute coronary syndrome management:
	AKI-MATRIX.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2017;69:2592–2603.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2017.02.070">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">33.</font></p>
<div id="R483" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kooiman
	J, Seth M, Dixon S, et al. Risk of acute kidney injury after
	percutaneous coronary interventions using radial versus femoral
	vascular access: insights from the Blue Cross Blue Shield of
	Michigan Cardiovascular Consortium.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2014;7:190–198.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCINTERVENTIONS.113.000778">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24569598">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">34.</font></p>
<div id="R484" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Keeley
	EC, Boura JA, Grines CL. Primary angioplasty versus intravenous
	thrombolytic therapy for acute myocardial infarction: a quantitative
	review of 23 randomised trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2003;361:13–20.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(03)12113-7">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12517460">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">35.</font></p>
<div id="R485" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Santopinto
	JJ, Fox KA, Goldberg RJ, et al. Creatinine clearance and adverse
	hospital outcomes in patients with acute coronary syndromes:
	findings from the global registry of acute coronary events
	(GRACE).&nbsp;</font><font size="1" style="font-size: 8pt"><em>Heart</font></em><font size="1" style="font-size: 8pt">.
	2003;89:1003–1008.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1136/heart.89.9.1003">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12923009">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">36.</font></p>
<div id="R486" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Januzzi
	JL, Cannon CP, DiBattiste PM, et al. Effects of renal insufficiency
	on early invasive management in patients with acute coronary
	syndromes (The TACTICS-TIMI 18 Trial).&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2002;90:1246–1249.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0002-9149(02)02844-8">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12450608">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">37.</font></p>
<div id="R487" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Gibson
	CM, Dumaine RL, Gelfand EV, et al. Association of glomerular
	filtration rate on presentation with subsequent mortality in
	non-ST-segment elevation acute coronary syndrome; observations in 13
	307 patients in five TIMI trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2004;25:1998–2005.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.ehj.2004.08.016">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15541835">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">38.</font></p>
<div id="R488" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">ACT
	Investigators. Acetylcysteine for prevention of renal outcomes in
	patients undergoing coronary and peripheral vascular angiography:
	main results from the randomized Acetylcysteine for Contrast-induced
	nephropathy Trial (ACT).&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2011;124:1250–1259.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circulationaha.111.038943">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21859972">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">39.</font></p>
<div id="R489" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Thiele
	H, Hildebrand L, Schirdewahn C, et al. Impact of high-dose
	N-acetylcysteine versus placebo on contrast-induced nephropathy and
	myocardial reperfusion injury in unselected patients with ST-segment
	elevation myocardial infarction undergoing primary percutaneous
	coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind,
	Placebo-Controlled, Randomized Leipzig Immediate PercutaneouS
	Coronary Intervention Acute Myocardial Infarction N-ACC) Trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2010;55:2201–2209.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2009.08.091">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20466200">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">40.</font></p>
<div id="R490" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Gonzales
	DA, Norsworthy KJ, Kern SJ, et al. A meta-analysis of
	N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised
	clustering to resolve heterogeneity.&nbsp;</font><font size="1" style="font-size: 8pt"><em>BMC
	Med</font></em><font size="1" style="font-size: 8pt">.
	2007;5:32.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1186/1741-7015-5-32">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18001477">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">41.</font></p>
<div id="R491" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Vogt
	B, Ferrari P, Schönholzer C, et al. Prophylactic hemodialysis after
	radiocontrast media in patients with renal insufficiency is
	potentially harmful.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Med</font></em><font size="1" style="font-size: 8pt">.
	2001;111:692–698.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0002-9343(01)00983-4">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/11747848">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">42.</font></p>
<div id="R492" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Cruz
	DN, Goh CY, Marenzi G, et al. Renal replacement therapies for
	prevention of radiocontrast-induced nephropathy: a systematic
	review.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am J
	Med</font></em><font size="1" style="font-size: 8pt">.
	2012;125:66–78.e3.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.amjmed.2011.06.029">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22195531">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">43.</font></p>
<div id="R493" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Warren
	J, Mehran R, Baber U, et al. Incidence and impact of acute kidney
	injury in patients with acute coronary syndromes treated with
	coronary artery bypass grafting: insights from the Harmonizing
	Outcomes With Revascularization and Stents in Acute Myocardial
	Infarction (HORIZONS-AMI) and Acute Catheterization and Urgent
	Intervention Triage Strategy (ACUITY) trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2016;171:40–47.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.ahj.2015.07.001">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26699599">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">44.</font></p>
<div id="R494" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Mehta
	RH, Honeycutt E, Patel UD, et al. Relationship of the time interval
	between cardiac catheterization and elective coronary artery bypass
	surgery with postprocedural acute kidney injury.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2011;124:S149–S155.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCULATIONAHA.110.011700">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21911805">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">45.</span></font></p>
<div id="R495" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Mariscalco
	G, Banach M. Editorial: atrial fibrillation after coronary surgery:
	the need for an effective pharmacological prophylaxis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Curr
	Vasc Pharmacol</font></em><font size="1" style="font-size: 8pt">.
	2013;11:985–987.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.2174/157016111106140128122637">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24484466">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>9.4.
Revascularization in Patients Before Noncardiac Surgery</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R496" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">McFalls
	EO, Ward HB, Moritz TE, et al. Coronary-artery revascularization
	before elective major vascular surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2004;351:2795–2804.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa041905">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15625331">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R497" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Smilowitz
	NR, Guo Y, Rao S, et al. Perioperative cardiovascular outcomes of
	non-cardiac solid organ transplant surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J Qual Care Clin Outcomes</font></em><font size="1" style="font-size: 8pt">.
	2019;5:72–78.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/ehjqcco/qcy028">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29961872">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">3.</span></font></p>
<div id="R498" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Garcia
	S, Moritz TE, Ward HB, et al. Usefulness of revascularization of
	patients with multivessel coronary artery disease before elective
	vascular surgery for abdominal aortic and peripheral occlusive
	disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am J
	Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2008;102:809–813.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.amjcard.2008.05.022">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18805102">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>9.5.
Revascularization in Patients to Reduce Ventricular Arrhythmias</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R499" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Cook
	JR, Rizo-Patron C, Curtis AB, et al. Effect of surgical
	revascularization in patients with coronary artery disease and
	ventricular tachycardia or fibrillation in the Antiarrhythmics
	Versus Implantable Defibrillators (AVID) Registry.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2002;143:821–826.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1067/mhj.2002.121732">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12040343">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R500" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Dumas
	F, Cariou A, Manzo-Silberman S, et al. Immediate percutaneous
	coronary intervention is associated with better survival after
	out-of-hospital cardiac arrest: insights from the PROCAT (Parisian
	Region Out of hospital Cardiac ArresT) registry.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2010;3:200–207.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCINTERVENTIONS.109.913665">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20484098">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R501" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Every
	NR, Fahrenbruch CE, Hallstrom AP, et al. Influence of coronary
	bypass surgery on subsequent outcome of patients resuscitated from
	out of hospital cardiac arrest.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	1992;19:1435–1439.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/0735-1097(92)90599-I">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/1593036">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R502" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Dumas
	F, Bougouin W, Geri G, et al. Emergency percutaneous coronary
	intervention in post-cardiac arrest patients without ST-segment
	elevation pattern: insights from the PROCAT II Registry.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2016;9:1011–1018.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jcin.2016.02.001">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27131438">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R503" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Brugada
	J, Aguinaga L, Mont L, et al. Coronary artery revascularization in
	patients with sustained ventricular arrhythmias in the chronic phase
	of a myocardial infarction: effects on the electrophysiologic
	substrate and outcome.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2001;37:529–533.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0735-1097(00)01133-5">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/11216974">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R504" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Chiriac
	L, Dumitrescu S, Samoilă M, et al. Evaluation at patients with
	ventricular arrhythmias and coronary artery disease of myocardial
	revascularization effects.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Rom
	J Intern Med</font></em><font size="1" style="font-size: 8pt">.
	2010;48:47–50.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21180240">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R505" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Mondésert
	B, Khairy P, Schram G, et al. Impact of revascularization in
	patients with sustained ventricular arrhythmias, prior myocardial
	infarction, and preserved left ventricular ejection fraction.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Heart
	Rhythm</font></em><font size="1" style="font-size: 8pt">.
	2016;13:1221–1227.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.hrthm.2016.01.019">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26806581">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R506" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Elsokkari
	I, Parkash R, Gray CJ, et al. Effect of coronary revascularization
	on long-term clinical outcomes in patients with ischemic
	cardiomyopathy and recurrent ventricular arrhythmia.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Pacing
	Clin Electrophysiol</font></em><font size="1" style="font-size: 8pt">.
	2018;41:775–779.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1111/pace.13375">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29750365">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">9.</font></p>
<div id="R507" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Chi
	WK, Gong M, Bazoukis G, et al. Impact of coronary artery chronic
	total occlusion on arrhythmic and mortality outcomes: a systematic
	review and meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Clin Electrophysiol</font></em><font size="1" style="font-size: 8pt">.
	2018;4:1214–1223.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacep.2018.06.011">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30236396">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">10.</font></p>
<div id="R508" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Cronier
	P, Vignon P, Bouferrache K, et al. Impact of routine percutaneous
	coronary intervention after out-of-hospital cardiac arrest due to
	ventricular fibrillation.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Crit
	Care (London, England)</font></em><font size="1" style="font-size: 8pt">.
	2011;15:R122.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1186/cc10227">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21569361">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">11.</font></p>
<div id="R509" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Spaulding
	CM, Joly LM, Rosenberg A, et al. Immediate coronary angiography in
	survivors of out-of-hospital cardiac arrest.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	1997;336:1629–1633.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJM199706053362302">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/9171064">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">12.</font></p>
<div id="R510" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Al-Khatib
	SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for
	management of patients with ventricular arrhythmias and the
	prevention of sudden cardiac death: a report of the American College
	of Cardiology/American Heart Association Task Force on Clinical
	Practice Guidelines and the Heart Rhythm Society.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2018;138:e272–e391.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0000000000000549">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29084731">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">13.</font></p>
<div id="R511" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Ngaage
	DL, Cale AR, Cowen ME, et al. Early and late survival after surgical
	revascularization for ischemic ventricular
	fibrillation/tachycardia.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2008;85:1278–1281.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.athoracsur.2007.12.035">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18355509">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">14.</font></p>
<div id="R512" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Zanuttini
	D, Armellini I, Nucifora G, et al. Impact of emergency coronary
	angiography on in-hospital outcome of unconscious survivors after
	out-of-hospital cardiac arrest.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2012;110:1723–1728.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.amjcard.2012.08.006">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22975468">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">15.</font></p>
<div id="R513" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kalarus
	Z, Svendsen JH, Capodanno D, et al. Cardiac arrhythmias in the
	emergency settings of acute coronary syndrome and revascularization:
	an European Heart Rhythm Association (EHRA) consensus
	document.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Europace</font></em><font size="1" style="font-size: 8pt">.
	2019;21:1603–1604.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/europace/euz163">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31353412">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">16.</font></p>
<div id="R514" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Milojevic
	M, Head SJ, Parasca CA, et al. Causes of death following PCI versus
	CABG in complex CAD: 5-year follow-up of SYNTAX.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2016;67:42–55.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2015.10.043">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26764065">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">17.</font></p>
<div id="R515" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Velazquez
	EJ, Lee KL, Jones RH, et al. Coronary-artery bypass surgery in
	patients with ischemic cardiomyopathy.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2016;374:1511–1520.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1602001">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27040723">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">18.</font></p>
<div id="R516" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Carson
	P, Wertheimer J, Miller A, et al. The STICH trial (Surgical
	Treatment for Ischemic Heart Failure): mode-of-death results.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Heart Fail</font></em><font size="1" style="font-size: 8pt">.
	2013;1:400–408.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jchf.2013.04.012">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24621972">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">19.</font></p>
<div id="R517" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Berntsen
	RF, Gunnes P, Lie M, et al. Surgical revascularization in the
	treatment of ventricular tachycardia and fibrillation exposed by
	exercise-induced ischaemia.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	1993;14:1297–1303.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/eurheartj/14.10.1297">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/8262074">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">20.</font></p>
<div id="R518" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Andersen
	JA, Freeman P, Larsen JM, et al. Monomorphic ventricular tachycardia
	as the primary presentation of an anterior STEMI.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Clin
	Case Rep</font></em><font size="1" style="font-size: 8pt">.
	2019;7:1680–1684.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1002/ccr3.2324">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31534726">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">21.</font></p>
<div id="R519" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Marrakchi
	S, Laroussi L, Bennour E, et al. Coronary PCI revascularization
	novel treatment of bundle branch reentrant ventricular
	tachycardia.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Cardiol Cases</font></em><font size="1" style="font-size: 8pt">.
	2019;20:151–154.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jccase.2019.08.003">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31719932">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">22.</font></p>
<div id="R520" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Mathes
	P. The effect of coronary revascularization on exercise-induced
	ventricular arrhythmias.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	1987;8(SupplD):79–81.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/eurheartj/8.suppl_D.79">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/3500046">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">23.</span></font></p>
<div id="R521" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Raja
	V, Wiegn P, Obel O, et al. Impact of chronic total occlusions and
	coronary revascularization on all-cause mortality and the incidence
	of ventricular arrhythmias in patients with ischemic
	cardiomyopathy.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2015;116:1358–1362.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.amjcard.2015.07.057">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26341182">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>9.6.
Revascularization in Patients With SCAD</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R522" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Jamil
	A, Tajrishi FZ, Kahe F, et al. Spontaneous coronary artery
	dissection managed with a conservative or revascularization
	approach: a meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Cardiovasc Med</font></em><font size="1" style="font-size: 8pt">.
	2020;21:42–50.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.2459/JCM.0000000000000891">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R523" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Lettieri
	C, Zavalloni D, Rossini R, et al. Management and long-term prognosis
	of spontaneous coronary artery dissection.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2015;116:66–73.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.amjcard.2015.03.039">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25937347">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R524" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Lobo
	AS, Cantu SM, Sharkey SW, et al. Revascularization in patients with
	spontaneous coronary artery dissection and ST-segment elevation
	myocardial infarction.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2019;74:1290–1300.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2019.06.065">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31488265">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R525" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Martins
	JL, Afreixo V, Santos L, et al. Medical treatment or
	revascularisation as the best approach for spontaneous coronary
	artery dissection: a systematic review and meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J Acute Cardiovasc Care</font></em><font size="1" style="font-size: 8pt">.
	2018;7:614–623.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1177/2048872617706502">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28452228">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R526" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Tweet
	MS, Eleid MF, Best PJ, et al. Spontaneous coronary artery
	dissection: revascularization versus conservative therapy.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2014;7:777–786.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCINTERVENTIONS.114.001659">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25406203">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R527" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Hayes
	SN, Kim ESH, Saw J, et al. Spontaneous coronary artery dissection:
	current state of the science: a scientific statement from the
	American Heart Association.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2018;137:e523–e557.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0000000000000564">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29472380">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">7.</span></font></p>
<div id="R528" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Saw
	J, Aymong E, Sedlak T, et al. Spontaneous coronary artery
	dissection: association with predisposing arteriopathies and
	precipitating stressors and cardiovascular outcomes.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2014;7:645–655.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circinterventions.114.001760">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25294399">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>9.7.
Revascularization in Patients With Cardiac Allografts</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R529" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Lee
	MS, Lluri G, Finch W, et al. Role of percutaneous coronary
	intervention in the treatment of cardiac allograft vasculopathy.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2018;121:1051–1055.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.amjcard.2018.01.025">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29598855">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R530" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Luc
	JGY, Choi JH, Rizvi SA, et al. Percutaneous coronary intervention
	versus coronary artery bypass grafting in heart transplant
	recipients with coronary allograft vasculopathy: a systematic review
	and meta-analysis of 1,520 patients.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Cardiothorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2018;7:19–30.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.21037/acs.2018.01.10">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29492381">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R531" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Taylor
	DO, Stehlik J, Edwards LB, et al. Registry of the International
	Society for Heart and Lung Transplantation: Twenty-sixth Official
	Adult Heart Transplant Report-2009.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Heart Lung Transplant</font></em><font size="1" style="font-size: 8pt">.
	2009;28:1007–1022.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.healun.2009.08.014">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19782283">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R532" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Dasari
	TW, Hennebry TA, Hanna EB, et al. Drug eluting versus bare metal
	stents in cardiac allograft vasculopathy: a systematic review of
	literature.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Catheter
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2011;77:962–969.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1002/ccd.22975">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21413135">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R533" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Gao
	SZ, Hunt SA, Schroeder JS, et al. Does rapidity of development of
	transplant coronary artery disease portend a worse prognosis?&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Heart Lung Transplant</font></em><font size="1" style="font-size: 8pt">.
	1994;13:1119–1124.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/7865519">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R534" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Agarwal
	S, Parashar A, Kapadia SR, et al. Long-term mortality after cardiac
	allograft vasculopathy: implications of percutaneous
	intervention.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Heart Fail</font></em><font size="1" style="font-size: 8pt">.
	2014;2:281–288.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jchf.2014.01.003">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24952696">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R535" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Johnson
	DE, Alderman EL, Schroeder JS, et al. Transplant coronary artery
	disease: histopathologic correlations with angiographic
	morphology.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	1991;17:449–457.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0735-1097(10)80114-7">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/1991903">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R536" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Raichlin
	ER, McConnell JP, Lerman A, et al. Systemic inflammation and
	metabolic syndrome in cardiac allograft vasculopathy.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Heart Lung Transplant</font></em><font size="1" style="font-size: 8pt">.
	2007;26:826–833.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.healun.2007.05.008">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17692787">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">9.</font></p>
<div id="R537" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Colombo
	P, Bruschi G, Sacco A, et al. Percutaneous coronary interventions in
	cardiac allograft vasculopathy: a single-center
	experience.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Transplant
	Proc</font></em><font size="1" style="font-size: 8pt">.
	2010;42:1286–1290.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.transproceed.2010.03.065">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20534283">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">10.</font></p>
<div id="R538" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Serruys
	PW, Morice MC, Kappetein AP, et al. Percutaneous coronary
	intervention versus coronary-artery bypass grafting for severe
	coronary artery disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2009;360:961–972.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa0804626">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19228612">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">11.</font></p>
<div id="R539" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kobashigawa
	J. What is the optimal prophylaxis for treatment of cardiac
	allograft vasculopathy?&nbsp;</font><font size="1" style="font-size: 8pt"><em>Curr
	Control Trials Cardiovasc Med</font></em><font size="1" style="font-size: 8pt">.
	2000;1:166–171.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1186/CVM-1-3-166">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/11714434">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">12.</font></p>
<div id="R540" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Srivastava
	R, Keck BM, Bennett LE, et al. The results of cardiac
	retransplantation: an analysis of the Joint International Society
	for Heart and Lung Transplantation/United Network for Organ Sharing
	Thoracic Registry.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Transplantation</font></em><font size="1" style="font-size: 8pt">.
	2000;70:606–612.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1097/00007890-200008270-00013">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/10972218">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">13.</font></p>
<div id="R541" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Schmauss
	D, Weis M. Cardiac allograft vasculopathy: recent
	developments.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2008;117:2131–2141.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circulationaha.107.711911">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18427143">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">14.</font></p>
<div id="R542" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Jonas
	M, Fang JC, Wang JC, et al. In-stent restenosis and remote coronary
	lesion progression are coupled in cardiac transplant vasculopathy
	but not in native coronary artery disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2006;48:453–461.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2006.01.081">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16875968">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">15.</font></p>
<div id="R543" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Tremmel
	JA, Ng MK, Ikeno F, et al. Comparison of drug-eluting versus bare
	metal stents in cardiac allograft vasculopathy.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2011;108:665–668.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.amjcard.2011.04.014">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21684511">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">16.</span></font></p>
<div id="R544" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Lee
	MS, Kobashigawa J, Tobis J. Comparison of percutaneous coronary
	intervention with bare-metal and drug-eluting stents for cardiac
	allograft vasculopathy.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2008;1:710–715.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jcin.2008.10.001">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19463388">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>9.8.
Revascularization in Patients Before Transcatheter Aortic Valve
Replacement (TAVR)</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">1.</span></font></p>
<div id="R545" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Otto
	CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the
	management of patients with valvular heart disease: a report of the
	American College of Cardiology/American Heart Association Joint
	Committee on Clinical Practice Guidelines.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2021;143:e72–e227.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0000000000000923">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/33332150">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>9.9.
Revascularization in Patients With Anomalous Coronary Artery</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R546" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Angelini
	P. Coronary artery anomalies: an entity in search of an
	identity.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2007;115:1296–1305.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circulationaha.106.618082">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17353457">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R547" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Cheezum
	MK, Liberthson RR, Shah NR, et al. Anomalous aortic origin of a
	coronary artery from the inappropriate sinus of valsalva.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2017;69:1592–1608.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2017.01.031">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28335843">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">3.</span></font></p>
<div id="R548" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Stout
	KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC guideline for the
	management of adults with congenital heart disease: a report of the
	American College of Cardiology/American Heart Association Task Force
	on Clinical Practice Guidelines.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2019;139:e698–e800.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0000000000000603">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30586767">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>10.1.
Radial and Femoral Approaches for PCI</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R549" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Romagnoli
	E, Biondi-Zoccai G, Sciahbasi A, et al. Radial versus femoral
	randomized investigation in ST-segment elevation acute coronary
	syndrome: the RIFLE-STEACS (Radial Versus Femoral Randomized
	Investigation in ST-Elevation Acute Coronary Syndrome) study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2012;60:2481–2489.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2012.06.017">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22858390">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R550" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Valgimigli
	M, Gagnor A, Calabró P, et al. Radial versus femoral access in
	patients with acute coronary syndromes undergoing invasive
	management: a randomised multicentre trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2015;385:2465–2476.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(15)60292-6">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25791214">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R551" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Andò
	G, Capodanno D. Radial versus femoral access in invasively managed
	patients with acute coronary syndrome: a systematic review and
	meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Intern Med</font></em><font size="1" style="font-size: 8pt">.
	2015;163:932–940.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.7326/M15-1277">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26551857">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R552" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Ferrante
	G, Rao SV, Jüni P, et al. Radial versus femoral access for coronary
	interventions across the entire spectrum of patients with coronary
	artery disease: a meta-analysis of randomized trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2016;9:1419–1434.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jcin.2016.04.014">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27372195">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R553" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Feldman
	DN, Swaminathan RV, Kaltenbach LA, et al. Adoption of radial access
	and comparison of outcomes to femoral access in percutaneous
	coronary intervention: an updated report from the national
	cardiovascular data registry (2007-2012).&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2013;127:2295–2306.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCULATIONAHA.112.000536">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23753843">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R554" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Louvard
	Y, Benamer H, Garot P, et al. Comparison of transradial and
	transfemoral approaches for coronary angiography and angioplasty in
	octogenarians (the OCTOPLUS study).&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2004;94:1177–1180.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.amjcard.2004.07.089">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15518616">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R555" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Santas
	E, Bodi V, Sanchis J, et al. The left radial approach in daily
	practice. A randomized study comparing femoral and right and left
	radial approaches.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Rev
	Esp Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2009;62:482–490.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0300-8932(09)71028-0">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19406062">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R556" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Masoudi
	FA, Ponirakis A, de Lemos JA, et al. Trends in US cardiovascular
	care: 2016 report from 4 ACC national cardiovascular data
	registries.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2017;69:1427–1450.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2016.12.005">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28025065">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">9.</font></p>
<div id="R557" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Jolly
	SS, Yusuf S, Cairns J, et al. Radial versus femoral access for
	coronary angiography and intervention in patients with acute
	coronary syndromes (RIVAL): a randomised, parallel group,
	multicentre trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2011;377:1409–1420.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(11)60404-2">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21470671">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">10.</span></font></p>
<div id="R558" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Le
	May M, Wells G, So D, et al. Safety and efficacy of femoral access
	vs radial access in ST-segment elevation myocardial infarction: the
	SAFARI-STEMI randomized clinical trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA
	Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2020;5:126–134.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jamacardio.2019.4852">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31895439">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>10.2.
Choice of Stent Type</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R559" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Piccolo
	R, Bonaa KH, Efthimiou O, et al. Drug-eluting or bare-metal stents
	for percutaneous coronary intervention: a systematic review and
	individual patient data meta-analysis of randomised clinical
	trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2019;393:2503–2510.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(19)30474-X">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31056295">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R560" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Palmerini
	T, Benedetto U, Biondi-Zoccai G, et al. Long-term safety of
	drug-eluting and bare-metal stents: evidence from a comprehensive
	network meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2015;65:2496–2507.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2015.04.017">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26065988">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R561" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kang
	SH, Park KW, Kang DY, et al. Biodegradable-polymer drug-eluting
	stents vs. bare metal stents vs. durable-polymer drug-eluting
	stents: a systematic review and Bayesian approach network
	meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2014;35:1147–1158.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/eurheartj/eht570">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24459196">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R562" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Bangalore
	S, Toklu B, Amoroso N, et al. Bare metal stents, durable polymer
	drug eluting stents, and biodegradable polymer drug eluting stents
	for coronary artery disease: mixed treatment comparison
	meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>BMJ</font></em><font size="1" style="font-size: 8pt">.
	2013;347:f6625.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1136/bmj.f6625">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24212107">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R563" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Bavry
	AA, Kumbhani DJ, Helton TJ, et al. Late thrombosis of drug-eluting
	stents: a meta-analysis of randomized clinical trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Med</font></em><font size="1" style="font-size: 8pt">.
	2006;119:1056–1061.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.amjmed.2006.01.023">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17145250">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R564" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Lagerqvist
	B, James SK, Stenestrand U, et al. Long-term outcomes with
	drug-eluting stents versus bare-metal stents in Sweden.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2007;356:1009–1019.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa067722">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17296822">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R565" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Ong
	AT, McFadden EP, Regar E, et al. Late angiographic stent thrombosis
	(LAST) events with drug-eluting stents.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2005;45:2088–2092.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2005.02.086">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15963413">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">8.</span></font></p>
<div id="R566" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Nordmann
	AJ, Briel M, Bucher HC. Mortality in randomized controlled trials
	comparing drug-eluting vs. bare metal stents in coronary artery
	disease: a meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2006;27:2784–2814.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/eurheartj/ehl282">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17020889">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>10.3.
Use of Intravascular Imaging</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R567" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Bavishi
	C, Sardar P, Chatterjee S, et al. Intravascular ultrasound-guided vs
	angiography-guided drug-eluting stent implantation in complex
	coronary lesions: Meta-analysis of randomized trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2017;185:26–34.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.ahj.2016.10.008">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28267472">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R568" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Buccheri
	S, Franchina G, Romano S, et al. Clinical outcomes following
	intravascular imaging-guided versus coronary angiography-guided
	percutaneous coronary intervention with stent implantation: a
	systematic review and Bayesian network meta-analysis of 31 studies
	and 17 882 patients.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2017;10:2488–2498.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jcin.2017.08.051">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29153502">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R569" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Elgendy
	IY, Mahmoud AN, Elgendy AY, et al. Outcomes with intravascular
	ultrasound-guided stent implantation: a meta-analysis of randomized
	trials in the era of drug-eluting stents.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2016;9:e003700.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circinterventions.116.003700">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26980883">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R570" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Hong
	S-J, Kim B-K, Shin D-H, et al. Effect of intravascular
	ultrasound-guided vs angiography-guided everolimus-eluting stent
	implantation: the IVUS-XPL randomized clinical trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA</font></em><font size="1" style="font-size: 8pt">.
	2015;314:2155–2163.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jama.2015.15454">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26556051">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R571" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Ladwiniec
	A, Walsh SJ, Holm NR, et al. Intravascular ultrasound to guide left
	main stem intervention: a NOBLE trial substudy.&nbsp;</font><font size="1" style="font-size: 8pt"><em>EuroIntervention</font></em><font size="1" style="font-size: 8pt">.
	2020;16:201–209.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.4244/EIJ-D-19-01003">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/32122821">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R572" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Zhang
	J, Gao X, Kan J, et al. Intravascular ultrasound versus
	angiography-guided drug-eluting stent implantation: the ULTIMATE
	trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J Am
	Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2018;72:3126–3137.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2018.09.013">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30261237">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R573" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Andell
	P, Karlsson S, Mohammad MA, et al. Intravascular ultrasound guidance
	is associated with better outcome in patients undergoing unprotected
	left main coronary artery stenting compared with angiography
	guidance alone.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2017;10:e004813.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circinterventions.116.004813">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28487356">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R574" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kim
	B-K, Shin D-H, Hong M-K, et al. Clinical impact of intravascular
	ultrasound-guided chronic total occlusion intervention with
	zotarolimus-eluting versus biolimus-eluting stent implantation:
	randomized study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2015;8:e002592.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCINTERVENTIONS.115.002592">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26156151">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">9.</font></p>
<div id="R575" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Witzenbichler
	B, Maehara A, Weisz G, et al. Relationship between intravascular
	ultrasound guidance and clinical outcomes after drug-eluting stents:
	the assessment of dual antiplatelet therapy with drug-eluting stents
	(ADAPT-DES) study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2014;129:463–470.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circulationaha.113.003942">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24281330">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">10.</font></p>
<div id="R576" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Gao
	X-F, Ge Z, Kong X-Q, et al. 3-year outcomes of the ULTIMATE trial
	comparing intravascular ultrasound versus angiography-guided
	drug-eluting stent implantation.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2021;14:247–257.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jcin.2020.10.001">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/33541535">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">11.</font></p>
<div id="R577" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Ali
	ZA, Maehara A, Généreux P, et al. Optical coherence tomography
	compared with intravascular ultrasound and with angiography to guide
	coronary stent implantation (ILUMIEN III: OPTIMIZE PCI): a
	randomised controlled trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2016;388:2618–2628.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(16)31922-5">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27806900">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">12.</font></p>
<div id="R578" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Meneveau
	N, Souteyrand G, Motreff P, et al. Optical coherence tomography to
	optimize results of percutaneous coronary intervention in patients
	with non-ST-elevation acute coronary syndrome: results of the
	multicenter, randomized DOCTORS study (Does Optical Coherence
	Tomography Optimize Results of Stenting).&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2016;134:906–917.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circulationaha.116.024393">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27573032">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">13.</font></p>
<div id="R579" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Antonsen
	L, Thayssen P, Maehara A, et al. Optical coherence tomography guided
	percutaneous coronary intervention with nobori stent implantation in
	patients with non-ST-segment-elevation myocardial infarction
	(OCTACS) trial: difference in strut coverage and dynamic
	malapposition patterns at 6 months.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2015;8:e002446.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCINTERVENTIONS.114.002446">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26253735">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">14.</font></p>
<div id="R580" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Dangas
	GD, Claessen BE, Caixeta A, et al. In-stent restenosis in the
	drug-eluting stent era.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2010;56:1897–1907.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2010.07.028">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21109112">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">15.</font></p>
<div id="R581" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Fujii
	K, Mintz GS, Kobayashi Y, et al. Contribution of stent
	underexpansion to recurrence after sirolimus-eluting stent
	implantation for in-stent restenosis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2004;109:1085–1088.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/01.cir.0000121327.67756.19">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/14993129">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">16.</font></p>
<div id="R582" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Choi
	S-Y, Witzenbichler B, Maehara A, et al. Intravascular ultrasound
	findings of early stent thrombosis after primary percutaneous
	intervention in acute myocardial infarction: a Harmonizing Outcomes
	with Revascularization and Stents in Acute Myocardial Infarction
	(HORIZONS-AMI) substudy.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2011;4:239–247.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circinterventions.110.959791">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21586693">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">17.</font></p>
<div id="R583" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Souteyrand
	G, Amabile N, Mangin L, et al. Mechanisms of stent thrombosis
	analysed by optical coherence tomography: insights from the national
	PESTO French registry.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2016;37:1208–1216.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/eurheartj/ehv711">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26757787">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">18.</font></p>
<div id="R584" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Steinberg
	DH, Mintz GS, Mandinov L, et al. Long-term impact of routinely
	detected early and late incomplete stent apposition: an integrated
	intravascular ultrasound analysis of the TAXUS IV, V, and VI and
	TAXUS ATLAS workhorse, long lesion, and direct stent studies.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2010;3:486–494.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jcin.2010.03.007">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20488404">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">19.</font></p>
<div id="R585" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kobayashi
	N, Mintz GS, Witzenbichler B, et al. Prevalence, features, and
	prognostic importance of edge dissection after drug-eluting stent
	implantation: an ADAPT-DES intravascular ultrasound substudy.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2016;9:e003553.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCINTERVENTIONS.115.003553">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27402854">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">20.</font></p>
<div id="R586" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Maehara
	A, Matsumura M, Ali ZA, et al. IVUS-guided versus OCT-guided
	coronary stent implantation: a critical appraisal.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Cardiovasc Imaging</font></em><font size="1" style="font-size: 8pt">.
	2017;10:1487–1503.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jcmg.2017.09.008">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29216976">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">21.</font></p>
<div id="R587" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Zhang
	Y-J, Pang S, Chen X-Y, et al. Comparison of intravascular ultrasound
	guided versus angiography guided drug eluting stent implantation: a
	systematic review and meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>BMC
	Cardiovasc Disord</font></em><font size="1" style="font-size: 8pt">.
	2015;15:153.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1186/s12872-015-0144-8">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26577590">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">22.</font></p>
<div id="R588" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Nerlekar
	N, Cheshire CJ, Verma KP, et al. Intravascular ultrasound guidance
	improves clinical outcomes during implantation of both first- and
	second-generation drug-eluting stents: a
	meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>EuroIntervention</font></em><font size="1" style="font-size: 8pt">.
	2017;12:1632–1642.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.4244/EIJ-D-16-00769">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27840327">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">23.</font></p>
<div id="R589" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Ahn
	J-M, Kang S-J, Yoon S-H, et al. Meta-analysis of outcomes after
	intravascular ultrasound-guided versus angiography-guided
	drug-eluting stent implantation in 26 503 patients enrolled in three
	randomized trials and 14 observational studies.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2014;113:1338–1347.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.amjcard.2013.12.043">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24685326">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">24.</font></p>
<div id="R590" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kubo
	T, Shinke T, Okamura T, et al. Optical frequency domain imaging vs.
	intravascular ultrasound in percutaneous coronary intervention
	(OPINION trial): one-year angiographic and clinical results.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2017;38:3139–3147.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/eurheartj/ehx351">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29121226">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">25.</font></p>
<div id="R591" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Prati
	F, Romagnoli E, Burzotta F, et al. Clinical impact of OCT findings
	during PCI: the CLI-OPCI II study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Cardiovasc Imaging</font></em><font size="1" style="font-size: 8pt">.
	2015;8:1297–1305.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jcmg.2015.08.013">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26563859">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">26.</font></p>
<div id="R592" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Soeda
	T, Uemura S, Park S-J, et al. Incidence and clinical significance of
	poststent optical coherence tomography findings: one-year follow-up
	study from a multicenter registry.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2015;132:1020–1029.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circulationaha.114.014704">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26162917">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">27.</font></p>
<div id="R593" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Holmes
	DR, Kereiakes DJ, Garg S, et al. Stent thrombosis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2010;56:1357–1365.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2010.07.016">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20946992">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">28.</font></p>
<div id="R594" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Malle
	C, Tada T, Steigerwald K, et al. Tissue characterization after
	drug-eluting stent implantation using optical coherence
	tomography.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Arterioscler
	Thromb Vasc Biol</font></em><font size="1" style="font-size: 8pt">.
	2013;33:1376–1383.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/atvbaha.113.301227">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23539216">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">29.</font></p>
<div id="R595" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Hassan
	AKM, Bergheanu SC, Stijnen T, et al. Late stent malapposition risk
	is higher after drug-eluting stent compared with bare-metal stent
	implantation and associates with late stent thrombosis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2010;31:1172–1180.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/eurheartj/ehn553">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19158118">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">30.</font></p>
<div id="R596" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Alfonso
	F, Sandoval J, Cárdenas A, et al. Optical coherence tomography:
	from research to clinical application.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Minerva
	Med</font></em><font size="1" style="font-size: 8pt">.
	2012;103:441–464.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23229366">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">31.</span></font></p>
<div id="R597" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Moses
	JW, Dangas G, Mehran R, et al. Drug-eluting stents in the real
	world: how intravascular ultrasound can improve clinical outcome.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2008;102(9suppl):24J–28J.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.amjcard.2008.09.006">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18928789">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>10.4.
Thrombectomy</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R598" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Fröbert
	O, Lagerqvist B, Olivecrona GK, et al. Thrombus aspiration during
	ST-segment elevation myocardial infarction.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2013;369:1587–1597.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1308789">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23991656">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R599" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Jolly
	SS, Cairns JA, Yusuf S, et al. Randomized trial of primary PCI with
	or without routine manual thrombectomy.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2015;372:1389–1398.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1415098">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25853743">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R600" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Jolly
	SS, Cairns JA, Yusuf S, et al. Outcomes after thrombus aspiration
	for ST elevation myocardial infarction: 1-year follow-up of the
	prospective randomised TOTAL trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2016;387:127–135.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(15)00448-1">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26474811">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R601" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Lagerqvist
	B, Fröbert O, Olivecrona GK, et al. Outcomes 1 year after thrombus
	aspiration for myocardial infarction.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2014;371:1111–1120.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1405707">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25176395">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R602" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Stone
	GW, Maehara A, Witzenbichler B, et al. Intracoronary abciximab and
	aspiration thrombectomy in patients with large anterior myocardial
	infarction: the INFUSE-AMI randomized trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA</font></em><font size="1" style="font-size: 8pt">.
	2012;307:1817–1826.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jama.2012.421">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22447888">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R603" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Ali
	A, Cox D, Dib N, et al. Rheolytic thrombectomy with percutaneous
	coronary intervention for infarct size reduction in acute myocardial
	infarction: 30-day results from a multicenter randomized study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2006;48:244–252.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2006.03.044">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16843170">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R604" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Migliorini
	A, Stabile A, Rodriguez AE, et al. Comparison of AngioJet rheolytic
	thrombectomy before direct infarct artery stenting with direct
	stenting alone in patients with acute myocardial infarction. The
	JETSTENT trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2010;56:1298–1306.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2010.06.011">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20691553">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R605" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Sardella
	G, Mancone M, Bucciarelli-Ducci C, et al. Thrombus aspiration during
	primary percutaneous coronary intervention improves myocardial
	reperfusion and reduces infarct size: the EXPIRA (thrombectomy with
	export catheter in infarct-related artery during primary
	percutaneous coronary intervention) prospective, randomized trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2009;53:309–315.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2008.10.017">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19161878">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">9.</font></p>
<div id="R606" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Svilaas
	T, Vlaar PJ, van der Horst IC, et al. Thrombus aspiration during
	primary percutaneous coronary intervention.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2008;358:557–567.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa0706416">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18256391">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">10.</font></p>
<div id="R607" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Vlaar
	PJ, Svilaas T, van der Horst IC, et al. Cardiac death and
	reinfarction after 1 year in the Thrombus Aspiration during
	Percutaneous coronary intervention in Acute myocardial infarction
	Study (TAPAS): a 1-year follow-up study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2008;371:1915–1920.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(08)60833-8">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18539223">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">11.</span></font></p>
<div id="R608" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Jolly
	SS, James S, Džavík V, et al. Thrombus aspiration in
	ST-segment-elevation myocardial infarction: an individual patient
	meta-analysis: Thrombectomy Trialists Collaboration.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2017;135:143–152.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circulationaha.116.025371">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27941066">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>10.5.
Treatment of Calcified Lesions</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R609" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Abdel-Wahab
	M, Richardt G, Joachim Büttner H, et al. High-speed rotational
	atherectomy before paclitaxel-eluting stent implantation in complex
	calcified coronary lesions: the randomized ROTAXUS (Rotational
	Atherectomy Prior to Taxus Stent Treatment for Complex Native
	Coronary Artery Disease) trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2013;6:10–19.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jcin.2012.07.017">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23266232">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R610" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Abdel-Wahab
	M, Toelg R, Byrne RA, et al. High-speed rotational atherectomy
	versus modified balloons prior to drug-eluting stent implantation in
	severely calcified coronary lesions.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2018;11:e007415.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCINTERVENTIONS.118.007415">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30354632">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R611" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Bittl
	JA, Chew DP, Topol EJ, et al. Meta-analysis of randomized trials of
	percutaneous transluminal coronary angioplasty versus atherectomy,
	cutting balloon atherotomy, or laser angioplasty.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2004;43:936–942.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2003.10.039">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15028347">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R612" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Parikh
	K, Chandra P, Choksi N, et al. Safety and feasibility of orbital
	atherectomy for the treatment of calcified coronary lesions: the
	ORBIT I trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Catheter
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2013;81:1134–1139.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1002/ccd.24700">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23460596">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R613" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Chambers
	JW, Feldman RL, Himmelstein SI, et al. Pivotal trial to evaluate the
	safety and efficacy of the orbital atherectomy system in treating de
	novo, severely calcified coronary lesions (ORBIT II).&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2014;7:510–518.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jcin.2014.01.158">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24852804">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R614" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Albiero
	R, Silber S, Di Mario C, et al. Cutting balloon versus conventional
	balloon angioplasty for the treatment of in-stent restenosis:
	results of the restenosis cutting balloon evaluation trial
	(RESCUT).&nbsp;</font><font size="1" style="font-size: 8pt"><em>J Am
	Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2004;43:943–949.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2003.09.054">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15028348">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R615" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kufner
	S, Joner M, Schneider S, et al. Neointimal modification with scoring
	balloon and efficacy of drug-coated balloon therapy in patients with
	restenosis in drug-eluting coronary stents: a randomized controlled
	trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2017;10:1332–1340.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jcin.2017.04.024">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28683939">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R616" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kereiakes
	DJ, Di Mario C, Riley RF, et al. Intravascular lithotripsy for
	treatment of calcified coronary lesions: patient-level pooled
	analysis of the disrupt CAD studies.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2021;14:1337–1348.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jcin.2021.04.015">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/33939604">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">9.</font></p>
<div id="R617" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Mehanna
	E, Abbott JD, Bezerra HG. Optimizing percutaneous coronary
	intervention in calcified lesions: insights from optical coherence
	tomography of atherectomy.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2018;11:e006813.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCINTERVENTIONS.118.006813">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29743161">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">10.</font></p>
<div id="R618" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Bittl,
	JA. Role of adjunctive devices—atherectomy, cutting balloon, and
	laser. Topol, EJ, Teirstein, PS&nbsp;</font><font size="1" style="font-size: 8pt"><em>Textbook
	of Interventional Cardiology</font></em><font size="1" style="font-size: 8pt">.
	8th ed. Elsevier Inc; 2019: 577–589.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">11.</font></p>
<div id="R619" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Bittl
	JA. Physical aspects of excimer laser angioplasty for undilatable
	lesions.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Catheter
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2008;71:808–809.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1002/ccd.21593">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18412077">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">12.</font></p>
<div id="R620" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Latib
	A, Takagi K, Chizzola G, et al. Excimer laser lesion modification to
	expand non-dilatable stents: the ELLEMENT registry.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Cardiovasc
	Revasc Med</font></em><font size="1" style="font-size: 8pt">.
	2014;15:8–12.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.carrev.2013.10.005">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24290659">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">13.</font></p>
<div id="R621" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Lee
	T, Shlofmitz RA, Song L, et al. The effectiveness of excimer laser
	angioplasty to treat coronary in-stent restenosis with peri-stent
	calcium as assessed by optical coherence
	tomography.&nbsp;</font><font size="1" style="font-size: 8pt"><em>EuroIntervention</font></em><font size="1" style="font-size: 8pt">.
	2019;15:e279–e288.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.4244/EIJ-D-18-00139">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29769164">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">14.</font></p>
<div id="R622" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Noble
	S, Bilodeau L. High energy excimer laser to treat coronary in-stent
	restenosis in an underexpanded stent.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Catheter
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2008;71:803–807.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1002/ccd.21490">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18324694">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">15.</span></font></p>
<div id="R623" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Ali
	ZA, Nef H, Escaned J, et al. Safety and effectiveness of coronary
	intravascular lithotripsy for treatment of severely calcified
	coronary stenoses: the Disrupt CAD II study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2019;12:e008434.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCINTERVENTIONS.119.008434">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31553205">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>10.6.
Treatment of Saphenous Vein Graft (SVG) Disease (Previous CABG)</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R624" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Baim
	DS, Wahr D, George B, et al. Randomized trial of a distal embolic
	protection device during percutaneous intervention of saphenous vein
	aorto-coronary bypass grafts.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2002;105:1285–1290.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/01.CIR.0000012783.63093.0C">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/11901037">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R625" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Stone
	GW, Rogers C, Hermiller J, et al. Randomized comparison of distal
	protection with a filter-based catheter and a balloon occlusion and
	aspiration system during percutaneous intervention of diseased
	saphenous vein aorto-coronary bypass grafts.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2003;108:548–553.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/01.cir.0000080894.51311.0a">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12874191">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R626" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Valle
	JA, Glorioso TJ, Schuetze KB, et al. Contemporary use of embolic
	protection devices during saphenous vein graft intervention.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2019;12:e007636.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCINTERVENTIONS.118.007636">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31014092">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R627" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Brilakis
	ES, Rao SV, Banerjee S, et al. Percutaneous coronary intervention in
	native arteries versus bypass grafts in prior coronary artery bypass
	grafting patients: a report from the National Cardiovascular Data
	Registry.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2011;4:844–850.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jcin.2011.03.018">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21851896">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R628" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Brilakis
	ES, O’Donnell CI, Penny W, et al. Percutaneous coronary
	intervention in native coronary arteries versus bypass grafts in
	patients with prior coronary artery bypass graft surgery: insights
	from the Veterans Affairs Clinical Assessment, Reporting, and
	Tracking Program.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2016;9:884–893.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jcin.2016.01.034">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27085582">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R629" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Hoffmann
	R, Hamm C, Nienaber CA, et al. Implantation of sirolimus-eluting
	stents in saphenous vein grafts is associated with high clinical
	follow-up event rates compared with treatment of native
	vessels.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Coron
	Artery Dis</font></em><font size="1" style="font-size: 8pt">.
	2007;18:559–564.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1097/MCA.0b013e3282ef5b40">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17925610">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R630" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Al-Lamee
	R, Ielasi A, Latib A, et al. Clinical and angiographic outcomes
	after percutaneous recanalization of chronic total saphenous vein
	graft occlusion using modern techniques.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2010;106:1721–1727.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.amjcard.2010.08.013">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21126616">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R631" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">de
	Feyter PJ, Serruys P, van den Brand M, et al. Percutaneous
	transluminal angioplasty of a totally occluded venous bypass graft:
	a challenge that should be resisted.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	1989;64:88–90.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/0002-9149(89)90658-9">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/2525867">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">9.</font></p>
<div id="R632" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">de
	Vries MR, Simons KH, Jukema JW, et al. Vein graft failure: from
	pathophysiology to clinical outcomes.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Nat
	Rev Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2016;13:451–470.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1038/nrcardio.2016.76">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27194091">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">10.</font></p>
<div id="R633" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Redfors
	B, Généreux P, Witzenbichler B, et al. Percutaneous coronary
	intervention of saphenous vein graft.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2017;10:e004953.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCINTERVENTIONS.117.004953">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28495896">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">11.</font></p>
<div id="R634" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Brennan
	JM, Al-Hejily W, Dai D, et al. Three-year outcomes associated with
	embolic protection in saphenous vein graft intervention: results in
	49 325 senior patients in the Medicare-linked National
	Cardiovascular Data Registry CathPCI Registry.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2015;8:e001403.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circinterventions.114.001403">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25714391">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">12.</font></p>
<div id="R635" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Shoaib
	A, Kinnaird T, Curzen N, et al. Outcomes following percutaneous
	coronary intervention in saphenous vein grafts with and without
	embolic protection devices.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2019;12:2286–2295.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jcin.2019.08.037">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31753300">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">13.</span></font></p>
<div id="R636" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Paul
	TK, Bhatheja S, Panchal HB, et al. Outcomes of saphenous vein graft
	intervention with and without embolic protection device: a
	comprehensive review and meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2017;10:e005538.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circinterventions.117.005538">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29246912">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>10.7.
Treatment of CTO</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R637" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Lee
	SW, Lee PH, Ahn JM, et al. Randomized trial evaluating percutaneous
	coronary intervention for the treatment of chronic total
	occlusion.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2019;139:1674–1683.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCULATIONAHA.118.031313">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30813758">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R638" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Werner
	GS, Martin-Yuste V, Hildick-Smith D, et al. A randomized multicentre
	trial to compare revascularization with optimal medical therapy for
	the treatment of chronic total coronary occlusions.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2018;39:2484–2493.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/eurheartj/ehy220">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29722796">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R639" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Obedinskiy
	AA, Kretov EI, Boukhris M, et al. The IMPACTOR-CTO trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2018;11:1309–1311.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jcin.2018.04.017">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29976368">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R640" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Henriques
	JP, Hoebers LP, Råmunddal T, et al. Percutaneous intervention for
	concurrent chronic total occlusions in patients with STEMI: the
	EXPLORE trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2016;68:1622–1632.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2016.07.744">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27712774">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R641" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Fefer
	P, Knudtson ML, Cheema AN, et al. Current perspectives on coronary
	chronic total occlusions: the Canadian Multicenter Chronic Total
	Occlusions Registry.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2012;59:991–997.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2011.12.007">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22402070">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R642" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Tsai
	TT, Stanislawski MA, Shunk KA, et al. Contemporary incidence,
	management, and long-term outcomes of percutaneous coronary
	interventions for chronic coronary artery total occlusions: insights
	from the VA CART Program.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2017;10:866–875.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jcin.2017.02.044">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28473108">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R643" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Tajti
	P, Burke MN, Karmpaliotis D, et al. Prevalence and outcomes of
	percutaneous coronary interventions for ostial chronic total
	occlusions: insights from a multicenter chronic total occlusion
	registry.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Can
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2018;34:1264–1274.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.cjca.2018.07.472">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30269827">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R644" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Sapontis
	J, Salisbury AC, Yeh RW, et al. Early procedural and health status
	outcomes after chronic total occlusion angioplasty: a report from
	the OPEN-CTO Registry (Outcomes, Patient Health Status, and
	Efficiency in Chronic Total Occlusion Hybrid Procedures).&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2017;10:1523–1534.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jcin.2017.05.065">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28797429">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">9.</font></p>
<div id="R645" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Stone
	GW, Reifart NJ, Moussa I, et al. Percutaneous recanalization of
	chronically occluded coronary arteries: a consensus document: part
	II.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2005;112:2530–2537.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circulationaha.105.583716">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16230504">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">10.</font></p>
<div id="R646" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Mashayekhi
	K, Nührenberg TG, Toma A, et al. A randomized trial to assess
	regional left ventricular function after stent implantation in
	chronic total occlusion: the REVASC trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2018;11:1982–1991.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jcin.2018.05.041">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30219327">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">11.</font></p>
<div id="R647" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Abo-Aly
	M, Misumida N, Backer N, et al. Percutaneous coronary intervention
	with drug-eluting stent versus optimal medical therapy for chronic
	total occlusion: systematic review and meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Angiology</font></em><font size="1" style="font-size: 8pt">.
	2019;70:908–915.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1177/0003319719858823">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31256614">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">12.</font></p>
<div id="R648" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Li
	KHC, Wong KHG, Gong M, et al. Percutaneous coronary intervention
	versus medical therapy for chronic total occlusion of coronary
	arteries: a systematic review and meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Curr
	Atheroscler Rep</font></em><font size="1" style="font-size: 8pt">.
	2019;21:42.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1007/s11883-019-0804-8">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31399762">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">13.</font></p>
<div id="R649" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Christiansen,
	E. ISCHEMIA-CTO Trial - Revascularisation or Optimal Medical Therapy
	of CTO (ISCHEMIA-CTO). 2018. Accessed August 15, 2019. Available
	at&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://clinicaltrials.gov/ct2/show/NCT03563417?term=03563417&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT03563417?term=03563417&amp;rank=1</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">14.</span></font></p>
<div id="R650" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Minneapolis
	Heart Institute Foundation. The SHINE-CTO Trial (SHINE-CTO). 2016
	Accessed August 15, 2019. Available
	at&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://clinicaltrials.gov/ct2/results?cond=&amp;term=02784418&amp;cntry=&amp;state=&amp;city=&amp;dist=">https://clinicaltrials.gov/ct2/results?cond=&amp;term=02784418&amp;cntry=&amp;state=&amp;city=&amp;dist=</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>10.8.
Treatment of Patients With Stent Restenosis</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R651" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Siontis
	GC, Stefanini GG, Mavridis D, et al. Percutaneous coronary
	interventional strategies for treatment of in-stent restenosis: a
	network meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2015;386:655–664.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(15)60657-2">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26334160">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R652" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Giacoppo
	D, Gargiulo G, Aruta P, et al. Treatment strategies for coronary
	in-stent restenosis: systematic review and hierarchical Bayesian
	network meta-analysis of 24 randomised trials and 4880
	patients.&nbsp;</font><font size="1" style="font-size: 8pt"><em>BMJ</font></em><font size="1" style="font-size: 8pt">.
	2015;351:h5392.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1136/bmj.h5392">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26537292">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R653" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Mehilli
	J, Byrne RA, Tiroch K, et al. Randomized trial of paclitaxel- versus
	sirolimus-eluting stents for treatment of coronary restenosis in
	sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting
	and Angiographic Results: Drug Eluting Stents for In-Stent
	Restenosis 2) study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2010;55:2710–2716.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2010.02.009">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20226618">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R654" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kastrati
	A, Mehilli J, von Beckerath N, et al. Sirolimus-eluting stent or
	paclitaxel-eluting stent vs balloon angioplasty for prevention of
	recurrences in patients with coronary in-stent restenosis: a
	randomized controlled trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA</font></em><font size="1" style="font-size: 8pt">.
	2005;293:165–171.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jama.293.2.165">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15644543">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R655" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Negi
	SI, Torguson R, Gai J, et al. Intracoronary brachytherapy for
	recurrent drug-eluting stent failure.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2016;9:1259–1265.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jcin.2016.03.018">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27339842">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R656" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Tada
	T, Byrne RA, Simunovic I, et al. Risk of stent thrombosis among
	bare-metal stents, first-generation drug-eluting stents, and
	second-generation drug-eluting stents: results from a registry of 18
	334 patients.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2013;6:1267–1274.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jcin.2013.06.015">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24355117">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R657" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Alfonso
	F, Fernandez C. Second-generation drug-eluting stents. Moving the
	field forward.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2011;58:26–29.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2011.03.013">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21514085">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R658" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Gada
	H, Kirtane AJ, Newman W, et al. 5-year results of a randomized
	comparison of XIENCE V everolimus-eluting and TAXUS
	paclitaxel-eluting stents: final results from the SPIRIT III trial
	(clinical evaluation of the XIENCE V everolimus eluting coronary
	stent system in the treatment of patients with de novo native
	coronary artery lesions).&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2013;6:1263–1266.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jcin.2013.07.009">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24239202">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">9.</font></p>
<div id="R659" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Dangas
	GD, Claessen BE, Caixeta A, et al. In-stent restenosis in the
	drug-eluting stent era.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2010;56:1897–1907.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2010.07.028">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21109112">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">10.</font></p>
<div id="R660" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Alfonso
	F, Byrne RA, Rivero F, et al. Current treatment of in-stent
	restenosis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2014;63:2659–2673.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2014.02.545">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24632282">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">11.</font></p>
<div id="R661" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Mehran
	R, Dangas G, Abizaid AS, et al. Angiographic patterns of in-stent
	restenosis: classification and implications for long-term
	outcome.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	1999;100:1872–1878.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/01.CIR.100.18.1872">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/10545431">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">12.</font></p>
<div id="R662" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Goto
	K, Zhao Z, Matsumura M, et al. Mechanisms and patterns of
	intravascular ultrasound in-stent restenosis among bare metal stents
	and first- and second-generation drug-eluting stents.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2015;116:1351–1357.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.amjcard.2015.07.058">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26341188">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">13.</font></p>
<div id="R663" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kang
	SJ, Mintz GS, Park DW, et al. Mechanisms of in-stent restenosis
	after drug-eluting stent implantation: intravascular ultrasound
	analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2011;4:9–14.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circinterventions.110.940320">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21266707">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">14.</font></p>
<div id="R664" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Farb
	A, Sangiorgi G, Carter AJ, et al. Pathology of acute and chronic
	coronary stenting in humans.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	1999;99:44–52.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/01.CIR.99.1.44">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/9884378">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">15.</font></p>
<div id="R665" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Singh
	M, Gersh BJ, McClelland RL, et al. Clinical and angiographic
	predictors of restenosis after percutaneous coronary intervention:
	insights from the Prevention of Restenosis With Tranilast and Its
	Outcomes (PRESTO) trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2004;109:2727–2731.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/01.CIR.0000131898.18849.65">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15173022">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">16.</font></p>
<div id="R666" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Stolker
	JM, Kennedy KF, Lindsey JB, et al. Predicting restenosis of
	drug-eluting stents placed in real-world clinical practice:
	derivation and validation of a risk model from the EVENT
	registry.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2010;3:327–334.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circinterventions.110.946939">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20606136">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">17.</span></font></p>
<div id="R667" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Dibra
	A, Kastrati A, Alfonso F, et al. Effectiveness of drug-eluting
	stents in patients with bare-metal in-stent restenosis:
	meta-analysis of randomized trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2007;49:616–623.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2006.10.049">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17276188">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>10.9.
Hemodynamic Support for Complex PCI</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R668" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Perera
	D, Stables R, Thomas M, et al. Elective intra-aortic balloon
	counterpulsation during high-risk percutaneous coronary
	intervention: a randomized controlled trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA</font></em><font size="1" style="font-size: 8pt">.
	2010;304:867–874.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jama.2010.1190">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20736470">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R669" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">O’Neill
	WW, Kleiman NS, Moses J, et al. A prospective, randomized clinical
	trial of hemodynamic support with Impella 2.5 versus intra-aortic
	balloon pump in patients undergoing high-risk percutaneous coronary
	intervention: the PROTECT II study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2012;126:1717–1727.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circulationaha.112.098194">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22935569">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R670" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Amin
	AP, Spertus JA, Curtis JP, et al. The evolving landscape of Impella
	use in the United States among patients undergoing percutaneous
	coronary intervention with mechanical circulatory
	support.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2020;141:273–284.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCULATIONAHA.119.044007">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31735078">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R671" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Dhruva
	SS, Ross JS, Mortazavi BJ, et al. Association of use of an
	intravascular microaxial left ventricular assist device vs
	intra-aortic balloon pump with in-hospital mortality and major
	bleeding among patients with acute myocardial infarction complicated
	by cardiogenic shock.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA</font></em><font size="1" style="font-size: 8pt">.
	2020;323:734–745.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jama.2020.0254">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/32040163">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R672" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Baumann
	S, Werner N, Ibrahim K, et al. Indication and short-term clinical
	outcomes of high-risk percutaneous coronary intervention with
	microaxial Impella® pump: results from the German Impella®
	registry.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Clin
	Res Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2018;107:653–657.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1007/s00392-018-1230-6">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29520699">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R673" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Curtis
	JP, Rathore SS, Wang Y, et al. Use and effectiveness of intra-aortic
	balloon pumps among patients undergoing high risk percutaneous
	coronary intervention: insights from the National Cardiovascular
	Data Registry.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Qual Outcomes</font></em><font size="1" style="font-size: 8pt">.
	2012;5:21–30.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCOUTCOMES.110.960385">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22147887">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R674" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Maini
	B, Naidu SS, Mulukutla S, et al. Real-world use of the Impella 2.5
	circulatory support system in complex high-risk percutaneous
	coronary intervention: the USpella Registry.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Catheter
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2012;80:717–725.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1002/ccd.23403">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22105829">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R675" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Rihal
	CS, Naidu SS, Givertz MM, et al. 2015 SCAI/ACC/HFSA/STS clinical
	expert consensus statement on the use of percutaneous mechanical
	circulatory support devices in cardiovascular care.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2015;65:e7–e26.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2015.03.036">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25861963">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">9.</span></font></p>
<div id="R676" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Vetrovec
	GW, Anderson M, Schreiber T, et al. The cVAD registry for
	percutaneous temporary hemodynamic support: a prospective registry
	of Impella mechanical circulatory support use in high-risk PCI,
	cardiogenic shock, and decompensated heart failure.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2018;199:115–121.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.ahj.2017.09.007">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29754648">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>11.1.
Aspirin and Oral P2Y12 Inhibitors in Patients Undergoing PCI</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R677" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Barnathan
	ES, Schwartz JS, Taylor L, et al. Aspirin and dipyridamole in the
	prevention of acute coronary thrombosis complicating coronary
	angioplasty.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	1987;76:125–134.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/01.CIR.76.1.125">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/2954724">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R678" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Antithrombotic
	Trialists’ Collaboration. Collaborative meta-analysis of
	randomised trials of antiplatelet therapy for prevention of death,
	myocardial infarction, and stroke in high risk patients.&nbsp;</font><font size="1" style="font-size: 8pt"><em>BMJ</font></em><font size="1" style="font-size: 8pt">.
	2002;324:71–86.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1136/bmj.324.7329.71">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/11786451">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R679" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Collaborative
	overview of randomised trials of antiplatelet therapy–I:
	prevention of death, myocardial infarction, and stroke by prolonged
	antiplatelet therapy in various categories of patients. Antiplatelet
	Trialists’ Collaboration.&nbsp;</font><font size="1" style="font-size: 8pt"><em>BMJ</font></em><font size="1" style="font-size: 8pt">.
	1994;308:81–106.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1136/bmj.308.6921.81">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/8298418">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R680" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Baigent
	C, Blackwell L, Collins R, et al. Aspirin in the primary and
	secondary prevention of vascular disease: collaborative
	meta-analysis of individual participant data from randomised trials.
	Antithrombotic Trialists’ (ATT) Collaboration.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2009;373:1849–1860.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(09)60503-1">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19482214">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R681" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Sabatine
	MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment
	before percutaneous coronary intervention in patients with
	ST-elevation myocardial infarction treated with fibrinolytics: the
	PCI-CLARITY study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA</font></em><font size="1" style="font-size: 8pt">.
	2005;294:1224–1232.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jama.294.10.1224">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16143698">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R682" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Wiviott
	SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in
	patients with acute coronary syndromes.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2007;357:2001–2015.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa0706482">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17982182">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R683" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Montalescot
	G, van’t Hof AW, Lapostolle F, et al. Prehospital ticagrelor in
	ST-segment elevation myocardial infarction.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2014;371:1016–1027.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1407024">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25175921">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R684" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Taniuchi
	M, Kurz HI, Lasala JM. Randomized comparison of ticlopidine and
	clopidogrel after intracoronary stent implantation in a broad
	patient population.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2001;104:539–543.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/hc3001.093435">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/11479250">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">9.</font></p>
<div id="R685" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Bellemain-Appaix
	A, O’Connor SA, Silvain J, et al. Association of clopidogrel
	pretreatment with mortality, cardiovascular events, and major
	bleeding among patients undergoing percutaneous coronary
	intervention: a systematic review and meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA</font></em><font size="1" style="font-size: 8pt">.
	2012;308:2507–2516.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jama.2012.50788">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23287889">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">10.</font></p>
<div id="R686" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Schömig
	A, Neumann FJ, Kastrati A, et al. A randomized comparison of
	antiplatelet and anticoagulant therapy after the placement of
	coronary-artery stents.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	1996;334:1084–1089.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJM199604253341702">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/8598866">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">11.</font></p>
<div id="R687" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Leon
	MB, Baim DS, Popma JJ, et al. A clinical trial comparing three
	antithrombotic-drug regimens after coronary-artery stenting. Stent
	Anticoagulation Restenosis Study Investigators.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	1998;339:1665–1671.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJM199812033392303">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/9834303">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">12.</font></p>
<div id="R688" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Moussa
	I, Oetgen M, Roubin G, et al. Effectiveness of clopidogrel and
	aspirin versus ticlopidine and aspirin in preventing stent
	thrombosis after coronary stent implantation.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	1999;99:2364–2366.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/01.CIR.99.18.2364">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/10318654">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">13.</font></p>
<div id="R689" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Calver
	AL, Blows LJ, Harmer S, et al. Clopidogrel for prevention of major
	cardiac events after coronary stent implantation: 30-day and 6-month
	results in patients with smaller stents.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2000;140:483–491.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1067/mhj.2000.108825">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/10966552">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">14.</font></p>
<div id="R690" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Wallentin
	L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in
	patients with acute coronary syndromes.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2009;361:1045–1057.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa0904327">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19717846">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">15.</font></p>
<div id="R691" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Müller
	C, Büttner HJ, Petersen J, et al. A randomized comparison of
	clopidogrel and aspirin versus ticlopidine and aspirin after the
	placement of coronary-artery stents.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2000;101:590–593.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/01.CIR.101.6.590">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/10673248">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">16.</font></p>
<div id="R692" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Bertrand
	ME, Rupprecht HJ, Urban P, et al. Double-blind study of the safety
	of clopidogrel with and without a loading dose in combination with
	aspirin compared with ticlopidine in combination with aspirin after
	coronary stenting: the clopidogrel aspirin stent international
	cooperative study (CLASSICS).&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2000;102:624–629.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/01.CIR.102.6.624">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/10931801">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">17.</font></p>
<div id="R693" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Di
	Sciascio G, Patti G, Pasceri V, et al. Effectiveness of
	in-laboratory high-dose clopidogrel loading versus routine pre-load
	in patients undergoing percutaneous coronary intervention: results
	of the ARMYDA-5 PRELOAD (Antiplatelet therapy for Reduction of
	MYocardial Damage during Angioplasty) randomized trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2010;56:550–557.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2010.01.067">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20688209">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">18.</font></p>
<div id="R694" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Steinhubl
	SR, Berger PB, Mann JT, et al. Early and sustained dual oral
	antiplatelet therapy following percutaneous coronary intervention: a
	randomized controlled trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA</font></em><font size="1" style="font-size: 8pt">.
	2002;288:2411–2420.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jama.288.19.2411">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12435254">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">19.</font></p>
<div id="R695" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">von
	Beckerath N, Taubert D, Pogatsa-Murray G, et al. Absorption,
	metabolization, and antiplatelet effects of 300-, 600-, and 900-mg
	loading doses of clopidogrel: results of the ISAR-CHOICE
	(Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3
	High Oral Doses for Immediate Clopidogrel Effect)
	trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2005;112:2946–2950.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCULATIONAHA.105.559088">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16260639">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">20.</font></p>
<div id="R696" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Montalescot
	G, Wiviott SD, Braunwald E, et al. Prasugrel compared with
	clopidogrel in patients undergoing percutaneous coronary
	intervention for ST-elevation myocardial infarction (TRITON-TIMI
	38): double-blind, randomised controlled trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2009;373:723–731.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(09)60441-4">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19249633">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">21.</font></p>
<div id="R697" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Berwanger
	O, Nicolau JC, Carvalho AC, et al. Ticagrelor vs clopidogrel after
	fibrinolytic therapy in patients with ST-elevation myocardial
	infarction: a randomized clinical trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA
	Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2018;3:391–399.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jamacardio.2018.0612">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29525822">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">22.</font></p>
<div id="R698" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Widimsky
	P, Motovská Z, Simek S, et al. Clopidogrel pre-treatment in stable
	angina: for all patients &gt;6 h before elective coronary
	angiography or only for angiographically selected patients a few
	minutes before PCI? A randomized multicentre trial PRAGUE-8.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2008;29:1495–1503.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/eurheartj/ehn169">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18441320">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">23.</font></p>
<div id="R699" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Schwartz
	L, Bourassa MG, Lespérance J, et al. Aspirin and dipyridamole in
	the prevention of restenosis after percutaneous transluminal
	coronary angioplasty.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	1988;318:1714–1719.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJM198806303182603">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/2967433">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">24.</font></p>
<div id="R700" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Jolly
	SS, Pogue J, Haladyn K, et al. Effects of aspirin dose on ischaemic
	events and bleeding after percutaneous coronary intervention:
	insights from the PCI-CURE study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2009;30:900–907.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/eurheartj/ehn417">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18819961">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">25.</font></p>
<div id="R701" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Serebruany
	VL, Steinhubl SR, Berger PB, et al. Analysis of risk of bleeding
	complications after different doses of aspirin in 192 036 patients
	enrolled in 31 randomized controlled trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2005;95:1218–1222.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.amjcard.2005.01.049">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15877994">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">26.</font></p>
<div id="R702" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Mahaffey
	KW, Wojdyla DM, Carroll K, et al. Ticagrelor compared with
	clopidogrel by geographic region in the Platelet Inhibition and
	Patient Outcomes (PLATO) trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2011;124:544–554.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circulationaha.111.047498">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21709065">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">27.</font></p>
<div id="R703" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Nordt
	SP, Clark RF, Castillo EM, et al. Comparison of three aspirin
	formulations in human volunteers.&nbsp;</font><font size="1" style="font-size: 8pt"><em>West
	J Emerg Med</font></em><font size="1" style="font-size: 8pt">.
	2011;12:381–385.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.5811/westjem.2011.4.2222">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22224124">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">28.</font></p>
<div id="R704" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Dörler
	J, Edlinger M, Alber HF, et al. Clopidogrel pre-treatment is
	associated with reduced in-hospital mortality in primary
	percutaneous coronary intervention for acute ST-elevation myocardial
	infarction.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2011;32:2954–2961.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/eurheartj/ehr360">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21920970">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">29.</font></p>
<div id="R705" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Zeymer
	U, Arntz H-R, Mark B, et al. Efficacy and safety of a high loading
	dose of clopidogrel administered prehospitally to improve primary
	percutaneous coronary intervention in acute myocardial infarction:
	the randomized CIPAMI trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Clin
	Res Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2012;101:305–312.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1007/s00392-011-0393-1">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22186968">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">30.</font></p>
<div id="R706" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Montalescot
	G, Bolognese L, Dudek D, et al. Pretreatment with prasugrel in
	non-ST-segment elevation acute coronary syndromes.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2013;369:999–1010.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1308075">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23991622">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">31.</font></p>
<div id="R707" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Tarantini
	G, Mojoli M, Varbella F, et al. Timing of Oral P2Y12 Inhibitor
	administration in patients with non-ST-segment elevation acute
	coronary syndrome.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2020;76:2450–2459.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2020.08.053">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/32882390">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">32.</font></p>
<div id="R708" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Gimbel
	M, Qaderdan K, Willemsen L, et al. Clopidogrel versus ticagrelor or
	prasugrel in patients aged 70 years or older with non-ST-elevation
	acute coronary syndrome (POPular AGE): the randomised, open-label,
	non-inferiority trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2020;395:1374–1381.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(20)30325-1">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/32334703">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">33.</font></p>
<div id="R709" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Dehghani
	P, Lavoie A, Lavi S, et al. Effects of ticagrelor versus clopidogrel
	on platelet function in fibrinolytic-treated STEMI patients
	undergoing early PCI.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2017;192:105–112.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.ahj.2017.07.013">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28938956">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">34.</font></p>
<div id="R710" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Mehta
	SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with
	clopidogrel and aspirin followed by long-term therapy in patients
	undergoing percutaneous coronary intervention: the PCI-CURE
	study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2001;358:527–533.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(01)05701-4">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/11520521">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">35.</font></p>
<div id="R711" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Menichelli
	M, Neumann F-J, Ndrepepa G, et al. Age- and weight-adapted dose of
	prasugrel versus standard dose of ticagrelor in patients with acute
	coronary syndromes: results from a randomized trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Intern Med</font></em><font size="1" style="font-size: 8pt">.
	2020;173:436–444.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.7326/M20-1806">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/32687741">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">36.</font></p>
<div id="R712" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Stone
	GW, Grines CL, Cox DA, et al. Comparison of angioplasty with
	stenting, with or without abciximab, in acute myocardial
	infarction.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2002;346:957–966.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa013404">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/11919304">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">37.</font></p>
<div id="R713" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Giugliano
	RP, White JA, Bode C, et al. Early versus delayed, provisional
	eptifibatide in acute coronary syndromes.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2009;360:2176–2190.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa0901316">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19332455">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">38.</font></p>
<div id="R714" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Valgimigli
	M, Campo G, Percoco G, et al. Comparison of angioplasty with
	infusion of tirofiban or abciximab and with implantation of
	sirolimus-eluting or uncoated stents for acute myocardial
	infarction: the MULTISTRATEGY randomized trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA</font></em><font size="1" style="font-size: 8pt">.
	2008;299:1788–1799.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jama.299.15.joc80026">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18375998">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">39.</span></font></p>
<div id="R715" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Bhatt
	DL, Stone GW, Mahaffey KW, et al. Effect of platelet inhibition with
	cangrelor during PCI on ischemic events.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2013;368:1303–1313.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1300815">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23473369">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>11.2.
Intravenous P2Y12 Inhibitors in Patients Undergoing PCI</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R716" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Bhatt
	DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with
	cangrelor during PCI.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2009;361:2330–2341.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa0908629">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19915222">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R717" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Bhatt
	DL, Stone GW, Mahaffey KW, et al. Effect of platelet inhibition with
	cangrelor during PCI on ischemic events.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2013;368:1303–1313.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1300815">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23473369">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R718" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Steg
	PG, Bhatt DL, Hamm CW, et al. Effect of cangrelor on periprocedural
	outcomes in percutaneous coronary interventions: a pooled analysis
	of patient-level data.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2013;382:1981–1992.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(13)61615-3">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24011551">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">4.</span></font></p>
<div id="R719" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Harrington
	RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor
	in patients undergoing PCI.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2009;361:2318–2329.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa0908628">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19915221">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>11.3.
Intravenous Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing
PCI</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R720" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Stone
	GW, Maehara A, Witzenbichler B, et al. Intracoronary abciximab and
	aspiration thrombectomy in patients with large anterior myocardial
	infarction: the INFUSE-AMI randomized trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA</font></em><font size="1" style="font-size: 8pt">.
	2012;307:1817–1826.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jama.2012.421">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22447888">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R721" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Montalescot
	G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa
	inhibition with coronary stenting for acute myocardial infarction.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2001;344:1895–1903.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJM200106213442503">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/11419426">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R722" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kastrati
	A, Mehilli J, Schühlen H, et al. A clinical trial of abciximab in
	elective percutaneous coronary intervention after pretreatment with
	clopidogrel.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2004;350:232–238.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa031859">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/14724302">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R723" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">O’Shea
	JC, Hafley GE, Greenberg S, et al. Platelet glycoprotein IIb/IIIa
	integrin blockade with eptifibatide in coronary stent intervention:
	the ESPRIT trial: a randomized controlled trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA</font></em><font size="1" style="font-size: 8pt">.
	2001;285:2468–2473.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jama.285.19.2468">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/11368699">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R724" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Espirit
	Investigators. Enhanced Suppression of the Platelet IIb/IIIa
	Receptor with Integrilin Therapy. Novel dosing regimen of
	eptifibatide in planned coronary stent implantation (ESPRIT): a
	randomised, placebo-controlled trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2000;356:2037–2044.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(00)03400-0">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/11145489">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R725" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Platelet
	Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using
	Integrilin Therapy (PURSUIT) Trial Investigators. Inhibition of
	platelet glycoprotein IIb/IIIa with eptifibatide in patients with
	acute coronary syndromes.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	1998;339:436–443.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJM199808133390704">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/9705684">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R726" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kastrati
	A, Neumann FJ, Schulz S, et al. Abciximab and heparin versus
	bivalirudin for non-ST-elevation myocardial infarction.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2011;365:1980–1989.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1109596">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22077909">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R727" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Stone
	GW, Grines CL, Cox DA, et al. Comparison of angioplasty with
	stenting, with or without abciximab, in acute myocardial
	infarction.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2002;346:957–966.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa013404">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/11919304">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">9.</span></font></p>
<div id="R728" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Moser
	M, Bertram U, Peter K, et al. Abciximab, eptifibatide, and tirofiban
	exhibit dose-dependent potencies to dissolve platelet aggregates.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Cardiovasc Pharmacol</font></em><font size="1" style="font-size: 8pt">.
	2003;41:586–592.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1097/00005344-200304000-00011">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12658060">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>11.4.
Heparin, Low-Molecular-Weight Heparin, and Bivalirudin in Patients
Undergoing PCI</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R729" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Lewis
	BE, Matthai WH, Cohen M, et al. Argatroban anticoagulation during
	percutaneous coronary intervention in patients with heparin-induced
	thrombocytopenia.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Catheter
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2002;57:177–184.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1002/ccd.10276">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12357516">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R730" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Mahaffey
	KW, Lewis BE, Wildermann NM, et al. The anticoagulant therapy with
	bivalirudin to assist in the performance of percutaneous coronary
	intervention in patients with heparin-induced thrombocytopenia
	(ATBAT) study: main results.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Invasive Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2003;15:611–616.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/14608128">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R731" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kastrati
	A, Neumann FJ, Mehilli J, et al. Bivalirudin versus unfractionated
	heparin during percutaneous coronary intervention.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2008;359:688–696.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa0802944">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18703471">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R732" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Lincoff
	AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional
	glycoprotein IIb/IIIa blockade compared with heparin and planned
	glycoprotein IIb/IIIa blockade during percutaneous coronary
	intervention: REPLACE-2 randomized trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA</font></em><font size="1" style="font-size: 8pt">.
	2003;289:853–863.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jama.289.7.853">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12588269">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R733" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Stone
	GW, White HD, Ohman EM, et al. Bivalirudin in patients with acute
	coronary syndromes undergoing percutaneous coronary intervention: a
	subgroup analysis from the Acute Catheterization and Urgent
	Intervention Triage strategy (ACUITY) trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2007;369:907–919.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(07)60450-4">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17368152">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R734" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kastrati
	A, Neumann FJ, Schulz S, et al. Abciximab and heparin versus
	bivalirudin for non-ST-elevation myocardial infarction.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2011;365:1980–1989.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1109596">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22077909">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R735" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Valgimigli
	M, Gagnor A, Calabró P, et al. Radial versus femoral access in
	patients with acute coronary syndromes undergoing invasive
	management: a randomised multicentre trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2015;385:2465–2476.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(15)60292-6">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25791214">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R736" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Steg
	PG, van’t Hof A, Hamm CW, et al. Bivalirudin started during
	emergency transport for primary PCI.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2013;369:2207–2217.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1311096">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24171490">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">9.</font></p>
<div id="R737" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Stone
	GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary
	PCI in acute myocardial infarction.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2008;358:2218–2230.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa0708191">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18499566">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">10.</font></p>
<div id="R738" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Capodanno
	D, Gargiulo G, Capranzano P, et al. Bivalirudin versus heparin with
	or without glycoprotein IIb/IIIa inhibitors in patients with STEMI
	undergoing primary PCI: an updated meta-analysis of 10 350 patients
	from five randomized clinical trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J Acute Cardiovasc Care</font></em><font size="1" style="font-size: 8pt">.
	2016;5:253–262.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1177/2048872615572599">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25746943">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">11.</font></p>
<div id="R739" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Cavender
	MA, Sabatine MS. Bivalirudin versus heparin in patients planned for
	percutaneous coronary intervention: a meta-analysis of randomised
	controlled trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2014;384:599–606.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(14)61216-2">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25131979">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">12.</font></p>
<div id="R740" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Shah
	R, Latham SB, Porta JM, et al. Bivalirudin with a post-procedure
	infusion versus heparin monotherapy for the prevention of stent
	thrombosis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Catheter
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2019;94:210–215.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1002/ccd.28065">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30636368">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">13.</font></p>
<div id="R741" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Blazing
	MA, De Lemos JA, Dyke CK, et al. The A-to-Z Trial: methods and
	rationale for a single trial investigating combined use of
	low-molecular-weight heparin with the glycoprotein IIb/IIIa
	inhibitor tirofiban and defining the efficacy of early aggressive
	simvastatin therapy.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2001;142:211–217.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1067/mhj.2001.116959">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/11479456">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">14.</font></p>
<div id="R742" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Ferguson
	JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated
	heparin in high-risk patients with non-ST-segment elevation acute
	coronary syndromes managed with an intended early invasive strategy:
	primary results of the SYNERGY randomized trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA</font></em><font size="1" style="font-size: 8pt">.
	2004;292:45–54.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15238590">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">15.</font></p>
<div id="R743" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Montalescot
	G, Zeymer U, Silvain J, et al. Intravenous enoxaparin or
	unfractionated heparin in primary percutaneous coronary intervention
	for ST-elevation myocardial infarction: the international randomised
	open-label ATOLL trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2011;378:693–703.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(11)60876-3">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21856483">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">16.</font></p>
<div id="R744" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Silvain
	J, Beygui F, Barthelemy O, et al. Efficacy and safety of enoxaparin
	versus unfractionated heparin during percutaneous coronary
	intervention: systematic review and meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>BMJ</font></em><font size="1" style="font-size: 8pt">.
	2012;344:e553.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1136/bmj.e553">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22306479">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">17.</font></p>
<div id="R745" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Montalescot
	G, White HD, Gallo R, et al. Enoxaparin versus unfractionated
	heparin in elective percutaneous coronary intervention.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2006;355:1006–1017.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa052711">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16957147">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">18.</font></p>
<div id="R746" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Drouet
	L, Bal dit Sollier C, Martin J. Adding intravenous unfractionated
	heparin to standard enoxaparin causes excessive anticoagulation not
	detected by activated clotting time: results of the STACK-on to
	ENOXaparin (STACKENOX) study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2009;158:177–184.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.ahj.2009.05.022">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19619692">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">19.</font></p>
<div id="R747" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Cohen
	M, Mahaffey KW, Pieper K, et al. A subgroup analysis of the impact
	of prerandomization antithrombin therapy on outcomes in the SYNERGY
	trial: enoxaparin versus unfractionated heparin in non-ST-segment
	elevation acute coronary syndromes.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2006;48:1346–1354.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2006.05.058">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17010793">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">20.</font></p>
<div id="R748" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Yusuf
	S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and
	enoxaparin in acute coronary syndromes.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2006;354:1464–1476.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa055443">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16537663">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">21.</font></p>
<div id="R749" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Yusuf
	S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on
	mortality and reinfarction in patients with acute ST-segment
	elevation myocardial infarction: the OASIS-6 randomized trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA</font></em><font size="1" style="font-size: 8pt">.
	2006;295:1519–1530.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jama.295.13.joc60038">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16537725">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">22.</font></p>
<div id="R750" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Rao
	SC, Chhatriwalla AK, Kennedy KF, et al. Pre-procedural estimate of
	individualized bleeding risk impacts physicians’ utilization of
	bivalirudin during percutaneous coronary intervention.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2013;61:1847–1852.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2013.02.017">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23500304">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">23.</font></p>
<div id="R751" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Bittl
	JA, Strony J, Brinker JA, et al. Treatment with bivalirudin
	(Hirulog) as compared with heparin during coronary angioplasty for
	unstable or postinfarction angina. Hirulog Angioplasty Study
	Investigators.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	1995;333:764–769.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJM199509213331204">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/7643883">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">24.</font></p>
<div id="R752" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Ferguson
	JJ, Dougherty KG, Gaos CM, et al. Relation between procedural
	activated coagulation time and outcome after percutaneous
	transluminal coronary angioplasty.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	1994;23:1061–1065.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/0735-1097(94)90590-8">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/8144768">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">25.</font></p>
<div id="R753" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">McGarry
	TF, Gottlieb RS, Morganroth J, et al. The relationship of
	anticoagulation level and complications after successful
	percutaneous transluminal coronary angioplasty.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	1992;123:1445–1451.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/0002-8703(92)90793-U">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/1595522">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">26.</font></p>
<div id="R754" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Narins
	CR, Hillegass WB, Nelson CL, et al. Relation between activated
	clotting time during angioplasty and abrupt closure.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	1996;93:667–671.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/01.CIR.93.4.667">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/8640994">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">27.</font></p>
<div id="R755" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Brener
	SJ, Moliterno DJ, Lincoff AM, et al. Relationship between activated
	clotting time and ischemic or hemorrhagic complications: analysis of
	4 recent randomized clinical trials of percutaneous coronary
	intervention.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2004;110:994–998.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/01.cir.0000139868.53594.24">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15302778">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">28.</font></p>
<div id="R756" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Mottillo
	S, Filion KB, Joseph L, et al. Defining optimal activated clotting
	time for percutaneous coronary intervention: a systematic review and
	Bayesian meta-regression.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Catheter
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2017;89:351–366.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1002/ccd.26652">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27545117">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">29.</font></p>
<div id="R757" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Schulz
	S, Angiolillo DJ, Antoniucci D, et al. Randomized comparison of
	ticagrelor versus prasugrel in patients with acute coronary syndrome
	and planned invasive strategy--design and rationale of the
	iNtracoronary Stenting and Antithrombotic Regimen: Rapid Early
	Action for Coronary Treatment (ISAR-REACT) 5 trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Cardiovasc Transl Res</font></em><font size="1" style="font-size: 8pt">.
	2014;7:91–100.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1007/s12265-013-9527-3">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24371012">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">30.</font></p>
<div id="R758" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Tolleson
	TR, O’Shea JC, Bittl JA, et al. Relationship between heparin
	anticoagulation and clinical outcomes in coronary stent
	intervention: observations from the ESPRIT trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2003;41:386–393.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0735-1097(02)02767-5">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12575964">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">31.</font></p>
<div id="R759" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Montalescot
	G, Cohen M, Salette G, et al. Impact of anticoagulation levels on
	outcomes in patients undergoing elective percutaneous coronary
	intervention: insights from the STEEPLE trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2008;29:462–471.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/eurheartj/ehn008">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18276619">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">32.</font></p>
<div id="R760" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Fabris
	E, Kilic S, Van’t Hof AWJ, et al. One-year mortality for
	bivalirudin vs heparins plus optional glycoprotein iib/iiia
	inhibitor treatment started in the ambulance for ST-segment
	elevation myocardial infarction: a secondary analysis of the EUROMAX
	randomized clinical trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA
	Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2017;2:791–796.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jamacardio.2016.5975">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28273285">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">33.</font></p>
<div id="R761" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Han
	Y, Guo J, Zheng Y, et al. Bivalirudin vs heparin with or without
	tirofiban during primary percutaneous coronary intervention in acute
	myocardial infarction: the BRIGHT randomized clinical trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA</font></em><font size="1" style="font-size: 8pt">.
	2015;313:1336–1346.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jama.2015.2323">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25775052">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">34.</font></p>
<div id="R762" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Mehran
	R, Lansky AJ, Witzenbichler B, et al. Bivalirudin in patients
	undergoing primary angioplasty for acute myocardial infarction
	(HORIZONS-AMI): 1-year results of a randomised controlled
	trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2009;374:1149–1159.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(09)61484-7">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19717185">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">35.</font></p>
<div id="R763" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Schulz
	S, Richardt G, Laugwitz KL, et al. Comparison of prasugrel and
	bivalirudin vs clopidogrel and heparin in patients with ST-segment
	elevation myocardial infarction: Design and rationale of the
	Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Clin
	Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2014;37:270–276.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1002/clc.22268">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24633823">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">36.</font></p>
<div id="R764" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Shahzad
	A, Kemp I, Mars C, et al. Unfractionated heparin versus bivalirudin
	in primary percutaneous coronary intervention (HEAT-PPCI): an
	open-label, single centre, randomised controlled trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2014;384:1849–1858.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(14)60924-7">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25002178">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">37.</font></p>
<div id="R765" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Stone
	GW, Clayton T, Deliargyris EN, et al. Reduction in cardiac mortality
	with bivalirudin in patients with and without major bleeding: the
	HORIZONS-AMI trial (Harmonizing Outcomes with Revascularization and
	Stents in Acute Myocardial Infarction).&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2014;63:15–20.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2013.09.027">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24140664">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">38.</font></p>
<div id="R766" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Erlinge
	D, Omerovic E, Frobert O, et al. Bivalirudin versus heparin
	monotherapy in myocardial infarction.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2017;377:1132–1142.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1706443">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28844201">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">39.</font></p>
<div id="R767" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Choussat
	R, Montalescot G, Collet JP, et al. A unique, low dose of
	intravenous enoxaparin in elective percutaneous coronary
	intervention.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2002;40:1943–1950.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0735-1097(02)02531-7">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12475453">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">40.</font></p>
<div id="R768" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Chew
	DP, Bhatt DL, Lincoff AM, et al. Defining the optimal activated
	clotting time during percutaneous coronary intervention: aggregate
	results from 6 randomized, controlled trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2001;103:961–966.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/01.CIR.103.7.961">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/11181470">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">41.</font></p>
<div id="R769" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Boccara
	A, Benamer H, Juliard JM, et al. A randomized trial of a fixed high
	dose vs a weight-adjusted low dose of intravenous heparin during
	coronary angioplasty.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	1997;18:631–635.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/oxfordjournals.eurheartj.a015308">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/9129894">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">42.</font></p>
<div id="R770" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Schulz
	S, Mehilli J, Neumann FJ, et al. ISAR-REACT 3A: a study of reduced
	dose of unfractionated heparin in biomarker negative patients
	undergoing percutaneous coronary intervention.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2010;31:2482–2491.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/eurheartj/ehq330">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20805113">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">43.</font></p>
<div id="R771" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Gibson
	CM, Murphy SA, Montalescot G, et al. Percutaneous coronary
	intervention in patients receiving enoxaparin or unfractionated
	heparin after fibrinolytic therapy for ST-segment elevation
	myocardial infarction in the ExTRACT-TIMI 25 trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2007;49:2238–2246.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2007.01.093">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17560287">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">44.</font></p>
<div id="R772" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Levine
	GN, Ferrando T. Degree of anticoagulation after one subcutaneous and
	one subsequent intravenous booster dose of enoxaparin: implications
	for patients with acute coronary syndromes undergoing early
	percutaneous coronary intervention.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Thromb Thrombolysis</font></em><font size="1" style="font-size: 8pt">.
	2004;17:167–171.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1023/B:THRO.0000040484.99422.77">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15353913">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">45.</span></font></p>
<div id="R773" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Martin
	JL, Fry ET, Sanderink GJ, et al. Reliable anticoagulation with
	enoxaparin in patients undergoing percutaneous coronary
	intervention: the pharmacokinetics of enoxaparin in PCI (PEPCI)
	study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Catheter
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2004;61:163–170.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1002/ccd.10726">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/14755805">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>12.1.
Perioperative Considerations in Patients Undergoing CABG</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R774" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Grant
	MC, Isada T, Ruzankin P, et al. Results from an enhanced recovery
	program for cardiac surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Thorac Cardiovasc Surg</font></em><font size="1" style="font-size: 8pt">.
	2020;159:1393–1402.e7.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jtcvs.2019.05.035">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31279510">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R775" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Williams
	JB, McConnell G, Allender JE, et al. One-year results from the first
	US-based enhanced recovery after cardiac surgery (ERAS Cardiac)
	program.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Thorac Cardiovasc Surg</font></em><font size="1" style="font-size: 8pt">.
	2019;157:1881–1888.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jtcvs.2018.10.164">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30665758">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R776" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Li
	M, Zhang J, Gan TJ, et al. Enhanced recovery after surgery pathway
	for patients undergoing cardiac surgery: a randomized clinical
	trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur J
	Cardiothorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2018;54:491–497.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/ejcts/ezy100">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29514224">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R777" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Hillis
	LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for
	coronary artery bypass graft surgery: a report of the American
	College of Cardiology Foundation/American Heart Association Task
	Force on Practice Guidelines. Developed in collaboration with the
	American Association for Thoracic Surgery, Society of Cardiovascular
	Anesthesiologists, and Society of Thoracic Surgeons.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2011;124:e652–e735.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0b013e31823c074e">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22064599">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R778" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Silbert
	BS, Scott DA, Evered LA, et al. A comparison of the effect of high-
	and low-dose fentanyl on the incidence of postoperative cognitive
	dysfunction after coronary artery bypass surgery in the
	elderly.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Anesthesiology</font></em><font size="1" style="font-size: 8pt">.
	2006;104:1137–1145.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1097/00000542-200606000-00007">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16732083">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R779" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Ender
	J, Borger MA, Scholz M, et al. Cardiac surgery fast-track treatment
	in a postanesthetic care unit: six-month results of the Leipzig
	fast-track concept.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Anesthesiology</font></em><font size="1" style="font-size: 8pt">.
	2008;109:61–66.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1097/ALN.0b013e31817881b3">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18580173">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R780" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Myles
	PS, Daly DJ, Djaiani G, et al. A systematic review of the safety and
	effectiveness of fast-track cardiac anesthesia.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Anesthesiology</font></em><font size="1" style="font-size: 8pt">.
	2003;99:982–987.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1097/00000542-200310000-00035">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/14508335">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R781" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Wong
	W-T, Lai VK, Chee YE, et al. Fast-track cardiac care for adult
	cardiac surgical patients.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Cochrane
	Database Syst Rev</font></em><font size="1" style="font-size: 8pt">.
	2016;9:CD003587.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27616189">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">9.</font></p>
<div id="R782" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Borde
	DP, Futane SS, Asegaonkar B, et al. Effect of perioperative
	pregabalin on postoperative quality of recovery in patients
	undergoing Off-Pump Coronary Artery Bypass Grafting (OPCABG): a
	prospective, randomized, double-blind trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Cardiothorac Vasc Anesth</font></em><font size="1" style="font-size: 8pt">.
	2017;31:1241–1245.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1053/j.jvca.2016.09.029">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27939574">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">10.</font></p>
<div id="R783" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Jelacic
	S, Bollag L, Bowdle A, et al. Intravenous acetaminophen as an
	adjunct analgesic in cardiac surgery reduces opioid consumption but
	not opioid-related adverse effects: a randomized controlled trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Cardiothorac Vasc Anesth</font></em><font size="1" style="font-size: 8pt">.
	2016;30:997–1004.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1053/j.jvca.2016.02.010">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27521969">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">11.</font></p>
<div id="R784" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Joshi
	SS, Jagadeesh AM. Efficacy of perioperative pregabalin in acute and
	chronic post-operative pain after off-pump coronary artery bypass
	surgery: a randomized, double-blind placebo controlled trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Card Anaesth</font></em><font size="1" style="font-size: 8pt">.
	2013;16:180–185.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.4103/0971-9784.114239">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23816671">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">12.</font></p>
<div id="R785" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Khalil
	MA, Abdel Azeem MS. The impact of dexmedetomidine infusion in
	sparing morphine consumption in off-pump coronary artery bypass
	grafting.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Semin
	Cardiothorac Vasc Anesth</font></em><font size="1" style="font-size: 8pt">.
	2013;17:66–71.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1177/1089253212463969">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23108415">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">13.</font></p>
<div id="R786" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Lahtinen
	P, Kokki H, Hakala T, et al. S(+)-ketamine as an analgesic adjunct
	reduces opioid consumption after cardiac surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Anesth
	Analg</font></em><font size="1" style="font-size: 8pt">.
	2004;99:1295–1301.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1213/01.ANE.0000133913.07342.B9">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15502020">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">14.</font></p>
<div id="R787" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Menda
	F, Köner O, Sayin M, et al. Effects of single-dose gabapentin on
	postoperative pain and morphine consumption after cardiac surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Cardiothorac Vasc Anesth</font></em><font size="1" style="font-size: 8pt">.
	2010;24:808–813.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1053/j.jvca.2009.10.023">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20056448">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">15.</font></p>
<div id="R788" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Subramaniam
	B, Shankar P, Shaefi S, et al. Effect of intravenous acetaminophen
	vs placebo combined with propofol or dexmedetomidine on
	postoperative delirium among older patients following cardiac
	surgery: the DEXACET randomized clinical trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA</font></em><font size="1" style="font-size: 8pt">.
	2019;321:686–696.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jama.2019.0234">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30778597">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">16.</font></p>
<div id="R789" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Grant
	MC, Isada T, Ruzankin P, et al. Opioid-sparing cardiac anesthesia:
	secondary analysis of an enhanced recovery program for cardiac
	surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Anesth
	Analg</font></em><font size="1" style="font-size: 8pt">.
	2020;131:1852–1861.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1213/ANE.0000000000005152">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/32889848">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">17.</font></p>
<div id="R790" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Landoni
	G, Biondi-Zoccai GGL, Zangrillo A, et al. Desflurane and sevoflurane
	in cardiac surgery: a meta-analysis of randomized clinical trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Cardiothorac Vasc Anesth</font></em><font size="1" style="font-size: 8pt">.
	2007;21:502–511.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1053/j.jvca.2007.02.013">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17678775">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">18.</font></p>
<div id="R791" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Landoni
	G, Greco T, Biondi-Zoccai G, et al. Anaesthetic drugs and survival:
	a Bayesian network meta-analysis of randomized trials in cardiac
	surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Br J
	Anaesth</font></em><font size="1" style="font-size: 8pt">.
	2013;111:886–896.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/bja/aet231">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23852263">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">19.</font></p>
<div id="R792" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Landoni
	G, Guarracino F, Cariello C, et al. Volatile compared with total
	intravenous anaesthesia in patients undergoing high-risk cardiac
	surgery: a randomized multicentre study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Br
	J Anaesth</font></em><font size="1" style="font-size: 8pt">.
	2014;113:955–963.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/bja/aeu290">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25186820">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">20.</font></p>
<div id="R793" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Landoni
	G, Lomivorotov VV, Nigro Neto C, et al. Volatile anesthetics versus
	total intravenous anesthesia for cardiac surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2019;380:1214–1225.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1816476">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30888743">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">21.</font></p>
<div id="R794" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Symons
	JA, Myles PS. Myocardial protection with volatile anaesthetic agents
	during coronary artery bypass surgery: a meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Br
	J Anaesth</font></em><font size="1" style="font-size: 8pt">.
	2006;97:127–136.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/bja/ael149">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16793778">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">22.</font></p>
<div id="R795" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Zamani
	MM, Najafi A, Sehat S, et al. The effect of intraoperative lung
	protective ventilation vs conventional ventilation, on postoperative
	pulmonary complications after cardiopulmonary bypass.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Cardiovasc Thorac Res</font></em><font size="1" style="font-size: 8pt">.
	2017;9:221–228.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.15171/jcvtr.2017.38">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29391936">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">23.</font></p>
<div id="R796" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Zochios
	V, Klein AA, Gao F. Protective invasive ventilation in cardiac
	surgery: a systematic review with a focus on acute lung injury in
	adult cardiac surgical patients.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Cardiothorac Vasc Anesth</font></em><font size="1" style="font-size: 8pt">.
	2018;32:1922–1936.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1053/j.jvca.2017.10.031">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29199052">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">24.</font></p>
<div id="R797" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Sundar
	S, Novack V, Jervis K, et al. Influence of low tidal volume
	ventilation on time to extubation in cardiac surgical
	patients.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Anesthesiology</font></em><font size="1" style="font-size: 8pt">.
	2011;114:1102–1110.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1097/ALN.0b013e318215e254">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21430518">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">25.</font></p>
<div id="R798" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Yang
	D, Grant MC, Stone A, et al. A meta-analysis of intraoperative
	ventilation strategies to prevent pulmonary complications: is low
	tidal volume alone sufficient to protect healthy lungs?&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Surg</font></em><font size="1" style="font-size: 8pt">.
	2016;263:881–887.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1097/SLA.0000000000001443">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26720429">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">26.</font></p>
<div id="R799" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Aya
	HD, Cecconi M, Hamilton M, et al. Goal-directed therapy in cardiac
	surgery: a systematic review and meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Br
	J Anaesth</font></em><font size="1" style="font-size: 8pt">.
	2013;110:510–517.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/bja/aet020">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23447502">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">27.</font></p>
<div id="R800" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Li
	P, Qu L-P, Qi D, et al. Significance of perioperative goal-directed
	hemodynamic approach in preventing postoperative complications in
	patients after cardiac surgery: a meta-analysis and systematic
	review.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Med</font></em><font size="1" style="font-size: 8pt">.
	2017;49:343–351.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1080/07853890.2016.1271956">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27936959">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">28.</font></p>
<div id="R801" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kihara
	C, Murata K, Wada Y, et al. Impact of intraoperative transesophageal
	echocardiography in cardiac and thoracic aortic surgery: experience
	in 1011 cases.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2009;54:282–288.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jjcc.2009.06.001">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19782266">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">29.</font></p>
<div id="R802" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Savage
	RM, Lytle BW, Aronson S, et al. Intraoperative echocardiography is
	indicated in high-risk coronary artery bypass grafting.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	1997;64:368–373. discussion 73-4.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0003-4975(97)00612-7">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/9262577">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">30.</font></p>
<div id="R803" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Eltzschig
	HK, Rosenberger P, Löffler M, et al. Impact of intraoperative
	transesophageal echocardiography on surgical decisions in 12 566
	patients undergoing cardiac surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2008;85:845–852.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.athoracsur.2007.11.015">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18291154">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">31.</font></p>
<div id="R804" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Qaddoura
	FE, Abel MD, Mecklenburg KL, et al. Role of intraoperative
	transesophageal echocardiography in patients having coronary artery
	bypass graft surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2004;78:1586–1590.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.athoracsur.2004.05.001">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15511437">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">32.</font></p>
<div id="R805" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Swaminathan
	M, Morris RW, De Meyts DD, et al. Deterioration of regional wall
	motion immediately after coronary artery bypass graft surgery is
	associated with long-term major adverse cardiac
	events.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Anesthesiology</font></em><font size="1" style="font-size: 8pt">.
	2007;107:739–745.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1097/01.anes.0000287008.70453.81">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18073549">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">33.</font></p>
<div id="R806" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Swaminathan
	M, Nicoara A, Phillips-Bute BG, et al. Utility of a simple algorithm
	to grade diastolic dysfunction and predict outcome after coronary
	artery bypass graft surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2011;91:1844–1850.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.athoracsur.2011.02.008">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21492828">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">34.</font></p>
<div id="R807" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Suehiro
	K, Tanaka K, Yamada T, et al. The utility of intra-operative
	three-dimensional transoesophageal echocardiography for dynamic
	measurement of stroke volume.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Anaesthesia</font></em><font size="1" style="font-size: 8pt">.
	2015;70:150–159.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1111/anae.12857">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25265890">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">35.</font></p>
<div id="R808" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Aggarwal
	N, Unnikrishnan KP, Biswas I, et al. Intraoperative assessment of
	transient and persistent regional left ventricular wall motion
	abnormalities in patients undergoing coronary revascularization
	surgery using real time three-dimensional transesophageal
	echocardiography: a prospective observational
	study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Echocardiography</font></em><font size="1" style="font-size: 8pt">.
	2017;34:1649–1659.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1111/echo.13661">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28833528">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">36.</font></p>
<div id="R809" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Chiang
	Y, Hosseinian L, Rhee A, et al. Questionable benefit of the
	pulmonary artery catheter after cardiac surgery in high-risk
	patients.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Cardiothorac Vasc Anesth</font></em><font size="1" style="font-size: 8pt">.
	2015;29:76–81.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1053/j.jvca.2014.07.017">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25620141">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">37.</font></p>
<div id="R810" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Schwann
	TA, Zacharias A, Riordan CJ, et al. Safe, highly selective use of
	pulmonary artery catheters in coronary artery bypass grafting: an
	objective patient selection method.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2002;73:1394–1401. discussion 401-2.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0003-4975(02)03422-7">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12022523">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">38.</font></p>
<div id="R811" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Schwann
	NM, Hillel Z, Hoeft A, et al. Lack of effectiveness of the pulmonary
	artery catheter in cardiac surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Anesth
	Analg</font></em><font size="1" style="font-size: 8pt">.
	2011;113:994–1002.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1213/ANE.0b013e31822c94a8">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21918165">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">39.</font></p>
<div id="R812" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Ramsey
	SD, Saint S, Sullivan SD, et al. Clinical and economic effects of
	pulmonary artery catheterization in nonemergent coronary artery
	bypass graft surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Cardiothorac Vasc Anesth</font></em><font size="1" style="font-size: 8pt">.
	2000;14:113–118.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S1053-0770(00)90001-6">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/10794325">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">40.</font></p>
<div id="R813" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Resano
	FG, Kapetanakis EI, Hill PC, et al. Clinical outcomes of low-risk
	patients undergoing beating-heart surgery with or without pulmonary
	artery catheterization.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Cardiothorac Vasc Anesth</font></em><font size="1" style="font-size: 8pt">.
	2006;20:300–306.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1053/j.jvca.2006.01.017">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16750726">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">41.</font></p>
<div id="R814" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Zorrilla-Vaca
	A, Healy R, Grant MC, et al. Intraoperative cerebral oximetry-based
	management for optimizing perioperative outcomes: a meta-analysis of
	randomized controlled trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Can
	J Anaesth</font></em><font size="1" style="font-size: 8pt">.
	2018;65:529–542.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1007/s12630-018-1065-7">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29427259">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">42.</font></p>
<div id="R815" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Colak
	Z, Borojevic M, Bogovic A, et al. Influence of intraoperative
	cerebral oximetry monitoring on neurocognitive function after
	coronary artery bypass surgery: a randomized, prospective study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	J Cardiothorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2015;47:447–454.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/ejcts/ezu193">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24810757">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">43.</font></p>
<div id="R816" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Vretzakis
	G, Georgopoulou S, Stamoulis K, et al. Monitoring of brain oxygen
	saturation (INVOS) in a protocol to direct blood transfusions during
	cardiac surgery: a prospective randomized clinical trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Cardiothorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2013;8:145.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1186/1749-8090-8-145">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23758929">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">44.</font></p>
<div id="R817" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kara
	I, Erkin A, Sacli H, et al. The effects of near-infrared
	spectroscopy on the neurocognitive functions in the patients
	undergoing coronary artery bypass grafting with asymptomatic carotid
	artery disease: a randomized prospective study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Cardiovasc Surg</font></em><font size="1" style="font-size: 8pt">.
	2015;21:544–550.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.5761/atcs.oa.15-00118">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26133933">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">45.</font></p>
<div id="R818" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Rogers
	CA, Stoica S, Ellis L, et al. Randomized trial of near-infrared
	spectroscopy for personalized optimization of cerebral tissue
	oxygenation during cardiac surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Br
	J Anaesth</font></em><font size="1" style="font-size: 8pt">.
	2017;119:384–393.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/bja/aex182">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28969313">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">46.</font></p>
<div id="R819" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Uysal
	S, Lin H-M, Trinh M, et al. Optimizing cerebral oxygenation in
	cardiac surgery: a randomized controlled trial examining
	neurocognitive and perioperative outcomes.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Thorac Cardiovasc Surg</font></em><font size="1" style="font-size: 8pt">.
	2020;159:943–953.e3.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jtcvs.2019.03.036">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31056357">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">47.</font></p>
<div id="R820" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Deschamps
	A, Hall R, Grocott H, et al. Cerebral oximetry monitoring to
	maintain normal cerebral oxygen saturation during high-risk cardiac
	surgery: a randomized controlled feasibility trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Anesthesiology</font></em><font size="1" style="font-size: 8pt">.
	2016;124:826–836.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1097/ALN.0000000000001029">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26808629">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">48.</font></p>
<div id="R821" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kertai
	MD, Pal N, Palanca BJA, et al. Association of perioperative risk
	factors and cumulative duration of low bispectral index with
	intermediate-term mortality after cardiac surgery in the B-Unaware
	Trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Anesthesiology</font></em><font size="1" style="font-size: 8pt">.
	2010;112:1116–1127.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1097/ALN.0b013e3181d5e0a3">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20418692">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">49.</font></p>
<div id="R822" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Vance
	JL, Shanks AM, Woodrum DT. Intraoperative bispectral index
	monitoring and time to extubation after cardiac surgery: secondary
	analysis of a randomized controlled trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>BMC
	Anesthesiol</font></em><font size="1" style="font-size: 8pt">.
	2014;14:79.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1186/1471-2253-14-79">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25249789">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">50.</font></p>
<div id="R823" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Villafranca
	A, Thomson IA, Grocott HP, et al. The impact of bispectral index
	versus end-tidal anesthetic concentration-guided anesthesia on time
	to tracheal extubation in fast-track cardiac surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Anesth
	Analg</font></em><font size="1" style="font-size: 8pt">.
	2013;116:541–548.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1213/ANE.0b013e31827b117e">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23400982">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">51.</span></font></p>
<div id="R824" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Vretzakis
	G, Ferdi E, Argiriadou H, et al. Influence of bispectral index
	monitoring on decision making during cardiac anesthesia.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Clin Anesth</font></em><font size="1" style="font-size: 8pt">.
	2005;17:509–516.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jclinane.2004.12.018">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16297750">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>12.2.
Bypass Conduits in Patients Undergoing CABG</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R825" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Gaudino
	M, Benedetto U, Fremes S, et al. Radial-artery or saphenous-vein
	grafts in coronary-artery bypass surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2018;378:2069–2077.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1716026">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29708851">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R826" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Cao
	C, Manganas C, Horton M, et al. Angiographic outcomes of radial
	artery versus saphenous vein in coronary artery bypass graft
	surgery: a meta-analysis of randomized controlled trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Thorac Cardiovasc Surg</font></em><font size="1" style="font-size: 8pt">.
	2013;146:255–261.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jtcvs.2012.07.014">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22871565">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R827" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Gaudino
	M, Lorusso R, Rahouma M, et al. Radial artery versus right internal
	thoracic artery versus saphenous vein as the second conduit for
	coronary artery bypass surgery: a network meta-analysis of clinical
	outcomes.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J Am
	Heart Assoc</font></em><font size="1" style="font-size: 8pt">.
	2019;8:e010839.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/JAHA.118.010839">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30636525">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R828" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Zeff
	RH, Kongtahworn C, Iannone LA, et al. Internal mammary artery versus
	saphenous vein graft to the left anterior descending coronary
	artery: prospective randomized study with 10-year follow-up.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	1988;45:533–536.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0003-4975(10)64526-2">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/3259128">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R829" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Boylan
	MJ, Lytle BW, Loop FD, et al. Surgical treatment of isolated left
	anterior descending coronary stenosis. Comparison of left internal
	mammary artery and venous autograft at 18 to 20 years of
	follow-up.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Thorac Cardiovasc Surg</font></em><font size="1" style="font-size: 8pt">.
	1994;107:657–662.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0022-5223(94)70320-5">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/8127094">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R830" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Loop
	FD, Lytle BW, Cosgrove DM, et al. Influence of the
	internal-mammary-artery graft on 10-year survival and other cardiac
	events.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N Engl
	J Med</font></em><font size="1" style="font-size: 8pt">.
	1986;314:1–6.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJM198601023140101">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/3484393">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R831" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Cameron
	A, Davis KB, Green G, et al. Coronary bypass surgery with
	internal-thoracic-artery grafts--effects on survival over a 15-year
	period.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N Engl
	J Med</font></em><font size="1" style="font-size: 8pt">.
	1996;334:216–219.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJM199601253340402">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/8531997">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R832" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Tatoulis
	J, Buxton BF, Fuller JA. The right internal thoracic artery: the
	forgotten conduit–5 766 patients and 991 angiograms.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2011;92:9–15; discussion-7.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.athoracsur.2011.03.099">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21718825">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">9.</font></p>
<div id="R833" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Magruder
	JT, Young A, Grimm JC, et al. Bilateral internal thoracic artery
	grafting: does graft configuration affect outcome?&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Thorac Cardiovasc Surg</font></em><font size="1" style="font-size: 8pt">.
	2016;152:120–127.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jtcvs.2016.03.022">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27343909">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">10.</font></p>
<div id="R834" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Yi
	G, Shine B, Rehman SM, et al. Effect of bilateral internal mammary
	artery grafts on long-term survival: a meta-analysis
	approach.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2014;130:539–545.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circulationaha.113.004255">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24916209">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">11.</font></p>
<div id="R835" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Takagi
	H, Goto SN, Watanabe T, et al. A meta-analysis of adjusted hazard
	ratios from 20 observational studies of bilateral versus single
	internal thoracic artery coronary artery bypass grafting.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Thorac Cardiovasc Surg</font></em><font size="1" style="font-size: 8pt">.
	2014;148:1282–1290.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jtcvs.2014.01.010">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24521973">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">12.</font></p>
<div id="R836" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Taggart
	DP, Benedetto U, Gerry S, et al. Bilateral versus single
	internal-thoracic-artery grafts at 10 years.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2019;380:437–446.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1808783">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30699314">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">13.</font></p>
<div id="R837" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Gaudino
	M, Benedetto U, Fremes S, et al. Association of radial artery graft
	vs saphenous vein graft with long-term cardiovascular outcomes among
	patients undergoing coronary artery bypass grafting: a systematic
	review and meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA</font></em><font size="1" style="font-size: 8pt">.
	2020;324:179–187.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jama.2020.8228">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/32662861">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">14.</font></p>
<div id="R838" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Benedetto
	U, Raja SG, Albanese A, et al. Searching for the second best graft
	for coronary artery bypass surgery: a network meta-analysis of
	randomized controlled trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	J Cardiothorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2015;47:59–65.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/ejcts/ezu111">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24686003">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">15.</font></p>
<div id="R839" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Abu-Omar
	Y, Mussa S, Anastasiadis K, et al. Duplex ultrasonography predicts
	safety of radial artery harvest in the presence of an abnormal Allen
	test.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2004;77:116–119.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0003-4975(03)01515-7">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/14726046">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">16.</font></p>
<div id="R840" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Gaudino
	M, Di Franco A, Rahouma M, et al. Unmeasured confounders in
	observational studies comparing bilateral versus single internal
	thoracic artery for coronary artery bypass grafting: a
	meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Heart Assoc</font></em><font size="1" style="font-size: 8pt">.
	2018;7:e008010.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/JAHA.117.008010">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29306899">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">17.</font></p>
<div id="R841" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Schwann
	TA, Habib RH, Wallace A, et al. Operative outcomes of
	multiple-arterial versus single-arterial coronary bypass
	grafting.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2018;105:1109–1119.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.athoracsur.2017.10.058">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29453002">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">18.</font></p>
<div id="R842" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Gaudino
	M, Puskas JD, Di Franco A, et al. Three arterial grafts improve late
	survival: a meta-analysis of propensity-matched
	studies.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2017;135:1036–1044.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCULATIONAHA.116.025453">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28119382">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">19.</span></font></p>
<div id="R843" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Yanagawa
	B, Verma S, Mazine A, et al. Impact of total arterial
	revascularization on long term survival: a systematic review and
	meta-analysis of 130 305 patients.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Int
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2017;233:29–36.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.ijcard.2017.02.010">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28185702">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>12.3.
CABG in Patients Undergoing Other Cardiac Surgery</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R844" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Abel
	NJ, Rogal GJ, Burns P, et al. Aortic valve replacement with and
	without coronary artery bypass graft surgery in octogenarians: is it
	safe and feasible?&nbsp;</font><font size="1" style="font-size: 8pt"><em>Cardiology</font></em><font size="1" style="font-size: 8pt">.
	2013;124:163–173.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1159/000346153">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23467192">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R845" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Agarwal
	S, Garg A, Parashar A, et al. In-hospital mortality and stroke after
	surgical aortic valve replacement: a nationwide perspective.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Thorac Cardiovasc Surg</font></em><font size="1" style="font-size: 8pt">.
	2015;150:571–578.e8.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jtcvs.2015.05.068">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26183193">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R846" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Biancari
	F, Martin M, Bordin G, et al. Basic data from 176 studies on the
	immediate outcome after aortic valve replacement with or without
	coronary artery bypass surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Cardiothorac Vasc Anesth</font></em><font size="1" style="font-size: 8pt">.
	2014;28:1251–1256.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1053/j.jvca.2013.07.020">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24290746">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R847" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Carnero-Alcázar
	M, Reguillo-Lacruz F, Alswies A, et al. Short- and mid-term results
	for aortic valve replacement in octogenarians.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Interact
	Cardiovasc Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2010;10:549–554.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1510/icvts.2009.218040">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20100705">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R848" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Di
	Gioia G, Pellicano M, Toth GG, et al. Clinical outcome of patients
	with aortic stenosis and coronary artery disease not treated
	according to current recommendations.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Cardiovasc Transl Res</font></em><font size="1" style="font-size: 8pt">.
	2016;9:145–152.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1007/s12265-016-9680-6">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26883368">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R849" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Roberts
	WC, Roberts CC, Vowels TJ, et al. Effect of coronary bypass and
	valve structure on outcome in isolated valve replacement for aortic
	stenosis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am J
	Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2012;109:1334–1340.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.amjcard.2011.12.028">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22386959">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R850" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Beach
	JM, Mihaljevic T, Svensson LG, et al. Coronary artery disease and
	outcomes of aortic valve replacement for severe aortic stenosis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2013;61:837–848.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2012.10.049">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23428216">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R851" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Shan
	L, Saxena A, McMahon R, et al. A systematic review on the quality of
	life benefits after aortic valve replacement in the elderly.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Thorac Cardiovasc Surg</font></em><font size="1" style="font-size: 8pt">.
	2013;145:1173–1189.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jtcvs.2013.01.004">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23415689">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">9.</font></p>
<div id="R852" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Vasques
	F, Lucenteforte E, Paone R, et al. Outcome of patients aged ≥80
	years undergoing combined aortic valve replacement and coronary
	artery bypass grafting: a systematic review and meta-analysis of 40
	studies.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2012;164:410–418.e1.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.ahj.2012.06.019">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22980309">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">10.</font></p>
<div id="R853" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Thalji
	NM, Suri RM, Daly RC, et al. The prognostic impact of concomitant
	coronary artery bypass grafting during aortic valve surgery:
	implications for revascularization in the transcatheter era.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Thorac Cardiovasc Surg</font></em><font size="1" style="font-size: 8pt">.
	2015;149:451–460.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jtcvs.2014.08.073">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25308117">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">11.</font></p>
<div id="R854" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Yamanaka
	K, Komiya T, Tsuneyoshi H, et al. Outcomes of Concomitant Total
	Aortic Arch Replacement with Coronary Artery Bypass Grafting.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Cardiovasc Surg</font></em><font size="1" style="font-size: 8pt">.
	2016;22:251–257.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.5761/atcs.oa.16-00056">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27237968">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">12.</span></font></p>
<div id="R855" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Li
	Z, Anderson I, Amsterdam EA, et al. Effect of coronary artery
	disease extent on contemporary outcomes of combined aortic valve
	replacement and coronary artery bypass graft surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2013;96:2075–2082.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.athoracsur.2013.07.035">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24070699">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>12.4.
Use of Epiaortic Ultrasound in Patients Undergoing CABG</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R856" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Biancari
	F, Santini F, Tauriainen T, et al. Epiaortic ultrasound to prevent
	stroke in coronary artery bypass grafting.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2020;109:294–301.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.athoracsur.2019.06.078">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31421104">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R857" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Yamaguchi
	A, Adachi H, Tanaka M, et al. Efficacy of intraoperative epiaortic
	ultrasound scanning for preventing stroke after coronary artery
	bypass surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Cardiovasc Surg</font></em><font size="1" style="font-size: 8pt">.
	2009;15:98–104.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19471223">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R858" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Das
	S, Dunning J. Can epiaortic ultrasound reduce the incidence of
	intraoperative stroke during cardiac surgery?&nbsp;</font><font size="1" style="font-size: 8pt"><em>Interact
	Cardiovasc Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2004;3:71–75.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S1569-9293(03)00220-2">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17670180">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R859" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Djaiani
	G, Ali M, Borger MA, et al. Epiaortic scanning modifies planned
	intraoperative surgical management but not cerebral embolic load
	during coronary artery bypass surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Anesth
	Analg</font></em><font size="1" style="font-size: 8pt">.
	2008;106:1611–1618.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1213/ane.0b013e318172b044">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18499587">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R860" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Gold
	JP, Torres KE, Maldarelli W, et al. Improving outcomes in coronary
	surgery: the impact of echo-directed aortic cannulation and
	perioperative hemodynamic management in 500 patients.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2004;78:1579–1585.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.athoracsur.2004.05.051">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15511435">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R861" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Joo
	HC, Youn YN, Kwak YL, et al. Intraoperative epiaortic scanning for
	preventing early stroke after off-pump coronary artery bypass.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Br
	J Anaesth</font></em><font size="1" style="font-size: 8pt">.
	2013;111:374–381.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/bja/aet113">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23611913">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R862" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Lyons
	JM, Thourani VH, Puskas JD, et al. Intraoperative epiaortic
	ultrasound scanning guides operative strategies and identifies
	patients at high risk during coronary artery bypass
	grafting.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Innovations
	(Phila)</font></em><font size="1" style="font-size: 8pt">.
	2009;4:99–105.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1097/imi.0b013e3181a3476f">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22436990">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R863" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Nakamura
	M, Okamoto F, Nakanishi K, et al. Does intensive management of
	cerebral hemodynamics and atheromatous aorta reduce stroke after
	coronary artery surgery?&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2008;85:513–519.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.athoracsur.2007.08.056">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18222254">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">9.</font></p>
<div id="R864" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Rosenberger
	P, Shernan SK, Löffler M, et al. The influence of epiaortic
	ultrasonography on intraoperative surgical management in 6051
	cardiac surgical patients.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2008;85:548–553.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.athoracsur.2007.08.061">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18222262">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">10.</font></p>
<div id="R865" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Zingone
	B, Rauber E, Gatti G, et al. The impact of epiaortic
	ultrasonographic scanning on the risk of perioperative stroke.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	J Cardiothorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2006;29:720–728.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.ejcts.2006.02.001">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16522368">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">11.</font></p>
<div id="R866" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Blauth
	CI, Cosgrove DM, Webb BW, et al. Atheroembolism from the ascending
	aorta. An emerging problem in cardiac surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Thorac Cardiovasc Surg</font></em><font size="1" style="font-size: 8pt">.
	1992;103:1104–1111. discussion 11-2.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0022-5223(19)34874-3">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/1597974">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">12.</font></p>
<div id="R867" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Dávila-Román
	VG, Barzilai B, Wareing TH, et al. Atherosclerosis of the ascending
	aorta. Prevalence and role as an independent predictor of
	cerebrovascular events in cardiac patients.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Stroke</font></em><font size="1" style="font-size: 8pt">.
	1994;25:2010–2016.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/01.STR.25.10.2010">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/8091446">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">13.</font></p>
<div id="R868" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Bolotin
	G, Domany Y, de Perini L, et al. Use of intraoperative epiaortic
	ultrasonography to delineate aortic atheroma.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Chest</font></em><font size="1" style="font-size: 8pt">.
	2005;127:60–65.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1378/chest.127.1.60">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15653963">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">14.</font></p>
<div id="R869" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Suvarna
	S, Smith A, Stygall J, et al. An intraoperative assessment of the
	ascending aorta: a comparison of digital palpation, transesophageal
	echocardiography, and epiaortic ultrasonography.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Cardiothorac Vasc Anesth</font></em><font size="1" style="font-size: 8pt">.
	2007;21:805–809.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1053/j.jvca.2007.05.014">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18068056">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">15.</font></p>
<div id="R870" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Sylivris
	S, Calafiore P, Matalanis G, et al. The intraoperative assessment of
	ascending aortic atheroma: epiaortic imaging is superior to both
	transesophageal echocardiography and direct palpation.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Cardiothorac Vasc Anesth</font></em><font size="1" style="font-size: 8pt">.
	1997;11:704–707.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S1053-0770(97)90161-0">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/9327309">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">16.</font></p>
<div id="R871" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Hangler
	HB, Nagele G, Danzmayr M, et al. Modification of surgical technique
	for ascending aortic atherosclerosis: impact on stroke reduction in
	coronary artery bypass grafting.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Thorac Cardiovasc Surg</font></em><font size="1" style="font-size: 8pt">.
	2003;126:391–400.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0022-5223(03)00395-7">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12928635">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">17.</font></p>
<div id="R872" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Meissner
	I, Khandheria BK, Sheps SG, et al. Atherosclerosis of the aorta:
	risk factor, risk marker, or innocent bystander? A prospective
	population-based transesophageal echocardiography study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2004;44:1018–1024.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2004.05.075">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15337213">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">18.</font></p>
<div id="R873" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Hogue
	CW, Murphy SF, Schechtman KB, et al. Risk factors for early or
	delayed stroke after cardiac surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	1999;100:642–647.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/01.CIR.100.6.642">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/10441102">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">19.</font></p>
<div id="R874" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Roach
	GW, Kanchuger M, Mangano CM, et al. Adverse cerebral outcomes after
	coronary bypass surgery. Multicenter Study of Perioperative Ischemia
	Research Group and the Ischemia Research and Education Foundation
	Investigators.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	1996;335:1857–1863.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJM199612193352501">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/8948560">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">20.</font></p>
<div id="R875" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Djaiani
	G, Fedorko L, Borger M, et al. Mild to moderate atheromatous disease
	of the thoracic aorta and new ischemic brain lesions after
	conventional coronary artery bypass graft surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Stroke</font></em><font size="1" style="font-size: 8pt">.
	2004;35:e356–e358.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/01.str.0000138783.63858.62">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15284448">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">21.</font></p>
<div id="R876" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Schachner
	T, Zimmer A, Nagele G, et al. The influence of ascending aortic
	atherosclerosis on the long-term survival after CABG.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	J Cardiothorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2005;28:558–562.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.ejcts.2005.07.004">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16126401">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">22.</font></p>
<div id="R877" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Dávila-Román
	VG, Phillips KJ, Daily BB, et al. Intraoperative transesophageal
	echocardiography and epiaortic ultrasound for assessment of
	atherosclerosis of the thoracic aorta.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	1996;28:942–947.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0735-1097(96)00263-X">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/8837572">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">23.</font></p>
<div id="R878" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Royse
	C, Royse A, Blake D, et al. Screening the thoracic aorta for
	atheroma: a comparison of manual palpation, transesophageal and
	epiaortic ultrasonography.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Cardiovasc Surg</font></em><font size="1" style="font-size: 8pt">.
	1998;4:347–350.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/9914464">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">24.</span></font></p>
<div id="R879" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Van
	Zaane B, Zuithoff NP, Reitsma JB, et al. Meta-analysis of the
	diagnostic accuracy of transesophageal echocardiography for
	assessment of atherosclerosis in the ascending aorta in patients
	undergoing cardiac surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Acta
	Anaesthesiol Scand</font></em><font size="1" style="font-size: 8pt">.
	2008;52:1179–1187.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1111/j.1399-6576.2008.01694.x">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18823455">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>12.5.
Use of Cardiopulmonary Bypass in Patients Undergoing CABG</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R880" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Lamy
	A, Devereaux PJ, Prabhakaran D, et al. Off-pump or on-pump
	coronary-artery bypass grafting at 30 days.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2012;366:1489–1497.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1200388">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22449296">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R881" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Smart
	NA, Dieberg G, King N. Long-term outcomes of on- versus off-pump
	coronary artery bypass grafting.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2018;71:983–991.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2017.12.049">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29495998">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R882" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Al-Ruzzeh
	S, George S, Bustami M, et al. Effect of off-pump coronary artery
	bypass surgery on clinical, angiographic, neurocognitive, and
	quality of life outcomes: randomised controlled trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>BMJ</font></em><font size="1" style="font-size: 8pt">.
	2006;332:1365.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1136/bmj.38852.479907.7C">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16740529">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R883" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Angelini
	GD, Taylor FC, Reeves BC, et al. Early and midterm outcome after
	off-pump and on-pump surgery in Beating Heart Against Cardioplegic
	Arrest Studies (BHACAS 1 and 2): a pooled analysis of two randomised
	controlled trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2002;359:1194–1199.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(02)08216-8">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/11955537">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R884" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Houlind
	K, Kjeldsen BJ, Madsen SN, et al. On-pump versus off-pump coronary
	artery bypass surgery in elderly patients: results from the Danish
	on-pump versus off-pump randomization study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2012;125:2431–2439.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circulationaha.111.052571">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22523305">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R885" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Lamy
	A, Devereaux PJ, Prabhakaran D, et al. Effects of off-pump and
	on-pump coronary-artery bypass grafting at 1 year.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2013;368:1179–1188.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1301228">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23477676">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R886" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Nathoe
	HM, van Dijk D, Jansen EW, et al. A comparison of on-pump and
	off-pump coronary bypass surgery in low-risk patients.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2003;348:394–402.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa021775">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12556542">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R887" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Puskas
	JD, Williams WH, Duke PG, et al. Off-pump coronary artery bypass
	grafting provides complete revascularization with reduced myocardial
	injury, transfusion requirements, and length of stay: a prospective
	randomized comparison of two hundred unselected patients undergoing
	off-pump versus conventional coronary artery bypass grafting.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Thorac Cardiovasc Surg</font></em><font size="1" style="font-size: 8pt">.
	2003;125:797–808.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1067/mtc.2003.324">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12698142">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">9.</font></p>
<div id="R888" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Houlind,
	K, Fenger-Gron, M, Holme, SJ, et al. Graft patency after off-pump
	coronary artery bypass surgery is inferior even with identical
	heparinization protocols: results from the Danish On-pump Versus
	Off-pump Randomization Study (DOORS).&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Thorac Cardiovasc Surg</font></em><font size="1" style="font-size: 8pt">.
	2014;148:1812–1819.e2.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">10.</font></p>
<div id="R889" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Hueb
	W, Lopes NH, Pereira AC, et al. Five-year follow-up of a randomized
	comparison between off-pump and on-pump stable multivessel coronary
	artery bypass grafting. The MASS III Trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2010;122:S48–S52.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCULATIONAHA.109.924258">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20837925">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">11.</font></p>
<div id="R890" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Moller
	CH, Perko MJ, Lund JT, et al. No major differences in 30-day
	outcomes in high-risk patients randomized to off-pump versus on-pump
	coronary bypass surgery: the best bypass surgery trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2010;121:498–504.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCULATIONAHA.109.880443">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20083683">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">12.</font></p>
<div id="R891" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Diegeler
	A, Börgermann J, Kappert U, et al. Five-year outcome after off-pump
	or on-pump coronary artery bypass grafting in ederly
	patients.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2019;139:1865–1871.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCULATIONAHA.118.035857">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30732456">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">13.</font></p>
<div id="R892" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Garg
	AX, Devereaux PJ, Yusuf S, et al. Kidney function after off-pump or
	on-pump coronary artery bypass graft surgery: a randomized clinical
	trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA</font></em><font size="1" style="font-size: 8pt">.
	2014;311:2191–2198.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jama.2014.4952">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24886787">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">14.</font></p>
<div id="R893" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Noiseux
	N, Stevens L, Chartrand-Lefebvre C, et al. Evaluation of graft
	patency in off-pump versus on-pump CABG: the PATENCY-CORONARY
	trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Can J
	Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2015;31(Suppl):S110.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.cjca.2015.07.243">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">15.</font></p>
<div id="R894" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Deppe
	A-C, Arbash W, Kuhn EW, et al. Current evidence of coronary artery
	bypass grafting off-pump versus on-pump: a systematic review with
	meta-analysis of over 16 900 patients investigated in randomized
	controlled trials†.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	J Cardiothorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2016;49:1031–1041. discussion 41.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/ejcts/ezv268">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26276839">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">16.</font></p>
<div id="R895" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Edelman
	JJ, Yan TD, Bannon PG, et al. Coronary artery bypass grafting with
	and without manipulation of the ascending aorta--a
	meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Heart
	Lung Circ</font></em><font size="1" style="font-size: 8pt">.
	2011;20:318–324.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.hlc.2011.02.003">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21511187">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">17.</font></p>
<div id="R896" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Lamy
	A, Devereaux PJ, Prabhakaran D, et al. Five-year outcomes after
	off-pump or on-pump coronary-artery bypass grafting.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2016;375:2359–2368.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1601564">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27771985">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">18.</font></p>
<div id="R897" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Shroyer
	AL, Hattler B, Wagner TH, et al. Five-year outcomes after on-pump
	and off-pump coronary-artery bypass.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2017;377:623–632.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1614341">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28813218">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">19.</font></p>
<div id="R898" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Takagi
	H, Matsui M, Umemoto T. Off-pump coronary artery bypass may increase
	late mortality: a meta-analysis of randomized trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2010;89:1881–1888.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.athoracsur.2010.03.010">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20494043">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">20.</font></p>
<div id="R899" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Møller
	CH, Penninga L, Wetterslev J, et al. Off-pump versus on-pump
	coronary artery bypass grafting for ischaemic heart
	disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Cochrane
	Database Syst Rev</font></em><font size="1" style="font-size: 8pt">.
	2012;3:CD007224.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">21.</font></p>
<div id="R900" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kuss
	O, von Salviati B, Börgermann J. Off-pump versus on-pump coronary
	artery bypass grafting: a systematic review and meta-analysis of
	propensity score analyses.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Thorac Cardiovasc Surg</font></em><font size="1" style="font-size: 8pt">.
	2010;140:829–835, 35.e1-13.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jtcvs.2009.12.022">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20167334">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">22.</font></p>
<div id="R901" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">D’Agostino
	RS, Jacobs JP, Badhwar V, et al. The Society of Thoracic Surgeons
	Adult Cardiac Surgery Database: 2019 update on outcomes and
	quality.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2019;107:24–32.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.athoracsur.2018.10.004">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30423335">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">23.</span></font></p>
<div id="R902" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Diegeler
	A, Borgermann J, Kappert U, et al. Off-pump versus on-pump
	coronary-artery bypass grafting in elderly patients.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2013;368:1189–1198.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1211666">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23477657">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>13.1.
Insulin Infusion and Other Measures to Reduce Sternal Wound Infection
in Patients Undergoing CABG</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R903" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Furnary
	AP, Zerr KJ, Grunkemeier GL, et al. Continuous intravenous insulin
	infusion reduces the incidence of deep sternal wound infection in
	diabetic patients after cardiac surgical procedures.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	1999;67:352–360; discussion 60-2.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0003-4975(99)00014-4">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/10197653">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R904" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Hruska
	LA, Smith JM, Hendy MP, et al. Continuous insulin infusion reduces
	infectious complications in diabetics following coronary surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Card Surg</font></em><font size="1" style="font-size: 8pt">.
	2005;20:403–407.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1111/j.1540-8191.2005.200472.x">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16153268">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R905" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Lazar
	HL, Chipkin SR, Fitzgerald CA, et al. Tight glycemic control in
	diabetic coronary artery bypass graft patients improves
	perioperative outcomes and decreases recurrent ischemic
	events.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2004;109:1497–1502.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/01.CIR.0000121747.71054.79">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15006999">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R906" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Umpierrez
	G, Cardona S, Pasquel F, et al. Randomized Controlled Trial of
	Intensive Versus Conservative Glucose Control in Patients Undergoing
	Coronary Artery Bypass Graft Surgery: GLUCO-CABG Trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Diabetes
	Care</font></em><font size="1" style="font-size: 8pt">.
	2015;38:1665–1672.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.2337/dc15-0303">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26180108">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R907" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Furnary
	AP, Gao G, Grunkemeier GL, et al. Continuous insulin infusion
	reduces mortality in patients with diabetes undergoing coronary
	artery bypass grafting.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Thorac Cardiovasc Surg</font></em><font size="1" style="font-size: 8pt">.
	2003;125:1007–1021.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1067/mtc.2003.181">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12771873">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R908" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Furnary
	AP, Wu Y. Eliminating the diabetic disadvantage: the Portland
	Diabetic Project.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Semin
	Thorac Cardiovasc Surg</font></em><font size="1" style="font-size: 8pt">.
	2006;18:302–308.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1053/j.semtcvs.2006.04.005">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17395026">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R909" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Rogers
	L, Vaja R, Bleetman D, et al. Interventions to prevent surgical site
	infection in adults undergoing cardiac surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Cochrane
	Database of Syst Rev</font></em><font size="1" style="font-size: 8pt">.
	2019;5:CD013332.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R910" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Edwards
	LD. The epidemiology of 2056 remote site infections and 1966
	surgical wound infections occurring in 1865 patients: a four year
	study of 40 923 operations at Rush-Presbyterian-St. Luke’s
	Hospital, Chicago.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Surg</font></em><font size="1" style="font-size: 8pt">.
	1976;184:758–766.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1097/00000658-197612000-00017">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/999352">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">9.</font></p>
<div id="R911" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Engelman
	R, Shahian D, Shemin R, et al. The Society of Thoracic Surgeons
	practice guideline series: antibiotic prophylaxis in cardiac
	surgery, part II: antibiotic choice.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2007;83:1569–1576.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.athoracsur.2006.09.046">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17383396">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">10.</font></p>
<div id="R912" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Lazar
	HL, Salm TV, Engelman R, et al. Prevention and management of sternal
	wound infections.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Thorac Cardiovasc Surg</font></em><font size="1" style="font-size: 8pt">.
	2016;152:962–972.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jtcvs.2016.01.060">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27555340">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">11.</font></p>
<div id="R913" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Vander
	Salm TJ, Okike ON, Pasque MK, et al. Reduction of sternal infection
	by application of topical vancomycin.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Thorac Cardiovasc Surg</font></em><font size="1" style="font-size: 8pt">.
	1989;98:618–622.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0022-5223(19)34366-1">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/2796369">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">12.</font></p>
<div id="R914" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Steingrímsson
	S, Gustafsson R, Gudbjartsson T, et al. Sternocutaneous fistulas
	after cardiac surgery: incidence and late outcome during a ten-year
	follow-up.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2009;88:1910–1915.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.athoracsur.2009.07.012">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19932261">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">13.</font></p>
<div id="R915" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Bhatti
	F, Dunning J. Does liberal use of bone wax increase the risk of
	mediastinitis?&nbsp;</font><font size="1" style="font-size: 8pt"><em>Interact
	Cardiovasc Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2003;2:410–412.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S1569-9293(03)00180-4">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17670085">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">14.</font></p>
<div id="R916" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kieser
	TM, Rose MS, Aluthman U, et al. Toward zero: deep sternal wound
	infection after 1001 consecutive coronary artery bypass procedures
	using arterial grafts: implications for diabetic patients.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Thorac Cardiovasc Surg</font></em><font size="1" style="font-size: 8pt">.
	2014;148:1887–1895.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jtcvs.2014.02.022">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24613159">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">15.</font></p>
<div id="R917" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Gandhi
	GY, Nuttall GA, Abel MD, et al. Intensive intraoperative insulin
	therapy versus conventional glucose management during cardiac
	surgery: a randomized trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Intern Med</font></em><font size="1" style="font-size: 8pt">.
	2007;146:233–243.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.7326/0003-4819-146-4-200702200-00002">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17310047">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">16.</font></p>
<div id="R918" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">D’Agostino
	RS, Jacobs JP, Badhwar V, et al. The Society of Thoracic Surgeons
	Adult Cardiac Surgery Database: 2019 update on outcomes and
	quality.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2019;107:24–32.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.athoracsur.2018.10.004">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30423335">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">17.</font></p>
<div id="R919" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Gelijns
	AC, Moskowitz AJ, Acker MA, et al. Management practices and major
	infections after cardiac surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2014;64:372–381.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2014.04.052">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25060372">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">18.</font></p>
<div id="R920" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Anderson
	DJ, Podgorny K, Berríos-Torres SI, et al. Strategies to prevent
	surgical site infections in acute care hospitals: 2014
	update.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Infect
	Control Hosp Epidemiol</font></em><font size="1" style="font-size: 8pt">.
	2014;35(suppl2):S66–S88.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1017/S0899823X00193869">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25376070">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">19.</font></p>
<div id="R921" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Lazar
	HL, McDonnell M, Chipkin SR, et al. The Society of Thoracic Surgeons
	practice guideline series: blood glucose management during adult
	cardiac surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2009;87:663–669.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.athoracsur.2008.11.011">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19161815">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">20.</font></p>
<div id="R922" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Abelev
	Z, Seth A, Patel R, et al. Continuous insulin infusion is associated
	with a reduced post-surgical length of stay, but not with the
	complication rate, in patients with diabetes mellitus undergoing
	coronary artery bypass graft.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Endocrinol Invest</font></em><font size="1" style="font-size: 8pt">.
	2011;34:770–774.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21623155">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">21.</font></p>
<div id="R923" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Ogawa
	S, Okawa Y, Sawada K, et al. Continuous postoperative insulin
	infusion reduces deep sternal wound infection in patients with
	diabetes undergoing coronary artery bypass grafting using bilateral
	internal mammary artery grafts: a propensity-matched analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	J Cardiothorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2016;49:420–426.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/ejcts/ezv106">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25825261">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">22.</font></p>
<div id="R924" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Lazar
	HL, Ketchedjian A, Haime M, et al. Topical vancomycin in combination
	with perioperative antibiotics and tight glycemic control helps to
	eliminate sternal wound infections.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Thorac Cardiovasc Surg</font></em><font size="1" style="font-size: 8pt">.
	2014;148:1035–1038, 8-40.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jtcvs.2014.06.045">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25129595">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">23.</font></p>
<div id="R925" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Koek
	MBG, Hopmans TEM, Soetens LC, et al. Adhering to a national surgical
	care bundle reduces the risk of surgical site infections.&nbsp;</font><font size="1" style="font-size: 8pt"><em>PLoS
	One</font></em><font size="1" style="font-size: 8pt">.
	2017;12:e0184200.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1371/journal.pone.0184200">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28877223">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">24.</font></p>
<div id="R926" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Lavallée
	JF, Gray TA, Dumville J, et al. The effects of care bundles on
	patient outcomes: a systematic review and meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Implement
	Sci</font></em><font size="1" style="font-size: 8pt">.
	2017;12:142.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1186/s13012-017-0670-0">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29187217">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">25.</font></p>
<div id="R927" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Andrade
	LS, Siliprandi EMO, Karsburg LL, et al. Surgical site infection
	prevention bundle in cardiac surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Arq
	Bras Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2019;112:769–774.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30970144">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">26.</font></p>
<div id="R928" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Edwards
	FH, Engelman RM, Houck P, et al. The Society of Thoracic Surgeons
	practice guideline series: antibiotic prophylaxis in cardiac
	surgery, part I: duration.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2006;81:397–404.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.athoracsur.2005.06.034">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16368422">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">27.</font></p>
<div id="R929" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Vestergaard
	RF, Jensen H, Vind-Kezunovic S, et al. Bone healing after median
	sternotomy: a comparison of two hemostatic devices.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Cardiothorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2010;5:117.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1186/1749-8090-5-117">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21106051">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">28.</font></p>
<div id="R930" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Schwann
	TA, Habib RH, Wallace A, et al. Operative outcomes of
	multiple-arterial versus single-arterial coronary bypass
	grafting.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2018;105:1109–1119.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.athoracsur.2017.10.058">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29453002">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">29.</font></p>
<div id="R931" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Sa
	MP, Ferraz PE, Escobar RR, et al. Skeletonized versus pedicled
	internal thoracic artery and risk of sternal wound infection after
	coronary bypass surgery: meta-analysis and meta-regression of 4817
	patients.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Interact
	Cardiovasc Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2013;16:849–857.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/icvts/ivt012">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23446674">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">30.</font></p>
<div id="R932" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Butterworth
	J, Wagenknecht LE, Legault C, et al. Attempted control of
	hyperglycemia during cardiopulmonary bypass fails to improve
	neurologic or neurobehavioral outcomes in patients without diabetes
	mellitus undergoing coronary artery bypass grafting.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Thorac Cardiovasc Surg</font></em><font size="1" style="font-size: 8pt">.
	2005;130:1319.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jtcvs.2005.02.049">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16256784">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">31.</font></p>
<div id="R933" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Cardona
	S, Pasquel FJ, Fayfman M, et al. Hospitalization costs and clinical
	outcomes in CABG patients treated with intensive insulin therapy.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Diabetes Complications</font></em><font size="1" style="font-size: 8pt">.
	2017;31:742–747.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jdiacomp.2017.01.003">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28161384">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">32.</span></font></p>
<div id="R934" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Hillis
	LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for
	coronary artery bypass graft surgery: a report of the American
	College of Cardiology Foundation/American Heart Association Task
	Force on Practice Guidelines.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2011;124:e652–e735.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0b013e31823c074e">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22064599">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>13.2.
Antiplatelet Therapy in Patients Undergoing CABG</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R935" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Bybee
	KA, Powell BD, Valeti U, et al. Preoperative aspirin therapy is
	associated with improved postoperative outcomes in patients
	undergoing coronary artery bypass grafting.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2005;112(suppl I):I-286–I-292.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCULATIONAHA.104.522805">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R936" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Dacey
	LJ, Munoz JJ, Johnson ER, et al. Effect of preoperative aspirin use
	on mortality in coronary artery bypass grafting patients.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2000;70:1986–1990.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0003-4975(00)02133-0">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/11156107">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R937" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Hastings
	S, Myles P, McIlroy D. Aspirin and coronary artery surgery: a
	systematic review and meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Br
	J Anaesth</font></em><font size="1" style="font-size: 8pt">.
	2015;115:376–385.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/bja/aev164">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26082471">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R938" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Ma
	X, Ma C, Yun Y, et al. Safety and efficacy outcomes of preoperative
	aspirin in patients undergoing coronary artery bypass grafting: a
	systematic review and meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Cardiovasc Pharmacol Ther</font></em><font size="1" style="font-size: 8pt">.
	2014;19:97–113.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1177/1074248413509026">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24212980">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R939" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Sá
	MPBO, Soares AF, Miranda RGA, et al. Stopping versus continuing
	acetylsalicylic acid before coronary artery bypass surgery: a
	systematic review and meta-analysis of 14 randomized controlled
	trials with 4499 patients.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	J Cardiothorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2017;52:838–847.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/ejcts/ezx293">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28950378">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R940" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Jacob
	M, Smedira N, Blackstone E, et al. Effect of timing of chronic
	preoperative aspirin discontinuation on morbidity and mortality in
	coronary artery bypass surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2011;123:577–583.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCULATIONAHA.110.957373">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21282503">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R941" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Mikkola
	R, Wistbacka J-O, Gunn J, et al. Timing of preoperative aspirin
	discontinuation and outcome after elective coronary artery bypass
	graft surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Cardiothorac Vasc Anesth</font></em><font size="1" style="font-size: 8pt">.
	2012;26:245–250.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1053/j.jvca.2011.09.024">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22138313">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R942" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Hansson
	EC, Jidéus L, Åberg B, et al. Coronary artery bypass
	grafting-related bleeding complications in patients treated with
	ticagrelor or clopidogrel: a nationwide study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2016;37:189–197.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/eurheartj/ehv381">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26330426">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">9.</font></p>
<div id="R943" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Herman
	CR, Buth KJ, Kent BA, et al. Clopidogrel increases blood transfusion
	and hemorrhagic complications in patients undergoing cardiac
	surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2010;89:397–402.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.athoracsur.2009.10.051">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20103308">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">10.</font></p>
<div id="R944" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Firanescu
	CE, Martens EJ, Schönberger JPAM, et al. Postoperative blood loss
	in patients undergoing coronary artery bypass surgery after
	preoperative treatment with clopidogrel: a prospective randomised
	controlled study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	J Cardiothorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2009;36:856–862.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.ejcts.2009.05.032">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19616440">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">11.</font></p>
<div id="R945" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Held
	C, Asenblad N, Bassand JP, et al. Ticagrelor versus clopidogrel in
	patients with acute coronary syndromes undergoing coronary artery
	bypass surgery: results from the PLATO (Platelet Inhibition and
	Patient Outcomes) trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2011;57:672–684.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2010.10.029">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21194870">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">12.</font></p>
<div id="R946" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Bizzarri
	F, Scolletta S, Tucci E, et al. Perioperative use of tirofiban
	hydrochloride (Aggrastat) does not increase surgical bleeding after
	emergency or urgent coronary artery bypass grafting.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Thorac Cardiovasc Surg</font></em><font size="1" style="font-size: 8pt">.
	2001;122:1181–1185.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1067/mtc.2001.117838">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/11726894">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">13.</font></p>
<div id="R947" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Dyke
	CM, Bhatia D, Lorenz TJ, et al. Immediate coronary artery bypass
	surgery after platelet inhibition with eptifibatide: results from
	PURSUIT. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor
	Suppression Using Integrelin Therapy.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2000;70:866–871. discussion 71-2.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0003-4975(00)01654-4">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/11016325">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">14.</font></p>
<div id="R948" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Lincoff
	AM, LeNarz LA, Despotis GJ, et al. Abciximab and bleeding during
	coronary surgery: results from the EPILOG and EPISTENT trials.
	Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.
	Evaluation of Platelet IIb/IIIa Inhibition in STENTing.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2000;70:516–526.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0003-4975(00)01343-6">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/10969673">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">15.</font></p>
<div id="R949" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Berger
	JS, Frye CB, Harshaw Q, et al. Impact of clopidogrel in patients
	with acute coronary syndromes requiring coronary artery bypass
	surgery: a multicenter analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2008;52:1693–1701.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2008.08.031">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19007688">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">16.</font></p>
<div id="R950" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Siller-Matula
	JM, Petre A, Delle-Karth G, et al. Impact of preoperative use of
	P2Y12 receptor inhibitors on clinical outcomes in cardiac and
	non-cardiac surgery: a systematic review and meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J Acute Cardiovasc Care</font></em><font size="1" style="font-size: 8pt">.
	2017;6:753–770.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1177/2048872615585516">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25943554">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">17.</font></p>
<div id="R951" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Biancari
	F, Airaksinen KEJ, Lip GYH. Benefits and risks of using clopidogrel
	before coronary artery bypass surgery: systematic review and
	meta-analysis of randomized trials and observational studies.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Thorac Cardiovasc Surg</font></em><font size="1" style="font-size: 8pt">.
	2012;143:665–675.e4.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jtcvs.2011.01.069">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21703636">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">18.</font></p>
<div id="R952" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kremke
	M, Tang M, Bak M, et al. Antiplatelet therapy at the time of
	coronary artery bypass grafting: a multicentre cohort
	study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>European
	J Cardiothorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2013;44:e133–e140.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/ejcts/ezt230">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23660554">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">19.</font></p>
<div id="R953" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Gherli
	R, Mariscalco G, Dalén M, et al. Safety of preoperative use of
	ticagrelor with or without aspirin compared with aspirin alone in
	patients with acute coronary syndromes undergoing coronary artery
	bypass grafting.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA
	Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2016;1:921–928.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jamacardio.2016.3028">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27653165">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">20.</font></p>
<div id="R954" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Gurbel
	PA, Bliden KP, Butler K, et al. Randomized double-blind assessment
	of the ONSET and OFFSET of the antiplatelet effects of ticagrelor
	versus clopidogrel in patients with stable coronary artery disease:
	the ONSET/OFFSET study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2009;120:2577–2585.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circulationaha.109.912550">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19923168">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">21.</font></p>
<div id="R955" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Tomšič
	A, Schotborgh MA, Manshanden JSJ, et al. Coronary artery bypass
	grafting-related bleeding complications in patients treated with
	dual antiplatelet treatment.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	J Cardiothorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2016;50:849–856.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/ejcts/ezw149">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27174551">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">22.</font></p>
<div id="R956" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Smith
	PK, Goodnough LT, Levy JH, et al. Mortality benefit with prasugrel
	in the TRITON-TIMI 38 coronary artery bypass grafting cohort:
	risk-adjusted retrospective data analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2012;60:388–396.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2012.03.030">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22633653">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">23.</font></p>
<div id="R957" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Dudek
	D, Dziewierz A, Widimsky P, et al. Impact of prasugrel pretreatment
	and timing of coronary artery bypass grafting on clinical outcomes
	of patients with non-ST-segment elevation myocardial infarction:
	from the A Comparison of Prasugrel at PCI or Time of Diagnosis of
	Non-ST-Elevation Myocardial Infarction (ACCOAST) study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2015;170:1025–1032.e2.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.ahj.2015.07.017">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26542513">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">24.</font></p>
<div id="R958" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Myles
	PS, Smith JA, Forbes A, et al. Stopping vs. continuing aspirin
	before coronary artery surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2016;374:728–737.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1507688">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26933848">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">25.</font></p>
<div id="R959" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Deja
	MA, Kargul T, Domaradzki W, et al. Effects of preoperative aspirin
	in coronary artery bypass grafting: a double-blind,
	placebo-controlled, randomized trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Thorac Cardiovasc Surg</font></em><font size="1" style="font-size: 8pt">.
	2012;144:204–209.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jtcvs.2012.04.004">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22554721">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">26.</font></p>
<div id="R960" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">STS.
	ACSD Training Manual. 2019. Accessed March 30, 2021. Available
	at&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.sts.org/sites/default/files/ACSD_TrainingManualV2-9_July2019.pdf">https://www.sts.org/sites/default/files/ACSD_TrainingManualV2-9_July2019.pdf</span></font></span></font></a></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">27.</span></font></p>
<div id="R961" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Eagle
	KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update for
	coronary artery bypass graft surgery: a report of the American
	College of Cardiology/American Heart Association Task Force on
	Practice Guidelines (Committee to Update the 1999 Guidelines for
	Coronary Artery Bypass Graft Surgery).&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2004;110:e340–e437.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/01.CIR.0000138790.14877.7D">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15466654">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>13.3.
Beta Blockers and Amiodarone in Patients Undergoing CABG</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R962" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Auer
	J, Weber T, Berent R, et al. A comparison between oral
	antiarrhythmic drugs in the prevention of atrial fibrillation after
	cardiac surgery: the pilot study of prevention of postoperative
	atrial fibrillation (SPPAF), a randomized, placebo-controlled
	trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2004;147:636–643.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.ahj.2003.10.041">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15077078">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R963" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Imren
	Y, Benson AA, Zor H, et al. Preoperative beta-blocker use reduces
	atrial fibrillation in off-pump coronary bypass surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>ANZ
	J Surg</font></em><font size="1" style="font-size: 8pt">.
	2007;77:429–432.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1111/j.1445-2197.2007.04088.x">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17501880">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R964" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Pfisterer
	ME, Klöter-Weber UC, Huber M, et al. Prevention of supraventricular
	tachyarrhythmias after open heart operation by low-dose sotalol: a
	prospective, double-blind, randomized, placebo-controlled study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	1997;64:1113–1119.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0003-4975(97)00804-7">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/9354537">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R965" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Gomes
	JA, Ip J, Santoni-Rugiu F, et al. Oral d,l sotalol reduces the
	incidence of postoperative atrial fibrillation in coronary artery
	bypass surgery patients: a randomized, double-blind,
	placebo-controlled study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	1999;34:334–339.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0735-1097(99)00213-2">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/10440141">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R966" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Yazicioglu
	L, Eryilmaz S, Sirlak M, et al. The effect of preoperative digitalis
	and atenolol combination on postoperative atrial fibrillation
	incidence.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	J Cardiothorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2002;22:397–401.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S1010-7940(02)00308-1">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12204730">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R967" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Blessberger
	H, Kammler J, Domanovits H, et al. Perioperative beta-blockers for
	preventing surgery-related mortality and morbidity.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Cochrane
	Database Syst Rev</font></em><font size="1" style="font-size: 8pt">.
	2014:Cd004476.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25233038">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R968" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Thein
	PM, White K, Banker K, et al. Preoperative se of oral
	beta-adrenergic blocking agents and the incidence of new-onset
	atrial fibrillation after cardiac surgery. A systematic review and
	meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Heart
	Lung Circ</font></em><font size="1" style="font-size: 8pt">.
	2018;27:310–321.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.hlc.2017.08.026">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29129562">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R969" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Crystal
	E, Connolly SJ, Sleik K, et al. Interventions on prevention of
	postoperative atrial fibrillation in patients undergoing heart
	surgery: a meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2002;106:75–80.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/01.cir.0000021113.44111.3e">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12093773">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">9.</font></p>
<div id="R970" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Arsenault
	KA, Yusuf AM, Crystal E, et al. Interventions for preventing
	post-operative atrial fibrillation in patients undergoing heart
	surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Cochrane
	Database Syst Rev</font></em><font size="1" style="font-size: 8pt">.
	2013;1:CD003611.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">10.</font></p>
<div id="R971" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Chatterjee
	S, Sardar P, Mukherjee D, et al. Timing and route of amiodarone for
	prevention of postoperative atrial fibrillation after cardiac
	surgery: a network regression meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Pacing
	Clin Electrophysiol</font></em><font size="1" style="font-size: 8pt">.
	2013;36:1017–1023.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1111/pace.12140">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23627761">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">11.</font></p>
<div id="R972" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Mitchell
	LB, Exner DV, Wyse DG, et al. Prophylactic Oral Amiodarone for the
	Prevention of Arrhythmias that Begin Early After Revascularization,
	Valve Replacement, or Repair: PAPABEAR: a randomized controlled
	trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA</font></em><font size="1" style="font-size: 8pt">.
	2005;294:3093–3100.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jama.294.24.3093">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16380589">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">12.</font></p>
<div id="R973" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Brinkman
	WT, Herbert MA, Prince SL, et al. Preoperative beta-blocker usage:
	is it really worthy of being a quality indicator?&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2011;92:788–795. discussion 95-6.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.athoracsur.2011.03.088">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21704300">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">13.</font></p>
<div id="R974" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kohsaka
	S, Miyata H, Motomura N, et al. Effects of preoperative β-blocker
	use on clinical outcomes after coronary artery bypass grafting: a
	report from the Japanese Cardiovascular Surgery
	Database.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Anesthesiology</font></em><font size="1" style="font-size: 8pt">.
	2016;124:45–55.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1097/ALN.0000000000000901">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26517856">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">14.</font></p>
<div id="R975" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">O’Neal
	JB, FTt Billings, Liu X, et al. Effect of preoperative beta-blocker
	use on outcomes following cardiac surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2017;120:1293–1297.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.amjcard.2017.07.012">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28826895">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">15.</font></p>
<div id="R976" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Lin
	T, Hasaniya NW, Krider S, et al. Mortality reduction with
	beta-blockers in ischemic cardiomyopathy patients undergoing
	coronary artery bypass grafting.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Congest
	Heart Fail</font></em><font size="1" style="font-size: 8pt">.
	2010;16:170–174.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1111/j.1751-7133.2010.00146.x">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20662870">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">16.</font></p>
<div id="R977" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Ferguson
	TB, Coombs LP, Peterson ED. Preoperative beta-blocker use and
	mortality and morbidity following CABG surgery in North
	America.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA</font></em><font size="1" style="font-size: 8pt">.
	2002;287:2221–2227.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jama.287.17.2221">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/11980522">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">17.</font></p>
<div id="R978" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kertai
	MD, Esper SA, Akushevich I, et al. Preoperative CYP2D6
	metabolism-dependent β-blocker use and mortality after coronary
	artery bypass grafting surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Thorac Cardiovasc Surg</font></em><font size="1" style="font-size: 8pt">.
	2014;147:1368–1375.e3.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jtcvs.2013.09.067">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24269121">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">18.</font></p>
<div id="R979" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Blessberger
	H, Lewis SR, Pritchard MW, et al. Perioperative beta-blockers for
	preventing surgery-related mortality and morbidity in adults
	undergoing cardiac surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Cochrane
	Database Syst Rev</font></em><font size="1" style="font-size: 8pt">.
	2019;9:Cd013435.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31544227">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">19.</span></font></p>
<div id="R980" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Aasbo
	JD, Lawrence AT, Krishnan K, et al. Amiodarone prophylaxis reduces
	major cardiovascular morbidity and length of stay after cardiac
	surgery: a meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Intern Med</font></em><font size="1" style="font-size: 8pt">.
	2005;143:327–336.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.7326/0003-4819-143-5-200509060-00008">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16144891">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>14.1.
Pharmacotherapy for Risk Factor Control in Patients After
Revascularization</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R981" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Grundy
	SM, Stone NJ, Bailey AL, et al. 2018
	AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on
	the management of blood cholesterol: a report of the American
	College of Cardiology/American Heart Association Task Force on
	Clinical Practice Guidelines.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2019;139:e1082–e1143.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0000000000000625">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30586774">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R982" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Arnett
	DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the
	primary prevention of cardiovascular disease: a report of the
	American College of Cardiology/American Heart Association Task Force
	on Clinical Practice Guidelines.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2019;140:e596–e646.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0000000000000678">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30879355">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R983" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Whelton
	PK, Carey RM, Aronow WS, et al. 2017
	ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the
	prevention, detection, evaluation, and management of high blood
	pressure in adults: a report of the American College of
	Cardiology/American Heart Association Task Force on Clinical
	Practice Guidelines.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Hypertension</font></em><font size="1" style="font-size: 8pt">.
	2018;71:e13–e115.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/HYP.0000000000000065">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29133356">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">4.</span></font></p>
<div id="R984" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">American
	Diabetes Association. 8. Pharmacologic approaches to glycemic
	treatment: standards of medical care in diabetes-2018.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Diabetes
	Care</font></em><font size="1" style="font-size: 8pt">.
	2018;41:S73–S85.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.2337/dc18-S008">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29222379">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>14.2.
Dual Antiplatelet Therapy in Patients After PCI</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R985" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Mehran
	R, Baber U, Sharma SK, et al. Ticagrelor with or without aspirin in
	high-risk patients after PCI.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2019;381:2032–2042.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1908419">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31556978">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R986" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Hahn
	JY, Song YB, Oh JH, et al. Effect of P2Y12 inhibitor monotherapy vs
	dual antiplatelet therapy on cardiovascular events in patients
	undergoing percutaneous coronary intervention: the SMART-CHOICE
	randomized clinical trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA</font></em><font size="1" style="font-size: 8pt">.
	2019;321:2428–2437.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jama.2019.8146">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31237645">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R987" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Watanabe
	H, Domei T, Morimoto T, et al. Effect of 1-month dual antiplatelet
	therapy followed by clopidogrel vs 12-month dual antiplatelet
	therapy on cardiovascular and bleeding events in patients receiving
	PCI: the STOPDAPT-2 randomized clinical trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA</font></em><font size="1" style="font-size: 8pt">.
	2019;321:2414–2427.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jama.2019.8145">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31237644">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R988" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kim
	BK, Hong SJ, Cho YH, et al. Effect of ticagrelor monotherapy vs
	ticagrelor with aspirin on major bleeding and cardiovascular events
	in patients with acute coronary syndrome: the TICO randomized
	clinical trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA</font></em><font size="1" style="font-size: 8pt">.
	2020;323:2407–2416.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jama.2020.7580">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/32543684">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R989" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Bittl
	JA, Baber U, Bradley SM, et al. Duration of dual antiplatelet
	therapy: a systematic review for the 2016 ACC/AHA guideline focused
	update on duration of dual antiplatelet therapy in patients with
	coronary artery disease: a report of the American College of
	Cardiology/American Heart Association Task Force on Clinical
	Practice Guidelines.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2016;134:e156–e178.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27026019">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R990" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Levine
	GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update
	on duration of dual antiplatelet therapy in patients with coronary
	artery disease: a report of the American College of
	Cardiology/American Heart Association Task Force on Clinical
	Practice Guidelines: an update of the 2011 ACCF/AHA/SCAI guideline
	for percutaneous coronary intervention, 2011 ACCF/AHA guideline for
	coronary artery bypass graft surgery, 2012
	ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and
	management of patients with stable ischemic heart disease, 2013
	ACCF/AHA guideline for the management of ST-elevation myocardial
	infarction, 2014 AHA/ACC guideline for the management of patients
	with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA
	guideline on perioperative cardiovascular evaluation and management
	of patients undergoing noncardiac surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2016;134:e123–e155.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/cir.0000000000000404">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27026020">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">7.</span></font></p>
<div id="R991" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Vranckx
	P, Valgimigli M, Juni P, et al. Ticagrelor plus aspirin for 1 month,
	followed by ticagrelor monotherapy for 23 months vs aspirin plus
	clopidogrel or ticagrelor for 12 months, followed by aspirin
	monotherapy for 12 months after implantation of a drug-eluting
	stent: a multicentre, open-label, randomised superiority
	trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2018;392:940–949.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(18)31858-0">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30166073">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>14.3.
Antiplatelet Therapy in Patients After CABG</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R992" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Mangano
	DT, Multicenter Study of Perioperative Ischemia Research Group.
	Aspirin and mortality from coronary bypass surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2002;347:1309–1317.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa020798">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12397188">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R993" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Lorenz
	RL, Schacky CV, Weber M, et al. Improved aortocoronary bypass
	patency by low-dose aspirin (100 mg daily). Effects on platelet
	aggregation and thromboxane formation.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	1984;1:1261–1264.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(84)92446-2">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/6144975">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R994" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Antithrombotic
	Trialists’ Collaboration. Collaborative meta-analysis of
	randomised trials of antiplatelet therapy for prevention of death,
	myocardial infarction, and stroke in high risk patients.&nbsp;</font><font size="1" style="font-size: 8pt"><em>BMJ</font></em><font size="1" style="font-size: 8pt">.
	2002;324:71–86.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1136/bmj.324.7329.71">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/11786451">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R995" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Chakos
	A, Jbara D, Singh K, et al. Network meta-analysis of antiplatelet
	therapy following coronary artery bypass grafting (CABG): none
	versus one versus two antiplatelet agents.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Cardiothorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2018;7:577–585.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.21037/acs.2018.09.02">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30505741">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R996" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Goldman
	S, Copeland J, Moritz T, et al. Saphenous vein graft patency 1 year
	after coronary artery bypass surgery and effects of antiplatelet
	therapy. Results of a Veterans Administration Cooperative
	Study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	1989;80:1190–1197.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/01.CIR.80.5.1190">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/2680158">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R997" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Brown
	BG, Cukingnan RA, DeRouen T, et al. Improved graft patency in
	patients treated with platelet-inhibiting therapy after coronary
	bypass surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	1985;72:138–146.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/01.CIR.72.1.138">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/3874009">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R998" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Meister
	W, von Schacky C, Weber M, et al. Low-dose acetylsalicylic acid (100
	mg/day) after aortocoronary bypass surgery: a placebo-controlled
	trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Br J
	Clin Pharmacol</font></em><font size="1" style="font-size: 8pt">.
	1984;17:703–711.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1111/j.1365-2125.1984.tb02407.x">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/6378232">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R999" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Cardoso
	R, Knijnik L, Whelton SP, et al. Dual versus single antiplatelet
	therapy after coronary artery bypass graft surgery: an updated
	meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Int
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2018;269:80–88.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.ijcard.2018.07.083">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30072154">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">9.</font></p>
<div id="R1000" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Solo
	K, Lavi S, Kabali C, et al. Antithrombotic treatment after coronary
	artery bypass graft surgery: systematic review and network
	meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>BMJ</font></em><font size="1" style="font-size: 8pt">.
	2019;367:l5476.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1136/bmj.l5476">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31601578">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">10.</font></p>
<div id="R1001" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Zhao
	Q, Zhu Y, Xu Z, et al. Effect of ticagrelor plus aspirin, ticagrelor
	alone, or aspirin alone on saphenous vein graft patency 1 year after
	coronary artery bypass grafting: a randomized clinical trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA</font></em><font size="1" style="font-size: 8pt">.
	2018;319:1677–1686.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jama.2018.3197">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29710164">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">11.</font></p>
<div id="R1002" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Levine
	GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update
	on duration of dual antiplatelet therapy in patients with coronary
	artery disease: a report of the American College of
	Cardiology/American Heart Association Task Force on Clinical
	Practice Guidelines: an update of the 2011 ACCF/AHA/SCAI guideline
	for percutaneous coronary intervention, 2011 ACCF/AHA guideline for
	coronary artery bypass graft surgery, 2012
	ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and
	management of patients with stable ischemic heart disease, 2013
	ACCF/AHA guideline for the management of ST-elevation myocardial
	infarction, 2014 AHA/ACC guideline for the management of patients
	with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA
	guideline on perioperative cardiovascular evaluation and management
	of patients undergoing noncardiac surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2016;134:e123–e155.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/cir.0000000000000404">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27026020">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">12.</span></font></p>
<div id="R1003" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Sethi
	GK, Copeland JG, Goldman S, et al. Implications of preoperative
	administration of aspirin in patients undergoing coronary artery
	bypass grafting. Department of Veterans Affairs Cooperative Study on
	Antiplatelet Therapy.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	1990;15:15–20.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/0735-1097(90)90168-O">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/2404046">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>14.4.
Beta Blockers in Patients After Revascularization</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R1004" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Motivala
	AA, Parikh V, Roe M, et al. Predictors, trends, and outcomes (among
	older patients ≥65 years of age) associated with beta-blocker use
	in patients with stable angina undergoing elective percutaneous
	coronary intervention: insights from the NCDR Registry.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2016;9:1639–1648.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jcin.2016.05.048">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27539683">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R1005" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Bangalore
	S, Steg G, Deedwania P, et al. β-Blocker use and clinical outcomes
	in stable outpatients with and without coronary artery
	disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA</font></em><font size="1" style="font-size: 8pt">.
	2012;308:1340–1349.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jama.2012.12559">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23032550">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R1006" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Bangalore
	S, Makani H, Radford M, et al. Clinical outcomes with β-blockers
	for myocardial infarction: a meta-analysis of randomized trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Med</font></em><font size="1" style="font-size: 8pt">.
	2014;127:939–953.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.amjmed.2014.05.032">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24927909">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R1007" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Andersson
	C, Shilane D, Go AS, et al. β-blocker therapy and cardiac events
	among patients with newly diagnosed coronary heart disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2014;64:247–252.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2014.04.042">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25034059">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R1008" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Angeloni
	E, Melina G, Roscitano A, et al. β-Blockers improve survival of
	patients with chronic obstructive pulmonary disease after coronary
	artery bypass grafting.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2013;95:525–531.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.athoracsur.2012.07.080">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23040827">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R1009" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Zhang
	H, Yuan X, Zhang H, et al. Efficacy of long-term β-blocker therapy
	for secondary prevention of long-term outcomes after coronary artery
	bypass grafting surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2015;131:2194–2201.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCULATIONAHA.114.014209">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25908770">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R1010" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Amsterdam
	EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the
	management of patients with non-ST-elevation acute coronary
	syndromes: a report of the American College of Cardiology/American
	Heart Association Task Force on Practice Guidelines.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2014;130:e344–e426.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0000000000000134">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25249585">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R1011" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">O’Gara
	PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the
	management of ST-elevation myocardial infarction: a report of the
	American College of Cardiology Foundation/American Heart Association
	Task Force on Practice Guidelines.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2013;127:e362–e425.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0b013e3182742c84">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23247304">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">9.</span></font></p>
<div id="R1012" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Bangalore
	S, Makani H, Radford M, et al. Clinical outcomes with beta-blockers
	for myocardial infarction: a meta-analysis of randomized trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Med</font></em><font size="1" style="font-size: 8pt">.
	2014;127:939–953.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.amjmed.2014.05.032">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24927909">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>14.5.
Beta Blockers for the Prevention of Atrial Fibrillation After CABG</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R1013" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Arsenault
	KA, Yusuf AM, Crystal E, et al. Interventions for preventing
	post-operative atrial fibrillation in patients undergoing heart
	surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Cochrane
	Database Syst Rev</font></em><font size="1" style="font-size: 8pt">.
	2013;1:CD003611.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R1014" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Crystal
	E, Garfinkle MS, Connolly SS, et al. Interventions for preventing
	post-operative atrial fibrillation in patients undergoing heart
	surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Cochrane
	Database Syst Rev</font></em><font size="1" style="font-size: 8pt">.
	2004:Cd003611.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15495059">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R1015" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Burgess
	DC, Kilborn MJ, Keech AC. Interventions for prevention of
	post-operative atrial fibrillation and its complications after
	cardiac surgery: a meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2006;27:2846–2857.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/eurheartj/ehl272">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17015402">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R1016" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Khan
	MF, Wendel CS, Movahed MR. Prevention of post-coronary artery bypass
	grafting (CABG) atrial fibrillation: efficacy of prophylactic
	beta-blockers in the modern era: a meta-analysis of latest
	randomized controlled trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Noninvasive Electrocardiol</font></em><font size="1" style="font-size: 8pt">.
	2013;18:58–68.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1111/anec.12004">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23347027">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R1017" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Hillis
	LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for
	coronary artery bypass graft surgery: a report of the American
	College of Cardiology Foundation/American Heart Association Task
	Force on Practice Guidelines.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2011;124:e652–e735.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0b013e31823c074e">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22064599">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R1018" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Fuster
	V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the
	management of patients with atrial fibrillation: a report of the
	American College of Cardiology/American Heart Association Task Force
	on Practice Guidelines and the European Society of Cardiology
	Committee for Practice Guidelines (Writing Committee to Revise the
	2001 Guidelines for the Management of Patients With Atrial
	Fibrillation).&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2006;114:e257–e354.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circ.114.4.257">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16908781">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R1019" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Fuster
	V, Rydén LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates
	incorporated into the ACC/AHA/ESC 2006 guidelines for the management
	of patients with atrial fibrillation: a report of the American
	College of Cardiology Foundation/American Heart Association Task
	Force on practice guidelines.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2011;123:e269–e367.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/cir.0b013e318214876d">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21382897">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R1020" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kaw
	R, Hernandez AV, Masood I, et al. Short- and long-term mortality
	associated with new-onset atrial fibrillation after coronary artery
	bypass grafting: a systematic review and meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Thorac Cardiovasc Surg</font></em><font size="1" style="font-size: 8pt">.
	2011;141:1305–1312.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jtcvs.2010.10.040">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21247589">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">9.</font></p>
<div id="R1021" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kosmidou
	I, Chen S, Kappetein AP, et al. New-onset atrial fibrillation after
	PCI or CABG for left main disease: the EXCEL trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2018;71:739–748.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2017.12.012">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29447735">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">10.</span></font></p>
<div id="R1022" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Blessberger
	H, Lewis SR, Pritchard MW, et al. Perioperative beta-blockers for
	preventing surgery-related mortality and morbidity in adults
	undergoing non-cardiac surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Cochrane
	Database Syst Rev</font></em><font size="1" style="font-size: 8pt">.
	2019;9:Cd013438.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31556094">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>14.6.
Antiplatelet Therapy in Patients With Atrial Fibrillation on
Anticoagulation After PCI</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R1023" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Lopes
	RD, Heizer G, Aronson R, et al. Antithrombotic therapy after acute
	coronary syndrome or PCI in atrial fibrillation.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2019;380:1509–1524.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1817083">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30883055">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R1024" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Lopes
	RD, Hong H, Harskamp RE, et al. Safety and efficacy of
	antithrombotic strategies in patients with atrial fibrillation
	undergoing percutaneous coronary intervention: a network
	meta-analysis of randomized controlled trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA
	Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2019;4:747–755.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jamacardio.2019.1880">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31215979">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R1025" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Lopes
	RD, Leonardi S, Wojdyla DM, et al. Stent Thrombosis in Patients With
	Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS
	Trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2020;141:781–783.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCULATIONAHA.119.044584">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31707833">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R1026" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Vranckx
	P, Valgimigli M, Eckardt L, et al. Edoxaban-based versus vitamin K
	antagonist-based antithrombotic regimen after successful coronary
	stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a
	randomised, open-label, phase 3b trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2019;394:1335–1343.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(19)31872-0">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31492505">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R1027" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Dewilde
	WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or
	without aspirin in patients taking oral anticoagulant therapy and
	undergoing percutaneous coronary intervention: an open-label,
	randomised, controlled trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2013;381:1107–1115.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(12)62177-1">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23415013">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R1028" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Cannon
	CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with
	dabigatran after PCI in atrial fibrillation.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2017;377:1513–1524.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1708454">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28844193">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R1029" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Gibson
	CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with
	atrial fibrillation undergoing PCI.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2016;375:2423–2434.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1611594">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27959713">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">8.</span></font></p>
<div id="R1030" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">January
	CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of
	the 2014 AHA/ACC/HRS guideline for the management of patients with
	atrial fibrillation: a report of the American College of
	Cardiology/American Heart Association Task Force on Clinical
	Practice Guidelines and the Heart Rhythm Society.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2019;140:e125–e151.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0000000000000665">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30686041">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>15.1.
Cardiac Rehabilitation and Education</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R1031" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Anderson,
	L, Sharp, GA, Norton, RJ, et al. Home-based versus centre-based
	cardiac rehabilitation.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Cochrane
	Database Syst Rev</font></em><font size="1" style="font-size: 8pt">.
	2017;6: Cd007130.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R1032" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Anderson
	L, Oldridge N, Thompson DR, et al. Exercise-based cardiac
	rehabilitation for coronary heart disease: Cochrane systematic
	review and meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2016;67:1–12.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2015.10.044">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26764059">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R1033" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Janssen
	V, De Gucht V, Dusseldorp E, et al. Lifestyle modification
	programmes for patients with coronary heart disease: a systematic
	review and meta-analysis of randomized controlled trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	J Prev Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2013;20:620–640.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1177/2047487312462824">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23022703">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R1034" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Anderson
	L, Brown JP, Clark AM, et al. Patient education in the management of
	coronary heart disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Cochrane
	Database Syst Rev</font></em><font size="1" style="font-size: 8pt">.
	2017;6:CD008895.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28658719">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R1035" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Eckel
	RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle
	management to reduce cardiovascular risk: a report of the American
	College of Cardiology/American Heart Association Task Force on
	Practice Guidelines.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2014;63:2960–2984.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2013.11.003">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24239922">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R1036" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Riegel
	B, Moser DK, Buck HG, et al. Self-care for the prevention and
	management of cardiovascular disease and stroke: a scientific
	statement for healthcare professionals from the American Heart
	Association.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Heart Assoc</font></em><font size="1" style="font-size: 8pt">&nbsp;6;2017,
	e006997.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/JAHA.117.006997">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28860232">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R1037" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Smith
	SC, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and
	risk reduction therapy for patients with coronary and other
	atherosclerotic vascular disease: 2011 update: a guideline from the
	American Heart Association and American College of Cardiology
	Foundation.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2011;124:2458–2473.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0b013e318235eb4d">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22052934">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R1038" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Dalal
	HM, Doherty P, Taylor RS. Cardiac rehabilitation.&nbsp;</font><font size="1" style="font-size: 8pt"><em>BMJ</font></em><font size="1" style="font-size: 8pt">.
	2015;351:h5000.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1136/bmj.h5000">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26419744">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">9.</font></p>
<div id="R1039" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Thomas
	RJ, Balady G, Banka G, et al. 2018 ACC/AHA clinical performance and
	quality measures for cardiac rehabilitation: a report of the
	American College of Cardiology/American Heart Association Task Force
	on Performance Measures.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Qual Outcomes</font></em><font size="1" style="font-size: 8pt">.
	2018;11:e000037.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/HCQ.0000000000000037">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29599285">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">10.</font></p>
<div id="R1040" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Balady
	GJ, Williams MA, Ades PA, et al. Core components of cardiac
	rehabilitation/secondary prevention programs: 2007 update: a
	scientific statement from the American Heart Association Exercise,
	Cardiac Rehabilitation, and Prevention Committee, the Council on
	Clinical Cardiology; the Councils on Cardiovascular Nursing,
	Epidemiology and Prevention, and Nutrition, Physical Activity, and
	Metabolism; and the American Association of Cardiovascular and
	Pulmonary Rehabilitation.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2007;115:2675–2682.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCULATIONAHA.106.180945">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17513578">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">11.</font></p>
<div id="R1041" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Dunlay
	SM, Pack QR, Thomas RJ, et al. Participation in cardiac
	rehabilitation, readmissions, and death after acute myocardial
	infarction.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Med</font></em><font size="1" style="font-size: 8pt">.
	2014;127:538–546.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.amjmed.2014.02.008">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24556195">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">12.</font></p>
<div id="R1042" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Hamm
	LF, Sanderson BK, Ades PA, et al. Core competencies for cardiac
	rehabilitation/secondary prevention professionals: 2010 update:
	position statement of the American Association of Cardiovascular and
	Pulmonary Rehabilitation.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Cardiopulm Rehabil Prev</font></em><font size="1" style="font-size: 8pt">.
	2011;31:2–10.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1097/HCR.0b013e318203999d">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21217254">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">13.</font></p>
<div id="R1043" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">American
	Association of Cardiovascular and Pulmonary
	Rehabilitation.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Guidelines
	for Cardiac Rehabilitation and Secondary Prevention Programs</font></em><font size="1" style="font-size: 8pt">.
	5th ed. Human Kinetics;2013:323.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">14.</font></p>
<div id="R1044" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Thomas
	RJ, Beatty AL, Beckie TM, et al. Home-based cardiac rehabilitation:
	a scientific statement from the American Association of
	Cardiovascular and Pulmonary Rehabilitation, the American Heart
	Association, and the American College of Cardiology.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2019;140:e69–e89.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0000000000000663">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31082266">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">15.</font></p>
<div id="R1045" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Buckingham
	SA, Taylor RS, Jolly K, et al. Home-based versus centre-based
	cardiac rehabilitation: abridged Cochrane systematic review and
	meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Open
	Heart</font></em><font size="1" style="font-size: 8pt">. 2016;3:
	e000463.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1136/openhrt-2016-000463">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27738516">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">16.</font></p>
<div id="R1046" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Dalal
	HM, Zawada A, Jolly K, et al. Home based versus centre based cardiac
	rehabilitation: Cochrane systematic review and meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>BMJ</font></em><font size="1" style="font-size: 8pt">.
	2010;340:b5631.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1136/bmj.b5631">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20085991">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">17.</font></p>
<div id="R1047" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Taylor
	RS, Dalal H, Jolly K, et al. Home-based versus centre-based cardiac
	rehabilitation.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Cochrane
	Database Syst Rev</font></em><font size="1" style="font-size: 8pt">.
	2015;8:CD007130.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">18.</font></p>
<div id="R1048" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Arnett
	DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the
	primary prevention of cardiovascular disease: a report of the
	American College of Cardiology/American Heart Association Task Force
	on Clinical Practice Guidelines.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2019;140:e596–e646.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0000000000000678">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30879355">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">19.</span></font></p>
<div id="R1049" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Lloyd-Jones
	DM, Hong Y, Labarthe D, et al. Defining and setting national goals
	for cardiovascular health promotion and disease reduction: the
	American Heart Association’s strategic impact goal through 2020
	and beyond.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2010;121:586–613.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circulationaha.109.192703">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20089546">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>15.2.
Smoking Cessation in Patients After Revascularization</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R1050" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Cahill
	K, Lindson-Hawley N, Thomas KH, et al. Nicotine receptor partial
	agonists for smoking cessation.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Cochrane
	Database Syst Rev</font></em><font size="1" style="font-size: 8pt">.
	2016;2016:Cd006103.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R1051" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Stead
	LF, Koilpillai P, Fanshawe TR, et al. Combined pharmacotherapy and
	behavioural interventions for smoking cessation.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Cochrane
	Database Syst Rev</font></em><font size="1" style="font-size: 8pt">.
	2016;3:Cd008286.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27009521">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R1052" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Ebbert
	JO, Elrashidi MY, Stead LF. Interventions for smokeless tobacco use
	cessation.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Cochrane
	Database Syst Rev</font></em><font size="1" style="font-size: 8pt">.
	2015;2015:Cd004306.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R1053" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Rigotti
	NA, Clair C, Munafò MR, et al. Interventions for smoking cessation
	in hospitalised patients.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Cochrane
	Database Syst Rev</font></em><font size="1" style="font-size: 8pt">.
	2012;5:Cd001837.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22592676">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R1054" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Suissa
	K, Larivière J, Eisenberg MJ, et al. Efficacy and safety of smoking
	cessation interventions in patients with cardiovascular disease: a
	network meta-analysis of randomized controlled trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Qual Outcomes</font></em><font size="1" style="font-size: 8pt">.
	2017;10:e002458.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCOUTCOMES.115.002458">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28093398">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R1055" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">US
	Department of Health and Human Services. Smoking Cessation. A Report
	of the Surgeon General. 2020. Accessed March 23, 2020. Available
	at:&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.hhs.gov/sites/default/files/2020-cessation-sgr-full-report.pdf">https://www.hhs.gov/sites/default/files/2020-cessation-sgr-full-report.pdf</span></font></span></font></a></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R1056" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Barua
	RS, Rigotti NA, Benowitz NL, et al. 2018 ACC expert consensus
	decision pathway on tobacco cessation treatment: a report of the
	American College of Cardiology Task Force on Clinical Expert
	Consensus Documents.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2018;72:3332–3365.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2018.10.027">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30527452">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R1057" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Zhang
	YJ, Iqbal J, van Klaveren D, et al. Smoking is associated with
	adverse clinical outcomes in patients undergoing revascularization
	with PCI or CABG: the SYNTAX trial at 5-year follow-up.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2015;65:1107–1115.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2015.01.014">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25790882">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">9.</font></p>
<div id="R1058" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">D’Ascenzo
	F, Bollati M, Clementi F, et al. Incidence and predictors of
	coronary stent thrombosis: evidence from an international
	collaborative meta-analysis including 30 studies, 221 066 patients,
	and 4276 thromboses.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Int
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2013;167:575–584.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.ijcard.2012.01.080">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22360945">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">10.</font></p>
<div id="R1059" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Bhatnagar
	A, Whitsel LP, Ribisl KM, et al. Electronic cigarettes: a policy
	statement from the American Heart Association.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2014;130:1418–1436.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0000000000000107">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25156991">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">11.</font></p>
<div id="R1060" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Bhatnagar
	A, Whitsel LP, Blaha MJ, et al. New and emerging tobacco products
	and the nicotine endgame: the role of robust regulation and
	comprehensive tobacco control and prevention: a presidential
	advisory from the American Heart Association.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2019;139:e937–e958.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0000000000000669">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30862181">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">12.</font></p>
<div id="R1061" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Conklin
	DJ, Schick S, Blaha MJ, et al. Cardiovascular injury induced by
	tobacco products: assessment of risk factors and biomarkers of harm.
	A Tobacco Centers of Regulatory Science compilation.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Physiol Heart Circ Physiol</font></em><font size="1" style="font-size: 8pt">.
	2019;316:H801–H827.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1152/ajpheart.00591.2018">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30707616">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">13.</font></p>
<div id="R1062" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Bhatnagar
	A. Cardiovascular perspective of the promises and perils of
	e-cigarettes.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Res</font></em><font size="1" style="font-size: 8pt">.
	2016;118:1872–1875.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circresaha.116.308723">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27283531">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">14.</font></p>
<div id="R1063" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Mirbolouk
	M, Charkhchi P, Kianoush S, et al. Prevalence and distribution of
	e-cigarette use among US adults: behavioral risk factor surveillance
	system, 2016.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Intern Med</font></em><font size="1" style="font-size: 8pt">.
	2018;169:429–438.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.7326/M17-3440">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30167658">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">15.</font></p>
<div id="R1064" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Bao
	W, Xu G, Lu J, et al. Changes in electronic cigarette use among
	adults in the United States, 2014-2016.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA</font></em><font size="1" style="font-size: 8pt">.
	2018;319:2039–2041.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jama.2018.4658">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29800201">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">16.</font></p>
<div id="R1065" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Arnett
	DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the
	primary prevention of cardiovascular disease: a report of the
	American College of Cardiology/American Heart Association Task Force
	on Clinical Practice Guidelines.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2019;140:e596–e646.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0000000000000678">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30879355">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">17.</font></p>
<div id="R1066" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Clinical
	Practice Guideline Treating Tobacco Use and Dependence 2008 Update
	Panel Liaisons, and Staff. A clinical practice guideline for
	treating tobacco use and dependence: 2008 update. A US Public Health
	Service report.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Prev Med</font></em><font size="1" style="font-size: 8pt">.
	2008;35:158–176.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.amepre.2008.04.009">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18617085">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">18.</font></p>
<div id="R1067" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Anthenelli
	RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy
	of varenicline, bupropion, and nicotine patch in smokers with and
	without psychiatric disorders (EAGLES): a double-blind, randomised,
	placebo-controlled clinical trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2016;387:2507–2520.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(16)30272-0">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27116918">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">19.</font></p>
<div id="R1068" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Rigotti
	NA, Pipe AL, Benowitz NL, et al. Efficacy and safety of varenicline
	for smoking cessation in patients with cardiovascular disease: a
	randomized trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2010;121:221–229.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circulationaha.109.869008">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20048210">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">20.</font></p>
<div id="R1069" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Windle
	SB, Bata I, Madan M, et al. A randomized controlled trial of the
	efficacy and safety of varenicline for smoking cessation after acute
	coronary syndrome: design and methods of the Evaluation of
	Varenicline in Smoking Cessation for Patients Post-Acute Coronary
	Syndrome trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2015;170:635–640.e1.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.ahj.2015.07.010">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26386786">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">21.</font></p>
<div id="R1070" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Windle
	SB, Dehghani P, Roy N, et al. Smoking abstinence 1 year after acute
	coronary syndrome: follow-up from a randomized controlled trial of
	varenicline in patients admitted to hospital.&nbsp;</font><font size="1" style="font-size: 8pt"><em>CMAJ</font></em><font size="1" style="font-size: 8pt">.
	2018;190:E347–E354.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1503/cmaj.170377">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29581161">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">22.</font></p>
<div id="R1071" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Eisenberg
	MJ, Windle SB, Roy N, et al. Varenicline for smoking cessation in
	hospitalized patients with acute coronary syndrome.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2016;133:21–30.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circulationaha.115.019634">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26553744">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">23.</span></font></p>
<div id="R1072" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Benowitz
	NL, Pipe A, West R, et al. Cardiovascular safety of varenicline,
	bupropion, and nicotine patch in smokers: a randomized clinical
	trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA
	Intern Med</font></em><font size="1" style="font-size: 8pt">.
	2018;178:622–631.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jamainternmed.2018.0397">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29630702">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>15.3.
Psychological Interventions in Patients After Revascularization</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R1073" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Richards
	SH, Anderson L, Jenkinson CE, et al. Psychological interventions for
	coronary heart disease: Cochrane systematic review and
	meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	J Prev Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2018;25:247–259.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1177/2047487317739978">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29212370">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R1074" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kim
	JM, Stewart R, Lee YS, et al. Effect of escitalopram vs placebo
	treatment for depression on long-term cardiac outcomes in patients
	with acute coronary syndrome: a randomized clinical trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA</font></em><font size="1" style="font-size: 8pt">.
	2018;320:350–358.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jama.2018.9422">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30043065">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R1075" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Blumenthal
	JA, Sherwood A, Smith PJ, et al. Enhancing cardiac rehabilitation
	with stress management training: a randomized, clinical efficacy
	trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2016;133:1341–1350.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCULATIONAHA.115.018926">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27045127">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R1076" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Rakowska
	JM. Brief strategic therapy in first myocardial infarction patients
	with increased levels of stress: a randomized clinical
	trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Anxiety
	Stress Coping</font></em><font size="1" style="font-size: 8pt">.
	2015;28:687–705.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1080/10615806.2015.1004323">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25567031">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R1077" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Berkman
	LF, Blumenthal J, Burg M, et al. Effects of treating depression and
	low perceived social support on clinical events after myocardial
	infarction: the Enhancing Recovery in Coronary Heart Disease
	Patients (ENRICHD) Randomized Trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA</font></em><font size="1" style="font-size: 8pt">.
	2003;289:3106–3116.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jama.289.23.3106">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12813116">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R1078" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Waterman
	LA, Belnap BH, Gebara MA, et al. Bypassing the blues: insomnia in
	the depressed post-CABG population.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Clin Psychiatry</font></em><font size="1" style="font-size: 8pt">.
	2020;32:17–26.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31675390">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R1079" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Rollman
	BL, Belnap BH, LeMenager MS, et al. Telephone-delivered
	collaborative care for treating post-CABG depression: a randomized
	controlled trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA</font></em><font size="1" style="font-size: 8pt">.
	2009;302:2095–2103.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jama.2009.1670">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19918088">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R1080" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Siu
	AL, Bibbins-Domingo K, Grossman DC, et al. Screening for depression
	in adults: US Preventive Services Task Force Recommendation
	Statement.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA</font></em><font size="1" style="font-size: 8pt">.
	2016;315:380–387.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jama.2015.18392">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26813211">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">9.</font></p>
<div id="R1081" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kronish
	IM, Moise N, Cheung YK, et al. Effect of depression screening after
	acute coronary syndromes on quality of life: the CODIACS-QoL
	randomized clinical trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA
	Intern Med</font></em><font size="1" style="font-size: 8pt">.
	2019;180:45–53.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jamainternmed.2019.4518">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">10.</font></p>
<div id="R1082" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Tully
	PJ, Cosh SM, Baumeister H. The anxious heart in whose mind? A
	systematic review and meta-regression of factors associated with
	anxiety disorder diagnosis, treatment and morbidity risk in coronary
	heart disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Psychosom Res</font></em><font size="1" style="font-size: 8pt">.
	2014;77:439–448.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jpsychores.2014.10.001">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25455809">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">11.</font></p>
<div id="R1083" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Dickens
	C. Depression in people with coronary heart disease: prognostic
	significance and mechanisms.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Curr
	Cardiol Rep</font></em><font size="1" style="font-size: 8pt">.
	2015;17:83.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1007/s11886-015-0640-6">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26277367">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">12.</font></p>
<div id="R1084" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Davidson
	KW, Alcántara C, Miller GE. Selected psychological comorbidities in
	coronary heart disease: challenges and grand opportunities.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	Psychol</font></em><font size="1" style="font-size: 8pt">.
	2018;73:1019–1030.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1037/amp0000239">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30394780">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">13.</font></p>
<div id="R1085" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Thombs
	BD, Bass EB, Ford DE, et al. Prevalence of depression in survivors
	of acute myocardial infarction.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Gen Intern Med</font></em><font size="1" style="font-size: 8pt">.
	2006;21:30–38.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1111/j.1525-1497.2005.00269.x">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16423120">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">14.</font></p>
<div id="R1086" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Stenman
	M, Holzmann MJ, Sartipy U. Association between preoperative
	depression and long-term survival following coronary artery bypass
	surgery - a systematic review and meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Int
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2016;222:462–466.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.ijcard.2016.07.216">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27505334">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">15.</font></p>
<div id="R1087" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Okunrintemi
	V, Valero-Elizondo J, Michos ED, et al. Association of depression
	risk with patient experience, healthcare expenditure, and health
	resource utilization among adults with atherosclerotic
	cardiovascular disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Gen Intern Med</font></em><font size="1" style="font-size: 8pt">.
	2019;34:2427–2434.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1007/s11606-019-05325-8">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31489560">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">16.</font></p>
<div id="R1088" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Bangalore
	S, Shah R, Pappadopulos E, et al. Cardiovascular hazards of
	insufficient treatment of depression among patients with known
	cardiovascular disease: a propensity score adjusted analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J Qual Care Clin Outcomes</font></em><font size="1" style="font-size: 8pt">.
	2018;4:258–266.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/ehjqcco/qcy023">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29893803">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">17.</font></p>
<div id="R1089" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Cohen
	BE, Edmondson D, Kronish IM. State of the art review: depression,
	stress, anxiety, and cardiovascular disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Hypertens</font></em><font size="1" style="font-size: 8pt">.
	2015;28:1295–1302.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/ajh/hpv047">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25911639">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">18.</font></p>
<div id="R1090" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Leifheit-Limson
	EC, Kasl SV, Lin H, et al. Adherence to risk factor management
	instructions after acute myocardial infarction: the role of
	emotional support and depressive symptoms.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Behav Med</font></em><font size="1" style="font-size: 8pt">.
	2012;43:198–207.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1007/s12160-011-9311-z">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22037964">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">19.</font></p>
<div id="R1091" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Lichtman
	JH, Froelicher ES, Blumenthal JA, et al. Depression as a risk factor
	for poor prognosis among patients with acute coronary syndrome:
	systematic review and recommendations: a scientific statement from
	the American Heart Association.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2014;129:1350–1369.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0000000000000019">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24566200">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">20.</font></p>
<div id="R1092" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Gale
	CR, Batty GD, Osborn DP, et al. Mental disorders across the adult
	life course and future coronary heart disease: evidence for general
	susceptibility.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2014;129:186–193.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCULATIONAHA.113.002065">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24190959">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">21.</font></p>
<div id="R1093" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Steptoe
	A, Kivimäki M. Stress and cardiovascular disease: an update on
	current knowledge.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Annu
	Rev Public Health</font></em><font size="1" style="font-size: 8pt">.
	2013;34:337–354.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1146/annurev-publhealth-031912-114452">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23297662">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">22.</font></p>
<div id="R1094" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Carney
	RM, Freedland KE, Steinmeyer B, et al. Depression and five year
	survival following acute myocardial infarction: a prospective
	study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Affect Disord</font></em><font size="1" style="font-size: 8pt">.
	2008;109:133–138.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jad.2007.12.005">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18191208">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">23.</font></p>
<div id="R1095" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Geulayov
	G, Novikov I, Dankner D, et al. Symptoms of depression and anxiety
	and 11-year all-cause mortality in men and women undergoing coronary
	artery bypass graft (CABG) surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Psychosom Res</font></em><font size="1" style="font-size: 8pt">.
	2018;105:106–114.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jpsychores.2017.11.017">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29332626">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">24.</font></p>
<div id="R1096" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Pedersen
	SS, von Känel R, Tully PJ, et al. Psychosocial perspectives in
	cardiovascular disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	J Prev Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2017;24:108–115.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1177/2047487317703827">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28618908">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">25.</font></p>
<div id="R1097" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Tully
	PJ, Baker RA, Turnbull D, et al. The role of depression and anxiety
	symptoms in hospital readmissions after cardiac surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Behav Med</font></em><font size="1" style="font-size: 8pt">.
	2008;31:281–290.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1007/s10865-008-9153-8">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18398676">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">26.</font></p>
<div id="R1098" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Blumenthal
	JA, Lett HS, Babyak MA, et al. Depression as a risk factor for
	mortality after coronary artery bypass surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Lancet</font></em><font size="1" style="font-size: 8pt">.
	2003;362:604–609.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0140-6736(03)14190-6">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12944059">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">27.</font></p>
<div id="R1099" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Tully
	PJ, Winefield HR, Baker RA, et al. Confirmatory factor analysis of
	the Beck Depression Inventory-II and the association with cardiac
	morbidity and mortality after coronary revascularization.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Health Psychol</font></em><font size="1" style="font-size: 8pt">.
	2011;16:584–595.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1177/1359105310383604">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21346014">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">28.</font></p>
<div id="R1100" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Poole
	L, Leigh E, Kidd T, et al. The combined association of depression
	and socioeconomic status with length of post-operative hospital stay
	following coronary artery bypass graft surgery: data from a
	prospective cohort study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Psychosom Res</font></em><font size="1" style="font-size: 8pt">.
	2014;76:34–40.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jpsychores.2013.10.019">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24360139">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">29.</font></p>
<div id="R1101" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Connerney
	I, Sloan RP, Shapiro PA, et al. Depression is associated with
	increased mortality 10 years after coronary artery bypass
	surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Psychosom
	Med</font></em><font size="1" style="font-size: 8pt">.
	2010;72:874–881.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1097/PSY.0b013e3181f65fc1">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20841558">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">30.</font></p>
<div id="R1102" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Ravven
	S, Bader C, Azar A, et al. Depressive symptoms after CABG surgery: a
	meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Harv
	Rev Psychiatry</font></em><font size="1" style="font-size: 8pt">.
	2013;21:59–69.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1097/HRP.0b013e31828a3612">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23656830">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">31.</font></p>
<div id="R1103" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Rutledge
	T, Redwine LS, Linke SE, et al. A meta-analysis of mental health
	treatments and cardiac rehabilitation for improving clinical
	outcomes and depression among patients with coronary heart
	disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Psychosom
	Med</font></em><font size="1" style="font-size: 8pt">.
	2013;75:335–349.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1097/PSY.0b013e318291d798">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23630306">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">32.</font></p>
<div id="R1104" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kim
	JM, Bae KY, Stewart R, et al. Escitalopram treatment for depressive
	disorder following acute coronary syndrome: a 24-week double-blind,
	placebo-controlled trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Clin Psychiatry</font></em><font size="1" style="font-size: 8pt">.
	2015;76:62–68.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.4088/JCP.14m09281">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25375836">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">33.</font></p>
<div id="R1105" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Taylor
	CB, Youngblood ME, Catellier D, et al. Effects of antidepressant
	medication on morbidity and mortality in depressed patients after
	myocardial infarction.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Arch
	Gen Psychiatry</font></em><font size="1" style="font-size: 8pt">.
	2005;62:792–798.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/archpsyc.62.7.792">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15997021">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">34.</font></p>
<div id="R1106" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Rollman
	BL, Belnap BH, LeMenager MS, et al. The Bypassing the Blues
	treatment protocol: stepped collaborative care for treating
	post-CABG depression.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Psychosom
	Med</font></em><font size="1" style="font-size: 8pt">.
	2009;71:217–230.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1097/PSY.0b013e3181970c1c">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19188529">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">35.</font></p>
<div id="R1107" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Nieuwsma
	JA, Williams JW, Namdari N, et al. Diagnostic accuracy of screening
	tests and treatment for post-acute coronary syndrome depression: a
	systematic review.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Intern Med</font></em><font size="1" style="font-size: 8pt">.
	2017;167:725–735.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.7326/M17-1811">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29132152">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">36.</font></p>
<div id="R1108" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Lichtman
	JH, Bigger JT, Blumenthal JA, et al. Depression and coronary heart
	disease: recommendations for screening, referral, and treatment: a
	science advisory from the American Heart Association Prevention
	Committee of the Council on Cardiovascular Nursing, Council on
	Clinical Cardiology, Council on Epidemiology and Prevention, and
	Interdisciplinary Council on Quality of Care and Outcomes
	Research.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2008;118:1768–1775.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circulationaha.108.190769">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18824640">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">37.</span></font></p>
<div id="R1109" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Smith
	SC, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and
	risk reduction therapy for patients with coronary and other
	atherosclerotic vascular disease: 2011 update: a guideline from the
	American Heart Association and American College of Cardiology
	Foundation.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2011;124:2458–2473.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0b013e318235eb4d">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22052934">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>16.1.
Assessment of Outcomes in Patients After Revascularization</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R1110" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Hannan
	EL, Wu C, Ryan TJ, et al. Do hospitals and surgeons with higher
	coronary artery bypass graft surgery volumes still have lower
	risk-adjusted mortality rates?&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2003;108:795–801.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/01.CIR.0000084551.52010.3B">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12885743">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R1111" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kim
	LK, Looser P, Swaminathan RV, et al. Outcomes in patients undergoing
	coronary artery bypass graft surgery in the United States based on
	hospital volume, 2007 to 2011.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Thorac Cardiovasc Surg</font></em><font size="1" style="font-size: 8pt">.
	2016;151:1686–1692.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jtcvs.2016.01.050">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26964912">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R1112" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Nallamothu
	BK, Saint S, Ramsey SD, et al. The role of hospital volume in
	coronary artery bypass grafting: is more always better?&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2001;38:1923–1930.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0735-1097(01)01647-3">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/11738295">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R1113" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Peterson
	ED, Coombs LP, DeLong ER, et al. Procedural volume as a marker of
	quality for CABG surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JAMA</font></em><font size="1" style="font-size: 8pt">.
	2004;291:195–201.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1001/jama.291.2.195">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/14722145">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R1114" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Shahian
	DM, O’Brien SM, Normand SL, et al. Association of hospital
	coronary artery bypass volume with processes of care, mortality,
	morbidity, and the Society of Thoracic Surgeons composite quality
	score.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Thorac Cardiovasc Surg</font></em><font size="1" style="font-size: 8pt">.
	2010;139:273–282.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jtcvs.2009.09.007">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20022608">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R1115" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Wu
	C, Hannan EL, Ryan TJ, et al. Is the impact of hospital and surgeon
	volumes on the in-hospital mortality rate for coronary artery bypass
	graft surgery limited to patients at high risk?&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2004;110:784–789.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/01.CIR.0000138744.13516.B5">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15302792">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R1116" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Shahian
	DM, Jacobs JP, Edwards FH, et al. The society of thoracic surgeons
	national database.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Heart</font></em><font size="1" style="font-size: 8pt">.
	2013;99:1494–1501.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1136/heartjnl-2012-303456">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23335498">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R1117" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Campanella
	P, Vukovic V, Parente P, et al. The impact of public reporting on
	clinical outcomes: a systematic review and meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>BMC
	Health Serv Res</font></em><font size="1" style="font-size: 8pt">.
	2016;16:296.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1186/s12913-016-1543-y">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27448999">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">9.</font></p>
<div id="R1118" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Harold
	JG, Bass TA, Bashore TM, et al. ACCF/AHA/SCAI 2013 update of the
	clinical competence statement on coronary artery interventional
	procedures: a report of the American College of Cardiology
	Foundation/American Heart Association/American College of Physicians
	Task Force on Clinical Competence and Training (Writing Committee to
	Revise the 2007 Clinical Competence Statement on Cardiac
	Interventional Procedures).&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2013;128:436–472.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/cir.0b013e318299cd8a">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23658439">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">10.</font></p>
<div id="R1119" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Naidu
	SS, Aronow HD, Box LC, et al. SCAI expert consensus statement: 2016
	best practices in the cardiac catheterization laboratory.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Catheter
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2016;88:407–423.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1002/ccd.26551">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27137680">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">11.</span></font></p>
<div id="R1120" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Levine
	GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline
	for percutaneous coronary intervention: a report of the American
	College of Cardiology Foundation/American Heart Association Task
	Force on Practice Guidelines and the Society for Cardiovascular
	Angiography and Interventions.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2011;124:e574–e651.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0b013e31823ba622">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22064601">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>17.
Unanswered Questions and Future Directions</b></font></font></h2>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">1.</font></p>
<div id="R1121" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Carnethon
	MR, Pu J, Howard G, et al. Cardiovascular health in African
	Americans: a scientific statement from the American Heart
	Association.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2017;136:e393–e423.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0000000000000534">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29061565">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">2.</font></p>
<div id="R1122" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Bucholz
	EM, Ma S, Normand S-LT, et al. Race, socioeconomic status, and life
	expectancy after acute myocardial infarction.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2015;132:1338–1346.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circulationaha.115.017009">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26369354">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">3.</font></p>
<div id="R1123" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Yong
	CM, Ungar L, Abnousi F, et al. Racial differences in quality of care
	and outcomes after acute coronary syndrome.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2018;121:1489–1495.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.amjcard.2018.02.036">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29655881">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">4.</font></p>
<div id="R1124" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Volgman
	AS, Palaniappan LS, Aggarwal NT, et al. Atherosclerotic
	cardiovascular disease in South Asians in the United States:
	epidemiology, risk factors, and treatments: a scientific statement
	from the American Heart Association.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2018;138:e1–e34.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0000000000000580">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29794080">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">5.</font></p>
<div id="R1125" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Jose
	PO, Frank ATH, Kapphahn KI, et al. Cardiovascular disease mortality
	in Asian Americans.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2014;64:2486–2494.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2014.08.048">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25500233">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">6.</font></p>
<div id="R1126" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Brister
	SJ, Hamdulay Z, Verma S, et al. Ethnic diversity: South Asian
	ethnicity is associated with increased coronary artery bypass
	grafting mortality.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Thorac Cardiovasc Surg</font></em><font size="1" style="font-size: 8pt">.
	2007;133:150–154.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jtcvs.2006.05.068">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17198803">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">7.</font></p>
<div id="R1127" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Toor
	IS, Jaumdally R, Lip GYH, et al. Differences between South Asians
	and White Europeans in five year outcome following percutaneous
	coronary intervention.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Int
	J Clin Pract</font></em><font size="1" style="font-size: 8pt">.
	2011;65:1259–1266.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1111/j.1742-1241.2011.02776.x">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22093532">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">8.</font></p>
<div id="R1128" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Burton
	BN, Munir NA, Labastide AS, et al. An update on racial disparities
	with 30-day outcomes after coronary artery bypass graft under the
	Affordable Care Act.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Cardiothorac Vasc Anesth</font></em><font size="1" style="font-size: 8pt">.
	2019;33:1890–1898.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1053/j.jvca.2018.10.021">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30455143">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">9.</font></p>
<div id="R1129" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Gupta
	T, Kolte D, Khera S, et al. Contemporary sex-based differences by
	age in presenting characteristics, use of an early invasive
	strategy, and inhospital mortality in patients with
	non-ST-segment-elevation myocardial infarction in the United
	States.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2018;11:e005735.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCINTERVENTIONS.117.005735">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29311289">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">10.</font></p>
<div id="R1130" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Zhang
	T, Tsang W, Wijeysundera HC, et al. Reporting and representation of
	ethnic minorities in cardiovascular trials: a systematic review.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2013;166:52–57.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.ahj.2013.03.022">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23816021">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">11.</font></p>
<div id="R1131" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Ortega
	RF, Yancy CW, Mehran R, et al. Overcoming lack of diversity in
	cardiovascular clinical trials: a new challenge and strategies for
	success.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2019;140:1690–1692.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCULATIONAHA.119.041728">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31738602">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">12.</font></p>
<div id="R1132" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Velazquez
	EJ, Lee KL, Deja MA, et al. Coronary-artery bypass surgery in
	patients with left ventricular dysfunction.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2011;364:1607–1616.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1100356">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21463150">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">13.</font></p>
<div id="R1133" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Petrie
	MC, Jhund PS, She L, et al. Ten-year outcomes after coronary artery
	bypass grafting according to age in patients with heart failure and
	left ventricular systolic dysfunction: an analysis of the extended
	follow-up of the STICH trial (Surgical Treatment for Ischemic Heart
	Failure).&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2016;134:1314–1324.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCULATIONAHA.116.024800">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27573034">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">14.</font></p>
<div id="R1134" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Velazquez
	EJ, Lee KL, Jones RH, et al. Coronary-artery bypass surgery in
	patients with ischemic cardiomyopathy.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2016;374:1511–1520.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1602001">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27040723">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">15.</font></p>
<div id="R1135" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Bonow
	RO, Maurer G, Lee KL, et al. Myocardial viability and survival in
	ischemic left ventricular dysfunction.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2011;364:1617–1625.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1100358">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21463153">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">16.</font></p>
<div id="R1136" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Orlandini
	A, Castellana N, Pascual A, et al. Myocardial viability for
	decision-making concerning revascularization in patients with left
	ventricular dysfunction and coronary artery disease: a meta-analysis
	of non-randomized and randomized studies.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Int
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2015;182:494–499.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.ijcard.2015.01.025">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25617608">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">17.</font></p>
<div id="R1137" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kunadian
	V, Zaman A, Qiu W. Revascularization among patients with severe left
	ventricular dysfunction: a meta-analysis of observational
	studies.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur J
	Heart Fail</font></em><font size="1" style="font-size: 8pt">.
	2011;13:773–784.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/eurjhf/hfr037">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21478241">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">18.</font></p>
<div id="R1138" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Cortigiani
	L, Bigi R, Sicari R. Is viability still viable after the STICH
	trial?&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J Cardiovasc Imaging</font></em><font size="1" style="font-size: 8pt">.
	2012;13:219–226.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/ejechocard/jer237">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22080451">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">19.</font></p>
<div id="R1139" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Perera
	D, Clayton T, Petrie MC, et al. Percutaneous revascularization for
	ischemic ventricular dysfunction: rationale and design of the
	REVIVED-BCIS2 Trial: percutaneous coronary intervention for ischemic
	cardiomyopathy.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Heart Fail</font></em><font size="1" style="font-size: 8pt">.
	2018;6:517–526.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jchf.2018.01.024">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29852933">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">20.</font></p>
<div id="R1140" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">ISCHEMIA
	Trial. Other Trials of Potential Interest. Accessed October 13,
	2021.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ischemiatrial.org/other-trials-potential-interest">https://www.ischemiatrial.org/other-trials-potential-interest</span></font></span></font></a></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">21.</font></p>
<div id="R1141" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Saw
	J, Aymong E, Mancini GBJ, et al. Nonatherosclerotic coronary artery
	disease in young women.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Can
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2014;30:814–819.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.cjca.2014.01.011">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24726091">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">22.</font></p>
<div id="R1142" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Tweet
	MS, Eleid MF, Best PJM, et al. Spontaneous coronary artery
	dissection: revascularization versus conservative therapy.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2014;7:777–786.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCINTERVENTIONS.114.001659">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25406203">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">23.</font></p>
<div id="R1143" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Hayes
	SN, Kim ESH, Saw J, et al. Spontaneous coronary artery dissection:
	current state of the science: a scientific statement from the
	American Heart Association.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2018;137:e523–e557.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0000000000000564">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29472380">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">24.</font></p>
<div id="R1144" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Crawley
	PD, Mahlow WJ, Huntsinger DR, et al. Giant coronary artery
	aneurysms: review and update.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Tex
	Heart Inst J</font></em><font size="1" style="font-size: 8pt">.
	2014;41:603–608.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.14503/THIJ-13-3896">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25593524">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">25.</font></p>
<div id="R1145" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Keyser
	A, Hilker MK, Husser O, et al. Giant coronary aneurysms exceeding 5
	cm in size.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Interact
	Cardiovasc Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2012;15:33–36.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/icvts/ivs111">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22505591">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">26.</font></p>
<div id="R1146" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Li
	Y-F, Zhang Z-W, Wang S-S, et al. Transcatheter closure of congenital
	coronary artery fistulas with a giant coronary artery aneurysm in
	children: experiences from a single center.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Chin
	Med J (Engl)</font></em><font size="1" style="font-size: 8pt">.
	2017;130:1919–1925.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.4103/0366-6999.211894">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28776543">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">27.</font></p>
<div id="R1147" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Hirata
	K, Yagi N, Wake M, et al. Coronary steal due to ruptured right
	coronary aneurysm causing myocardial infarction in a patient with
	systemic lupus erythematosus.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Cardiovasc
	Diagn Ther</font></em><font size="1" style="font-size: 8pt">.
	2014;4:333–336.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25276619">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">28.</font></p>
<div id="R1148" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Tarantini
	G, Migliore F, Cademartiri F, et al. Left anterior descending artery
	myocardial bridging: a clinical approach.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2016;68:2887–2899.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2016.09.973">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28007148">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">29.</font></p>
<div id="R1149" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Gould
	KL, Johnson NP. Myocardial bridges: lessons in clinical coronary
	pathophysiology.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Cardiovasc Imaging</font></em><font size="1" style="font-size: 8pt">.
	2015;8:705–709.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jcmg.2015.02.013">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26068287">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">30.</font></p>
<div id="R1150" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Boyd
	JH, Pargaonkar VS, Scoville DH, et al. Surgical unroofing of
	hemodynamically significant left anterior descending myocardial
	bridges.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2017;103:1443–1450.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.athoracsur.2016.08.035">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27745841">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">31.</font></p>
<div id="R1151" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Mason
	PJ, Shah B, Tamis-Holland JE, et al. An update on radial artery
	access and best practices for transradial coronary angiography and
	intervention in acute coronary syndrome: a scientific statement from
	the American Heart Association.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2018;11:e000035.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/HCV.0000000000000035">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30354598">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">32.</font></p>
<div id="R1152" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Gaudino
	M, Taggart D, Suma H, et al. The choice of conduits in coronary
	artery bypass surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2015;66:1729–1737.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2015.08.395">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26449144">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">33.</font></p>
<div id="R1153" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Ruzieh
	M, Moza A, Siddegowda Bangalore B, et al. Effect of transradial
	catheterisation on patency rates of radial arteries used as a
	conduit for coronary bypass.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Heart
	Lung Circ</font></em><font size="1" style="font-size: 8pt">.
	2017;26:296–300.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.hlc.2016.07.012">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27670584">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">34.</font></p>
<div id="R1154" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kamiya
	H, Ushijima T, Kanamori T, et al. Use of the radial artery graft
	after transradial catheterization: is it suitable as a bypass
	conduit?&nbsp;</font><font size="1" style="font-size: 8pt"><em>Ann
	Thorac Surg</font></em><font size="1" style="font-size: 8pt">.
	2003;76:1505–1509.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/S0003-4975(03)01018-X">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/14602276">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">35.</font></p>
<div id="R1155" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Yonetsu
	T, Kakuta T, Lee T, et al. Assessment of acute injuries and chronic
	intimal thickening of the radial artery after transradial coronary
	intervention by optical coherence tomography.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2010;31:1608–1615.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/eurheartj/ehq102">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20413398">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">36.</font></p>
<div id="R1156" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Ahn
	J-M, Park D-W, Lee CW, et al. Comparison of stenting versus bypass
	surgery according to the completeness of revascularization in severe
	coronary artery disease: patient-level pooled analysis of the
	SYNTAX, PRECOMBAT, and BEST trials.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2017;10:1415–1424.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jcin.2017.04.037">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28728654">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">37.</font></p>
<div id="R1157" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Ando
	T, Takagi H, Grines CL. Complete versus incomplete revascularization
	with drug-eluting stents for multi-vessel disease in stable,
	unstable angina or non-ST-segment elevation myocardial infarction: a
	meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Interv Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2017;30:309–317.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1111/joic.12390">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28573650">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">38.</font></p>
<div id="R1158" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Bangalore
	S, Guo Y, Samadashvili Z, et al. Outcomes with complete versus
	incomplete revascularization in patients with multivessel coronary
	disease undergoing percutaneous coronary intervention with
	everolimus eluting stents.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Am
	J Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2020;125:362–369.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.amjcard.2019.10.022">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31810515">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">39.</font></p>
<div id="R1159" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Farooq
	V, Serruys PW, Garcia-Garcia HM, et al. The negative impact of
	incomplete angiographic revascularization on clinical outcomes and
	its association with total occlusions: the SYNTAX (Synergy Between
	Percutaneous Coronary Intervention with Taxus and Cardiac Surgery)
	trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J Am
	Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2013;61:282–294.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2012.10.017">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23265332">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">40.</font></p>
<div id="R1160" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Zimarino
	M, Ricci F, Romanello M, et al. Complete myocardial
	revascularization confers a larger clinical benefit when performed
	with state-of-the-art techniques in high-risk patients with
	multivessel coronary artery disease: a meta-analysis of randomized
	and observational studies.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Catheter
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2016;87:3–12.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1002/ccd.25923">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25846673">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">41.</font></p>
<div id="R1161" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Schwartz
	L, Bertolet M, Feit F, et al. Impact of completeness of
	revascularization on long-term cardiovascular outcomes in patients
	with type 2 diabetes mellitus: results from the Bypass Angioplasty
	Revascularization Investigation 2 Diabetes (BARI 2D).&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circ
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2012;5:166–173.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIRCINTERVENTIONS.111.963512">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22496082">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">42.</font></p>
<div id="R1162" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Head
	SJ, Davierwala PM, Serruys PW, et al. Coronary artery bypass
	grafting vs. percutaneous coronary intervention for patients with
	three-vessel disease: final five-year follow-up of the SYNTAX
	trial.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Eur
	Heart J</font></em><font size="1" style="font-size: 8pt">.
	2014;35:2821–2830.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1093/eurheartj/ehu213">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24849105">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">43.</font></p>
<div id="R1163" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Mehta
	SR, Wood DA, Storey RF, et al. Complete revascularization with
	multivessel PCI for myocardial infarction.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2019;381:1411–1421.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1907775">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31475795">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">44.</font></p>
<div id="R1164" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Harskamp
	RE, Brennan JM, Xian Y, et al. Practice patterns and clinical
	outcomes after hybrid coronary revascularization in the United
	States: an analysis from the society of thoracic surgeons adult
	cardiac database.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2014;130:872–879.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/circulationaha.114.009479">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25055814">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">45.</font></p>
<div id="R1165" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Tajstra
	M, Hrapkowicz T, Hawranek M, et al. Hybrid coronary
	revascularization in selected patients with multivessel disease:
	5-year clinical outcomes of the prospective randomized pilot
	study.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2018;11:847–852.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jcin.2018.01.271">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29680218">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">46.</font></p>
<div id="R1166" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Gąsior
	M, Zembala MO, Tajstra M, et al. Hybrid revascularization for
	multivessel coronary artery disease.&nbsp;</font><font size="1" style="font-size: 8pt"><em>JACC
	Cardiovasc Interv</font></em><font size="1" style="font-size: 8pt">.
	2014;7:1277–1283.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jcin.2014.05.025">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25459040">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">47.</font></p>
<div id="R1167" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Shen
	L, Hu S, Wang H, et al. One-stop hybrid coronary revascularization
	versus coronary artery bypass grafting and percutaneous coronary
	intervention for the treatment of multivessel coronary artery
	disease: 3-year follow-up results from a single institution.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2013;61:2525–2533.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2013.04.007">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23623906">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">48.</font></p>
<div id="R1168" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Faroux
	L, Guimaraes L, Wintzer-Wehekind J, et al. Coronary artery disease
	and transcatheter aortic valve replacement: JACC state-of-the-art
	review.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J Am
	Coll Cardiol</font></em><font size="1" style="font-size: 8pt">.
	2019;74:362–372.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.jacc.2019.06.012">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31319919">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">49.</font></p>
<div id="R1169" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">D’Ascenzo
	F, Verardi R, Visconti M, et al. Independent impact of extent of
	coronary artery disease and percutaneous revascularisation on 30-day
	and one-year mortality after TAVI: a meta-analysis of adjusted
	observational results.&nbsp;</font><font size="1" style="font-size: 8pt"><em>EuroIntervention</font></em><font size="1" style="font-size: 8pt">.
	2018;14:e1169–e1177.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.4244/EIJ-D-18-00098">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30082258">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">50.</font></p>
<div id="R1170" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Kotronias
	RA, Kwok CS, George S, et al. Transcatheter aortic valve
	implantation with or without percutaneous coronary artery
	revascularization strategy: a systematic review and meta-analysis.&nbsp;</font><font size="1" style="font-size: 8pt"><em>J
	Am Heart Assoc</font></em><font size="1" style="font-size: 8pt">.
	2017;6: e005960.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/JAHA.117.005960">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28655733">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">51.</font></p>
<div id="R1171" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Leon
	MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve
	replacement in intermediate-risk patients.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2016;374:1609–1620.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa1514616">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27040324">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">52.</font></p>
<div id="R1172" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Otto
	CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the
	management of patients with valvular heart disease: a report of the
	American College of Cardiology/American Heart Association Joint
	Committee on Clinical Practice Guidelines.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Circulation</font></em><font size="1" style="font-size: 8pt">.
	2021;143:e72–e227.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1161/CIR.0000000000000923">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/33332150">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">53.</font></p>
<div id="R1173" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">McFalls
	EO, Ward HB, Moritz TE, et al. Coronary-artery revascularization
	before elective major vascular surgery.&nbsp;</font><font size="1" style="font-size: 8pt"><em>N
	Engl J Med</font></em><font size="1" style="font-size: 8pt">.
	2004;351:2795–2804.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1056/NEJMoa041905">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15625331">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<p align="right" style="line-height: 0.17in; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">54.</span></font></p>
<div id="R1174" dir="ltr"><p style="line-height: 0.17in; margin-bottom: 0in">
	<span style="display: inline-block; border: none; padding: 0in"><font size="1" style="font-size: 8pt">Rao
	NN, Coates PT. Cardiovascular disease after kidney transplant.&nbsp;</font><font size="1" style="font-size: 8pt"><em>Semin
	Nephrol</font></em><font size="1" style="font-size: 8pt">.
	2018;38:291–297.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://doi.org/10.1016/j.semnephrol.2018.02.008">Crossref</font></span></font></a><font size="1" style="font-size: 8pt">.&nbsp;</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 8pt"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29753404">PubMed</font></span></font></a><font size="1" style="font-size: 8pt">.</span></font></p>
</div>
<h2 class="western" align="left" style="line-height: 0.2in; margin-top: 0in; margin-bottom: 0in; border-top: 1.20pt solid #b6b7b9; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in">
<font color="#d93731"><font size="2" style="font-size: 10pt"><b>Appendix</b></font></font></h2>
<h3 class="western" align="left" style="line-height: 0.19in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><b>Appendix
1. Author Relationships With Industry and Other Entities
(Relevant)—2021 ACC/AHA/SCAI Guideline for Coronary Artery
Revascularization</b></font></font></h3>
<table cellpadding="2" cellspacing="2">
	<thead>
		<tr>
			<th style="border: 1px solid #2c2e35; padding: 0.02in"><p style="font-weight: normal">
				Committee Member</p>
			</th>
			<th style="border: 1px solid #2c2e35; padding: 0.02in"><p style="font-weight: normal">
				Employment</p>
			</th>
			<th style="border: 1px solid #2c2e35; padding: 0.02in"><p style="font-weight: normal">
				Consultant</p>
			</th>
			<th style="border: 1px solid #2c2e35; padding: 0.02in"><p style="font-weight: normal">
				Speakers Bureau</p>
			</th>
			<th style="border: 1px solid #2c2e35; padding: 0.02in"><p style="font-weight: normal">
				Ownership/Partnership/Principal</p>
			</th>
			<th style="border: 1px solid #2c2e35; padding: 0.02in"><p style="font-weight: normal">
				Personal Research</p>
			</th>
			<th style="border: 1px solid #2c2e35; padding: 0.02in"><p style="font-weight: normal">
				Institutional, Organizational, or Other Financial Benefit</p>
			</th>
			<th style="border: 1px solid #2c2e35; padding: 0.02in"><p style="font-weight: normal">
				Expert Witness</p>
			</th>
		</tr>
	</thead>
	<tbody>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Jennifer
				S. Lawton, Chair</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Johns
				Hopkins Medicine—Professor and Chief of Cardiac Surgery</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Jacqueline
				E. Tamis-Holland Vice-Chair/JCPG liaison</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Mount
				Sinai Morningside Hospital—Associate Director, Cardiac
				Catheterization Laboratory; Icahn School of Medicine at Mount
				Sinai—Professor of Medicine</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Sripal
				Bangalore</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">New
				York University School of Medicine,<br/>
The Leon H. Charney
				Division of Cardiology—Professor of Medicine and Director,
				Complex Coronary Intervention; Director of Research, Cardiac
				Catheterization Laboratory and Director, Cardiovascular Outcomes
				Group</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">Abbott</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab1fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Amgen</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab1fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Biotronik<br/>
• Meril<br/>
• Pfizer<br/>
• Reata<br/>
•
				SMT</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">Abbott</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab1fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Reata</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab1fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Eric
				R. Bates</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">University
				of Michigan Department of Internal Medicine—Professor of
				Internal Medicine</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Theresa
				M. Beckie</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">University
				of South Florida, Tampa—Professor and Associate Dean PhD
				Program, College of Nursing Professor, College of Medicine,
				Division of Cardiovascular Sciences</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">James
				M. Bischoff</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">AHA
				Volunteer (Patient Representative)</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">John
				A. Bittl</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Advent
				Health Ocala, Interventional Cardiology— Chief of Staff,
				Medical Director of Surgical Services, Research, and Education</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Mauricio
				G. Cohen (TFDS liaison)</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">University
				of Miami Hospital and Clinics—Professor of Medicine and
				Director, Cardiac Catheterization Laboratory</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">Abiomed</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab1fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				AstraZeneca</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab1fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Medtronic</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab1fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Merit Medical</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab1fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Terumo Medical<br/>
• Zoll</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">Accumed Radial Systems</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">J.
				Michael DiMaio</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Baylor
				Scott &amp; White Health System—Medical Director of Surgical
				Services</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Creighton
				W. Don (SCAI representative)</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">VA
				Puget Sound Medical Center—Associate Professor of Medicine and
				Section Chief Cardiology; University of Washington Division of
				Cardiology—Director of the Interventional Cardiology and
				Structural Heart Fellowships</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">Siemens</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">Abbott</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab1fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Boston Scientific</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab1fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				CSI</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab1fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Medtronic</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab1fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Spectranetics</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab1fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Stephen
				E. Fremes (AATS representative)</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">University
				of Toronto Schulich Heart Centre—Cardiovascular Surgery
				Professor</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">Bayer</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab1fn2"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">†</font></span></font></a><font size="1" style="font-size: 7pt">,</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab1fn3"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">‡</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Edwards</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab1fn3"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">‡</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Medtronic</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab1fn3"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">‡</font></span></font></a></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Mario
				F. Gaudino</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Weill
				Cornell Medicine Professor/Surgeon—<br/>
Cardiothoracic Surgery</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Zachary
				D. Goldberger</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">University
				of Wisconsin School of Medicine and Public Health—Associate
				Professor of Medicine, Division of Cardiovascular
				Medicine/Electrophysiology; University of Wisconsin School of
				Medicine and Public Health—Associate Program Director, Clinical
				Electrophysiology Fellowship</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Michael
				C. Grant</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">The
				Johns Hopkins Medical Institutions, The Armstrong Institute for
				Patient Safety and Quality—Associate Professor, Divisions of
				Cardiothoracic Anesthesia, Surgical Critical Care and Acute Care
				Surgery and Core Faculty, Departments of Anesthesiology/Critical
				Care Medicine and Surgery</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Jang
				B. Jaswal</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">National
				Ambassador for AHA (Patient Representative)</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Paul
				A. Kurlansky</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Columbia
				University College of Physicians and Surgeons—Associate
				Professor of Surgery, Division of Cardiothoracic Surgery;
				Columbia HeartSource—Director of Research, Recruitment and CQI;
				Center for Innovation and Outcomes Research—Associate Director</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Roxana
				Mehran</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Mount
				Sinai—Professor in Cardiovascular Clinical Research and
				Outcomes, Professor of Medicine (Cardiology); Icahn School of
				Medicine at Mount Sinai Population Health Science and
				Policy—Director of Interventional Cardiovascular Research and
				Clinical Trials</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">Bayer<br/>
• Boston
				Scientific<br/>
• Janssen Pharmaceuticals</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">Claret</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab1fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Boston Scientific</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab1fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Controlrad</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab1fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Elixir Medical</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab1fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">Abbott</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab1fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Abiomed</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab1fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				AstraZeneca</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab1fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Bayer</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab1fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Thomas
				S. Metkus</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Johns
				Hopkins University School of Medicine—Assistant Professor of
				Medicine and Surgery, Division of Cardiology, Department of
				Medicine and Division of Cardiac Surgery Department of Surgery</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Lorraine
				C. Nnacheta</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab1fn4"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">§</font></span></font></a></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">American
				Heart Association/American College of Cardiology—Guideline
				Advisor</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">AHA/ACC salaried employee</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Sunil
				V. Rao</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Duke
				University Health System—Professor of Medicine and Section
				Chief, Cardiology</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">Amgen</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab1fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Bayer<br/>
• Shockwave Medical<br/>
• Svelte Medical</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Frank
				W. Sellke</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Alpert
				Medical School of Brown University and Rhode Island
				Hospital—Director of the Cardiovascular Institute and Karl
				Karlson Professor and Chief of Cardiothoracic Surgery</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">Stryker</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">Bayer</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab1fn2"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">†</font></span></font></a></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Garima
				Sharma</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Johns
				Hopkins University School of Medicine, Department of Medicine,
				Ciccarone Center for the Prevention of Cardiovascular Disease,
				Division of Cardiology—Assistant Professor of Medicine and
				Director of Cardio-Obstetrics Program</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Celina
				M. Yong</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Stanford
				University School of Medicine—Assistant Professor, Division of
				Cardiovascular Medicine; VA Palo Alto Health care System—Director
				of Interventional Cardiology</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Brittany
				A. Zwischenberger</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Duke
				University—Assistant Professor, Division of Cardiothoracic
				Surgery</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
	</tbody>
</table>
<p align="justify" style="line-height: 0.11in; margin-bottom: 0in"><font size="1" style="font-size: 6pt">This
table represents the relationships of committee members with industry
and other entities that were determined to be relevant to this
document. These relationships were reviewed and updated in
conjunction with all meetings and/or conference calls of the writing
committee during the document development process. The table does not
necessarily reflect relationships with industry at the time of
publication. A person is deemed to have a significant interest in a
business if the interest represents ownership of ≥5% of the voting
stock or share of the business entity, or ownership of ≥$5000 of
the fair market value of the business entity; or if funds received by
the person from the business entity exceed 5% of the person’s gross
income for the previous year. Relationships that exist with no
financial benefit are also included for the purpose of transparency.
Relationships in this table are modest unless otherwise noted.</font></p>
<p align="justify" style="line-height: 0.11in; margin-bottom: 0in"><font size="1" style="font-size: 6pt">According
to the ACC/AHA, a person has a&nbsp;<i>relevant</i>&nbsp;relationship
IF: a) the&nbsp;<i>relationship or interest</i>&nbsp;relates to the
same or similar subject matter, intellectual property or asset,
topic, or issue addressed in the&nbsp;<i>document;</i>&nbsp;or b)
the&nbsp;<i>company/entity</i>&nbsp;(with whom the relationship
exists) makes a drug, drug class, or device addressed in
the&nbsp;<i>document</i>&nbsp;or makes a competing drug or device
addressed in the&nbsp;<i>document</i>; or c) the&nbsp;<i>person or a
member of the person’s household</i>, has a reasonable potential
for financial, professional or other personal gain or loss as a
result of the issues/content addressed in the&nbsp;<i>document</i>.
Writing committee members are required to recuse themselves from
voting on sections to which their specific relationships with
industry and other entities may apply.</font></p>
<p align="justify" style="line-height: 0.11in; margin-bottom: 0in"><font size="1" style="font-size: 6pt">*</font></p>
<div id="atab1fn1" dir="ltr"><p align="justify" style="line-height: 0.11in; margin-bottom: 0in">
	<font size="1" style="font-size: 6pt">Significant relationship.</font></p>
</div>
<p align="justify" style="line-height: 0.11in; margin-bottom: 0in">†</p>
<div id="atab1fn2" dir="ltr"><p align="justify" style="line-height: 0.11in; margin-bottom: 0in">
	<font size="1" style="font-size: 6pt">No financial benefit.</font></p>
</div>
<p align="justify" style="line-height: 0.11in; margin-bottom: 0in">‡</p>
<div id="atab1fn3" dir="ltr"><p align="justify" style="line-height: 0.11in; margin-bottom: 0in">
	<font size="1" style="font-size: 6pt">This disclosure was entered
	under the Clinical Trial Enroller category in the ACC’s disclosure
	system. To appear in this category, the author acknowledges that
	there is no&nbsp;<i>direct</i>&nbsp;or&nbsp;<i>institutional</i>&nbsp;relationship
	with the trial sponsor as defined in the (ACCF or ACC/AHA)
	Disclosure Policy for Writing Committees.</font></p>
</div>
<p align="justify" style="line-height: 0.11in; margin-bottom: 0in"><font size="1" style="font-size: 6pt">§</font></p>
<div id="atab1fn4" dir="ltr"><p align="justify" style="line-height: 0.11in; margin-bottom: 0in">
	<font size="1" style="font-size: 6pt">Lorraine Nnacheta is an
	AHA/ACC joint staff member and acts as the guideline advisor for the
	“2021 ACC/AHA/SCAI Guideline for Coronary Artery
	Revascularization.” No relevant relationships to report.
	Non-voting author on recommendations and not included/counted in the
	RWI balance for this committee.</font></p>
</div>
<p align="justify" style="line-height: 0.11in"><font size="1" style="font-size: 6pt">AATS
indicates American Association for Thoracic Surgery; ACC, American
College of Cardiology; ACCF, American College of Cardiology
Foundation; AHA, American Heart Association; CQI, Continuous Quality
Improvement; JCPG, Joint Committee on Clinical Practice Guidelines;
RWI, relationships with industry and other entities; SCAI, Society
for Cardiovascular Angiography and Interventions; TFDS, ACC/AHA Task
Force for Clinical Data Standards; and VA, Veterans Affairs.</font></p>
<h3 class="western" align="left" style="line-height: 0.19in; margin-top: 0in; margin-bottom: 0in">
<font color="#d93731"><font size="2" style="font-size: 9pt"><b>Appendix
2. Reviewer Relationships With Industry and Other Entities
(Comprehensive)—2021 ACC/AHA/SCAI Guideline for Coronary
Revascularization (January 2021)</b></font></font></h3>
<table cellpadding="2" cellspacing="2">
	<thead>
		<tr>
			<th style="border: 1px solid #2c2e35; padding: 0.02in"><p style="font-weight: normal">
				Reviewer</p>
			</th>
			<th style="border: 1px solid #2c2e35; padding: 0.02in"><p style="font-weight: normal">
				Representation</p>
			</th>
			<th style="border: 1px solid #2c2e35; padding: 0.02in"><p style="font-weight: normal">
				Employment</p>
			</th>
			<th style="border: 1px solid #2c2e35; padding: 0.02in"><p style="font-weight: normal">
				Consultant</p>
			</th>
			<th style="border: 1px solid #2c2e35; padding: 0.02in"><p style="font-weight: normal">
				Speakers Bureau</p>
			</th>
			<th style="border: 1px solid #2c2e35; padding: 0.02in"><p style="font-weight: normal">
				Ownership/Partnership/Principal</p>
			</th>
			<th style="border: 1px solid #2c2e35; padding: 0.02in"><p style="font-weight: normal">
				Personal Research</p>
			</th>
			<th style="border: 1px solid #2c2e35; padding: 0.02in"><p style="font-weight: normal">
				Institutional, Organizational, or Other Financial Benefit</p>
			</th>
			<th style="border: 1px solid #2c2e35; padding: 0.02in"><p style="font-weight: normal">
				Expert Witness</p>
			</th>
		</tr>
	</thead>
	<tbody>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Anastasia
				L. Armbruster</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Content
				Reviewer—Joint Committee on Clinical Practice Guidelines</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">University
				of Health Sciences and Pharmacy in St. Louis</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">AstraZeneca</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Joshua
				A. Beckman</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Official
				Reviewer—Joint Committee on Clinical Practice Guidelines</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Vanderbilt
				University Medical Center</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">Amgen<br/>
• JanOne<br/>
•
				Janssen Pharmaceuticals</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">EMX</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn2"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">†</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				JanaCare</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn2"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">†</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				VIA</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">Bayer (DSMB)<br/>
•
				Novartis (DSMB)</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">Amgen</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Kim
				K. Birtcher</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Content
				Reviewer—Joint Committee on Clinical Practice Guidelines</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">University
				of Houston College of Pharmacy</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">Jones &amp; Bartlett
				Learning</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Lynne
				T. Braun</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Content
				Reviewer—ACC/AHA</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Rush
				University (Retired)</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">AHA</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn2"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">†</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				PCNA</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn2"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">†</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				UptoDate</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Edward
				Butler</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Lay
				Reviewer</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Lay
				Stakeholder Representative<br/>
Retired, Mint Hill, NC</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Anita
				Deswal</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Content
				Reviewer—Joint Committee on Clinical Practice Guidelines</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">University
				of Texas MD Anderson Cancer Center</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">ACC<br/>
• AHA</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Dave
				L. Dixon</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Content
				Reviewer—Joint Committee on Clinical Practice Guidelines</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Virginia
				Commonwealth University School of Pharmacy</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">American Pharmacists
				Association</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">Centers for Disease Control
				and Prevention</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Community Pharmacy Foundation</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">Accreditation Council for
				Lipidology</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn2"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">†</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				American College of Pharmacy Cardiology Practice Research
				Network</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn2"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">†</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				National Lipid Association</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn2"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">†</font></span></font></a></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">David
				Faxon</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Content
				Reviewer—ACC/AHA</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Brigham
				and Women’s Hospital</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">Boston Scientific<br/>
•
				CSL Behring</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">Boston Scientific (DSMB)<br/>
•
				CSL Behring (DSMB)<br/>
• Medtronic</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn2"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">†</font></span></font></a></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">Akenia Therapeutics</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Medtronic<br/>
• REVA Medical</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Lisa
				de las Fuentes</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Content
				Reviewer—Joint Committee on Clinical Practice Guidelines</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Washington
				University in St. Louis</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">Acceleron<br/>
•
				Altavant<br/>
• Arena<br/>
• Bayer<br/>
• Express Scripts<br/>
•
				Gossamer<br/>
• Johnson &amp; Johnson<br/>
• Phase Bio<br/>
•
				V-wave<br/>
• Vaderis<br/>
• WebMD</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">Simply Speaking</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">Acceleron</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Altavant</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Bayer<br/>
• Complexa</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Foundation for the National Institutes of Health<br/>
• Johnson
				&amp; Johnson</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Liquidia</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Medtronic</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				NIH</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Reata</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Trio Analytics<br/>
• United Therapeutics</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				University of Kentucky (DSMB)</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn2"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">†</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				University of Toronto (DSMB)</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn2"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">†</font></span></font></a></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">ACC</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn2"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">†</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				AHA</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn2"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">†</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•&nbsp;</font><font size="1" style="font-size: 7pt"><i>Circulation</i></font><font size="1" style="font-size: 7pt">&nbsp;Journals<br/>
•
				Pulmonary Hypertension Association</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Kirk
				N. Garratt</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Official
				Reviewer—SCAI</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">ChristianaCare</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">LifeCuff Technologies</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">Abbott (DSMB)</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Jarvik Heart (DSMB)</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Zachary
				D. Goldberger</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Content
				Reviewer—Joint Committee on Clinical Practice Guidelines</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Associate
				Professor, University of Wisconsin-Madison, School of Medicine
				and Public Health</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Bulent
				Gorenek</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Content
				Reviewer—Joint Committee on Clinical Practice Guidelines</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Eskisehir
				Osmangazi University</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">AstraZeneca<br/>
• Sandoz</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Robert
				Guyton</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Official
				Reviewer—STS</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Emory
				University</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">Edwards Lifesciences</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">Edwards Lifesciences</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn2"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">†</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				NIH</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn2"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">†</font></span></font></a></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">Boston Scientific</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Edwards Lifesciences</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1">*</a><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn3">‡</a></font></span></font><font size="1" style="font-size: 7pt"><br/>
•
				Medtronic</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn3"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">‡</font></span></font></a></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Norissa
				Haynes</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Content
				Reviewer—Joint Committee on Clinical Practice Guidelines</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">University
				of Pennsylvania</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Adrian
				F. Hernandez</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Content
				Reviewer—Joint Committee on Clinical Practice Guidelines</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Duke
				University</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">Amgen<br/>
•
				AstraZeneca</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Bayer<br/>
• Biofourmis<br/>
• Boehringer Ingelheim<br/>
•
				Boston Scientific</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Cytokinetics<br/>
• Daiichi Sankyo<br/>
• Eli Lilly<br/>
•
				Merck</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Myokardia<br/>
• Novartis</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Pfizer<br/>
• Relypsa<br/>
• Sanofi-aventis</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Xogenex</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">American Regent<br/>
•
				AstraZeneca</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Eidos (DSMB)<br/>
• Genentech<br/>
• GlaxoSmithKline</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Janssen Pharmaceuticals<br/>
• Merck<br/>
• NIH</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn2"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">†</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Novartis</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				PCORI</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn2"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">†</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Verily</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">AHA</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn2"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">†</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				AstraZeneca<br/>
• Boston Scientific<br/>
• CSL Behring<br/>
•
				Janssen Pharmaceuticals</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Merck<br/>
• Novartis<br/>
• Genentech</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Relypsa<br/>
• Sanofi-aventis</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">Defendant, Patent Dispute,
				2019</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Jose
				A. Joglar</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Content
				Reviewer—Joint Committee on Clinical Practice Guidelines</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">UT
				Southwestern Medical Center</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">W.
				Schuyler Jones</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Content
				Reviewer—Joint Committee on Clinical Practice Guidelines</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Duke
				University</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">Amgen<br/>
• Bayer<br/>
•
				Janssen Pharmaceuticals</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Pfizer</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">Bristol Myers-Squibb</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				PCORI</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">Abbott</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Amgen<br/>
• AstraZeneca<br/>
• Boehringer Ingelheim<br/>
•
				Cardiovascular Systems Inc.</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Janssen Pharmaceuticals<br/>
• ZOLL Medical</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Andrew
				M. Kates</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Content
				Reviewer—ACC/AHA</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Washington
				University School of Medicine</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Jim
				LoFaso</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Lay
				Reviewer</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Veeco;
				Solomon Page (Contactor)</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Thomas
				MacGillivray</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Content
				Reviewer—ACC/AHA</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Houston
				Methodist Hospital</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">Xylocor Therapeutics</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn3"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">‡</font></span></font></a></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Daniel
				B. Mark</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Content
				Reviewer—Joint Committee on Clinical Practice Guidelines</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Duke
				University</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">HeartFlow</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Merck</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">HeartFlow</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Merck</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Sara
				C. Martinez</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Content
				Reviewer—ACC</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Providence
				Health and Services</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">Abiomed<br/>
• Boston
				Scientific<br/>
• Novartis<br/>
• Maquet Cardiovascular</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Venu
				Menon</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Content
				Reviewer—ACC/AHA</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Cleveland
				Clinic</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">Novartis</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn2"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">†</font></span></font></a></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">L.
				Kristin Newby</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Content
				Reviewer—ACC/AHA</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Duke
				University</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">Beckman-Coulter<br/>
•
				Bristol Myers Squibb<br/>
• CSL<br/>
• Medtronic<br/>
•
				NHLBI<br/>
• Quidel<br/>
• Roche Diagnostics</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">BioKier<br/>
• Boehringer
				Ingelheim<br/>
• CDC<br/>
• David H. Murdock Institute for
				Business and Culture<br/>
• NIH</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				North Carolina DHHS</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">AHA</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn2"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">†</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				ACC, Oregon Chapter<br/>
• AstraZeneca</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn2"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">†</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Boehringer Ingelheim<br/>
• David H. Murdock Research
				Institute</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn2"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">†</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•&nbsp;</font><font size="1" style="font-size: 7pt"><i>JACC</i></font><font size="1" style="font-size: 7pt">,
				Deputy Editor</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Michelle
				O’Donoghue</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Content
				Reviewer—ACC/AHA</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Brigham
				and Women’s Hospital</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">Amgen<br/>
• CVS
				Caremark<br/>
• Janssen Pharmaceuticals<br/>
• Novartis</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">Amgen</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				AstraZeneca (DSMB)</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Eisai</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Intarcia</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Janssen Pharmaceuticals</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				The Medicines Company/Novartis</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>• <font size="1" style="font-size: 7pt">Kowa
				Pharmaceuticals</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Patrick
				T. O’Gara</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Content
				Reviewer—Joint Committee on Clinical Practice Guidelines</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Brigham
				and Women’s Hospital</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">Edwards Lifesciences</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn2"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">†</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Medtrace</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn2"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">†</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Medtronic</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn2"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">†</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•</font><font size="1" style="font-size: 7pt"><i>JAMA
				Cardiology</i></font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				NIH</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Latha
				P. Palaniappan</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Content
				Reviewer—Joint Committee on Clinical Practice Guidelines</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Stanford
				Concierge and Executive Medicine</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">National Minority
				Cardiovascular Alliance</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>• <font size="1" style="font-size: 7pt">NIH</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Mariann
				R. Piano</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Content
				Reviewer—Joint Committee on Clinical Practice Guidelines</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Vanderbilt
				University</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Marc
				Ruel</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Official
				Reviewer—AHA</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">University
				of Ottawa Heart Institute</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">Edwards Lifesciences<br/>
•
				Medtronic</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">Cryolife<br/>
•
				Medtronic</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Jorge
				F. Saucedo</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Official
				Reviewer—AHA</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Medical
				College of Wisconsin</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>• <font size="1" style="font-size: 7pt">B.
				Braun Interventional Systems Inc.</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Erica
				S. Spatz</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Content
				Reviewer—Joint Committee on Clinical Practice Guidelines</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Yale
				University School of Medicine</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>• <font size="1" style="font-size: 7pt">FDA</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Elaine
				Tseng</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Content
				Reviewer—ACC/AHA</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">University
				of California San Francisco and San Francisco VA Medical Center</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">ReValve Med</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn2"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">†</font></span></font></a></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>• <font size="1" style="font-size: 7pt">NIH</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>•
				<font size="1" style="font-size: 7pt">AATS</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn2"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">†</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				AHA</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn2"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">†</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Cryolife</font><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt"><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn3">‡</a><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1">*</a></font></span></font><font size="1" style="font-size: 7pt"><br/>
•
				Edwards Lifesciences<br/>
•&nbsp;</font><font size="1" style="font-size: 7pt"><i>Journal
				of Heart Disease Valve</i></font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn2"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">†</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				Medtronic<br/>
• STS</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn2"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">†</font></span></font></a><font size="1" style="font-size: 7pt"><br/>
•
				University of California<br/>
• Zimmer Biomet</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Saraschandra
				Vallabhajosyula</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Content
				Reviewer—AHA</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Emory
				University School of Medicine</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Y.
				Joseph Woo</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Content
				Reviewer—Joint Committee on Clinical Practice Guidelines</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Stanford
				University School of Medicine</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>• <font size="1" style="font-size: 7pt">NIH</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
		<tr>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Marco
				Zenati</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Official
				Reviewer—AATS</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">Harvard
				Medical School</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p>• <font size="1" style="font-size: 7pt">NIH</font><a href="https://www.ahajournals.org/reader/content/1843fbad4e8/10.1161/CIR.0000000000001038/format/epub/EPUB/xhtml/index.xhtml?hmac=1698364701-N8QiG24Wv01ZfASCqF54wtKXBQ5fps1saBdsNwlC%2BWc%3D#atab2fn1"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 7pt">*</font></span></font></a></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
			<td style="border: 1px solid #2c2e35; padding: 0.02in"><p><font size="1" style="font-size: 7pt">None</font></p>
			</td>
		</tr>
	</tbody>
</table>
<p align="justify" style="line-height: 0.11in; margin-bottom: 0in"><font size="1" style="font-size: 6pt">This
table represents all relationships of reviewers with industry and
other entities that were reported at the time of peer review,
including those not deemed to be relevant to this document, at the
time this document was under review. The table does not necessarily
reflect relationships with industry at the time of publication. A
person is deemed to have a significant interest in a business if the
interest represents ownership of ≥5% of the voting stock or share
of the business entity, or ownership of ≥$5000 of the fair market
value of the business entity; or if funds received by the person from
the business entity exceed 5% of the person’s gross income for the
previous year. Relationships that exist with no financial benefit are
also included for the purpose of transparency. Relationships in this
table are modest unless otherwise noted. Names are listed in
alphabetical order within each category of review. Please refer
to&nbsp;</font><a href="https://www.acc.org/guidelines/about-guidelines-and-clinical-documents/"><font color="#2b7bb9"><span style="text-decoration: none"><font size="1" style="font-size: 6pt">https://www.acc.org/guidelines/about-guidelines-and-clinical-documents/</font></span></font></a><font size="1" style="font-size: 6pt">&nbsp;relationships-with-industry-policy
for definitions of disclosure categories or additional information
about the ACC/AHA Disclosure Policy for Writing Committees.</font></p>
<p align="justify" style="line-height: 0.11in; margin-bottom: 0in"><font size="1" style="font-size: 6pt">*</font></p>
<div id="atab2fn1" dir="ltr"><p align="justify" style="line-height: 0.11in; margin-bottom: 0in">
	<font size="1" style="font-size: 6pt">Significant relationship.</font></p>
</div>
<p align="justify" style="line-height: 0.11in; margin-bottom: 0in">†</p>
<div id="atab2fn2" dir="ltr"><p align="justify" style="line-height: 0.11in; margin-bottom: 0in">
	<font size="1" style="font-size: 6pt">No financial benefit.</font></p>
</div>
<p align="justify" style="line-height: 0.11in; margin-bottom: 0in">‡</p>
<div id="atab2fn3" dir="ltr"><p align="justify" style="line-height: 0.11in; margin-bottom: 0in">
	<font size="1" style="font-size: 6pt">This disclosure was entered
	under the Clinical Trial Enroller category in the ACC’s disclosure
	system. To appear in this category, the individual acknowledges that
	there is no direct or institutional relationship with the trial
	sponsor as defined in the (ACCF or AHA/ACC) Disclosure Policy for
	Writing Committees.</font></p>
</div>
<p align="justify" style="line-height: 0.11in; margin-bottom: 0in"><font size="1" style="font-size: 6pt">AATS
indicates American Association for Thoracic Surgery; ACC, American
College of Cardiology; ACCF, American College of Cardiology
Foundation; AHA, American Heart Association; DSMB, Data and Safety
Monitoring Board; FDA, US Food and Drug Administration;&nbsp;<i>JACC,
Journal of the American College of Cardiology; JAMA, Journal of the
American Medical Association</i>; NIH, National Institutes of Health;
PCNA, Preventive Cardiovascular Nurses Association; PCORI,
Patient-Centered Outcomes Research Institute; SCAI, Society for
Cardiovascular Angiography and Interventions; STS, Society of
Thoracic Surgeons; UT, University of Texas; and VA, Veterans Affairs.</font></p>
<hr/>

<div id="keywords" dir="ltr"><p align="left" style="line-height: 0.18in">
	<font color="#d93731"><font size="2" style="font-size: 9pt"><b>Key
	Words</b>:&nbsp;<font color="#000000">AHA Scientific
	Statements</font>&nbsp;■&nbsp;<font color="#000000">percutaneous
	coronary intervention</font>&nbsp;■&nbsp;<font color="#000000">angioplasty</font>&nbsp;■&nbsp;<font color="#000000">coronary
	artery bypass graft surgery</font>&nbsp;■&nbsp;<font color="#000000">myocardial
	infarction</font>&nbsp;■&nbsp;<font color="#000000">cardiac
	surgery, stent(s)</font>&nbsp;■&nbsp;<font color="#000000">angiogram</font>&nbsp;■&nbsp;<font color="#000000">angiography</font>&nbsp;■&nbsp;<font color="#000000">percutaneous
	transluminal coronary angioplasty</font>&nbsp;■&nbsp;<font color="#000000">coronary
	atherosclerosis</font>&nbsp;■&nbsp;<font color="#000000">saphenous
	vein graft</font>&nbsp;■&nbsp;<font color="#000000">internal
	mammary artery graft</font>&nbsp;■&nbsp;<font color="#000000">internal
	thoracic artery graft</font>&nbsp;■&nbsp;<font color="#000000">arterial
	graft</font>&nbsp;■&nbsp;<font color="#000000">post-bypass</font>&nbsp;■&nbsp;<font color="#000000">non–ST-segment–elevated
	myocardial infarction</font>&nbsp;■&nbsp;<font color="#000000">vein
	graft lesions</font>&nbsp;■&nbsp;<font color="#000000">myocardial
	revascularization</font>&nbsp;■&nbsp;<font color="#000000">multivessel
	PCI</font>&nbsp;■&nbsp;<font color="#000000">left ventricular
	dysfunction</font></font></font></p>
</div>
<hr/>

<p align="left" style="line-height: 0.17in; margin-bottom: 0in"><font size="1" style="font-size: 8pt">©
2021 by the American College of Cardiology Foundation and the
American Heart Association, Inc.</font></p>
<p style="line-height: 100%; margin-bottom: 0in"><br/>

</p>
</body>
</html>